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ABSTRACT
Background: The main strategy for rolling back malaria in Africa is prompt, presumptive 
treatment o f fever among those at risk. Most fevers in Africa are treated first with 
antipyretic or antimalarial drugs obtained from the retail sector. The objectives of the thesis 
were to understand retail provision of antimalarial drugs, drug use patterns and quality in 
four communities in Kenya to enable an exploration of impediments to effective 
antimalarial drug use in Kenya and how these might be redressed in the national 
antimalarial drug policy.
Methods: The thesis used an eclectic mix of methods: from review of policy documents; 
key informant interviews; laboratory-based pharmaceutical analytical techniques; 
mathematical modeling of effectiveness; to structured questionnaires administered to 
households/retailers in four districts of Kenya.
Results: The community survey revealed that less than 3% of children below five years 
accessed sulfadoxine/pyrimethamine (SP), the first-line drug. Adult and paediatric doses of 
SP and amodiaquine (AQ, second-line) in the retail retail sector were less than one US 
dollar; that of the new first-line drug, artemether-lumefantrine (ART-LUM) was eight US 
dollars. Less than a third of the retailers knew the correct dose o f AQ for an adult and even 
less (2%) could state the correct dose for a child of 2 years. About 41% of SP and AQ 
products sampled from the retail sector were sub-standard. The modeled effectiveness of 
SP and AQ was found to be 51 and 45%, respectively, when drug quality, use, and 
adherence were taken into consideration; that of ART-LUM was approximately 85%.
Conclusions: Effective drugs are not a panacea to therapy o f malaria if  they remain 
inaccessible to rural populations at risk in Kenya. The RBM targets on prompt, effective
II
treatment of fevers are unlikely to be met without an increased investment in behaviour 
change initiatives and provision o f effective and affordable therapeutics at all levels of the 
health service, including the retail sector.
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CHAPTER 1:
Introduction and literature review
1.1 Introduction
This chapter presents a broad overview of a number of issues around effective use of 
antimalarial drugs. A context for the issues is provided by reviewing the literature on the 
burden of malaria especially in sub-Saharan Africa and the consequences of P. falciparum  
infection (the principal malaria parasite in Africa and the most virulent), the historical 
context of malaria control and contemporary approaches to malaria control. Especially 
important is the Roll Back Malaria initiative and case management of clinical cases of 
malaria as the cornerstone of rolling back malaria globally. The challenges posed to 
appropriate case management by drug resistance are reviewed. Lastly, determinants of 
effective drug use (quality, efficacy, and appropriate use) are reviewed with a view to 
identifying research gaps that are pertinent to Kenya (the location for the thesis), which are 
contextually explored in more detail in Chapter 2.
1.2 Malaria: parasite life cycle, clinical presentation, and practical 
considerations
Human malaria is caused by four genetically recognised species of the genus Plasmodium 
-P. falciparum, P. ovale, P. malariae, and P. vivax- and transmitted by infected females of 
the Anopheles mosquito. Except P. malariae, which might infect higher primates, the other 
three are exclusively parasites of man. There are two broad phases of the Plasmodium life 
cycle, a sexual replication (sporogony) within the mosquito and an asexual one 
(schizogony) within the human (Gilles, 1993). In the first phase, the mosquito ingests male 
and female gametocytes (micro- and macro-gametocytes, respectively) while taking a 
blood meal from an infected human. These undergo maturation within the mosquito, then 
come together during fertilization in the gut of the mosquito to form a globular zygote. The 
zygote, which is initially immotile, becomes elongated and motile to form an ookinete. The 
ookinete then invades the midgut wall of the mosquito to develop into a static oocyst. After
2
maturation, the oocyst ruptures to release motile sporozoites which migrate to the mosquito 
salivary glands and are injected into humans during the next blood meal (Gamham, 1988). 
In the human, sporozoites, which survive the body’s defences, invade the liver cells and 
enter into the exo-erythrocytic stage, which culminates in the rupture of the resultant 
schizont releasing thousands o f merozoites into the blood stream. In P. vivax and P. ovale, 
some sporozoites remain in liver cells to form hypnozoites, which often lead to relapsing 
malaria. Circulating merozoites infect red blood cells (eiythrocytic stage). Merozoites 
develop within the erythrocytes from where they are released periodically into the blood 
stream to infect more and more red cells. Some merozoites differentiate into gametocytes, 
which are ingested by mosquitoes during a blood meal; ingested gametocytes go through a 
cycle of maturation within the mosquito gut to form sporozoites, which infect hosts in the 
next blood meal (Figure 1.1).
Figure 1.1: Life cycle of Plasmodium in man and in the mosquito 
(http://www.cdc.gov/malaria/biologv/life cvcle.htm. accessed 20/12/04).
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Malaria is an acute febrile illness with diverse clinical presentations. Many of its signs and 
symptoms (e.g. fever, headache, nausea) are non-specific and are common to other 
infectious febrile diseases, such as typhoid fever and upper respiratory tract infection and 
invariably, algorithms to interpret malaria illness are not generalisable and therefore pose 
problems for unique malaria diagnosis (Rooth & Bjorkman, 1992; Redd et a l,  1996; 
Weber et al., 1997; Olaleye et al., 1998; Muhe et al., 1999; Bojang et al., 2000; 
Chandramohan et al., 2002). Difficulties in diagnosis are compounded by the fact that most 
people living in endemic areas carry malaria parasites in their blood without developing 
overt symptoms of clinical malaria, i.e. not all those with circulating parasites in their 
blood have malaria, and not all fevers are malaria.
Despite difficulties in diagnosis, however, malaria typically presents as a febrile paroxysm 
characterised by a progression from feeling cold, then hot, and finally heat loss by way of 
profuse sweating. Paroxysms are coincident with the rupture of mature erythrocytic 
schizonts and are punctuated by periods of wellness, which are varied depending on the 
species of Plasmodium. For P. falciparum, paroxysms occur every other day (Wemsdorfer 
& McGregor, 1988). The majority of people living in malaria endemic countries (much of 
Africa) develop uncomplicated malaria and recover spontaneously or with the help of 
antimalarial drugs. However, a small proportion, particularly of non-immune children will 
progress to severe disease (Snow & Marsh, 2002), characterised mostly by three 
syndromes: impaired consciousness, severe respiratory distress and severe anaemia (Marsh 
et al., 1995), and some may eventually die.
Although fever is a non-specific symptom of malaria, and there are those who question its 
utility (Einterz & Bates, 1997), it is an important diagnostic and management tool in Africa 
because it is the single most important prompt for seeking treatment among populations in 
the continent. The World Health Organization (WHO) advocates presumptive diagnosis of
fever as “malaria” among children under five years living in malaria endemic areas (WHO, 
1986). This policy has been criticised by some as wasteful, since more children are treated 
than those who require antimalarial drugs (Olivar et al., 1991; Massaga et al., 1999), but 
remains practicable in Africa where laboratory and clinical facilities are wanting.
Snow et al. (2003) contend that the incidence of perceived fever is more important than the 
precise incidence of clinical malaria when examining the demand for services. They 
estimate that the age-structured annual burden of fever in 41 sub-Saharan African countries 
among children below 5 years of age is 0.85 billion cases, 0.64 billion cases among the 5 to 
14 year age group, and 1.35 cases among adults. They also show that, although the burden 
of malaria is borne mostly by children below the age o f five, adults and older children still 
seek treatment for fever, treated as malaria, despite a low biological risk.
1.3 Global malaria burden
Malaria remains a major cause of death and disability worldwide and is endemic to much 
of Africa, South America, and Southeast Asia. Other malaria risk areas include the Middle 
East, some countries in Central America and Polynesia, with most other continents 
virtually free of the disease (Figure 1.2). In a 5-year Global Burden of Disease Study, 
Murray & Lopez (1997a) estimated that infectious and parasitic diseases (malaria 
included) explained 22.9% of global disability-adjusted life years (DALYs). More 
specifically, malaria was ranked as the 11th most common cause of death globally and 
accounted for 856,000 deaths in 1990 alone (Murray & Lopez, 1997b). Even such high 
estimates and the higher and hackneyed “one-million deaths due to malaria annually” 
(Bruce-Chwatt, 1952) are thought to be conservative; recent empirical data suggest that the 
true burden of malaria is much higher especially in Africa, and rising, rather than declining 
(Snow etal., 1999; 2001a; 2003).
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Figure 1.2: The national falciparum prevalence (N/P*) cartogram for 2002 (Hay et al., 
2004).
* Using data from a variety o f sources a national prevalence (NP) was estimated by: (population exposed to hypoendemic 
x 0-05) + (population exposed to mesoendemic x 0'305) + (population exposed to hyperendemic x 0-63) + (population 
exposed to holoendemic x 0-875). The product of the NP and the 1993 P. falciparum  index then gives a national 
falciparum prevalence (N/P). Figure is weighted by population exposed to risks.
1.4 Burden of Malaria in Africa (BOMA)
The greatest burden of malaria lies in Africa south of the Sahara. Of an estimated 90-500 
million global cases of malaria reported annually, 90% occur in Africa (WHO, 1992). 
However, this view is increasingly being challenged with recent research showing that 
indeed the burden of malaria is higher than previously thought in Southeast Asia, where 
this region accounts for 25% of global clinical attacks due to P. falciparum  (Snow et al., 
2005). Majority of malaria cases in Africa are due to P. falciparum  (Brinkmann & 
Brinkmann, 1991) and occur mostly in children (Snow et al., 1999).
1.4.1 Morbidity and mortality due to malaria
Malaria has both direct and indirect consequences. Through a combination of empirical 
survey-derived data and modelling, Snow et al., (1999) have estimated that 987,466 people 
(including 765,442 children) may have died of the direct consequences of P. falciparum  
infection in sub-Saharan Africa in 1995. They also estimate that 207.5 million clinical 
attacks of malaria may have occurred among people living under stable endemic conditions 
in Africa in the same year.
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Chronic sub-clinical malaria infections predispose to anaemia or under-nutrition, which in 
turn lead to an increased susceptibility to general infections. Guyatt & Snow (2001a) have 
estimated that as many as 400,000 pregnant women in sub-Saharan Africa may have 
developed anaemia as a result of malaria infection in 1995, predisposing to low birth 
weight and premature mortality among children bom to such women (Guyatt & Snow, 
2001b). Anaemic mothers face the risk of HIV infections since they might require blood 
transfusion.
It is common practice for most communities in Africa to self-medicate for fevers and 
malaria, using sub-optimal doses of antimalarial or antipyretic dmgs (Section 1.8). Even 
when they are seen by formal, qualified health workers, such people can be prescribed 
dmgs inappropriately (Zurovac et al., 2004). A combination of poor health seeking 
behaviour and inappropriate use of dmgs increases patients’ chances of experiencing 
adverse dmg reactions, which exacerbate the malaria illness. Those who experience severe 
complications of the malaria illness and survive may experience overt effects like 
blindness or epilepsy or more subtle neurological sequealae such as behavioural and 
cognitive impairment (Holding et al., 1999; Holding & Snow, 2001). These overt and 
hidden burdens of malaria in Africa are summarised in Figure 1.3.
1.4.2 Economic burden o f malaria
In the past few decades, development partners (as part of structural adjustment 
programmes) in Africa have called for public sector reforms. Consequently, African 
governments have had to cut back on health expenditure to equitably finance other sectors 
of the economy. This means that households in Africa have had to pay more and more to 
access healthcare and malaria is no exception. Not only is direct household expenditure on 
malaria high (Ettling et al., 1994; Asenso-Okyere & Dzator, 1997; Asenso-Okyere et al., 
1998; Chima et al., 2003), but malaria has also had a deleterious effect on economic
prosperity on the continent in general. Gallup & Sachs (2001) have shown that in 1995 
alone, countries with “intensive malaria” had on average, income levels 33% that of 
countries without malaria when controlled for other confounding factors, and that countries 
where malaria was eliminated had since shown a substantial increase in economic growth 
compared to neighbouring malarious countries. They argue therefore that malaria is a 
major cause o f poverty in Africa.
Figure 1.3: Direct and indirect consequences of P. falciparum  malaria infection (Snow & 
Gilles, 2002)
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1.5 Malaria control initiatives
1.5.1 History o f malaria control
Following the elucidation of the link between malaria, Plasmodia and Anopheles 
mosquitoes through the discoveries of Ronald Ross and various researchers (largely Italian 
malariologists) and the discovery of highly efficacious synthetic and natural insecticides 
(organochlorines like DDT and the permethrins for instance), efforts to eradicate the vector 
from human habitations were made. Most notable were the large-scale global malaria 
eradication programmes undertaken by the WHO in the 1950s and 1960s. These were
carried out in parts of North America, Europe and Asia with mixed success; malaria was 
successfully eradicated from much of the temperate world (Europe, North America and 
Australia) and some Asian countries (Dobson, 1999).
In Africa, such programmes were contentious from the beginning since some researchers 
argued that they would lead to loss of natural immunity and subsequent resurgence of 
malaria should the control strategies fail to be sustained. Further, it has been argued that 
programmes at best were patchy and uncoordinated and failed because of lack of 
commitment (Dobson et al., 2000). In Kenya, as in the rest of Africa, vector eradication 
programmes were tried (notably in Kisumu and Taveta) without much success (Gamham, 
1929; Smith & Draper, 1959; Fontaine et al., 1978). It was generally accepted that malaria 
eradication was unsustainable in areas of high transmission (most of Africa) and that a 
more suitable method would be malaria control using efficacious tools such as personal 
protection and chemotherapy.
Antimalarial drugs also played an important role in the control of malaria. Historically, 
they have been used in three ways: in the treatment of clinical cases of malaria, in the 
prevention of malaria or chemoprophylaxis and in aid of the vector eradication schemes of 
the 1950s and 1960s. In the latter, antimalarial drugs were used in three ways: in the 
presumptive treatment of suspected malaria cases, the radical treatment of confirmed cases 
and mass drug administration, either directly by distribution of drugs or indirectly in the 
form of medicated salt (Beales, 1988). The use of antimalarial drugs in malaria eradication 
has fallen by the wayside, but more recently intermittent presumptive treatment, especially 
among pregnant women has received renewed interest (van Eijk et al., 2004). In Kenya for 
instance, this has been incorporated into the Kenya National Malaria Strategy to help 
reduce morbidity and mortality due to malaria.
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1.5.2 Contemporary control strategies
Following the eradication of malaria from much of the temperate (and developed) world, 
malaria is now largely a disease of the tropics. Two contemporary approaches are being 
promoted in the control of malaria in Africa: use of insecticide treated bed nets (ITN) in 
the prevention of malaria and appropriate case management of malaria using safe, 
efficacious antimalarial drugs.
1.5.2.1 Roll Back Malaria (RBM)
The arguments concerning failure of the global malaria eradication programmes 
notwithstanding, emphasis on malaria control in the last few decades has slowly shifted to 
effective management of disease outcomes. Interest in malaria control has re-emerged 
through the impetus provided by the Roll Back Malaria (RBM) movement, a global 
partnership jointly founded by WHO, UNICEF, The World Bank and UNDP and launched 
in November 1998 by WHO in conjunction with African Heads of State in Abuja, Nigeria. 
The RBM initiative’s key objective is to halve malaria morbidity and mortality by the year 
2010 (Nabarro & Taylor, 1998). To attain this objective, four core strategies have been 
promulgated: 1) rapid, effective treatment of persons with malaria as close to home as 
possible within the first 24 hours; 2) increased use o f ITN to limit human-mosquito 
contact; 3) prevention of malaria in pregnancy and 4) better epidemic preparedness and 
appropriate response (www.rbm.who.int. accessed 20/12/04). Following the launch of 
RBM, several African governments have adopted these core strategies as part of their 
malaria control activities. In Kenya, RBM strategies form the basis of the Kenya National 
Malaria Strategy discussed in Section 2.4.2.
1.5.2.2 Insecticide treated bed nets (ITN)
ITN represent an old method which has been given a new lease o f life in the past 15 years 
(Dobson et al., 2000). Several studies have demonstrated the efficacy o f ITN in a variety of
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African settings. In a recent Cochrane review of the efficacy of ITN, Lengeler (2004) 
demonstrates that ITN provided protective efficacy against child mortality of 17% 
compared to no nets, and 23% compared to untreated nets and reduced the incidence of 
uncomplicated malaria, severe malaria, parasite prevalence, high parasitaemia, 
splenomegaly, and anaemia. ITN have therefore been adopted as a key strategy in malaria 
control in many malaria endemic countries, alongside effective case management of febrile 
events.
1.5.2.3 Case management
Despite the significance of reducing the risks of infection through ITN, many believe that 
the foundation to any successful efforts to reduce the mortality burden posed by malaria 
will be through effective case-management of febrile illness (Marsh, 1998; Trape et al. 
2002; Snow & Marsh 2002). Case management has prompt diagnosis and effective 
management as its key pillars. These pillars in turn rest on the adherence to good clinical 
practices usually espoused in national and international treatment guidelines that use best 
evidence to define standards of care. Good clinical practice in turn requires a well- 
functioning health care system, which readily and equitably avails effective drugs and 
medical supplies and sufficient numbers of well-trained health care personnel to deliver 
services to populations in need.
Under the RBM core strategies case management involves rapid, effective treatment of 
cases as close to home as possible. A number of guidelines have been developed in this 
respect, both at national and international levels. Nationally, standard treatment guidelines 
have been promoted as part of the broader essential drugs concept. In Kenya for instance, a 
national guideline for the diagnosis and management of malaria has been developed and 
has been in use since 1998 (DOMC, 1998). Internationally, such guidelines are 
increasingly being harmonised with efforts to manage sick children under the Integrated
Management for Childhood Illness (IMCI) developed by WHO and UNICEF (WHO, 
2000a).
Whilst an apparently simple strategy, the majority of the African continent has a number of 
distinguishing features which make case-management of malaria complex. Malaria is a 
common illness, most frequently occurring as a minor illness, especially among immune 
adult populations. It may not therefore be perceived as a high-risk disease. Diagnosis of 
malaria is difficult; resources to make a parasitological diagnosis, and algorithms to 
interpret the findings, present management problems, especially in endemic settings 
(Section 1.2). At the same time, rapid clinical deterioration and death are a common feature 
of malaria cases, implying a narrow window of opportunity for instituting effective 
treatment in these most severe cases (Greenwood et al., 1987). The greatest burden of 
disease occurs in resource-poor environments, where geographic access to government 
health facilities is limited, and both regulatory and communication strategies are 
compromised. This commonly leads to inappropriate treatment strategies being adopted, 
for those seeking treatment through the formal health sector and the retail sector (Section 
1.8). Inadequate resources further compromise regulatory strategies, and lead to widely 
varying quality amongst available antimalarial drugs, especially within the private retail 
sector (Chapters 3 and 6). Additional complications derive from emerging antimalarial 
drug resistance, and the lack of cheap, safe, and efficacious replacements (Chapter 2).
1.6 Drugs used to treat malaria
A wide range of drugs is available in the chemotherapy of malaria (Table 1.1). In the 
literature, antimalarial drugs are largely classified using either their chemical properties 
(chemical classification) or their biological properties (bio-functional classification), 
although mode of action (antifolates) is sometimes cited. In the bio-functional
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classification, dmgs that kill schizonts of the malaria parasite for instance are termed 
schizontocides, those that kill the gametocytes are termed gametocytocides, and so on 
(Reynolds, 1993; Warrell et al., 2002).
Table 1.1: Summary o f selected characteristics of contemporary registered antimalarial drugs (WHO, 2000b)
Option Effective against P. 
vivax
Effective against P. 
falciparum  resistant 
to:
C ross-resistance Cost (USD) per adult 
treatment course
Chloroquine (CQ) Yes Hydroxy-CQ. Possibly  
AQ, PMT, QN
Tablets: 0.072 
(0.062-0.08)
Syrup: 0.85 (0.21-2.37) 
Injection: 0.54 (0.49-0.63)
Amodiaquine (AQ) Yes CQ (partially) CQ 0.15
Sulfadoxine/pyrimethamine (SP) No CQ Antifolates 0.082 (0.065-0.098)
Sulfalene/pyrimethamine (SLP) No CQ Antifolates 0.28
Quinine (QN) Active against sexual 
and asexual 
erythrocytic forms
CQ and SP 
(sometimes cross­
resistance with CQ)
Mefloquine (rare; with 
4-aminoquinolines);
QN is generally 
effective against CQ 
and SP resistant 
malaria parasites
Tablets: 1.35 (1.22-1.63) 
Injection: 2.57 (2.21-3.0) 
(7 days)
Quinimax (a combination o f  QN, 
quinidine, cinchonine and 
cinchonidine)
As for QN CQ and SP Mefloquine na
Quinidine As for QN CQ and SP 
(sometimes cross­
resistance with CQ)
Mefloquine 8.82
Mefloquine (15 mg/kg) Yes 4-aminoquinolines and 
SP combinations
Halofantrine, reduced 
sensitivity to QN
2.14(1 .55-3 .18)
Mefloquine (25 mg/kg) Yes As for mefloquine (15 
mg/kg)
As for mefloquine (15 
mg/kg)
3.22 (2.33-4.77)
Halofan trine Yes CQ, SP, QN Mefloquine Tablets: 4.75 
Syrup: 0.28
Artemether Yes CQ, SP, QN Tablets: 4.20  
(China) 
Injection: 8.8 (China)
Artemisinin Yes CQ, SP, QN Tablets: 2.10 (Vietnam)
Artesunate Yes CQ, SP, QN 2.16(1 .98-2 .33) 
Injection: 11.2
Dihydroartemisinin Yes CQ, SP, QN na
Artelinic acid na
Primaquine Yes Antirelapse:
0.06-0.24
(0.04-3.15)
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Table 1.1: continued.
Option Effective against P. 
vivax
Effective against P. 
falciparum  resistant 
to:
Cross-resistance C ost (USD) per adult 
treatment course
Doxycycline No Used in combination 
with QN in areas o f  
reduced QN 
susceptibility
0.08-0.11
(0.06-0.21)
Tetracycline Yes Used in combination 
with QN in areas o f  
reduced QN 
susceptibility
0.14-0.20
(0.12-0.25)
Proguanil Yes PMT
Dapsone No
Atovaquone/proguanil No CQ, SP, halofantrine, 
mefloquine, AQ
42
Pyronaridine No
Quinine+doxycycline Yes QN alone As for quinine and 
doxycycline
QN-sensitive areas, QN-3+D- 
3
0.63 (0.55-0.84) 
QN-resistant areas, 
QN-7+D-7 
1.47(1.3-1.66)
QN+tetracycline Yes QN alone As for quinine and 
tetracycline
QN-sensitive areas, QN-3+T- 
5
0.79(0 .66-1 .16) 
QN-resistant areas, 
QN-7+T-7 
1.65 (1.42-2.27)
QN+SP Yes QN alone As for QN and SP 0.66 (0.59-0.8)
Artesunate+mefloquine Yes CQ, SP, mefloquine As for mefloquine 5.38 (4.06-7.04)
Artemisinin+mefloquine Almost no data As for mefloquine
Artesunate+SP Yes CQ As for SP 2.24 (2.05-2.43)
CQ+SP Yes CQ 0.154 (0.127-0.18)
CQ+SLP Yes CQ 0.35 (0.34-0.36)
Artemether+lumefantrine No CQ, SP As for artemether 2.5
Dapsone-chlorproguanil No CQ, SP Possibly other 
antifolates
Possibly <0.50
Dapsone-chlorproguanil/
artesunate
Yes CQ, SP na
Pyronaridine+artesunate Yes CQ, SP na
*na-not available
The seemingly wide range of antimalarial drugs in Table 1.1, however, is tempered by 
economic realities on the African continent. Contemporary malaria chemotherapy in sub- 
Saharan Africa makes use of only a handful of antimalarial drugs (Winstanley et al., 2004). 
Chloroquine (CQ) was used in many countries in sub-Saharan Africa as first-line drug until
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recently and is still used extensively in parts of the continent. Amodiaquine (AQ), another 
4-aminoquinoline, has similar properties to CQ. However, the drug’s utility has been 
limited by concerns about its safety, specifically, agranulocytosis and acute hepatitis have 
been well-documented following use of AQ in prophylaxis (Hatton et a l,  1986; Larrey et 
a l, 1986; Neftel et a l, 1986; Rhodes et a l,  1986; WHO, 1987; Rouveix et a l, 1989; 
Phillips-Howard, 1990; Orrell et a l, 2001). Safety concerns have kept AQ off the WHO 
list of essential drugs until recently when a systematic review showed that the drug was not 
more toxic than sulfadoxine-pyrimethamine when used to treat uncomplicated malaria 
(Olliaro et a l,  1996).
Another class of antimalarial drugs with great utility in sub-Saharan Africa is the antifolate 
combinations. Sulfadoxine or sulfalene combined with pyrimethemine (SP) is the first-line 
drug in many countries, although resistance has emerged quite rapidly. Another antifolate 
combination that is more efficacious than SP and less prone to drug resistance is 
chlorproguanil-dapsone (Lapdap®). This drug became available in the last two years and its 
safety in routine use is being evaluated under the auspices of the WHO. Its utility however 
has been greatly limited following a push towards artemisinin-based combination therapy 
(ACT) in the continent, thus the drug is being combined with artesunate (chlorproguanil- 
dapsone-artesunate, CD A) to make it more attractive as a policy option in the fight against 
malaria. Quinine has been used for generations in Africa and throughout the world, 
especially as a reserve drug for complicated malaria. In most countries therefore, it is 
usually second- or third-line drug. In some countries like Kenya, oral quinine is used as 
second-line therapy for uncomplicated malaria, but symptomatic toxicity (e.g. “tinnitus”,
i.e. ringing sound in the ears) and a complicated dosing regimen (several doses a day for 
seven days) makes it impractical as an oral drug. Other antimalarial drugs which are less 
commonly used include mefloquine, halofantrine, atovaquone-proguanil and the antibiotic 
antimalarials such as doxycycline, tetracycline and clindamycin (Winstanley et a l ,  2004).
ACTs are widely regarded as safe and highly efficacious and the way forward for malaria 
control in sub-Saharan Africa. The rationale for ACTs lies in the fact that the odds of a 
parasite developing resistance to two drugs in combination at the same time is considered 
to be very small, a principle which has been used effectively to confront other infectious 
diseases like tuberculosis and HIV/AIDS (White, 1999; White et al., 1999; Nosten & 
Brasseur, 2002). However, ACTs pose an enormous cost challenge to already resource- 
constrained governments in sub-Saharan Africa (Bloland et al., 2000; Snow et al., 2003). 
Snow and colleagues (2003) estimate that between 1.6 and 3.4 billion US dollars are 
required to give Africa a chance to ensure a drug policy based on ACTs. It is envisaged 
that such funds will be paid for by the international donor community by way of funds 
availed through the Global Fund for AIDS, tuberculosis and malaria (GFATM). It is also 
envisaged that the cost burden of ACTs would be substantially reduced by targeting 
resources more effectively by for instance availing them free of charge only to at-risk 
populations like paediatric patients. Costs would still be reduced further by availing better 
diagnostic facilities (e.g. rapid diagnostic tests) for malaria (Snow et al., 2003).
In its recently released seminal report entitled “Saving lives, buying time: economics of 
malaria drugs in an age of resistance”, the United States Institute of Medicine (IOM) 
makes a similar observation about malaria therapy in Africa and the need for ACTs. The 
IOM notes that in the era of chloroquine resistance, the artemisinins are the only first-line 
antimalarial drugs appropriate for widespread use that still work against all chloroquine- 
resistant malaria parasites (IOM, 2004). Further, the report notes the relatively high cost of 
the artemisinins compared to failed or currently failing first-line antimalarial drugs, which 
are five to 10 times higher than CQ or SP, and recommends “.. .a sustained global subsidy 
of the artemisinins co-formulated with other antimalarial drugs (i.e. ACTs) as the most 
economically and biomedically sound means to meet the challenge of malaria”.
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1.7 Drug resistance
1.7.1 Definition and determinants
Dmgs act by interfering with cellular or biochemical processes, often called targets. A 
classical target is the inhibition of enzymes necessary for parasite biochemical processes 
thus interfering with parasite growth. The antimalarial dmg SP for instance acts by 
sequentially blocking two malaria parasite enzymes: dihydropteroate synthase (DHPS) and 
dihydrofolate reductase (DHFR) that are necessary for the synthesis o f folic acid which is 
in turn used in the synthesis of purines, a precursor for amino acid synthesis. Dmg 
resistance refers to the continued growth of a parasite in the presence of a standard dose of 
a dmg to which it was previously sensitive. The dmg or its metabolite selectively 
eliminates susceptible parasites and leaves parasites that have become resistant to it, i.e. 
mutants. Resistant parasites therefore multiply in the host and with time become the 
dominant parasite population (James & Gilles, 1985).
The main determinant of the length of the useful therapeutic life (UTL) of a dmg is the 
pace of development of resistance. Hastings (2001) postulates that this pace depends on a 
number of factors: (i) the starting frequency of resistance; (ii) the level and pattern of dmg 
use; (iii) the dmg’s pharmacokinetic properties; (iii) the number of genes required to 
encode resistance; (v) the level of sexual recombination in the parasite population; (vi) 
intra-host dynamics; (vii) the genetic basis of resistance; and (viii) the number of 
individual parasites in an infection.
1.7.2 The geography o f antimalarial drug resistance
The spread of resistance to antimalarial dmgs is best exemplified by that of P. falciparum  
to CQ. CQ-resistant P. falciparum  was first reported in 1957 in the Thai-Cambodian 
border and soon after in Thailand. Resistance soon spread to South America (in 1960) and
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to Papua New Guinea (in 1976). In Africa, confirmed cases of CQ-resistant infections were 
first reported in non-immune tourists to Kenya and Tanzania in 1978 and in semi-immune 
Kenyans in 1982. Resistance soon spread inland to countries such as Sudan, Uganda, 
Zambia, and to Malawi, leading to the view that resistance first spread from Southeast Asia 
to Africa because of population movements. This view has been confirmed by population 
genetics studies which have noted the similarities between African and Asian strains of 
CQ-resistant P. falciparum  and their difference from those found in South America and 
Papua New Guinea (Talisuna et al., 2004).
In contrast to resistance to CQ, which emerged slowly, that of P. falciparum  to the 
antifolates emerged almost instantaneously. That to proguanil was noted in Malaya in 
1947, one year after it was introduced. It is believed that resistance to pyrimethamine and 
cross-resistance to proguanil, chlorproguanil, and cycloguanil first emerged in Muheza, 
Tanzania in 1953 and spread slowly to northern Tanzania. SP was introduced in Thailand 
in 1967 and resistance was reported the same year. Resistance to mefloquine was reported 
in 1982, five years after its introduction while that to atovaquone was reported the same 
year it was introduced (1996). Resistance to the artemisinins has not been reported, 
although recrudescence among patients who have received a short course of therapy (i.e. 
less than 5 days) is not uncommon (Talisuna et a l, 2004).
1.7.3 Measurement o f antimalarial drug resistance
Broadly, three methods are used to measure resistance to the antimalarial drugs: in vivo 
tests, in vitro tests, and molecular markers. In vivo tests involve the use of human subjects 
and parasitological and/or clinical markers as endpoints. Typically, patients are enrolled 
into the study, given the drug of interest, monitored over a given period, and assessed for 
response to the drug in terms of parasite clearance or clinical outcomes such as fever, or 
both. There has always been a great deal of controversy around the suitability of pure
parasitological or pure clinical definitions of efficacy/resistance leading the WHO to adopt 
both methods in its most recent definition of adequate clinical and parasitological response 
(ACPR, Table 1.2). Another controversy has been the number of days of follow-up 
(needed to differentiate true recrudescence from re-infection), this however has not been 
resolved satisfactorily in the literature and guidelines still give recommended follow-up 
periods ranging form 7 to 28 days for most antimalarial drugs (WHO, 1996; 2003a; Olliaro 
& Bloland, 2001).
Table 1.2: Definitions of antimalarial drug efficacy (WHO, 1996; 2003a)
Indicator Definition
Early treatment failure (ETF) Development o f  danger signs or severe malaria within the first three days (with 
parasitaemia) or a history o f fever (axillary temperature >37.5°C) on Day 2 or 3 in 
the presence o f parasitaemia. Parasitaemia on Day 3 >  25% o f  the count on Day 0 on 
its own also qualifies as ETF
Late treatment failure (LTF) Recorded if  danger signs or severe malaria occur on Days 4 to 14 (with 
parasitaemia), or there is fever with parasitaemia on Days 4 to 14 without previously 
meeting criteria for ETF
Adequate clinical response (ACR) Achieved if there is no parasitaemia or no fever on Day 14 without previously 
meeting the criteria for ETF or LTF
Late parasitological failure (LPF) Presence o f parasitaemia on Day 14 or 28 and axillary temperature < 37.5°C, without 
previously meeting criteria for ETF or LTF
Adequate clinical and 
parasitological response (ACPR)
Absence o f parasitaemia on Day 14 (or Day 28), irrespective o f  axillary temperature, 
without previously meeting any o f  the criteria for ETF, LTF or LPF
In vitro tests involve obtaining samples from patients, which are then tested to estimate 
resistance patterns found among parasites circulating in a given area. They therefore reflect 
intrinsic parasite susceptibility to a given drug whereas in vivo tests demonstrate the 
interaction between parasite, drug, and host immune systems to effect a therapeutic 
response. Current in vitro tests include the WHO Mark II test, use of radio-labelled 
hypoxanthine, and the pLDH microtest. Use of molecular markers involves monitoring 
known mutations at certain points in the parasite genetic material and using this to predict 
the pattern and pace of development of antimalarial drug resistance. For example, it is
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know that there is a correlation between increased frequency of mutations in DHFR (at 
codons 108, 51, 59, and 164) and DHPS (codons 436, 437, 540, 581, and 613) genes and 
SP resistance across the world. The utility of these methods however is limited by 
technical difficulties and a poor understanding of mechanisms of resistance for most 
antimalarial drugs (Olliaro & Bloland, 2001).
1.7.4 P. falciparum resistance to common antimalarial drugs and current first-line 
policies in sub-Saharan Africa
Table 1.3 shows countries in the WHO Africa Regional Office (AFRO) where P. 
falciparum  is the predominant parasite in malaria infections. Algeria and Mauritius have 
been excluded from the table because the predominant parasite is P. vivax whose public 
health impact in Africa is negligible. The table demonstrates that the majority of countries 
in the AFRO region have reported resistance to CQ and the next favourite first-line drug, 
SP. Resistance to AQ is less common. In December 2004, most countries had changed to 
ACT, especially artesunate-AQ or artemether-lumefantrine (ART-LUM). However, 15 of 
these countries, including Kenya, had not yet implemented the new first-line policy.
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Table 1.3: Antimalarial drug resistance to P. falciparum  and current policy in the WHO 
Africa Regional Office (WHO AFRO*). Sources: Dr. Peter Olumese, WHO, personal 
communication and http://mosouito.who.int/amdp/amdp afro.htm, accessed 20/12/04.
Country Reported resistance to: Current first line policy for 
presumptive diagnosis of
CQ SP AQ uncomplicated malaria
Angola Yes Yes Yes CQ
Benin Yes Yes No ART-LUMt
Botswana Yes No No SP
Burkina Faso Yes Yes Yes CQ
Burundi Yes Yes No AS-AQ
Cameroon Yes Yes Yes AS-AQt
Cape Verde na na na CQ
Central African Republic Yes No No CQ
Chad Yes Yes Yes CQ
Comoros Yes Yes No ART-LUMt
Congo Brazzaville Yes No No CQ
Cote d’Ivoire Yes Yes No AQ or SP
Democratic Republic o f  Congo Yes Yes No SP
Equatorial Guinea Yes Yes No CQ
Eritrea Yes Yes No CQ+SP
Ethiopia Yes Yes Yes ART-LUM
Gabon Yes Yes Yes AS-AQt
Gambia Yes No No CQ
Ghana Yes Yes No a s -a q t
Guinea Yes No No CQ
Guinea-Bissau Yes No No CQ
Kenya Yes Yes Yes ART-LUMt
Liberia Yes No Yes a s -a q t
Madagascar Yes No No a s -a q t
Malawi Yes Yes No SP
Mali Yes Yes No ART-LUMt
Mauritania Yes No No CQ
Mozambique Yes Yes Yes AQ+SP
Namibia Yes Yes No ART-LUMt
Niger Yes No No CQ
Nigeria Yes Yes Yes CQ
Rwanda Yes Yes No AQ+SP
Sao Tome and Principe na na na AS-AQt
Senegal Yes Yes Yes AQ+SPt
Sierra Leone Yes Yes Yes AS-AQt
Somalia Yes Yes No na5
South Africa (Kwazulu Natal) Yes Yes No ART-LUM1
South Africa (Mpumalanga) Yes Yes No AS+SP
Sudan Yes Yes Yes na
Swaziland Yes No No CQ
Togo Yes No No CQ
Uganda Yes Yes Yes ART-LUMt
United Republic o f  Tanzania Yes Yes Yes ART-LUM1
Zambia Yes Yes No ART-LUM
Zanzibar Yes Yes Yes AS+AQ
Zimbabwe Yes Yes No CQ+SP
’Algeria and Mauritius excluded because P. vivax predominates 
f  Policy adopted, not presently being deployed, implementation process on-going 
i Laboratory confirmation o f  malaria required 
§ na-not available
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1.7.5 Public health impacts o f  drug resistance
The public health implications of resistance to the antimalarial drugs are enormous. 
Antimalarial drug resistance leads to increase in malaria transmission in an area. Failure to 
clear parasites from patients means that more and more patients will carry resistant 
parasites in their blood, which in turn increases the biomass of resistance parasites in the 
population. Drug resistance also increases transmission by increasing gametocyte carriage 
in a given population as a result of longer parasite clearance times, which are associated 
with increased gametocyte carriage or increased frequency of recrudescent infections, 
which are twice as likely to carry gametocytes compared to primary infections (Olliaro & 
Bloland, 2001).
Furthermore, antimalarial drug resistance results in an increase in the frequency of severe 
malaria in the population since failing first-line drugs means patients will delay treatment 
and present to health facilities where second- and third-line drugs are mostly available 
when it is perhaps too late. Data from Malawi showed that in 1993, during the policy 
change from CQ to SP, hospital admissions due to uncomplicated malaria, anaemia and 
cerebral malaria had increased by 14%, 22% and 10%, respectively. The rates of anaemia 
and cerebral malaria however declined substantially after the policy change to SP, which 
was more efficacious at the time (Olliaro & Bloland, 2001).
Most significantly, antimalarial drug resistance results in increased mortality. Trape and 
colleagues (2002) demonstrate this aptly in a study in Mlomp, Senegal. In an area well 
catered for by an efficient health system run by catholic nuns, CQ was for a long time the 
mainstay therapy for malaria therapy. The authors show that following the emergence of 
CQ resistance in the early 90s, malaria mortality increased 11-fold among children 0-4 
years old. In a review of trends in childhood mortality in Africa spanning several decades, 
Snow et al. (2001a) demonstrate that there was an increase in malaria-specific mortality in
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Africa in the 1990s despite an overall decline in all-cause mortality (Figure 1.4). They 
postulate that the most plausible explanation for this was the concomitant precipitous 
decline in the clinical efficacy of CQ, which had been in use as a first-line drug across 
much of Africa at the time. Korenromp et al. (2003) show a similar rise in malaria-specific 
mortality in Africa in the 1990s, coincident with the precipitous decline in the clinical 
efficacy of CQ, using more robust statistical methods than previous work by Snow and 
colleagues’.
Figure 1.4: Trends in malaria-specific mortality in African children aged 0-4 years 
between 1912 and 1995 (Snow et al., 2001a).
1900-1989 > '.90C
Failing first-line drugs means patients have to resort to increasingly expensive medications 
to self-treat and governments spend more in terms of hospitalisation costs and more 
importantly in changing first-line policies to more efficacious and invariably more 
expensive antimalarial drugs (for instance, 20 out of 45 countries in the WHO AFRO 
region have had to change first-line policy to ACTs in the last decade 
(http://mosquito.who.int/amdp/amdp afro.htm, accessed 20/12/04; Table 1.3). A key issue
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that has been debated is the stage at which it is economically viable for a country to change 
policy. This is a complex decision which involves trade-offs between competing 
alternatives (Goodman et al., 2001) and is even more important in the advent of the ACTs 
which are several times the cost of failing first-line drugs like SP, but which are more 
efficacious.
The World Health Organisation (WHO) advises national drug policy makers to consider 
AM drugs fitting into the following efficacy Phases (using results from in vivo efficacy 
tests): ‘grace’, ‘alert’, ‘action’ and ‘change’(WHO, 1996; 2003a; Kitua, 2000). During the 
period of ‘grace’, the parasite is maximally sensitive to the drug, and this period lasts until 
treatment failure rates reach 4%. The ‘alert’ phase represents a period of treatment failure 
rates between 5-14%. This is followed by the ‘action’ phase (15-24%), during which 
period WHO advises that changes to policy be planned. Lastly, WHO recommends 
initiation of policy change when treatment failure rates exceed 25% (Figure 1.5). Although 
this rubric for policy change has been suggested and is therefore not absolute, it has 
nonetheless proved to be a useful tool for first-line antimalarial drug policy changes in 
many malaria endemic African countries (EANMAT, 2003).
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Figure 1.5: Phases o f antimalarial drug policy change using the WHO efficacy model (WHO, 1996; 2003a)
a  50  -
I
Grace (0-4%) A lert (5-14%) A ction  (15-24%) C hange  (>25%) 
Steps tow ards policy  c h an g e
1.8 Treatment seeking for fevers and malaria in sub-Saharan Africa
In many low and middle-income countries, public service providers provide health services 
to only a fraction of the population with most people obtaining their public health products1 
(PHPs, which include condoms, mosquito nets and antimalarial drugs), from a myriad of 
private service providers ranging from private medical clinics, pharmacists and their clerks, 
indigenous herbal practitioners, general provisions shops, mobile hawkers and licensed and 
unlicensed medicine shops. The lines are blurred between what constitutes formal or 
informal health service providers, licensed or unlicensed providers, and licit and illicit trade 
in PHPs. In some countries for instance, “medicine shops” are licensed and may legally sell 
proprietary, over-the-counter (OTC) drugs such as analgesics, cough syrups, vitamins, and 
a variety of antimalarials. In practice, however, these shops also often illegally sell 
injectable antimalarials, antibiotics, tranquillisers, and other prescription drugs. General
1 D efined by C onteh  &  H anson (2003) as “ ...co m m o d itie s  th at are  used  for trea tm en t o f  d iseases o f  public  
health  im portance or for the  prom otion  o f  health, w hich  can be prov ided  at the retail level w ithout a ‘se rv ice ’ 
a ttached  to  th em ” .
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provision shops usually do not qualify a license to sell even OTC drugs, but they often 
stock antimalarials and antipyretics and occasionally a limited range of prescription drugs 
(RBM, 2004). Further, while pharmacies are considered “formal” on paper since there are 
minimum de jure  training and licensing requirements for staff, in practice most of them are 
only so in name since they are mostly run by assistants with little or no health-related 
training (Conteh & Hanson). Therefore, these lines can at best be said to be country 
specific.
Conteh & Hanson (2003) suggest three useful typologies that might be used to classify 
private providers o f PHPs: commercial orientation (profit/not-for-profit), qualifications of 
staff (formal health-related training/little or no training) and organizational complexity 
(single hawker to multi-department institutions such as hospitals). In this thesis, a slight 
modification of the first two typologies is used within the context of each chapter. The term 
“formal” for instance is used to denote providers with formal, health-related training, for 
instance government clinics and hospitals, mission clinics and hospitals and doctors and 
nurses in private practice (Chapter 2). At times a distinction is made between providers 
within the “formal” sector by using their commercial orientation as a sub-typology; thus the 
terms “public formal” (meaning not-for-profit formal service providers) and “private 
formal” service providers (e.g. doctors and nurses in private practice). Public formal service 
providers are classified further in some chapters to see if  there are any patterns in terms of 
community drug use or costs (Chapter 4).
There are two contexts in which the term “home” is used in the thesis: first is the treatment 
of fevers at home using western medications (Chapters 1 and 2). Some of the drugs used at 
home will already be in the household, left over from previous fever episodes, but most 
will be obtained from shops or pharmacies. Moreover, the use of western drugs already at 
home as a fever treatment action constitutes less than 4% of first actions (Chapter 4) and
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these drugs would largely have been obtained from shops or pharmacies in a previous fever 
episode (Deming et al., 1989; Marsh et al., 1999; Molyneux et al., 1999). Therefore, where 
the key distinction is between the use of western drugs at home and drugs obtained from 
formal providers, western drugs at home are put together with those obtained from the 
retail sector (the most likely source of drugs used at home). The term “home” also appears 
in Section 1.8.2 under the World Health Organization’s home-based management of 
malaria (HMM). HMM is defined by WHO as “...early recognition of, and prompt and 
appropriate response (treatment) to malarial illness in children under 5 years of age in the 
home or community”fhttp://www.who.int/malaria/homemanagement.html) and would 
naturally include actions involving the use of the retail sector (which is the most common 
for fevers and malaria in Africa)”. The term “retail” strictly denotes Conteh & Hanson’s 
(2003) commercial orientation typology and is used to denote retail pharmacies, mobile 
drug vendors and general provision shops. Footnotes (for tables) and definitions in the text 
are used to remind the reader the context in which the terms are used throughout the thesis.
1.8.1 Literature review
As part of the present literature review, 48 studies across 17 countries in sub-Saharan 
Africa and one recent review were selected and these have been used to outline some basic 
features using medians of various categories of behaviour. No formal search strategy was 
used and therefore the coverage and completeness of the information obtained from these 
studies must be viewed with caution. Similar data for Kenya have not been included here 
because this is dealt with in more detail (and in context) in Chapter 2, which is Kenya- 
specific. The following account is based on an analysis of these studies.
The literature on treatment seeking for fevers and malaria in sub-Saharan Africa is copious. 
There are, however, a number of methodological difficulties in trying to compare these 
across time and studies to bring out generalisable patterns of behaviour. In a recent review,
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McCombie (2002) observes that authors use a variety of methods of inquiry. Some use 
hypothetical questions such as ‘how would you treat malaria or fever in your child or 
yourself, others ask about specific actions taken in response to fever or malaria. In 
addition, authors use different recall periods to define fever or malaria and definitions of 
treatment actions or terminologies used to elicit responses from interviewees are varied or 
simply not apparent. Regardless of these methodological challenges, a number of broad 
generalisations can be inferred.
1.8.1.1 Definition o f  fever
Communities use different terminologies to describe fever or malaria. Sometimes these 
definitions closely approximate the biomedical definitions of fever or malaria, but more 
commonly, they incorporate broader connotations of illness. In northern Ghana for 
instance, pua  or paa  are used to describe febrile illnesses including headaches, skin rashes, 
diarrhoea, and/or vomiting. When compared with biomedical definitions of malaria (raised 
body temperature and parasite density >=4,000/pi blood), the lay definition afforded a 
sensitivity of 42% and a specificity of 79% during the peak malaria season (Binka et al., 
1994). Similarly, in Uganda, lay definitions of malaria when compared with gold standard 
biomedical definitions afforded a sensitivity of 37% and a specificity of 58% (Lubanga et 
al., 1997). In some communities, there are a number of illness categories and malaria may 
be divided into different types. Among the Dangme of Ghana, asra is used to denote fever, 
while asraku refers to a high fever (Agyepong & Manderson, 1994). Overall, local 
definitions of fever and malaria are poorly predictive of biomedical malaria.
1.8.1.2 Treatment o f  fevers
Treatment of fever and malaria is very high. Table 1.4 shows 48 studies conducted in 17 
countries across sub-Saharan Africa between 1978 and 2002 (see Table 1.5 for summary 
statistics). From these studies, the majority of fevers were reportedly treated (median 96%,
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interquartile range (IQR) 89%, 100%). For the same fever episode, multiple treatments are 
not uncommon; about a third of all fevers are treated from at least two sources (median 
33%, IQR 11%, 43%). Most fevers are treated at home (median 51%, IQR 26%, 73%) or 
from the public or private sector clinics (median 49%, IQR 29%, 64%). Fevers treated at 
home mostly receive antipyretic (median 63%, IQR 60%, 79%) or antimalarial drugs 
(median 42%, IQR 28%, 57%). Fevers treated at public or private clinics are more likely to 
receive an antimalarial drug than are those treated at home (median of 73% versus 42%). 
Adherence to antimalarial drugs (dose and duration of treatment) is generally poor among 
populations in the continent (median 30%, IQR 11%, 37%).
1.8.1.3 Timing o f  treatment
From the literature, a delay in seeking treatment is common. In a study in Kabale, Uganda, 
Lindblade et al. (2000) report that over 80% of adults and children sought treatment on the 
day of illness or on the second day. However, Deressa et al. (2003a) report that over 60% 
of patients in Butajira district, Ethiopia sought treatment after 2 days of illness and in 
Shewa a delay of 3 days or greater was observed among the majority of children aged less 
than five who sought treatment (>75%). The main reasons for the delay were: perceived 
mildness of illness, high workload of guardians, financial problems or guardians thought 
they were dealing with another disease and not malaria (Deressa et a l,  2003b). Studies in 
Kenya report delay periods of two to three days (Chapters 2 and 4).
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1.8.2 Promotion o f home-based management offevers and malaria by WHO 
Because of the importance of private service providers (including the retail sector) in 
providing prompt access to drugs for fever and malaria (mostly antipyretic and antimalarial 
drugs), WHO has recognised the role of this sector in helping to meet international targets 
on access to antimalarial drugs, chiefly RBM’s target of making sure the majority of 
children receive prompt, effective treatment for malaria within 24 hours. To this end, 
WHO has put forward four strategies to correct the common inadequacies of service 
provision in this sector ('http://mosquito.who.int. accessed 20/12/04). These four strategies 
are:
1. Ensure access to effective and good quality antimalarial drugs (preferably pre­
packaged) at the community level
2. Ensure that community drug or service providers have the necessary skills and 
knowledge to manage malarial illness (fever)
3. Ensure an effective communication strategy to enable caretakers recognise malaria 
illness early and take an appropriate action
4. Ensure a good mechanism for the supervision and monitoring of community 
activities
These strategies have largely been informed by lessons learnt from pilot research projects 
on the delivery of antimalarial services in many countries in Africa and plans are underway 
to scale them up to the national level in several countries including Kenya (WHO, 2003b).
1.9 Drug quality
It is important to consider the quality of drugs because of the intuitive link between drug 
quality and drug resistance. Sub-standard and counterfeit drugs could have either of two 
outcomes for therapeutics: a) they avail too much drug to the body (high content and 
dissolution scores, see Chapter 6) thus precipitating toxic or adverse reactions, or b) avail 
too little (low content and dissolution scores) resulting in sub-therapeutic levels of the drug
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in plasma. Drug action is such that a minimum concentration is required to elicit a 
physiological response (lowering of blood pressure in hypertension for instance) or parasite 
kill in the case of malaria and other infectious diseases. The link between sub-therapeutic 
levels of antimalarial drugs and antimalarial drug resistance is usually explained in terms of 
“selection pressure” in the literature, i.e. low levels of a drug selectively kill susceptible 
parasites, leaving resistant parasites to flourish in their stead (sustained and haphazard use 
of drugs has the same effect). This is especially true for drugs with long half-lives (such as 
SP) and which therefore are more likely to spend part of their time in the body below the 
minimum inhibitory concentration required for parasite kill. This residual and sub- 
therapeutic drug in the host is likely to encounter re-infecting parasites, a common feature 
in areas of high transmission (most of sub-Saharan Africa), resulting in selective kill of 
susceptible parasites (Watkins & Mosobo, 1993; Nzila etal., 2000).
Concern about the quality of drugs dates back to antiquity. As early as the fourth century 
BC, people were warned about the dangers of adulterated medicines, and despite all the 
advances made over the years, this concern is still apparent (WHO, 1999a). Although 
global standards for drug quality are becoming increasingly rigorous, the quality of drugs 
on the market in many countries, especially the developing ones, remains a major public 
health concern (WHO, 1999b; Newton et al., 2001). The quality of antimalarial drugs is no 
exception and is part of the wider drug quality problem in developing countries.
1.9.1 Southeast Asia and Latin America
In Southeast Asia, Newton et al. (2001) investigated the distribution of counterfeit 
artesunate tablets. Of 104 shop-bought “artesunate” samples from Cambodia, Laos, 
Myanmar (Burma), Thailand, and Vietnam, 38% did not contain artesunate. Characteristics 
such as the cost and physical appearance of the tablets and packaging reliably predicted 
authenticity. In an earlier study in Cambodia, a total of 242 vendors and pharmacies were
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mapped in 12 market places, and 133 of these selected at random for investigation. In this 
study, fake artesunate was sold by 71% and fake mefloquine by 60%. Patients and village 
health providers frequently bought the fakes because of the lower price (Rozendaal, 2001).
In a study in the Amazonian region, Petralanda (1995) found that of 12 samples of 
primaquine (PQ) submitted for analysis to an independent laboratory, 50% failed to 
comply with the United States Pharmacopoeia (USP) qualitative requirements. None 
conformed to the USP quantitative requirements. A third of the samples analysed using the 
British Pharmacopoeia (BP) qualitative criteria failed.
1.9.2 Africa
In a recent study in Nigeria, for all groups of drugs investigated, more than 50% failed to 
comply with the BP specifications. Some preparations contained no active ingredient; 
some had too much and others too little. To illustrate two extremes, whereas all 19 
proguanil tablet samples analysed complied with the BP specifications, all 20-chloroquine 
phosphate syrup samples failed to do so. For the other antimalarial drugs, pooled data for 
the active ingredients (regardless of type of salt or formulation) shows an average failure 
rate of 8% for quinine (QN) and 22% for SP (Taylor et al., 2001).
Similar concerns about drug quality have been raised in Tanzania. In a recent study 
investigating the quality of nine brands of SP drugs marketed in Dar es Salaam, only four 
passed dissolution (an in vitro test for bioavailability) although all nine samples were 
within the limits for content of the active ingredients (Jande et al., 2000). During screening 
tests for CQ intake in patients, Abdi et al. (1995) encountered one patient who tested 
negative for CQ, although she claimed to have taken CQ only 2 days earlier. This 
observation together with reports of poor quality of drugs elsewhere in Africa prompted
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them to conduct a quality survey on nine CQ brands in Dar es Salaam. Although all brands 
passed tests for CQ content, a sugar coated brand failed dissolution.
A study in Uganda demonstrated problems with quality of CQ in the market. Up to 30% of 
the tablet samples and 33% of injections contained less than the stated amount of CQ 
(Ogwal-Okeng et al., 1998). A number of studies, both published and unpublished have 
been done on the quality of antimalarial drugs in Kenya. Analysis of pooled unpublished 
data from two quality control (QC) laboratories (National Quality Control Laboratory 
(NQCL) and Mission for Essential Drugs & Supplies (MEDS) between 1998 and 2001 
showed an average failure rate of 13.8% for AQ and 41.9% for SP products2. Further data 
from the NQCL showed a failure rate of 26.7% for CQ and 30% for QN. Too little, too 
much, or complete absence of the active ingredient has been noted amongst test failures. 
The active ingredient was sometimes substituted with a closely related (for instance 
sulphamethoxypyrazine with sulphamethoxypyridazine) or unrelated one 
(sulphamethoxypyrazine with paracetamol). Other problems included poor dissolution 
profiles, inadequate labelling, and faulty packaging.
The findings of a third QC laboratory (Drug Analysis and Research Unit (DARU) are 
summarised in Table 1.6 and demonstrate that the quality of antimalarial drugs in Kenya is 
highly variable. Most SP drugs tend to fail the dissolution test, especially with regard to the 
pyrimethamine component. However, QC results from the three laboratories need to be 
interpreted with caution since they are likely to be skewed. This is because analyses are 
done on samples submitted to the laboratories by a wide variety of clients, from those who 
suspect that the product of interest is of poor quality (e.g. in medico-legal cases) to those 
who seek first-time registration for a new product intended for the Kenyan market (Maitai
2 Data provided by Dr. Sarah Chuchu on 141 tests conducted between 1996 and 2001 on AM samples 
submitted to NQCL. Dr. Jane Masiga provided the unpublished, anonymous data from 103 tests undertaken 
by MEDS between 1998 and February 2001
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et al., 1982; Ogeto et al., 1983; Kibwage et al., 1992; 1999; Mang'era et a l,  1992; Vugigi 
et a l, 1997; Kibwage & Ngugi, 2000; Thoithi et a l, 2002).
Table 1.6: Antimalarial drugs analysed over the years at the University of Nairobi’s Drug 
Analysis and Research Unit (DARU)
Study AM drug Number of requests for analysis Number which failed
Maitai et al., (1982) CQ 1 1
Ogeto et al., (1983) CQ 6 1
PQ 1 0
Kibwage et al., (1992) AQ 1 0
CQ 11 0
PQ 1 0
Mang’era et al., (1992) AQ 1 0
CQ 4 0
Vugigi et al., (1997) SP 1 1
CQ 21 3
Kibwage et al., (1999) SP 3 0
AQ 1 1
CQ 13 0
Kibwage & Ngugi, (2000) SP 33 21
Thoithi et al., (2002) AQ 2 0
CQ 30 4
SP 45 18
QN 4 0
1.10 Scope and role of the current thesis
Despite the importance of ITN in reducing morbidity and mortality due to malaria, the
cornerstone of contemporary malaria control remains appropriate case management of
febrile events. Case management is a key pillar of the RBM initiative and of the Kenya
National Malaria Strategy and relies on the provision of safe, efficacious antimalarial drugs
of adequate quality as close to home (or as early) as possible. In addition to ensuring that
antimalarial drugs are safe, efficacious, and produced to the highest possible quality,
39
antimalarial drugs, need to be used rationally. Prompt treatment of malaria is especially 
important in children where the progression from mild to severe symptoms is rapid, 
resulting in potentially fatal severe malaria.
A key finding which runs through studies of treatment seeking for fevers and malaria in 
sub-Saharan Africa is the dependence on the retail sector for antimalarial and antipyretic 
drugs, which are often accessed as first-line drugs in the management of febrile events 
(Table 1.5). Despite the obvious significance of the retail sector, there has been, until 
recently, very little interest in it. This state of affairs may be attributed to the view that 
governments in sub-Saharan Africa have very little resources to regulate the retail sector 
and have largely adopted a laissez faire attitude. The WHO now recognises the importance 
of the private service providers (including the retail sector) and has begun to redress the 
deficiencies in our knowledge of this service sector (Section 1.8.2), but there remains a 
dearth of information on the potential of this sector to deliver quality services. This thesis 
addresses this research gap and aims to explore the potential of the retail sector in 
antimalarial service delivery by investigating the Range, quality, and costs o f  antimalarial 
drugs available in the retail sector in Kenya.
The thesis addresses a series of linked issues related to effective drug use by communities 
in Kenya. First, the national historical, political, and economic context is presented against 
the ever-changing status of antimalarial drug sensitivities (Chapter 2). This chapter 
provides a description of the complexities of drug use in Kenya and the political and 
financial frameworks that determine effective drug policy change. Chapter 3 considers the 
efficiency of the legislative and regulatory mechanisms in Kenya that are required to 
control rational drug use at a national level.
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Chapter 43 presents the findings of a large community survey of paediatric fever treatment 
undertaken as part of the thesis in four districts. This work provides a contemporary (2001) 
series of findings related to sources, types, timing, and costs of treatment - all cornerstones 
of effective case-management strategies for RBM and the KNMS, with particular reference 
to the retail sector. Chapter 5 reports on a separate survey data to characterise the Kenyan 
retail sector in the same four study districts. It looks at the availability and affordability of 
antimalarial drugs and that of malaria preventative measures and explores shopkeeper 
knowledge of dosing for malaria with a view to understanding the limitations of the retail 
sector in antimalarial service delivery. Although there have been several reports o f sub­
standard and counterfeit drugs circulating in the market in Kenya, sampling of drugs for 
quality control (QC) has been focussed on major towns and cities or for the process of 
registration; there have been few district-level definitions of truly randomly sampled 
product ranges and QC of anti-malarial products. Chapter 6 presents the quality of first and 
second-line antimalarial drugs sampled during the retail surveys to overcome 
methodological deficiencies of previous studies.
Chapter 74 demonstrates the difference between the effectiveness and efficacy of 
antimalarial drugs using a quantifiable and multiplicative linear model of effectiveness. 
Whereas clinical efficacy trials (on which drug policy changes are based) are conducted in 
controlled environments with carefully supervised dosing schedules using quality-assured 
antimalarial products, in Kenya and in Africa, real-life evidence suggests that the quality of 
antimalarial drugs and adherence to dosage regimen is highly variable. The thesis aims to 
explore a number of key issues related to effective drug use in Kenya to better understand 
the differences between efficacy and effectiveness of antimalarial drugs and how these
3 A digest of Chapter 4 has been published in Tropical Medicine and International Health, see details in 
bibliography under Amin et al. (2003).
4 A digest of Chapter 7 has been published in Tropical Medicine and International Health, see details in 
bibliography under Amin et al. (2004).
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might be used to redress deficiencies in national policy and legislation in Kenya. Finally, 
Chapter 8 pulls together the collective understanding of antimalarial drug use, quality and 
effectiveness in the context of Kenya’s complex drug policy and legislative framework to 
propose a number of areas requiring further attention, strengthening and prioritising to 
maximise the use of new, expensive drugs in Kenya.
The main objective of the thesis was to examine the spectrum of antimalarial drugs 
available through the retail sector in Kenya against variations in costs, quality and drug use 
and the specific objectives were as follows:
1. Develop a national database of antimalarial products, registration status, and costs.
2. Track the process of registering AM products in Kenya using tracer drugs against 
existing defined procedures by way of documentary reviews and interviews with 
key informants.
3. Define the community usage patterns of antimalarial drugs in the management of 
fevers from formal and retail sectors in four districts in Kenya.
4. Undertake a retail audit assessment (range, costs, packaging and storage) of 
antimalarial products available in rural and urban communities of four districts in 
Kenya.
5. Perform quality tests on frequently stocked antimalarial drugs in the Kenyan retail 
sector using standard QC techniques.
6. Demonstrate the difference between effectiveness and efficacy of SP and AQ in 
Kenya and explore how these might be used to redress deficiencies in national 
policy and legislation
7. Inform policy regarding the introduction of new antimalarial drugs and to increase 
the community effectiveness of the national antimalarial drug policy
The thesis therefore used an eclectic mix of research methods to tackle a range of issues
from policy review to pharmaceutical drug quality and mathematical modelling. The policy
and legislative reviews in Chapter 2 and 3 used a mixture o f documentary sources and key
informant interviews and were entirely my responsibility. The community survey of 2001
was a concerted effort by the KEMRI/Wellcome Trust team in Nairobi (of which I am
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part). The main aim of the bigger survey was to monitor progress towards targets set in the 
KNMS on various aspects of malaria in Kenya. Nested within this survey was a module on 
childhood fever management practices for which I was responsible and on which Chapter 4 
is based. I designed the survey tools, piloted them, and was responsible for supervision of 
fieldworkers and quality assurance of collected data. Some work from other modules (use 
of ITN and intermittent presumptive treatment among pregnant women) has been 
published by colleagues (Guyatt et al., 2004). The retail audit was split in two parts: a 
preliminary study where details on outlets were collected and antimalarial drug products 
were sampled for quality control (Chapter 6) and a more thorough review of range and 
costs of products (Chapter 5). I undertook the preliminary survey in the four study districts; 
I also trained and supervised field workers in the main survey. I was assisted in the quality 
control work by NQCL and MEDS and actively took part in the analysis of drug samples. 
Data on adherence for Chapter 7 were obtained from my colleague in Kilifi, Vicki Marsh, 
and the mathematical modelling of pooled data to estimate antimalarial drug effectiveness 
for the chapter were skills learnt whilst in Liverpool for which I am grateful to Dr Dyfrig 
Hughes.
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CHAPTER 2:
Kenyan health sector, malaria, and 
background to thesis
2.1 Introduction
This chapter seeks to lay out the country context for the thesis. It begins by a general 
description of Kenya, the organisation of the Kenyan health sector and aspects of health 
sector reform that affect access to health care services. It then moves on to other drug 
specific issues including treatment seeking for fevers, drug resistance, drug efficacy, and 
anti-malarial drug policy. A description of historical antimalarial drug policy changes in 
Kenya, the current situation with artemisinin-based combination therapies (ACTs), and the 
political issues affecting drug policy changes in Kenya are then presented. The latter was 
particularly important given the transition in national drug policy during the period of the 
thesis, a dynamic event hopefully captured up to the period of completion of this thesis in 
December 2004.
2.2 Kenya
2.2.1 Location and basic indicators
Kenya is located in East Africa and shares borders with Uganda to the west, Tanzania to 
the south, Ethiopia to the north, Sudan to the northwest and Somalia to the east. Kenya is 
also bordered to the southeast by the Indian Ocean on which is located the port of 
Mombasa, the second largest city in Kenya (after the capital Nairobi) and an important 
gateway for trade in Kenya and the landlocked countries in the Great Lakes region to the 
west. The country lies approximately between latitudes 5°00’N and 4°40’S, and between 
longitudes 33°83’E and 41°76’E. Kenya is approximately 580,367 km2 in area (Ojany & 
Ogendo, 1988).
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Figure 2.1: Map of Africa showing the location of Kenya
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The country is divided into five administrative levels for purposes of local government, 
resource allocation (including education and health) and population census. There are eight 
provinces (first-level), which are further sub-divided into 70 districts (second-level). 
Districts are further sub-divided into divisions, locations, and sub-locations (third, fourth 
and fifth-level, respectively). The last National Population and Housing Census was 
carried out in 1999, the fourth since independence. The country’s population was 
approximately 29 million persons in 1999, with most people living in the densely 
populated areas of Nairobi, the Coast and Western provinces o f the country. Like most
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developing countries, Kenya’s population is predominantly young, during the 1999 census, 
44% of Kenyans were aged below 15 years, 52% were aged between 15 and 64 years and 
4% were aged 65 years and above (CBS, 2001a).
The general trend in the health status of Kenya’s population was characterised by steady 
improvements from independence in 1963 until the early 1980s, this trend slowed in the 
mid 1980s and there followed a rapid decline during the 1990s. At independence, life 
expectancy at birth was 40 years (MoH, 2004a). This increased to 49 years by 1969 and to 
58 years by 1979 (Owino, 1997). There was a marginal increase in life-expectancy to 60 
years between 1979 and 1989 (Owino, 1997). However, life expectancy at birth dropped to 
48 years by 1999 (CBS, 2001a). Childhood mortality indicators show a similar trend 
(Figure 2.2): infant mortality rates had been halved by the mid 1980s; from 119 in 1969 
(MoH, 2004a) to 60 in the period 1984 to 1989 (NCPD, 1994). Likewise, in the same 
period, mortality among children under five years of age (per 1,000 live births) had 
dropped to 89 (NCPD, 1994). Both indicators show evidence of an increase by the early 
1990s (NCPD, 1989; 1994; 1999; CBS, 2003).
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Figure 2.2: Trends in infant* (dark blue line) and under five mortality  ^ (red line) in Kenya 
between 1969 and 2002 (NCPD, 1989; 1994; 1999; CBS, 2003; MoH, 2004a).
1969 1974-78 1979-83 1984-89 1988-93 1994-98 1998-02
Period
Probability (per 1,000 live births) o f  dying before the first birthday.
"t Probability (per 1,000 live births) o f  dying between birth and fifth birthday.
In terms of economic development, Kenya’s economy has been on the decline since the 
early 1990s. The total output of goods and services for final use produced by the Kenyan 
economy (Gross Domestic Product per capita) in 2000 was approximately Kenya Shillings 
(KES) 22,943 (US Dollars [USD] 316). Between 1996 and 1999, GDP growth plummeted 
from 4.6% to 1.4%. A negative growth of 0.3% was registered in the year 2000 (CBS, 
2001b). Further, Kenya has one o f the world’s highest wealth disparities, with the poorest 
10% of the population consuming only 1.8% of national income and the wealthiest 10% 
consuming 34.9%. In addition, almost half the population live below the national poverty 
line (World Bank, 2002). Efforts have been made to redress the situation: the Kenya 
government undertook a broad-based, consultative process in all districts of the country 
which resulted in the adoption of a “pro-poor” and “pro-growth” Poverty Reduction
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Strategy Paper which proposes to reverse economic decline and reduce poverty levels by 
half by 2015 (GoK, 2001).
2.2.2 Organisation o f the Kenyan health system
Health services in Kenya are provided by the government, partners in development like 
non-governmental organisations (NGOs), the mission sector, and the private sector. The 
government sector, which comprises Ministry of Health (MoH) facilities and facilities run 
by the Ministry of Local Government (in large municipalities, e.g. Nairobi), together with 
the NGO and mission sectors, are essentially non-profit making. Conversely, private-for- 
profit practitioners, clinics and hospitals provide curative and preventative services to those 
who can afford them (Owino, 1997).
The Government of Kenya (GoK) health care delivery system is organised according to 
three tiers, namely, the MoH headquarters in Nairobi, the provinces and the districts. At 
headquarters, the ministry is headed by a minister who is a political appointee assisted by 
two assistant ministers, a permanent secretary (PS) and a director of medical services 
(DMS). The PS plays an administrative role while the DMS’s responsibility is largely 
technical. The MoH is further divided into a number of divisions with different 
responsibilities (Figure 2.3). The Division of Malaria Control (DOMC) for instance is the 
operational arm (i.e. executes decisions) of the National Malaria Control Programme 
(NMCP) and is responsible for overseeing the implementation of the Kenya National 
Malaria Strategy (KNMS).
The provincial tier acts as an intermediary between headquarters and the districts and is 
responsible for the implementation of health policy at the district level. It also maintains 
quality standards and coordinates and controls all district health activities. In addition, it 
monitors and supervises district health management boards (DHMBs) that oversee the
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operations of health activities at the district level. The district level concentrates on the 
delivery of health services and generates their own expenditure plans and budget 
requirements based on guidelines from headquarters through the provinces (Owino, 1997).
GoK health services are organised through a network of facilities organised in a pyramid, 
starting from dispensaries to sub-health centres and health centres at the bottom through to 
rural health training centres, sub-district hospitals, district hospitals, provincial general 
hospitals and at the apex, the Kenyatta National Hospital (KNH) (Figure 2.4). Facilities 
become increasingly complex in diagnostic, therapeutic and rehabilitative services at the 
upper levels, which serve as the referral levels (Owino, 1997; Noor et al., 2004). Out­
patient and in-patient services are provided largely by hospitals and some health centres 
(Noor et al., 2004). In addition to these facilities, a number of specialist facilities at both 
district, provincial and national levels provide additional support. For instance, Mathare 
Mental Hospital serves as a national referral centre for mental illnesses. Other facilities 
include maternity hospitals and those for diseases like tuberculosis or conditions that 
require specialist treatment, for instance spinal injuries (Noor et al., 2004).
At the district level, facilities are managed by a District Health Management Team 
(DHMT), which implements the decisions of the DHMB. Although GoK health facilities 
are categorised as described above, in reality, there are difficulties distinguishing between 
middle levels of service, i.e. dispensaries versus clinics, sub-health centres versus health 
centres, and rural health training centres versus sub-district hospitals. This is because 
decisions made by the DHMTs to provide staffing are based upon actual patient load rather 
than infrastructure criteria on which the classification is based (Noor et al., 2004).
There are no systematic audit structures or processes that measure the quality of care at 
GoK facilities; consequently, there are varying estimates of even the most basic of
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indicators, i.e. the number of health facilities in Kenya (Owino, 1997; MoH, 2000; 2004a; 
Noor et al., 2004). The most rigorously derived estimates come from the work of Noor 
and colleagues (2004, Table 2.1), which showed that there were 6,674 health facilities in 
Kenya in 2004 and approximately a third of these were run by the government. A further 
18.2% were run by the mission and NGO sector and 1.4% by local authorities. Private 
sector facilities account for 44.2% of facilities mapped, a far greater estimate than 
previously thought, but still underestimated (Noor et al., 2004).
Table 2.1: Breakdown of the 6,674 health facilities identified in Kenya in 2004 by type 
and service provider (Noor et al. 2004).
MoH Mission/NGO M inistry of 
Local
Government
Employers 
and other 
ministries
Private
sector
Total
*
Hospitals 125 96 11 107 339
Health centres* 473 157 50 24 26 730
Dispensaries 1,471 907 40 252 289 2,958
Unspecified clinics* 45 2179 2,225
Specialist facilities^ 8 54 5 5 350 422
Total 2,077
(31.1%)
1,214
(18.2%)
95
(1.4%)
337
(5.1%)
2,951
(44.2%)
6,674
* Includes provincial, district, sub-district hospitals or unspecified private hospitals offering general in-patient clinical 
services.
* Includes all health centres, sub-health centres and rural health training centres as specified on national databases.
* Includes all clinics that were not classified in the private or employer sectors that provide generalized health services but 
were not classed as dispensaries or health centres.
§ Includes all hospitals that provide treatment for only special diseases such as leprosy, tuberculosis, cancer, 
ophthalmology, spinal injury etc and the large number o f maternity and nursing homes.
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Figure 2.4: Pyramidal structure of the Government of Kenya (GoK) health services and 
referral system.
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2.2.3 Health sector reform and health financing
From independence, the Kenya government placed a high premium on the health of its 
citizens. Plans were put in place to ensure equitable distribution of income, access to 
education and health services and a long-term objective to provide free basic health 
services to all citizens. In 1965, the government introduced free outpatient medical services 
throughout the country (Schwartz, 1996). Free healthcare, however, proved untenable as 
the number of health facilities expanded countrywide leading to a major strain on the 
government budget. For instance, total GoK spending on health increased from KES 255.4 
million (USD 36.0 million) in 1972 to KES 1.3 billion (USD 234.0 million) in 19965. This 
was compounded by structural adjustment programmes in the 1980s introduced by
5 The Central Bank of Kenya mean exchange rate o f the Kenya Shilling (KES) to the US dollar in 1972 was 
7.14 and 56.96 in 1996 (Mr. A Haret, personal communication).
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development partners whose main requirement was a cut-back on government expenditure, 
resulting among other things, in decreased spending on health care and consequent decline 
in quality of services provided (Owino, 1997).
The moves toward free universal health care for all Kenyans that were taken immediately 
following independence were gradually replaced in the 1980s and 1990s with user charges 
and cost sharing (Owino, 1997), and Kenya seems to have come full circle by 2004 when 
high level discussions were initiated on ways to introduce free health care for all. A 
Sessional Paper (Sessional Paper No. 2 of 2004) and a bill (The National Social Health 
Insurance Fund Bill, 2004), which seek to reintroduce free health care in Kenya, were 
published by the government (GoK, 2004; MoH, 2004a) on May 28th 2004. The bill was 
subsequently tabled, discussed, and passed by parliament in December 2004, but is yet to 
receive presidential assent to make it law (http://www.nationmedia.com, accessed 
14/12/04).
2.3 Malaria in Kenya
Kenya has a diverse ecology that supports the entire range of stable and unstable P. 
falciparum  transmission conditions (Snow et al., 1998) and malaria is a major public 
health risk in the country. The MoH’s Health Management Information Systems (HMIS) 
has collected imperfect data over the years by way of monthly reports from GoK facilities 
countrywide. Between 1996 and 1999, only 34 to 40% of facilities made submissions to 
headquarters, however, malaria was consistently reported as the leading cause of morbidity 
in Kenya accounting for approximately 30 to 34% of outpatient attendances over this 
period (representing over 4 million new cases of malaria annually) (HMIS, 2001).
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Although malaria affects millions of Kenyans per year, pregnant women and children 
below the age of five years are most at risk. Snow et al. (1998) have modelled the risks of 
malaria morbidity and mortality in Kenya using data from a variety of sources. In their 
study, the authors used data from 124 community-based, cross-sectional malaria parasite 
surveys conducted between 1966 and 1996 across Kenya among children aged 0 and 10 
years and linked these with climate data for the country to define malaria endemicities 
using a climate suitability model. Data were further linked with the 1989 population census 
figures for Kenya and paediatric admission and demographic surveillance data from across 
Africa to derive risk estimates for malaria morbidity and mortality. Results indicated that 
in 1997, approximately eight million people were exposed to unstable malaria and five 
million were exposed to a low risk of stable transmission in Kenya. About four million 
people including 677,000 children were judged to live under areas of high transmission 
intensity, while over 11 million people were estimated to be exposed to intermediate levels 
of P. falciparum  intensity. The authors concluded that in 1997 in Kenya, approximately 
26,000 malaria deaths might have occurred among children aged less than five years and 
that approximately 145,000 children aged 0-4 years would require intensive clinical 
management for severe malaria in hospital. The figures increase with epidemics in 
epidemic-prone and low risk arid areas of Kenya (Table 2.2).
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Table 2.2: Populations exposed to risk of different malaria endemicities in Kenya and risk 
estimates for mortality and morbidity (Snow et al., 1998).
Feature Rainfall
Limiting
Unstable
malaria
Non-rainfall
Unstable
Malaria
Low Stable 
Endemicity 
(PR* < 20%)
Moderate 
Stable 
Endemicity 
(PR 20-69%)
High Stable 
Endemicity 
(PR >=70% )
Number o f locations 85 287 234 382 92
1997 projected total population 680,247 7,834,477 4,945,381 11,113,368 3,737,639
1997 projected 0-4 population 115,961 1,375,255 848,946 1,960,626 677,006
Malaria mortality estimates per
1000 children
0-4 years per annum (p.a.)
0
or in epidemic 
29-125
0.55 0.55 9.33 9.77
Numbers o f  deaths 0-4 years 
each year
0
or
3 ,363-14 ,495
756 467 18,293 6,614
Malaria admission rates per 1000 
children 0-4 years p.a. under 
different endemicities
21.38 21.38 38.58 32.30
Expected malaria admissions 
0-4 years p.a.
29,403 18,150 75,641 21,867
* Parasite ratio
2.4 The Division of Malaria Control (DOMC) and the Kenya National 
Malaria Strategy (KNMS)
2,4.1 The DOMC
Until recently, malaria control activities in Kenya were largely subsumed under the 
activities of the Division of Vector Borne Diseases (DVBD). In the 1960s and 1970s for 
instance, this division was responsible for large-scale spraying of houses in western Kenya 
(Kisumu and Kericho) under both experimental and field conditions (Githeko, 1992) and 
as recently as 1998, the Malaria Control Unit (MCU) was operating from an office at 
DVBD (Snow et al., 2001b). However, in October 2000, following restructuring of the 
MoH and pressure from bilateral donors on the need to raise the profile of malaria in 
Kenya, the MCU was upgraded to a full division within the MoH under the Department of 
Preventive and Promotive Health Services. A National Malaria Coordinating Committee 
was established to coordinate and make decisions on overarching strategic and managerial
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issues. This committee, chaired by the PS MoH, is aided in its day-to-day activities by the 
DOMC which is the operational arm of the National Malaria Control Programme (NMCP) 
(Snow et al., 2001b).
2.4.2 Development o f the KNM S
In recognition of the public health importance of malaria in Kenya (Section 2.3), a need 
was identified for a concerted effort to control the disease. It was recognised that previous 
efforts to control the disease were piecemeal, sporadic and largely ineffective (MoH, 
1998). Therefore, a series of consultative meetings involving over 200 stakeholders drawn 
from government and the private sector, Missions and non-governmental organisations 
(NGO’s) at central, provincial and district level were held for consensus building on a 
number of issues pertinent to malaria control in Kenya. These series of meetings 
culminated in the adoption of a Kenya National Malaria Strategy (KNMS) launched in 
April 2001 whose main objective is “...to reduce the level o f malaria infection and 
consequent death in Kenya by 30% by the year 2006, and to sustain that improved level of 
control to 2010”.
The KNMS is in line with the broader Health Sector Strategic Plan where malaria is seen 
as part of six essential health packages to be delivered to Kenyans in a co-ordinated 
manner at the national, provincial, district and community levels by all stakeholders in the 
health sector. These six essential health packages are reproductive health, immunisation 
(Kenya Enhanced Programme on Immunisation, KEPI), Integrated Management of 
Childhood Illness (IMCI), control of HIV/AIDS, malaria, and that of environmentally 
related communicable diseases such as cholera, typhoid, and dysentery. The KNMS has 
four main pillars of disease management and prevention which are envisaged will help
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achieve its aims and objectives (DOMC, 2001a). The four pillars are congruent with those 
of the RBM initiative (Section 1.5.2.1) and comprise the following:
1. Effective case management of malaria at all levels of the health care system
2. Prevention of malaria in pregnancy
3. Increased and equitable access to insecticide treated bed nets (ITN) by at-risk 
groups (pregnant women and children under five years of age)
4. Early detection and containment of epidemics
These four pillars are supported by two crosscutting strategies: Information, Education, 
°  and Communication (IEC) to arm the public with preventative and treatment knowledge; 
and Monitoring, Evaluation and research to update and inform malaria control strategies 
(DOMC, 2001a).
2.4.3 Role o f DOMC in antimalarial drug use and quality
The role of the DOMC in drug use and quality is to ensure the rational use of efficacious, 
safe, quality antimalarial drugs in the case management of malaria and to ensure the 
constant supply of essential malaria drugs to communities in Kenya. To this end, the 
KNMS states that the DOMC will “... set policy and guidelines to ensure that:
1. All fevers are treated as early as possible and as close to a patient’s home as 
possible, with acceptable quality and correct dosages of the first line antimalarial 
drugs and supportive treatment.
2. First line therapeutic failures will be appropriately referred and managed with 
recommended second line treatment, and
3. All complications of malaria will be referred and managed according to national 
guidelines...”
The responsibility of overseeing that drugs are safe, efficacious, and of acceptable quality 
at registration and post-registration has been invested in the existing government
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structures, i.e. the Pharmacy and Poisons Board (PPB) of the MoH (of which the National 
Quality Control Laboratory (NQCL) is an arm). Ensuring constant supply of essential 
malaria drugs has likewise been invested in the existing Kenya Medical Supplies Agency 
(KEMSA). The structure and functions of these bodies are covered in more detail in 
Chapter 3.
In addition to allocating responsibility for the various components of the KNMS to the 
appropriate stakeholders, the KNMS also set targets for key strategies to be met and a clear 
monitoring and evaluation strategy to evaluate progress towards these targets. The 
following represent mid-term targets set for 2006 for drug use, quality and attendant IEC 
needs (DOMC, 2001a):
1. 80% of households at risk will receive targeted IEC materials
2. 80% of GoK facilities will have continuous and adequate supplies of drugs 
essential for the management of malaria
3. 80% of all antimalarial drugs provided through the public and private sectors will 
be of internationally acceptable standard of quality
4. 60% of all fevers which are treated at home by family members or caretakers will 
be managed appropriately
5. 80% of all cases of fever treated by community health workers (CHWs) or 
outpatient facilities will be managed according to national recommendations
6. 80% of first line therapeutic failures and severe, complicated malaria cases will be 
correctly managed by health personnel in appropriate health facilities.
A clear and consistent message throughout the KNMS is the importance of co-opting 
health workers and communities in achieving its goals. Clear guidelines have been 
developed for appropriate case management o f malaria by health workers, the most notable 
being the National guidelines for diagnosis, treatment and prevention of malaria for health 
workers (DOMC, 1998). IEC materials have also been developed to pass important
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messages to communities. The most notable are DOMC charts and posters for correct 
doses of first-line drugs and quality-assured brands of first-line drugs (see Chapter 5 for the 
coverage of these materials). More recently, a number of commercials have appeared in the 
print and electronic media on the need to treat malaria promptly with the right drugs and to 
protect pregnant women and children under five with ITN (http://www.nationmedia.com, 
accessed 07/12/04).
2.5 Treatment seeking for fevers and malaria in Kenya
Broad issues related to patterns of treatment seeking behaviour have been presented in 
Section 1.8; in this Section, the Kenya context is specifically reviewed. A number of 
studies have been carried out in Kenya on treatment seeking for fevers and malaria. From 
these studies, key themes have emerged which can be summarised as follows: first, 
Kenyan communities plagued by malaria and fevers have elaborate combined bio-medical 
and bio-cultural vernacular to describe fever and malaria. Significantly, local concepts of 
malaria overlap in many ways with clinical definitions of malaria although there are 
conditions that are locally called “malaria”, which are not always malaria (Mwenesi et al., 
1995; Munguti, 1998; Baume, 2002).
A second important observation from studies of treatment seeking for fever and malaria in 
Kenya is that most fevers are treated outside the formal health sector, mostly with shop- 
bought antipyretic or antimalarial drugs administered at home. Figures 2.5 to 2.7 
summarise the proportion of fevers first treated at various sources across a number of sites 
in Kenya. Only a minority of studies indicate greater than 50% use of the formal sector 
(Mwabu, 1986; NCPD, 1989; 1994; 1999; Munguti, 1998; CRS, 1999; Garg et a l, 2001; 
Kaburu, 2002; CBS, 2003) with most studies showing borderline use of the formal sector 
or greater use of the retail sector (Ongore et a l, 1989; Boerma, 1990; Snow et a l, 1992;
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UNICEF & CBS, 1992; Mwenesi et a l, 1995; Ruebush et al., 1995; Molyneux et a l, 
1999; PCA, 2000; Hamel et a l,  2001; Baume, 2002; Nyamongo, 2002). Distance, costs 
and unavailability of drugs in most public facilities, are often cited as the reasons why the 
retail sector plays an important role in the treatment process often forming the first choice 
in seeking treatment (Nantulya et a l, 2001). Between 0 and 25% of fevers remain 
untreated or are managed using prayers (Mwabu, 1986; Boerma, 1990; UNICEF & CBS, 
1992; Mwenesi et a l,  1995; Ruebush et a l, 1995; Munguti, 1998; Molyneux et a l, 1999; 
Hamel et a l, 2001; Kaburu, 2002; Nyamongo, 2002).
Third, treatment seeking for fevers and malaria in Kenya is usually described as a 
hierarchical process where caretakers or patients first seek easily available or cheaper 
alternatives before progressing to the formal sector in the course of the illness. The use of 
multiple sources of treatment for the same fever episode is, therefore, common with the 
typical patient first self-medicating with shop-bought anti-malarial and antipyretic drugs 
before presenting to the health facility (Snow et a l, 1992; Nyamongo, 1998; 1999; 2002; 
Marsh et a l, 1999; Kaburu, 2002).
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Figure 2.5: Percentage of fevers first treated at formal public and/or private facilities in
Kenya.
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Figure 2.6: Percent of fevers first treated using drugs at home or obtained from shops,
pharmacies, and mobile vendors in Kenya.
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Figure 2.7: Percent fevers where no action was taken or where prayers were used in 
Kenya.
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Further, a waiting period (usually one to three days) before seeking treatment when the 
severity of the fever or illness is monitored is not uncommon (Mwenesi et a l, 1995; 
Ruebush et al., 1995). Among children, adult involvement is crucial in treatment seeking. 
In a study among primary schoolchildren aged 11 to 17 years (median age 13 years) in 
Bondo district, 81% of illness episodes without adult involvement remained untreated, 
while 19% were treated by the children themselves. Older children were more likely to 
self-medicate than younger ones; boys were also more likely to self-medicate than girls 
(Geissler et al., 2000).
2.5.1 Use o f antimalarial drugs
Most fevers in Kenya are treated with western pharmaceuticals and only a small proportion 
is treated with non-western interventions. Of fevers treated with western pharmaceuticals, 
the most widely used class of drugs are the antipyretic drugs, followed by the antimalarial 
drugs (Snow et al., 1992; Mwenesi, 1994; Mwenesi et al., 1995; Molyneux et a l, 1999). 
There are varying estimates as to the proportion of fevers treated with antimalarial drugs in 
Kenya and this depends on the source of treatment. Figure 2.8 is derived from 11 studies 
carried out in eight districts in Kenya between 1980 and 2002, and shows proportion of 
fevers treated with antimalarial drugs from formal clinics and at home. The studies 
demonstrate that a little over a third of fevers [Median 38%, Interquartile range (IQR) 28% 
to 53%] managed at home are treated with antimalarial drugs (Schulpen & Swinkles, 1980; 
Snow et a l,  1992; Mwenesi et al., 1995; Ruebush et a l,  1995; Hamel et al., 2001; Kaburu,
2002). Conversely, 91% (IQR 89 to 94%) of fevers treated at formal clinics receive an 
antimalarial drug (Mwenesi et al., 1995; Ruebush et al., 1995; Abuya, 2001; Zurovac et 
a l,  2004).
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Fevers treated at home are usually managed with shop-bought antipyretic and antimalarial 
drugs (Marsh et a l , 1999; Molyneux et a l ,  1999); therefore, the types o f antimalarial 
drugs used to manage such fevers vary with time and place and depend on what is 
commonly stocked in the local shops and pharmacies. Conversely, the types of antimalarial 
drugs obtained from the formal sector tend to be more uniform since drug supply to this 
sector is by a few select suppliers who have won the national tender. Nonetheless, patients 
are usually unable to identify the brand names o f antimalarial drugs dispensed to them 
from the public sector (including the mission sector) because tablets are typically 
dispensed from large multi-dose containers into small envelopes while suspensions are 
dispensed in bottles (from large multi-dose containers) brought by patients (Zurovac et a l ,
2003).
Figure 2.8: Use o f antimalarial drugs among recent fevers in Kenya as described by 11 
studies conducted between 1980 and 2002 in eight districts o f Kenya.
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2.5.2 Adherence to antimalarial dosage regimen
Despite the importance of adherence to the antimalarial drugs for effective case- 
management, not many studies have been done in this area in Kenya. In one study in 
Bungoma district, among 79 recently febrile children given chloroquine (CQ) at home, 
62% received less than 20mg/kg of the drug (recommended dosage 25mg/kg) (Hamel et 
al., 2001). In another study in Kilifi district, Marsh and colleagues (1999) reported that 
only 2.8% of children who had received CQ had been given an adequate dose of 25mg/kg 
for the recommended three-day period (adequate adherence). In yet another study on CQ 
use among school children in Siaya district, only in 12% of cases was the correct dose of 
CQ administered and in the rest the dose was inadequate (Ruebush et al., 1995). In Busia 
in 2003 among recently febrile children under five years of age, Marsh et al. (2003) found 
that 11% of those who purchased amodiaquine (AQ) from shops and 50% of those who 
had purchased sulfadoxine/pyrimethamine (SP) had received the right amount of drug for 
the right duration (Marsh, 2003). In short, the few studies that have addressed adherence to 
antimalarial drugs obtained from the retail sector in Kenya suggest that adherence to one- 
day antimalarial regimen is generally better than that to multiple regimen and that under­
dosing is more common than over-dosing, especially among children.
Adherence in the public formal sector is at two levels: first, is whether health workers 
prescribe the first-line antimalarial drug to patients with clinical or confirmed malaria; 
second, is if  health workers prescribe the nationally recommended dosages. Zurovac et al. 
(2005) carried out an audit of case management of malaria among children below the age 
of five in Greater Kisii, Kwale, Bondo and Makueni districts between July 2001 and 
February 2002. At the time of the surveys, SP was the recommended first-line treatment 
for uncomplicated malaria at a dose of 25mg/kg body weight for the sulfonamide 
component, which is usually in a fixed combination with pyrimethamine in a ratio of 20:1.
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The authors report that only 55% of children presenting with fever to GoK outpatient 
departments were managed with SP and only in 34% of cases was an adequate dose 
consistent with national guidelines given. In a similar survey among older children (5-14 
years) and adults (>14 years) in Greater Kisii and Kwale districts between August 2002 
and May 2003, 67% of patients received SP and 84% of these patients received the 
nationally recommended dose (Zurovac et a l,  2003).
The WHO recommended dose of SP (calculated using 25mg/kg body weight of the 
sulfonamide component) is usually translated into age tables by the DOMC and children 
within a given age bracket are given the same dose of SP, e.g. children aged 3 to 11 
months are given half a tablet of SP (one tablet contains 500mg sulfadoxine or sulfalene 
and 25mg of pyrimethamine). Terlouw et al. (2003) argue that use of these tables has led to 
underdosing in the past and consequent decline in SP efficacy. Based on body weight, they 
estimate that 73% of children aged <24 months received less than the target dose and that 
underdosing accounted for 26% of cumulative treatment failures among these children. 
However, after the guidelines were revised in 1998 (doses increased for certain age 
groups), only 4.2% of patients received less than the recommended dose and consequently 
there was no association between dosing practices and treatment failure.
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2.6 Antimalarial drug resistance and drug policy in Kenya
In this section, issues relating to drug policy, its formulation, and implementation are 
discussed in detail because case management of clinical cases of malaria, which is the 
cornerstone of the KNMS can only take place within a favourable policy framework. 
Antimalarial drug resistance continues to pose a threat to this strategy. Kenya changed 
first-line antimalarial policy from CQ, which had been the mainstay of treatment for 50 
years since its introduction in the 1930s, to “sulphur”-pyrimethamine (SP) combinations in 
1998. In 2004, the policy was changed again to artemether-lumefantrine (ART-LUM) as 
first-line therapy following the precipitous decline in the clinical efficacy of SP. The 
efficacy of SP and amodiaquine (AQ), which have remained the most popular first and 
second-line therapies for malaria until recently, are reviewed. The attendant issues in 
antimalarial drug policy changes, especially the implications for artemisinin-based 
combination therapies (ACT) such as ART-LUM and the role of the East African Network 
for Monitoring Antimalarial Treatment (EANMAT), a regional network for monitoring P. 
falciparum  resistance to antimalarial drugs are discussed.
2.6.1 Efficacy o f antimalarial drugs in Kenya and the East African Network for 
Monitoring Antimalarial Treatment (EANMAT) countries
Drug policy changes in Kenya, like elsewhere in the sub-region, are based on an efficacy 
model where changes are envisaged as occurring in phases (see Section 1.7.5). Clinical 
efficacy data in the sub-region are generated largely under the auspices of EANMAT. 
EANMAT was formed in 1998 to monitor the clinical resistance of P. falciparum  to 
nationally recommended first and second-line antimalarial drugs. EANMAT is a 
collaborative venture between the National Malaria Control Programmes within the 
ministries of health of the five member states of Kenya, Uganda, Tanzania (mainland 
Tanganyika and the island of Zanzibar), Rwanda and Burundi and is managed by a
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secretariat that meets every three months to share data, technical difficulties and policy 
implications. In addition to the secretariat, each country has a national team responsible for 
the co-ordination of all EANMAT iri-country activities. EANMAT has sentinel districts in 
each member country. (EANMAT, 2001).
In Kenya, there are eight EANMAT sentinel districts for prospective surveillance of 
efficacy o f antimalarial drugs using lot quality assurance sampling6 and standardised WHO 
in vivo efficacy testing protocols (see Section 1.7.3 for measurement of antimalarial drug 
resistance). The sentinel districts were chosen to be representative of the local range of 
ecological and epidemiological conditions (EANMAT, 2001; 2003). Where possible, tests 
are conducted among children under five years of age (6-59 months) suffering from 
uncomplicated falciparum  malaria recruited in the sentinel sites in each member country 
using standard inclusion criteria (Table 2.3).
Table 2.3: Inclusion criteria for recruiting children into EANMAT clinical efficacy studies 
at sentinel sites (EANMAT, 1999).
Criteria _______________________________________________________________________________
•  Age between 6 and 59 months
• No general danger signs or severe malaria present
•  No other cause o f  fever is detectable
•  No severe malnutrition
•  Patient has only P. falciparum  with parasite counts between 2000-100,000/pl o f  blood
•  Patient has understood the procedures o f  the study and has agreed to participate
•  Patient is able to come for stipulated follow up visits and has easy access to the health unit
•  History o f  fever within 24 hours or axillary temperature >= 37.5°C but < 39.5°C at the visit
•  For those on SP: patient has no history o f skin rashes after sulphonamide use and patient has no skin
conditions such as eczema that might be mistaken for reactions to sulphonamides_________________
The unique placement of EANMAT within ministries of health affords a sense of data 
ownership and consequently an effective mechanism to provide direct operational
6 Lot quality assurance sampling (LQAS) is a technique that was developed in the pharmaceutical industry to 
help in decisions as to what products to release into the market. Using statistical means, a predetermined 
number of samples are set as “acceptable failures” for every batch or lot o f a given product intended for the 
market. Any failure rates more than this level means the entire batch or lot will be rejected. The technique 
has been adopted in health research and interventions in developing countries. For instance, intervention 
studies for HIV/AIDS typically set a certain level of awareness in the community as acceptable. Anything 
below that is deemed inappropriate and therefore intervention programmes are instituted to raise the level of 
awareness (Lanata & Black, 1991).
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monitoring and evaluation data to support policy (EANMAT, 2001; 2003; MoH, 2001a). A 
key unresolved question in first-line drug policy changes in Kenya is what proportion of 
EANMAT sentinel sites need to report clinical failure rates above 25% to warrant change 
in policy. This has been, and continues to be, the subject of debate (EANMAT, 2003).
2.6.2 Drug policy changes and the efficacy of antimalarial drugs in Kenya 
The evidence that led to the 1998 policy change from CQ to SP and the attendant political 
issues have been reviewed by Shretta et al. (2000). In summary, 49 studies on CQ among 
populations less than 18 years of age throughout the country with different definitions of 
favourable outcome (see footnotes) were abstracted and analysed. Between 1979 and 1990, 
34% of all studies had demonstrated that 25% of recruited children were unable to clear 
infections by day 77. Six of 10 (60%) studies showed that 25% of the study populations 
were unable to clear infections by day 148 and 5/17 (29%) studies reported >14% of 
subjects with RIII9 resistant infections. Between April 1987 and October 1997, eight 
studies, which employed the revised, WHO definitions of clinical failure10 were 
undertaken and seven indicated unacceptable levels of CQ failure (i.e. clinical failure rates 
>=25%).
Despite mounting evidence, the Kenyan MoH was reluctant to change policy from CQ to 
SP, which was considered more efficacious, and the only practicable, affordable alternative 
promoted by WHO and listed on the Kenya Essential Drugs List (AQ was not on the list at 
the time due to concerns about its safety). This reluctance to effect policy change was 
attributed to a general lack of consensus on the principles for assessing drug failures, the
7 WHO standard in vivo 7-day test. Test based on parasitological outcome and policy change suggested when 
parasitological failure rates >=25% on day 7 (Schapira et al., 1993b).
WHO extended 14 day in vivo test. Test based on parasitological outcome and policy change suggested 
when parasitological failure rates >=25% on day 14 (Schapira et al., 1993b).
9 RIII resistance is defined as clearance of asexual parasites by less than 75% during the first 48 hours of 
treatment. >14% RIII resistance deemed unacceptable by the authors (Sudre et al., 1992).
10 Adequate Clinical Response (ACR) on day 14 i.e. absence of fever or parasitaemia (WHO, 1996).
70
inclusion criteria for the study subjects and the relative benefits o f parasitological over 
clinical assessments. After much debate, a decision was finally taken to change first-line 
antimalarial policy from CQ and revised treatment guidelines launched, approving the use 
of SP in August 1998 (Shretta et al., 2000).
Between 1998 and 2004, the first-line antimalarial drug recommended for use in Kenya 
was SP with AQ and oral quinine (QN) reserved as second-line treatment (DOMC, 1998). 
Tables 2.4 and 2.5 show a summary of contemporary EANMAT fhttp://www.eanmat.org, 
accessed 28/08/04) and non-EANMAT (Obonyo et al., 2003; Alloueche et al., 2004; 
Makanga et al., personal communication) clinical efficacy data for SP and AQ in Kenya 
between the years 1999 to 2003. Using the new WHO definition of adequate clinical and 
parasitological response (ACPR) on day 14 (see Section 1.7.3), the data suggest that SP 
clinical failure rates were well above the 25% cut-off for most studies. In 1999, none of the 
three EANMAT studies showed ACPR below 75% (or clinical failure rates above 25%). 
By 2000 and 2001 however, the share of studies showing ACPR below 75% had risen to 
58% and 50%, respectively, further increasing to 75% in 2003.
With increasing resistance to SP (EANMAT, 2001; 2003), Kenya was faced with no option 
but to change first line therapy once again. The options were: 1) moving AQ from second- 
line treatment to first-line therapy; 2) combining SP with artesunate (SP-AS) or AQ with 
artesunate (AQ-AS); 3) or using ART-LUM. Because of the WHO’s position on ACT, AQ 
monotherapy was not an option. SP was failing; therefore, combining a failing drug with 
an efficacious one (AS) did not make for a rational therapeutic choice. Likewise, AQ-AS 
was opposed since P. falciparum’s sensitivity to AQ was also showing evidence of decline 
by day 28 and widespread use of AQ as monotherapy in the retail sector precluded its
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combination with other drugs as a long-term solution. First-line policy was therefore 
changed to the only remaining option, ART-LUM (DOMC, 2004a).
Because o f the cost implications and the fact that the use of ART-LUM under operational 
conditions has not been investigated, it has been proposed that the new first-line policy in 
Kenya be introduced in a staggered manner over a five-year period. It has been proposed 
that in the first two years (2004-2005), free doses of ACT will be provided to all patients 
presenting to GoK and mission health facilities. In the third year (2006), private service 
providers will be incorporated. In the fourth and fifth years (2007-2008), after safety of 
ART-LUM under operational conditions has been ascertained, mechanisms will be put in 
place to widen access to ART-LUM by including it in the general sales list to enable its 
sale over the counter (OTC) in the retail sector. Because of the staggered nature of the 
policy change, AQ will be promoted as the best alternative to SP among private service 
providers, including the retail sector, until ART-LUM can be availed in these sectors 
(DOMC, 2004b).
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Table 2.4: Day 14 clinical efficacy outcomes of SP studies conducted in various sites in
Kenya between 1999 and 2003.
Site Date Source Completed
follow-up
% ETF* + LTF* % ACR* % LPF’ % ACPR
Busia 1999 EANMAT 44 6.8 93.2 2.3 90.9
Kisumu 1999 EANMAT 36 11.1 88.9 0.0 88.9
Kirinyaga 1999 EANMAT 39 17.9 82.1 0.0 82.1
Bondo 2000 EANMAT 60 26.7 73.3 6.7 66.7
Kibwezi 2000 EANMAT 11 18.2 81.8 0.0 81.8
Kirinyaga 2000 EANMAT 59 18.7 81.3 20.3 61.0
Kisumu 2000 EANMAT 65 38.5 61.5 6.1 55.4
Busia 2000 EANMAT 57 7.0 93.0 19.3 73.7
Lamu 2000 EANMAT 45 0.0 100.0 2.2 97.8
Kwale 2000 EANMAT 63 0.0 100.0 3.2 96.8
Bungoma 2000 AMREF 48 35.4 64.6 0.0 64.6
Sirisia 2000 AMREF 44 27.3 72.7 0.0 72.7
Webuye 2000 AMREF 46 19.6 80.4 0.0 80.4
Kilifi 2000 Alluoche et al. 2004 62 17.7 82.3 0.3 82.0
Siaya 2000 Obonyo et al. 2003 191 25.7 74.3 0.0 74.3
Kibwezi 2001 EANMAT 19 15.8 84.2 10.5 73.7
Kirinyaga 2001 EANMAT 33 36.3 63.7 15.2 48.5
Busia 2001 EANMAT 57 8.9 91.1 10.5 80.7
Kwale 2001 EANMAT 53 7.6 92.4 5.7 86.8
Nandi 2001 EANMAT 46 6.5 93.5 10.9 82.6
Mwea 2001 AMREF 28 21.4 78.6 0.0 78.6
Kibwezi 2002 EANMAT 31 51.6 48.4 3.2 45.2
Kisumu 2002 EANMAT 59 3.4 96.6 13.6 83.1
BondoT 2003 EANMAT 112 21.4 78.6 16.1 62.5
Kibwezi1 2003 EANMAT 71 8.5 91.6 8.5 83.1
Gucha8 2003 EANMAT 108 29.6 70.4 0.0 70.4
Kilifi 2003 Makanga et al.
personal
communication
641 32.8 67.2 0.0 67.2
* See Table 1.2 for efficacy definitions
* Day 28 ACPR o f SP for this study was 30.9%.
* Day 28 ACPR for SP for this study was 46.4%. 
8 Day 28 ACPR for SP for this study was 39.6%
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Table 2.5: Day 14 clinical efficacy outcomes of AQ studies conducted in various sites in
Kenya between 1999 and 2003.
Site Date Source Completed
follow-up
% ETF* + LTF’ % ACR’ % LPF’ % ACPR*
Bondo 1999 EANMAT 46 0.0 100.0 0.0 100.0
Kirinyaga 1999 EANMAT 25 16.0 84.0 4.0 80.0
Busia 1999 EANMAT 39 12.9 87.1 0.0 87.1
Bondo 2000 EANMAT 59 0.0 100.0 0.0 100.0
Kibwezi 2000 EANMAT 14 7.1 92.9 0.0 92.9
Kirinyaga 2000 EANMAT 61 1.7 98.3 6.6 91.8
Kisumu 2000 EANMAT 55 7.3 92.7 1.8 90.9
Kisumu 2000 EANMAT 26 23.2 76.8 0.0 76.9
Busia 2000 EANMAT 60 0.0 100.0 0.0 100.0
Lamu 2000 EANMAT 36 2.8 97.2 0.0 97.2
Kwale 2000 EANMAT 64 0.0 100.0 1.6 98.4
Bungoma 2000 AMREF 66 10.6 89.4 0.0 89.4
Sirisia 2000 AMREF 43 16.3 83.7 0.0 83.7
Webuye 2000 AMREF 50 4.0 96.0 0.0 96.0
Kibwezi 2001 EANMAT 25 16.0 84.0 0.0 84.0
Kirinyaga 2001 EANMAT 37 8.1 91.9 16.2 75.7
Busia 2001 EANMAT 61 3.3 96.7 3.3 93.4
Kwale 2001 EANMAT 57 0.0 100.0 0.0 100.0
Nandi 2001 EANMAT 51 2.0 98.0 0.0 98.0
Mwea 2001 AMREF 31 38.7 80.7 0.0 61.3
Kibwezi 2002 EANMAT 34 0.0 100.0 0.0 100.0
Kisumu 2002 EANMAT 54 0.0 100.0 1.9 98.1
Bondo* 2003 EANMAT 114 0.9 99.1 0.9 98.2
Kibwezi* 2003 EANMAT 95 8.4 91.6 3.2 88.4
Gucha8 2003 EANMAT 131 5.3 94.7 0.0 94.7
* See Table 1.2 for efficacy definitions
Day 28 ACPR o f  AQ for this study was 83.0%
* Day 28 ACPR o f  AQ for this study was 68.5% 
® Day 28 ACPR for AQ for this study was 77.0%
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2.7 The political issues related to the new antimalarial drug policy
Antimalarial drug (AM) policy changes in Kenya are as much a political as they are a 
scientific exercise. As demonstrated by Shretta et a l (2000) in the case of the change from 
CQ to SP, overwhelming scientific evidence in support of policy change was not 
necessarily translated into speedy action. On the contrary, there was a long-drawn out 
consensus building process before a decision was finally taken to abandon CQ. In this 
section, Walt and Gilson’s (1994) policy analysis model will be used to describe the 
political issues surrounding the new AM policy change. The model is used to organise the 
goings-on into context, content, processes, and actors, and is not an attempt at health policy 
analysis which would require a critical appraisal of the model itself and its usefulness vis- 
a-vis other competing constructs.
2.7.1 The context
The Kenyan economic and health sector context has already been discussed in the 
preceding sections. In addition, significant developments which have taken place in the 
Kenyan political landscape over the past few years are likely to have an impact on the new 
policy. The most important occurred in December 2002 when a new, progressive 
government was elected by an overwhelming majority of Kenyans after decades of rule by 
a de facto  single party, authoritarian regime. The new coalition government was largely 
elected on an anticorruption platform, free primary education, free health care for Kenyans, 
and a promise to complete the constitutional review process, which had stalled under the 
previous regime.
Dissatisfaction in the ranks emerged soon after the elections, largely occasioned by the fact 
that part of the ruling coalition reneged on a pre-election pact that was meant to clip the 
excessive powers of the presidency (allegedly abused in the past) by creating the office of
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an executive Prime Minister. This pact was to be delivered through a new constitutional 
dispensation, but the constitutional review process is still in limbo, much to the chagrin of 
those who are unhappy with the status quo. In this hostile political environment, leaks of 
scandals in the corridors of power were not uncommon. Chief among these was the single 
sourcing o f passports from the UK-based Anglo-Leasing Limited (dubbed “Anglo- 
Fleecing” by the media) (http://nationmedia.com. accessed 07/12/04), contrary to GoK 
procurement rules, which stipulate competitive bidding for most government contracts. 
This saw the exit of a number of Permanent Secretaries from government and a cabinet 
reshuffle, resulting significantly in a new PS in the MoH in the midst of the policy change 
process described below. A wary Ministry of Finance (MoF), new faces at the MoH, 
dwindling donor confidence, and score settling within the government made for a 
challenging political context for ART-LUM.
2.7.2 The process
A number of consensus building workshops and meetings were organised by the DOMC 
from November 2003, under the auspices of the Drug Policy Technical Working Group 
(DPTWG) and its specialised sub-committees (drawn from a wide cross-section of national 
and international stakeholders) to iron out concerns of stakeholders and to come up with 
workable solutions. In this section, a description of this process is detailed.
In the first DPTWG meeting, preliminary evidence showing increasing SP failure was 
shared with the members and possible ACT replacements to failing SP monotherapy 
discussed. The need to test ACTs alongside SP and AQ monotherapies, the number of 
sentinel sites, avoidance of duplication of efficacy testing among the research community 
and adoption of the new WHO definition of day 28 ACPR, were agreed (DOMC, 2003a). 
In the second meeting, the deliberations revolved around the need for high quality data to
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advocate for policy change, although some stakeholders were of the view that Kenya 
should not wait too long and should instead learn from the experiences of other African 
countries. It was noted Zambia and Zanzibar for instance had used baseline data on failure 
of existing therapies to change policy to ACT and did not wait until conclusive evidence 
on comparative efficacy of ACT was generated. Significantly and prophetically, the WHO 
delegation to the meeting reminded participants that the operational complexities of 
carrying out drug policy change needed to be tackled early on so as not to hinder the 
process (e.g. at what level ACT could be dispensed). In this meeting also, the DPTWG was 
requested to consider forming sub-groups to address the drug and non-drug issues arising 
from the imminent policy change (DOMC, 2003b).
In the third meeting, queries were raised on the quality of data that were being fronted in 
support of the proposed policy change with different stakeholders who had done studies on 
AQ and SP coming to different conclusions. For instance, EANMAT data suggested that 
AQ was still efficacious by day 14, yet the African Medical Research Foundation 
(AMREF) results showed a decrease in AQ efficacy. It was argued that differences could 
possibly be attributed to non-quality controlled drugs used among study subjects; members 
therefore urged the National Quality Control Laboratory (NQCL) to address drug quality 
issues more proactively. Members agreed to use similar definitions of treatment outcomes 
for data comparability and agreed to monitor efficacy of SP, ART-LUM, and AQ-AS in 
three sites in different ecological zones and harmonise the work of researchers involved in 
drug efficacy testing. Preliminary data from a study done in Kilifi were availed on the 
efficacy and effectiveness of ART-LUM to allay fears of effect of poor adherence on 
effectiveness (see Chapter 7). Sub-committees were formed to look at the various drug and 
non-drug issues. These committees were: therapeutic efficacy testing (TET); legal issues, 
guidelines and formulations; logistics, procurement and supplies; case management
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(DOMC, 2004c). In the fourth meeting, the terms of reference of these sub-committees 
were defined and the need to monitor drug quality, to study registration requirements and 
procedures were reiterated (DOMC, 2004d).
The fifth DPTWG meeting was convened urgently against the backdrop of an impending 
GFATM deadline. The deadline for the GFATM 4th round of applications was the 5th of 
April and a decision had to be made on what the next first-line drug would be (see Table 
2.6 for ACT international milestones). From the deliberations of the sub-committees, the 
two viable options were considered ART-LUM and AQ-AS. It was agreed that ART-LUM 
would be the first-line drug of choice for Kenya. It was agreed also that the Zambia 
example be followed, i.e. that the new policy be rolled out and data collected alongside 
implementation. Although AQ monotherapy was failing by day 28, it was felt that data on 
AQ-AS would be needed to justify the decision to use ART-LUM instead of AQ-AS, thus 
it was decided that the two be compared in the next round of testing and that WHO and the 
UK Department for International Development (DfID) would be approached for funding. 
Although concerns were raised about the high cost of ART-LUM, it was deemed the only 
option because any other ACT would have a limited Useful Therapeutic Life (UTL) as all 
had been used as monotherapies and already showed evidence of failure. Committees were 
called upon to revise existing guidelines and make recommendations on the best strategies 
for implementing the new policy to be presented at a National Symposium in April 
(DOMC, 2004e).
In the sixth DPTWG meeting, a need was expressed to write a position paper based on the 
deliberations of the sub-committees. The TET sub-committee expressed concerns about 
funding arrangements for the proposed efficacy studies and asked for more time to discuss 
this at a latter stage. The case management sub-committee raised a number of issues, i.e.
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the need to harmonise proposed guidelines with IMCI; the management of malaria among 
pregnant women given that ART-LUM could only be used in the second and third 
trimester and only if  there is no alternative; the likely interaction between ART-LUM and 
quinine; and the fact that only a 4- dose regime of ART-LUM was registered instead of the 
recommended 6-dose regime in Kenya. The committee was granted a one-day retreat to 
harmonise their findings. The guidelines harmonisation, advocacy and legal issues sub­
committee stressed the need to learn from the change from CQ to SP in terms of drug 
sourcing, distribution, affordability, policy and legal issues, costs and quality assurance. It 
stressed the need for a staggered approach to policy change, intensive personnel training, 
and the involvement of the Pharmacy and Poisons Board (PPB). The logistics, 
procurement, and supplies sub-committee stressed the need to work closely with KEMSA 
in streamlining drug procurement in the public sector and Population Services International 
(PSI) in the private sector. The committee proposed to include some of its findings in the 
GFATM 4th round application (DOMC, 2004f).
In the seventh DPTWG meeting, the case-management sub-committee raised the need to 
use ACT in combination with good diagnostics to reduce unnecessary and inappropriate 
use of an expensive drug. It was also of the view that ART-LUM and AQ would not be 
used among pregnant women for Intermittent Presumptive Treatment (IPT). Instead, SP 
would continue to be used in the interim as the Centers for Disease Control (CDC) data 
suggested it was still effective. Lapdap® (chlorproguanil-dapsone) was not considered a 
good IPT option due to concerns about its safety raised by the WHO delegation. The 
committee also stressed the need to implement the policy in phases and to have consistent 
IEC messages for the members of the public. The logistics committee stressed the need to 
engage both KEMSA and MEDS in procurement and distribution (see Section 3.3.1 for 
AM procurement arrangements in Kenya) and the legal committee stressed the need to
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monitor drug quality. Although drug quality was not seen as a problem in the interim since 
ART-LUM was to be sourced from a single supplier (Novartis Pharma AG), in the long 
term it would pose a challenge to case management if other products, similar in nature, 
came into the market (see Chapter 6). The efficacy committee stressed the need to monitor 
the new drug routinely and compile reports as it had done in the past for monotherapies. In 
terms of funding, there was need to have partners on board especially at the National 
Symposium. Overall, members agreed to speak with one voice at the National Symposium 
in Naivasha where the Minister was expected to issue a statement on the proposed policy 
change in Kenya (DOMC, 2004g).
The consultative process described above culminated in a ‘National Symposium on Next 
Anti-Malaria Treatment Policy in Kenya’ in Naivasha on 5-6th April 2004. At the 
symposium, the DPTWG sub-committees and other invited guests summarised their 
deliberations over the preceding months and possible solutions to the issues that were 
raised at these meetings. The Minister informed the gathering that, after negotiations with 
relevant bodies and development partners, Kenya had opted to change policy to the WHO 
recommended ACT and ART-LUM in particular as the first-line treatment for 
uncomplicated malaria (MoH, 2004b). The new policy was officially announced on April 
25th 2004, coincident with Africa Malaria Day, in a speech delivered by Mr Francis 
Kimani, the Deputy DMS on behalf of the Minister at Kimbimbi sub-District Hospital in 
Kirinyaga ('http://www.eastandard.net. accessed 07/12/04; http://nationmedia.com. 
accessed 07/12/04).
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Table 2.6: International milestones in the push towards ACT therapy
Date Event
October 1996 to date (White & Olliaro, 1996; White, 
1999; Bloland et al., 2000; Nosten & Brasseur, 2002; 
WHO, 2003c)
Epistemic community11 argues for the rationale o f using 
combination therapy (CT) in malaria (especially ACT) in 
the face o f  antimalarial drug resistance and rising malaria 
morbidity and mortality. Drugs in combination would 
reduce the chances o f  resistance to either o f the 
components and thus increase the useful therapeutic life o f  
the product (UTL). Cost is identified as one o f the likely 
impediments to ACTs.
January 2002 Global Fund for Aids, Tuberculosis, and Malaria 
(GFATM) is launched to help cash-strapped African 
governments to roll back these major causes o f morbidity 
and mortality using international funds.
16 January 2004 Initial rounds o f GFATM funding termed as ‘medical 
malpractice’ by Attaran et al. (2004) in the Lancet because 
funds were approved for already failing therapies in some 
countries. This results in a flurry o f  correspondence to the 
Lancet for and against the GFATM.
June 2004 (Butler, 2004) Following pressure from epistemic community above, 
GFATM agrees to allow countries, which had been 
allowed to purchase ‘ineffective antimalarial drugs’ in 
rounds 1-3 to redirect this to more efficacious drugs like 
ACT.
September 30-October 2 2004 GFATM reprogramming meeting held in Nairobi Kenya.
2.7.3 Players and power
Following the announcement of the policy change by the minister of health in April, 
another ‘consultative process’ seemed to evolve which affected the operationalisation of 
the policy change. Stakeholders took “for”, “against” or “unconvinced” positions with 
regard to the new policy (Figure 2.9). Although these positions were not always explicit, 
they could be intuitively deduced from the interactions between the “for” and “against” 
camps with key MoH policy makers (the PS and DMS) who remained “unconvinced”.
2.7.3.1 The “F or” and the “Against”
The “for” group was championed by the DOMC in collaboration with the local malaria 
research community and its international epistemic counterpart. The effect of the latter on 
the swing to ACT has been demonstrated earlier (Table 2.6). Novartis Pharma AG, being
11 Defined by Haas (1992) as "groups of actors with an authoritative claim to scientific knowledge within 
their sphere of expertise or the domain in which they operate" (op cit Lang, 2003).
the sole supplier of ART-LUM (Coartem®), stood to benefit from the new policy and its 
position was therefore intuitively clear. On the other extreme, were competitors of Novartis 
for market share of antimalarial drugs broadly. These included local manufacturers (like 
Cosmos Limited) whose position was explicit by way of direct representations to the PS 
and DMS or indirectly through their professional associations like the Pharmaceutical 
Society of Kenya (PSK) to reconsider the new policy. In an opinion letter to the PS dated 
October 6th 2004, copied to the DMS and the Chief Pharmacist, Cosmos Limited (the 
market leader in the manufacture of generic AQ in Kenya, see Section 5.3.4) suggested AQ 
as first-line policy and AQ-AS as second-line.
Multinationals like the Swiss Mepha Limited and the French Sanofi Synthelabo Limited 
launched “alternative ACTs” shortly after the policy change (an implicit position). Sanofi- 
Synthelabo launched AQ-AS (Arsucam® at USD 2.4 for an adult course and 0.7 for a 
paediatric dose) on April 8th 2004 shortly after Naivasha, and Mepha launched ART-MEF 
(Artequin® at USD 7.4 per adult treatment course) on October 1st 2004 
('http://www.nationmedia.com, accessed 07/10/04). Both products were considered 
unsuitable for Kenya because the former contained AQ, a failing monotherapy and the 
latter contained mefloquine (MEF). Use of MEF has been associated with cross-resistance 
with halofantrine and reduced sensitivity to quinine (WHO, 2000b), making it unsuitable 
for use as monotherapy or in combination in East Africa where quinine is reserved for 
severe malaria. Nonetheless the Sanofi product raised “scientific eyebrows” because local 
newspaper reports and media houses quoted the Head of the DOMC as saying that AQ-AS 
was the new first-line policy in Kenya ('http://www.nationmedia.com. accessed 10/04/04) 
an allegation that was seen as mischievous by the “for” group (Prof RW Snow and Dr W 
Akhwale, personal communication).
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In a letter dated August 11th 2004 addressed to its members, the Pharmaceutical Society of 
Kenya (PSK) made its opposition to the new policy clear. PSK was opposed to dependence 
on donor finances in principle and more so for something as crucial as first-line 
antimalarial drug policy. It also maintained that the policy was at best vague and at worst 
unsuitable for Kenya. In addition, PSK cast doubts on the scientific evidence in support of 
ART-LUM (safety, efficacy) and specifically queried the safety of ART-LUM in children, 
the elderly and pregnant women. PSK pointed out possible interactions between ACT and 
quinine should patients fail to respond to ACT and require quinine in the course of therapy. 
Further, PSK argued that the new policy left out vulnerable sections of the population like 
children since there was no paediatric formulation of ART-LUM. Finally, PSK questioned 
the inclusiveness of the stakeholder consultative process leading to the policy change 
(PSK, 2004).
In a letter dated August 19th 2004, addressed to the Manager of the NMCP, Novartis 
Pharma AG argued that PSK’s position was informed by economic considerations of its 
members who were largely drawn from the local pharmaceutical industry who were in turn 
concerned about losing market for their SP, AQ and artemisinin monotherapies in the light 
of the new policy (Dr. W Muiruri, personal communication).
2.7.3.2 The “Unconvinced”
A key debate, which impeded the implementation of the new policy, was financial 
sustainability. ART-LUM is several times the cost of SP (Chapter 5) and could not be 
financed directly and solely by the GoK. Kenya successfully applied to the GFATM to 
finance the new policy and was granted approximately US$ 82 million (on July 1st 2004) 
for the first two years of the programme fhttp://www.theglobalfund.org. accessed 
08/10/04). However, as with all GFATM awards, funding is pegged to achievement of
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short-term performance targets. This caused reluctance among top decision makers in the 
MoH to fully commit to implementation of the new policy. The MoH therefore requested 
assurances from the GFATM that the new policy would not run out of money mid-stream. 
The GFTAM arranged for a meeting in Nairobi between September 30th and November 2nd 
2004 to clarify funding issues. Although no formal minutes were available, attendees 
reported that GFATM was non-committal.
The ministry was also concerned about access to ART-LUM in the private sector, where 
the drug is not offered at a concessionary price by the manufacturer and where a 
substantial proportion of Kenyans seek treatment. In addition, there are regulatory issues 
(for instance the need to deregulate ART-LUM from prescription-only medicines to the 
general sales list), which needed to be addressed to widen access to ART-LUM in the 
private sector (see Section 3.4.4 for more on the regulatory issues). Thus, on September 
14th 2004, the DMS requested stakeholders to come up with another position paper on 
these issues to strengthen his case in advocating for the new policy at the ministerial level 
(MoH, 2004c). At the time of writing this thesis, the implementation of the new policy 
remained unclear, and specific recommendations on the use of ART-LUM in the private 
sector had not been provided to the DMS. Further, the implementation of the proposed 
policy has been put in a quandary by a global shortage of ART-LUM. The WHO issued a 
statement on November 8th 2004 to the effect that only a third of the estimated 60 million 
doses global need for ART-LUM could be met by Novartis, and that most of these doses 
will only be delivered towards the end of 2005 
('http://mosQuito.who.int/rbm/Attachment/20041108/pr8nov2004.htm). The WHO thus 
recommended that countries increase procurement of their second-line drug; an advice that 
is unlikely to be heeded in Kenya since the second-line drug is oral quinine (both old and
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proposed policy), a drug that is regarded as a reserve drug (and whose increased use will 
most likely meet stiff opposition).
Figure 2.9: Position map of important stakeholders regarding implementation o f ART- 
LUM, the new first-line AM policy in Kenya.
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2.8 Summary
Kenya is a poor developing country with a declining health status o f its population since 
the early 1990s. In the same period, key economic indicators have been on the decline with 
negative growth being registered in the year 2000. In addition, the country witnessed 
momentous political changes, especially in the past two years, and is still in a state of 
political transition. This chapter reviewed the malaria situation, treatment seeking for 
fevers and for malaria, antimalarial drug resistance, and drug policy changes in the country 
in the context o f this socio-economic and political environment.
The review showed that malaria is a disease o f major public health importance in Kenya 
predominantly affecting children below the age o f five and pregnant women. The chapter 
also demonstrated that Kenyans seek treatment from a variety o f sources and that almost 
half of all fevers are self-medicated with drugs at home or those sourced from the retail
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sector. Malaria is taking its toll on Kenyans against a backdrop of declining efficacy of 
previously effective and cheap therapeutics like CQ and SP.
Increasing resistance to first-line antimalarial drugs in Kenya has resulted in a policy 
change twice in the past decade: first from CQ to SP in 1998, then from SP to ART-LUM 
in 2004. The work described in this thesis started at a time when SP and AQ 
monotherapies were showing decreased efficacy but there was no suggestion of changing 
policy, while the thesis was written at a time of precipitous decline in SP efficacy and 
emerging evidence of decline in AQ efficacy by day 28 in Kenya and in the sub-region. 
Internationally, the thesis was written amidst a push towards ACT by an increasingly vocal 
malaria epistemic community and at a time when there was a stated WHO policy of 
making sure countries in the region changed failing first-line AM monotherapy to the more 
efficacious, albeit expensive ACTs. The chapter demonstrated that from the available 
ACTs, Kenya had one option: ART-LUM, which was adopted following a national 
consultative process that included national and international stakeholders. The evidence 
also suggested that AM drug policy change in Kenya was not a linear, predictable and 
scientific process, but an iterative, both scientific and political one where powerful groups 
or individuals could impede change.
The proposed policy has not been implemented, largely due to concerns on financial 
sustainability. International hinds through GFATM would probably have allayed these 
fears and kick-started the process, but the Round IV agreement has not been signed to free 
up necessary monies to procure ART-LUM in appreciable quantities (although such 
procurement would now run into supply difficulties as mentioned in 2.7.3.2). Further, the 
proposed staggered implementation of the policy, concentrating first on the formal sector 
and slowly progressing to the private sector, has left the latter unsupported and with no
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obvious direction. Ultimately, the proposed engagement of the private sector requires 
careful strategic leadership of the DOMC, formative research, and broadening involvement 
of stakeholders. Many of these stakeholders have, as shown in this chapter, been adverse to 
ART-LUM, forming the “Against” lobby-most notably the local pharma industry. How to 
bring the private sector and its suppliers into the future drug policy implementation will 
pose a large challenge. The likely scenario of ignoring this sector in terms of community 
effectiveness of interventions is discussed in Chapter 8.
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CHAPTER 3:
Legal and policy framework for the regulation 
of antimalarial drugs in Kenya
3.1 Introduction
The regulation of the health sector in general and that of the pharmaceutical sector in low- 
and middle-income countries (LMICs) has been studied in a number of countries (Stenson 
et al., 1997; Hongoro & Kumaranayake, 2000; Kumaranayake et al., 2000; Meng et al., 
2000; Soderlund & Hansl, 2000; Soderlund & Tangcharoensathien, 2000; Stenson et al., 
2001; Kumaranayake et al., 2003). Soderlund & Tangcharoensathien (2000) propose that 
regulation of the private sector in LMICs in general can be conceptualised as occurring in 
phases of regulatory maturity: pre-regulation, “paper” regulation, mature regulatory 
response (consisting of appropriate, focused regulation, regulatory capture or over­
regulation) and deregulation. In the pre-regulation phase, private sector activity is either 
banned or ignored, for instance in China (Meng et al., 2000), because this is seen as an 
admission that the government is unable to provide essential services to its citizens. In the 
“paper” regulation stage, legislative efforts are made to regulate private health care 
provision, but such efforts are hardly enforced. This best describes regulation of the private 
health care providers in most of sub-Saharan Africa (Hongoro & Kumaranayake, 2000; 
Kumaranayake et al., 2000; 2003) and some parts of south-east Asia (Stenson et al., 1997; 
2001). In the third phase, i.e. mature regulatory response, the ideal situation is when 
governments liase with the private sector to find out what the challenges are and seek 
appropriate solutions for those challenges. In some cases however, the governments either 
end up serving the interests of the private sector more than those of public health 
(regulatory capture) or end-up over-regulating the private sector. In some instances, 
regulatory outcomes are deemed adverse, resulting in calls for de-regulation as was the 
case of the South African health insurance industry in the 1980s (Soderlund & Hansl, 
2000).
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With regard to drug regulation, drugs are an essential health commodity and need to be 
regulated to save lives and improve health. Drug regulation is achieved by way of legal and 
policy provisions that set lip the structures and processes that are needed to ensure public 
health. Contemporary drug regulation involves a number of tasks which include licensing 
and inspection of premises and professionals, licensing and inspection of manufacturers, 
drug registration and post-marketing surveillance (Quick et al., 1997). Theoretically, the 
drug registration process, by which national governments approve (or reject) a drug for 
commercialisation and marketing, is the gateway to drug supply in a country.
This chapter seeks to examine how antimalarial (AM) drugs find their way into the market 
by way of the drug registration process in Kenya and how they are regulated thereafter. 
Not only does AM drug regulation affect the level at which AM products are used (by way 
of drug scheduling) thus affecting access to much needed therapy in Kenya, but it also 
affects overall drug effectiveness. A poorly regulated system will most likely result in the 
presence of sub-standard drugs in the market (Chapter 6), which reduce the effectiveness 
of the products used to treat malaria (Chapter 7) and may lead to patient complications or 
death. Newly registered AM products are used to demonstrate the process, criteria and 
post-marketing surveillance for drugs under ordinary use in Kenya. This is done by way of 
a literature review, supplemented by interviews with key informants to demonstrate the 
view and experiences of a cross-section of stakeholders on drug regulation in Kenya.
3.2 Methods
A mixed-model comprising interviews and documentary review was used to gather data on 
drug regulation in Kenya (Abraham & Lewis, 2000; Lang, 2003). A thorough search of the 
literature on drug regulation was undertaken. This was followed by semi-structured 
interviews with key informants in academia, industry and the Pharmacy and Poisons Board
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to supplement information gathered from published sources and reports. Although there are 
many stakeholders in drug regulation, the key ones are industry (regulated), the drug 
regulatory authority (regulator), and academia. Apart from playing a key role in drug 
discovery and development, academics also sit on advisory boards that make regulatory 
decisions. In Kenya for instance, the PPB has a Committee for Drug Registration (CDR) 
on which a member of the Faculty of Pharmacy, University of Nairobi, represents 
members of academia. Secondly, it is also common for academics to provide consultancy 
services to industry.
A complementary qualitative approach (complementary to literature review) was used 
because of its obvious advantages. Not only is it a rapid way of collecting data, but also it 
is known that what is documented is not what always happens on the ground. For instance 
although drugs are registered on the basis of safety, quality and efficacy in most countries, 
there have been several reports of substandard drugs circulating in the markets of sub- 
Saharan Africa (Chapter 6). Furthermore, unregistered drugs also circulate in these markets 
(Chapter 5). In addition, the qualitative approach would provide an understanding of the 
views and experiences of the people involved in formulating and/or implementing 
regulatory decisions and thus help explain the context in which drug regulation takes place. 
Informants and companies were assured of their anonymity or that of their products to 
ensure cooperation, therefore no reference is made to specific informants or products in 
this thesis (Table 3.1). Instead, a coding scheme consisting o f the country (e.g. KEN for 
Kenya), sector (REG for regulator) and interviewee (1,2, etc) has been used and AMI and 
AM2 used to denote the two antimalarial products used to illustrate process and criteria for 
antimalarial drug registration.
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Table 3.1: Persons and organisations whose views and experiences on drug regulation in 
Kenya were sought in 2004
Study Site Academia Industry Regulator
Kenya Senior Researcher in Malaria and 
Clinical Pharmacologist 
Senior Lecturer in Pharmaceutical 
Chemistry
Regulatory Affairs 
Manager, Large Scale 
Local Manufacturer o f  
branded generics
Senior Regulator in 
Drug Registration, 
Pharmacy & Poisons 
Board (PPB).
Junior Regulator, Drug 
Registration, Pharmacy 
and Poisons Board, 
Kenya
Piloting *Supervisors Regulatory Affairs 
Manager o f  a Large Scale 
Importer and Distributor 
o f  pharmaceuticals in 
Kenya.
Senior Regulator, 
Pharmacy and Poisons 
Board, Zambia
* Background interviews were also conducted with Kenyan supervisors.
3.2.1 Procedures
Potential interviewees in the various sectors were identified in consultation with PhD 
supervisors and contacted for permission to interview them at a convenient date. 
Interviews were mostly conducted via telephone in a standardised manner and were tape- 
recorded (with the consent of the interviewees). The use of telephone was occasioned by 
time and resource constraints. Interviewee confidentiality was maintained at all times. The 
interview schedules were developed further by brainstorming with experienced people 
outside the target group and piloted in a similar group to the target group. The definitive 
interview schedules (see Appendix I for an example) were e-mailed to the final group of 
respondents and a follow-up appointment arranged for the interviews. The advantages of 
telephone interviews rest on their relative anonymity and the ability to talk to respondents 
in widely varying geographical locations. Telephone interviews also tend to be shorter and 
proceed in a brisk, business-like manner. Doubts have been raised about the quality of 
telephone interviews compared with face-to-face interviews (Donovan et al., 1997), but 
these have largely been discounted (Komer-Bitensky et al., 1991; van Wijck et al., 1998; 
Greenfield et al., 2000).
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3.2.2 Qualitative data analysis
Data analysis followed a Framework Analysis method, popular in health-related research 
and developed in the context of applied policy research. Analysis involved the following 
key stages as suggested by Ritchie and Spencer (1994): familiarisation, identifying a 
thematic framework, indexing, charting, mapping and interpretation.
1. Familiarisation: interview transcription, reading and re-reading
2. Identifying a thematic framework: development of coding framework both from a 
priori issues in drug regulation and from emergent themes from interviews
3. Indexing: applying thematic framework to the data using numerical or textual codes
4. Charting: developing thematic charts
5. Mapping and interpretation: searching for patterns, associations, concepts and 
explanations in data for observations
3.3 Results
The flow of medicines in Kenya and the place of regulation in medicines control can best 
be visualised by way of the drug management cycle which has the following key elements: 
selection, procurement, distribution and use (Figure 3.1). The four arms of the drug 
management cycle require management support and also rest on a policy and legal 
framework (Quick et al., 1997).
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Figure 3.1: Elements of the drug management cycle (Quick et al., 1997)
Selection
M anagement Support
Organization 
Financing 
Information Management 
Human Resources
ProcurementUse
Distribution
Policy and Legal Framework
3.3.1 Drug management cycle in Kenya: the fo u r  arms
In Kenya, drugs for procurement for the government public sector are selected from the 
Kenya Essential Drugs List (KEDL). This list was first published in 1981 (revised twice 
thereafter, in 1992 and in 2003) and based on the WHO model list of essential drugs, 
developed for all levels of healthcare (MoH, 1993). Drugs for the government sector were 
originally procured by an independent procurement agency (Crown Agents) by way of an 
annual international open tender (occasionally through restricted tenders), although the 
Kenya Medical Supplies Agency (KEMSA) is increasingly taking this role (Interview with 
KENAC1, 19/03/04). KEMSA is a government parastatal12 which replaced the former 
Medical Supplies Coordinating Unit (MSCU) of the Ministry of Health (MoH) and its
12 The term “parastatal” in Kenya refers to a semi-autonomous body that receives part of its funding from the 
government, but also has a mandate to generate its own funds. It is synonymous with “trading-fund status” in 
British parlance and such a body can thus sue or be sued.
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mandate includes procuring, warehousing and distribution of drugs to government 
facilities. Three departments within KEMSA procure drugs and medical supplies. These 
are the office of the pharmacist-in-charge that procures pharmaceuticals; the supplies 
department, which procures non-drug supplies; and a laboratory manager who procures 
laboratory reagents and equipment. These three departments are advised by a procurement 
committee, which meets twice a month. Decisions are passed to the Permanent Secretary in 
the MoH who is part of a Ministerial Tender Board. However, Kenyatta National Hospital, 
the national referral hospital (which is a parastatal of its own), is not part of this pooled 
procurement system and does its own procurement. Further, AM drugs are procured on 
behalf o f the government by a consortium composed of KEMSA, Crown Agents, the 
German Technical Cooperation Agency (GTZ) and John Snow Inc. (JSI), established in 
response to management prerequisites for monies disbursed by the Global Fund for AIDS, 
TB and Malaria (GFATM) (Tetteh & Mwangi, 2004).
After drugs have been procured by KEMSA from a given supplier, they are delivered to 
the central warehouse in Nairobi by the suppliers or to eight regional warehouses from 
where the drugs are distributed to the rest of the country (Figure 3.2). Nairobi and its 
adjacent districts (e.g. Makueni, Kajiado, Machakos) obtain their drug requirements from 
the central warehouse whereas other districts obtain drugs from the regional warehouses in 
the provincial headquarters. Provincial General Hospitals (PGHs) and District Hospitals 
(DHs) obtain their drug supplies either from the central or regional warehouses, depending 
on their location. Health Centres and facilities at the lower level of health care receive their 
drug requirements from the DHs. In addition to the central and regional warehouses, 
KEMSA manages warehouses for vertical programmes such as the Kenya Enhanced 
Programme for Immunization (KEPI) and the National Leprosy and TB Programme 
(NLTP) (Tetteh & Mwangi, 2004).
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Although now in a transition, drug distribution to the government health facilities is 
predominantly through a kit or the so-called “push” system. Depending on the level of care 
(primary, secondary, tertiary), different hospitals or clinics will receive different kits. Table
3.2 shows examples o f AM drugs contained in government kits for the financial year 
2001/2002 (Dr C Kandie, personal communication). Not all AM drugs are supplied by way 
of kits. AQ for instance is supplied loose to all facilities. Also, AM drugs to PGHs, DHs 
and sub-district hospitals (SDHs) are supplied loose in line with the fact that since July 
2003 KEMSA has been operating a requisition-based or “pull” system for these types of 
facilities (Tetteh & Mwangi, 2004). At present, KEMSA is undergoing some 
reorganization and a pilot study of a fully decentralized drug supply system is underway in 
Nyamira District. The key elements of this strategy are: giving the districts seed money 
(Revolving Drug Fund), districts determining their own drug requirements, then 
purchasing these from whatever source at competitive prices, all part of the health sector 
reform predicated on decentralization and taking services closer to the people (Interview 
withKENACl, 19/03/04).
Table 3.2: Antimalarial drug contents of Government of Kenya kits for the financial year 
2001/2002 (Dr C Kandie, personal communication).
Kit Type Item Description Unit Pack Quantity
Dispensary Ration Kit IIA Sulfadoxine/pyrimethamne tablets USP (500:25mg) 1000 2
Dispensary Ration Kit IIB Sulfadoxine/pyrimethamne tablets USP (500:25mg) 1000 1
Health Centre Ration Kit IIA Sulfadoxine/pyrimethamne tablets USP (500:25mg) 1000 3
Health Centre Ration Kit IIB Sulfadoxine/pyrimethamne tablets USP (500:25mg) 1000 1
Out-Patient (OPD Standard Kit) Sulfadoxine/pyrimethamne tablets USP (500:25mg) 1000 4
Quinine Bisulphate Tablets BP 300mg (film-coated) 1000 3
Quinine Paediatric Oral Drops BP/USP lOmg/drop (20%) 15 ml bottles 10
Hospital In-Patient Kit Quinine Dihydrochloride Injection BP 300mg/ml 2ml ampoules 500
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The mission and non-governmental organisations that provide substantial healthcare in 
Kenya (Chapter 2) largely follow a similar selection and procurement system, but may 
differ in how they distribute drugs. For instance the Mission for Essential Drugs and 
Supplies (MEDS), which supplies drugs and medical appliances to the mission sector, uses 
a “pull” system whereby hospitals and clinics requisition for what they need as opposed to 
all hospitals or clinics of a given level of care receiving a uniform kit (Quick et al., 1997).
Drug use in Kenya is ideally controlled by the use of national standard treatment guidelines 
and for some specific diseases categories like malaria there are, in addition, specialised 
treatment guidelines (MoH, 1994a; DOMC, 1998). Details of antimalarial drug use in 
Kenya are covered in Chapters 2 and 4.
Whilst it has been possible to describe drug supply in the mission and GoK sectors in detail 
above, the private sector poses a challenge. Not much is known about drug supply in this 
sector except that 1) almost half of essential drugs are supplied by this sector (Foster, 
1991), and 2) that selection, procurement, distribution, and use follows market forces 
(Interview with KENAC1, 19/03/04). Chapter 5 partially redresses this knowledge gap, but 
as will be shown, there is scope for more formative research.
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Figure 3.2: KEMSA government of Kenya central drug distribution system (Tetteh & 
Mwangi, 2004).
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3.3.2 Drug management cycle: the policy and legal framework for drugs in Kenya 
The Policy framework for drugs in Kenya is espoused in a Kenya National Drug Policy 
(KNDP) document, published in 1994. Inspired by the WHO essential drugs concept, 
KNDP’s main goal was to “...use available resources to develop pharmaceutical services 
to meet the requirements of all Kenyans in the prevention, diagnosis and treatment of 
diseases using efficacious, high quality, safe and cost effective pharmaceutical products.”. 
This goal was to be achieved via specific objectives, which captured five key elements for 
both human and veterinary medicines: availability, affordability, rational use, quality and 
local manufacture of medicines in Kenya (MoH, 1994b). An implementation programme- 
The Kenya National Drug Policy Implementation Programme (KNDPIP)-funded by both 
the government and development partners (mainly the Dutch Government) was quickly put 
in place. The national drug policy was to be implemented in phases and backed up by 
legislative changes to existing laws on medicines in Kenya. A mid-term review of 
KNDPIP was completed in February 1998 and three main components identified as being 
of immediate priority and relevance to reform the pharmaceutical sector (PPB, 1999). 
These were:
1. Drug regulation and control
2. Drug selection and procurement
3. Education and training
Although the success of the KNDIP is debatable, it has nonetheless given birth to a number 
of guidelines which it is envisaged will receive legislative backing with the revision of the 
Pharmacy and Poisons Act, Chapter 244 of the laws of Kenya (Interviews with KENAC1, 
19/03/04). Examples of these guidelines are those on drug donations (MoH, 2001b), safe 
disposal of pharmaceutical waste (MoH, 2001c), and clinical guidelines (MoH, 1994a).
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The KNDP proposed to promote the same principals of drug management in the private 
sector, but these obviously have not been achieved as evidenced by 1) high and inequitably 
priced essential drugs in this sector (Chapter 5); 2) importation of a substantial part of 
essential drugs (Chapter 5); and 3) the presence of sub-standard products in the market 
(Chapter 6).
3.3.3 History o f drug regulation in Kenya
Like most other Commonwealth countries, drug laws, and indeed other laws in Kenya are a 
legacy of British colonial rule. Kenya attained her independence from Great Britain on 
June 12th 1963.
In the early days, the colonial authority introduced training courses for Kenyans in 
compounding and dressing of wounds. 1927 saw the introduction of a two-year course 
leading to the African Compounder Certificate “A”. A course for the dressing of wounds 
which was in operation as far back as the First World War later matured into nursing 
training (Ombega, 1999). 1933 saw the commencement of the Dangerous Drugs Act which 
sought to regulate “.. .the importation, exportation, manufacture, sale and use of opium and 
other dangerous drugs” (GoK, 1992). On May 1st 1957, the Pharmacy and Poisons Act 
Chapter 244 of the Laws of Kenya came into operation and has been the cornerstone of 
drug regulation in Kenya ever since. Drug registration procedures, however, did not begin 
until much later (April of 1982) after the Ministry of Health gazetted the Pharmacy and 
Poisons (Registration of Drugs) rules 1981 (PPB 1996). Apart from miscellaneous 
amendments from time to time (e.g. revision of penalties), the Pharmacy and Poisons Act 
has not undergone a comprehensive and extensive review (Ombega, 1999).
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3.3.4 Key drug legislation and associated structures
In theory, there are many acts and laws dealing with drugs and poisons in Kenya. Drugs 
and poisons are controlled by the Dangerous Drugs Act, the Food Drugs and Chemical 
Substances Act, the Pest Control Act, among others. In addition, there are acts of 
parliament, which regulate the various groups of professionals who handle drugs and 
poisons on a day-to-day basis e.g. the Medical Practitioners and Dentists Act, the Nurses 
Act, and the Clinical Officers Act. In practice however, drugs in ordinary use (e.g. the sale 
and distribution of AM drugs) are largely covered under the Pharmacy and Poisons Act 
1957. This legislation and its related administrative structures are covered in detail below.
3.3.5 Pharmacy and Poisons Act 1957 and the Pharmacy and Poisons Board (PPB)
The mission o f the Pharmacy and Poisons Board (PPB) is “.. ..to implement the appropriate 
regulatory measures to achieve the highest standards of safety, efficacy and quality for all 
drugs, chemical substances and medical devices, locally manufactured, imported, exported, 
distributed, sold, or used, to ensure the protection of the consumer as envisaged by the laws 
regulating drugs in force in Kenya...”. The PPB was established by the Pharmacy and 
Poisons Act 1957, which was enacted just before independence. In its current form, the 
PPB is part of the Pharmacy Department of the MoH. At the top of the hierarchy is the 
Minister of Health, followed by the PPB. In line with its broad functions, PPB operations 
are divided into five main sections as shown in Figure 3.3. The Registrar is in direct 
control of all five sections. Although a separate office, the Registrar doubles up as the 
Chief Pharmacist (CP) in Kenya. The PPB became a body corporate in 1993 and can 
generate (and use) its own funds from its regulatory activities. In addition, the PPB 
receives salaried civil servants from the MoH to run some of its operations.
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As it is currently constituted, the PPB members comprise the following:
1. Chairman (Director of Medical Services, MoH),
2. Registrar (CP) who acts as the Secretary
3. Director of Veterinary Services,
4. Pharmacists (4) nominated by the Pharmaceutical Society of Kenya (PSK) of
whom one is from the Civil Service, one from Community Pharmacy, one from the
Pharmaceutical Industry and one from academia (a representative from University 
of Nairobi’s Faculty of Pharmacy)
5. Pharmaceutical Technologist
Figure 3.3: Organisational Structure of the Department of Pharmacy in the Ministry of 
Health, Kenya (MoH, undated).
Pharmacy & Poisons Board
Registrar
Administration
Pharmaceutical Inspectorate —1
NQCL
Drug Registration Drug Information
Minister of Health
The Pharmaceutical Inspectorate department monitors and evaluates industry compliance 
with the WHO GMP guidelines by regularly inspecting pharmaceutical manufacturing 
plants. Currently there are about 90 pharmaceutical companies (Odhiambo, 1999), 
approximately 40 of which manufacture products locally. The department was set up under 
the KNDIP in 1994, but started its operations in May 1999. Inspection findings are 
presented before the PPB for action; concerned industries are also sent copies of the report
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and given between a month and a year to correct anomalies, depending on their nature13. 
MoH drug inspectors carry out inspection of drug distribution channels, although the 
Pharmaceutical Inspectorate is also mandated to do so. In reality, inspection focuses 
mainly on the urban centres that are readily accessible.
The National Quality Control Laboratory (NQCL) undertakes quality checks of drugs 
mostly for the purposes of drug registration, although it also receives samples from private 
companies and individuals. The laboratory is also mandated to monitor drug quality post­
registration. The CDR at the PPB forwards samples to NQCL for analysis. CDR is the 
single biggest client of the laboratory and because of constraints at NQCL (financial, 
personnel), decisions as to which samples should be taken for a quality check are ad hoc 
and based on the committee’s judgment. “Suspect” drugs (incomplete documentation, poor 
product aesthetics) or “critical” drugs (AM drugs, anti-TB, anti-epileptics, and Anti- 
Retrovirals) are theoretically given priority for quality checks. NQCL is a body corporate, 
which in theory is the technical arm of the PPB, however, its legal standing is not entirely 
clear. The laboratory gets personnel seconded from the MoH (mostly pharmacists) and 
employs technicians from its own financial vote.
3.3.6 Drug registration: process and criteria
Registration of drugs in Kenya came into effect in April 1982, after the MoH gazetted the 
Pharmacy & Poisons (Registration of Drugs) rules 1981, under the Pharmacy & Poisons 
Act chapter 244, Laws of Kenya (PPB, undated). The PPB registers all products intended 
for the Kenyan market, as well as those for export using product quality, safety, and 
efficacy as the three most important criteria. Although not yet operationalised, the KNDP
13 Anomalies are categorised into those Requiring Urgent Attention (RUA, given between one to three 
months e.g. lack of Standard Operating Procedures or Quality Control laboratory), Requiring Attention (RA, 
given four to nine months e.g. use of outdated analytical methods) and Requiring Consideration (RC, given 
up to a year e.g. poor positioning of stores).
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also proposed specific medical need, proposed wholesale and retail prices and unique 
characteristics (life-saving drugs and orphan drugs) as additional important criteria to 
consider when registering drugs (MoH, 1994b).
The PPB has committees of experts in various disciplines including pharmacology, 
pharmaceutics, pharmacodynamics, pharmaceutical analysis, industrial pharmacy, 
dermatology, and veterinary medicine. Drug registration is handled by the CDR. The 
committee vets all documentation accompanying the application for registration of a drug. 
Applicants fill in six copies of a standard form, submit six commercial packs of the 
candidate drug (the smallest) and sufficient documentation to back their claims. They also 
pay a fee o f USD 500 for Kenyan products and USD 1,000 for imported products per 
application.
The next step is the vetting process that is primarily confined to scrutiny o f documentation 
supporting the drug in terms of safety, quality, and efficacy. In addition, the packaging or 
aesthetics of the product are also considered. When documentation is deemed inadequate, 
applicants are requested to supply additional information. Successful applicants are given a 
letter of approval, which allows them to market their product in Kenya, pending gazetting 
and the final letter of registration. Registration is valid for 5 years, after which a re­
registration is sought from the CDR for another 5 years and so on ad infinitum. Registered 
drugs are scheduled into two broad parts (each with sub-parts): part I poisons which can 
only be dispensed by a registered pharmacist or part II poisons which may be dispensed by 
a registered pharmacist or a pharmaceutical technologist (Table 3.3). Drug schedules, 
however, are not adhered to in practice and it is not uncommon to find POM drugs like AQ 
sold OTC (Chapter 4).
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Table 3.3: Drug schedules in Kenya (MoH, 1994b).
Poison Schedule
Part I Schedule I-These are Prescription Only Medicines (POM) 
and require a prescription from a registered doctor (human 
or veterinary) or dentist. They may however be dispensed 
by a registered pharmacist in small quantities in 
emergencies i.e. where an authorised prescriber is 
unavailable.
Schedule II-These are Pharmacy Only Medicines and 
require a prescription from an authorized prescriber.
Part II Schedule Ill-Dispensed by registered pharmacists without a 
prescription or by a pharmaceutical technologist on 
prescription.
Schedule IV-Over the Counter (OTC) medicines. Can be 
sold on authorized outlets without a prescription.
Imported drugs intended for registration in Kenya must be accompanied by a certificate of 
free sale or certificate of pharmaceutical products (CPP) from the country of origin as proof 
that the products are fit for human use. In addition, importers are required by law to have an 
import licence as stipulated in Cap 244 and also fill the necessary import declaration forms 
per consignment (GoK, 1989).
3.3.7 Post-marketing surveillance: safety, quality, and efficacy.
There is no functional post-marketing surveillance of medicines in Kenya. Product quality 
can theoretically be monitored and indeed NQCL is mandated to do so, but due to financial 
and personnel constraints, this has not been possible in the past:
Interviewer: And are all [drug] products taken for ...for quality check to the national 
quality control laboratory [NQCL] or are there certain products, which are taken there? 
KENREG2: Not all of them because there are quite a number; they [NQCL] would not 
cope. We just take the problematic products like antimalarials, anti-TBs and some 
antibiotics, carbamazepines and quite a number ...of those we think will require...by 
looking at it you can actually tell this one should go to the lab. And if there is a new 
company from India or elsewhere [whose products] we don’t know the trend of the quality, 
we send for analysis (Interview with KENREG2, 02/08/04).
There is no functional mechanism for monitoring safety or efficacy of medicines in Kenya 
either (interviews with KENAC1, 19/03/04; KENAC2, 07/07/04; KENIND, 30/06/04;
105
KENREG1, 05/07/04; KENREG2, 02/08/04). However, some disease specific programmes 
like the National Malaria Control Programme (NMCP) do limited monitoring of the 
efficacy of antimalarial drugs through a regional network for monitoring malaria therapy- 
the East African Network for Monitoring Antimalarial Therapy (Chapter 2). Further, there 
is no institutional framework for evaluating drug effectiveness in routine clinical use in 
Kenya; only limited efficacy testing (not effectiveness) is done and only for specific 
disease categories like malaria (Chapter 2).
3.3.8 Views and experiences o f industry, academia, and the PPB on drug regulation
3.3.8.1 Process and criteria fo r  drug registration
In Kenya, product dossiers are submitted to the PPB, which forwards these to a committee 
of experts that evaluates the dossier for registration (CDR). The PPB lacks its own internal 
capacity for product evaluation; it relies entirely on expert advice:
KENREG1: ...We normally have ... a drug registration committee, this is a committee of 
experts involving people who have expertise in pharmaceutical areas, others have expertise 
in clinical areas. Now, the application is in such a way that the pharmaceutical 
documentation will be evaluated by these pharmaceutical experts and the clinical 
documentation evaluated by the clinical experts. They will be able to make their comments 
and if need be that more information be submitted then they are able to communicate and 
send to the applicants. During the evaluation process, depending on the product, the 
samples may also be submitted to the laboratory [NQCL] for evaluation where the analysis 
has to be carried out. Now, depending on the outcome of both the documentation and the 
analysis, that is the time whatever comes out of that is what the applicant is normally told. 
Now, in the event that all of them are satisfactory, then the product is 
evaluated.. .recommended for registration (Interview with KENREG1, 05/07/04).
KENREG2:  we have a committee on drug registration [CDR] and we have a
chairman who is a medical doctor, right now. Then that committee looks at the documents 
[dossier], which have been submitted, and then they come up with their comments, which 
we take as the secretariat. There are three categories: either a product is deferred waiting 
various clarifications which we write to the company to bring more responses, the product 
can be recommended for registration to the Pharmacy and Poisons Board and the product 
can also be rejected if it does not fulfil the criteria for drug registration (Interview with 
KENREG2, 02/08/04).
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Antimalarial drugs and other drugs perceived to be important to public health are given 
priority in the regulatoiy pipeline than others i.e. a fast track mechanism exists for some 
products:
Interviewer: And on an average how long does the process.. .the registration process take? 
KENREG1: Now, when a product [licence] is applied for, there is normally some time 
taken before the document is evaluated ...on average, that takes around ...between... 
around six months on average, even though for priority products, like HIV 
preparations...antiretrovirals, we have a fast track [system] in place whereby within two to 
three months the product will have been evaluated...
Interviewer: And what is the rationale for fast tracking some products and not others? 
KENREG1: ...fast tracking some products is because ...for this particular market, the 
three indications .. .malaria, TB and HIV are considered to be contributing to a lot of the 
disease burden and ...there is always a lot of pressure to be able to have as many 
preparations as possible for this indications and it’s always been the Ministry’s policy also 
to try and fast track products for this particular indications (Interview with KENREG1, 
05/07/04).
It is also accepted that safety, quality, and efficacy are the criteria on which drug 
registration is based in Kenya. However, there is a perception that the process and criteria 
are not rigorously enforced. This is mostly explained in terms of little resources available 
to the PPB. This view however is not universal and some interviewees were of the opinion 
that there is an overarching structural problem with drug regulation in Kenya ranging from 
lack of independence of the PPB, deficiencies or contradictions in the legal framework for 
drug regulation, lack of an effective post-marketing surveillance for drugs, inadequate 
penalties imposed on those in contravention of the drug laws, to lack of political will to 
enforce the letter of the law. An oft-repeated example is that o f police officers with scant 
knowledge of pharmaceuticals doing drug inspections (Interviews with KENAC1, 
19/03/04; KENIND, 30/06/04; KENAC2, 07/07/04).
33.8.2 Illustrative case studies o f  registration o f  AM  drugs, the case o f  AM I and AM2 
This section summarises the salient points for selected AM drugs used to illustrate process 
and criteria and perceptions of the various players in the interviews. Although there were
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other products scheduled to be reviewed before it, AMI (from a multinational company) 
was put on the priority list in Kenya since it was for malaria. However, the process took 
longer than would have been the case since the NQCL did not have the required 
chromatographic column for analysing the product (Interview with KENREG1, 05/07/04). 
In addition, AMI was the first product in Kenya to make an electronic submission for 
registration (Interview with KENREG2, 02/08/04). The product took about six to eight 
months to be registered (Interview with KENREG1, 05/07/04).
KENREG1: .. .we put it [AMI] among the list of priority products because it is an anti­
malarial and because by the time it came we had already done scheduling for the next 
several weeks; but we put it on line so that it could definitely be in queue for evaluation. 
Now after ...once its time came it was evaluated. It was also sent for analysis because 
.. .for.. .that is what we do with all anti-malarials, anti-TB’s and any HIV preparations that 
the products have to be evaluated. What happened... the problem that arose is that ...the 
laboratory did not have.. .could not be able to analyse the product because in the analysis 
of the product it required a special column and ...what happened is that ...it delayed the 
process of registration because the documentation it went through ...after a few 
clarifications here and there which we were able to sort out. The analysis is what now 
started delaying the process .. .because of the .. .because of the hiccup in the analysis .. .but 
that was sorted out after a while and it was analysed. The results were found satisfactory 
and it was registered (Interview with KENREG1, 05/07/04).
There was a perception that the letter of the law was applied more strictly for local 
manufacturers (AM2) than was the case for large multinational companies who were given 
the benefit o f the doubt (Interview with KENIND, 30/06/04). The case of AM2 also 
brought to the fore the disconnect between the national antimalarial drug policy and drug 
registration. The national antimalarial drug policy recommends the use of combination 
therapies (specifically, ART-LUM) and for this reason discourages registration and use of 
antimalarial monotherapies (Chapter 2). However, by law, manufacturers are only required 
to prove the safety, efficacy, and quality o f their products (mostly in line with 
internationally recognised pharmacopoeia) and whether or not certain vertical programmes 
in the country adopt such products is considered to be outside the realm of registration. In
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order for the local companies to ‘profit’ from national policy, they need to provide what 
the policy demands, failure of which results in exclusion:
KENIND: Secondly, because it is a newer product, the drug registration and the malaria 
control programme policies don’t seem...they don’t synergise each other. Whereas AM2 is 
required [in the] pharmacopoeia, the monographs, Martindale’s and so forth will give five 
to seven days treatment, the malaria control programme will want it to be used for three 
days in combination and they are discouraging use as a single molecule. In effect, when we 
want to fulfil drug registration requirements, you’ve got to go with what is 
pharmacopoeial; and that is a seven day treatment regime, which is now different from 
what the situation is locally. In which case, there is no adaptation. In as much as we would 
like to adapt to the local situation, we cannot do because the two institutions are not...they 
don’t work.. .the are not harmonised (Interview with KENIND, 30/06/04).
KENREG1: Now the need...the issue of people saying that the drug registration working 
with the National] Malaria [Control] Programme, I think there is still a lot of work required 
in terms of probably coordinating so that they can be able to know what is available within 
the country because .. .it would be useful to know probably which other options, how many 
different options, but these are issues which even the companies are able to pick up 
because by the time they are putting in applications for registration they will have 
monitored what is selling out there and in terms of registration, we normally register based 
on documentation also and based on evidence. So the registration is normally not just for 
the purpose of registration, but there is also information that is provided to support the 
applications. Of course, the ones which have been registered, are the ones which have 
actually been able to prove that the drugs can actually work. There are so many others 
which have been registered...which have been rejected which probably could not be able 
to justify the reasons why they are putting forward the applications (Interview with 
KENREG1, 05/07/04).
Adding to this layer of policy disconnect is the inclusion of some artemisinin 
monotherapies like dihydroartemisinin in the latest edition of the KEDL (MoH, 2003), on 
which public sector procurement by KEMSA is largely based, although not legally binding 
(Section 3.3.1).
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3.4 Discussion
Whilst this chapter was meant to be a descriptive one laying out the country drug 
regulatory context for Kenya, and not a substantive one designed to contribute to the 
literature on regulation of the health sector and that of the pharmaceutical sector, it does 
nonetheless suggest that Kenya is probably in the “paper” regulation phase of Soderlund & 
Tangcharoensathien (2000); the legislative framework for effective drug regulation exists 
on paper, but this is rarely enforced. Indeed, the WHO estimates that only 17% of member 
states have well-developed drug regulatory capacity, 50% show varying levels of 
development and operational capacity and the rest have no drug regulatory authority 
(DRA) or the DRAs capacity is weak (WHO, 1999). This means that even if  there was 
political will to enforce drug-related regulations, the infrastructure in most countries is 
either lacking or wanting.
3.4.1 Criteria for drug registration
Traditionally, safety, quality, and efficacy are the criteria on which regulatory decisions are 
made (Videau, 2001; Waller, 2001). Although the cost of drugs is not a requirement at the 
point of registration in most countries (Videau, 2001), cost to the public sector is 
sometimes regulated, albeit indirectly. In developing countries like Kenya, this is done by 
way of the concept of essential drugs whose selection criteria involves cost as one of the 
considerations (MoH, 1994b), i.e. “a white list” of drugs to be used in a country is 
developed from registered alternatives. In developed countries like the UK, costs are 
contained by way of reimbursement schemes that place maximum allowable profits on 
drugs sold to the public sector (NAO, 2003), effectively “black-listing” products that will 
not be reimbursed by the health care system.
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3.4.2 Drug registration process
The registration process entails scrutiny of evidence submitted to regulators by the licence 
applicant. A company that wants to register a product in any given country will typically 
prepare what is termed a dossier for evaluation by the country’s drug regulatory authority 
(DRA). The dossier contains evidence as to the safety and efficacy of the drug’s active 
pharmaceutical ingredient (API) from the clinical trial data and the quality of the finished 
product. The dossier will also contain information on all aspects of the pharmaceutical 
manufacturing process. The type and amount of information and the level of scrutiny 
differs, depending on whether the drug is a new chemical substance or a generic. Generic 
drugs are manufactured after the patent period has expired for the originator or innovator 
product. In most countries, for new chemical substances, primary safety and clinical 
efficacy data are required. For generic products, however, the requirements are less 
stringent. This is because the drug molecule has been in use for a long time (typically 
patent periods range from 17 to 20 years) and its safety and efficacy are arguably well 
established. Hence, it is sufficient to demonstrate bioequivalence14 or pharmaceutical 
equivalence with the innovator or originator product.
3.4.3 Limitations o f drug registration and need for post-marketing surveillance
Drug registration process in Kenya is largely perceived as working (Tor those drugs which 
pass through it) and it is generally agreed that this is probably the strongest element in the 
Kenyan regulatory regime (Interviews with KENREG1, 05/07/04; KENAC2, 07/07/04; 
KENREG2, 02/08/04). However, the drug registration process has an inherent limitation, 
and more so for Kenya where only half the products pass through registration. By the time
a product is brought to market, only a few thousand people (about 2000) would have been
14 "Pharmaceutical equivalents" are drug products that contain identical active ingredients and are identical in strength or 
concentration, dosage form, and route o f administration. However, pharmaceutical equivalents do not necessarily contain 
the same inactive ingredients; various manufacturers' dosage forms may differ in colour, flavour, shape, and excipients. 
The terms "pharmaceutical equivalents" and "chemical equivalents" are often used interchangeably. "Bioequivalence" is a 
comparison o f the bioavailability o f two or more drug products. Thus, two products or formulations containing the same 
active ingredient are bioequivalent if  their rates and extents o f absorption are the same.
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exposed to it by way of clinical trials. Secondly, drugs are tested on a very narrow group of 
patients, in a tightly controlled environment. Conversely, under routine use, patients 
excluded during the clinical trials (e.g. pregnant women and children) might well use the 
drug. Because of these limitations, regulators see the registration process as a means to 
ensure public health and not as an end in itself. Therefore, continuous monitoring of safety 
(by way of post-marketing surveillance) is needed in order to detect adverse drug events 
that can only be seen under mass use. There is no effective post-marketing surveillance 
system in Kenya for pharmaceuticals and the other domains of drug regulation (licensing 
and inspection of personnel, premises, etc) are also perceived to be ineffective (Interviews 
with KENAC1, 19/03/04; KENIND, 30/06/04; KENREG1, 05/07/04; KENAC2, 07/07/04; 
KENREG2, 02/08/04).
The consequences of a lack of post-marketing surveillance system in Kenya has been 
enormous. There are a substantial number o f unregistered products in circulation and 
whose safety, quality and efficacy cannot therefore be guaranteed (Chapter 5). In terms of 
quality, manufacturers and importers of drugs typically present very good quality products 
at the time of registration, but market sub-standard products afterwards (Interviews with 
KENAC1, 19/03/04; KENREG1, 05/07/04; KENAC2, 07/07/04). In addition, drugs that 
have been withdrawn from developed country markets are in circulation in developing 
country markets like Kenya. In 1998 for instance, the NQCL analysed an AM drug that 
was submitted for registration and which was purporting to contain sulfalene 
(sulfamethopyrazine), but which instead contained sulfamethopyridazine, a closely related 
substance with the same physico-chemical properties, but which had been banned for 
human use almost a decade earlier arid is now found only in veterinary products. 
Sulfamethopyridazine had been included in the WHO’s 1991 Consolidated List o f  
Products Whose Consumption, and/or Sale Have Been Banned, Withdrawn, Severely
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Restricted or not Approved by Governments (WHO, 1991). On further investigation, it was 
noted that indeed at least seven other brands of SP containing sulfamethopyridazine were 
in circulation and as such NQCL recommended that they be withdrawn (Dr E Ogaja, 
personal communication). It is possible that some of these products are still in circulation 
given that a substantial number of products do not pass through the regulatory pipeline at 
all (see Chapter 5). Although it can be argued that the presence of such drugs might be 
because of a risk: benefit assessment that favours the retention of such products in the 
market (e.g. in the case of chloramphenicol), the fact that a drug like SP with many 
branded options that include banned substances in circulation points to a weak regulatory 
environment. Ineffective drug regulation in Kenya has been attributed variously to 
inadequate human and financial resources, inadequate or conflicting policy and legislative 
provisions and lack of political will (Interviews with KENAC1, 19/03/04; KENIND, 
30/06/04; KENREG1, 05/07/04; KENAC2, 07/07/04; KENREG2, 02/08/04).
A key strategy that has hitherto remained unexplored in Kenya to redress these deficiencies 
in post-marketing surveillance is that of conditional licensing. Under such a scheme, if  
there are concerns about a product at the time of registration (for instance the safety of  
artemisinin-combination therapies like ART-LUM, Coartem®), the product(s) could be 
licensed subject to a pharmacovigilance system being set up by the applicant. Such a 
system would first transfer the burden of proof to the applicant and secondly it would 
circumvent passive reporting, which depends on a well functioning health care delivery 
system (which is lacking in Kenya). This would save money for resource-constrained 
developing country drug regulatory authorities in the short term and save lives in the end. 
Regardless of the strategies adopted, there is clearly a need to strengthen post-marketing 
surveillance system and enforcement o f best practices (e.g. GMP) in Kenya to ensure the 
continued safety, efficacy, and quality of antimalarial drugs post-registration.
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3.4.4 Implications o f the Kenyan regulatory environment for ART-LUM, the new first- 
line antimalarial policy
The ambiguities and weaknesses of the Kenyan regulatory system are brought into sharp 
focus by the current antimalarial drug policy change from SP to ART-LUM (see Chapter 2 
for the evidence leading to this decision). Apart from the financial hurdle in its way, ART- 
LUM faces a number of regulatory hurdles that need to be addressed if it is to be accessible 
to all Kenyans. There is only one fixed-dose, co-formulated ART-LUM available on the 
market, i.e. Coartem®, manufactured by Novartis Pharma AG. Coartem® has been offered 
to the WHO at a concessionary price of USD 0.90 and 2.40 per child and adult doses, 
respectively and this deal is intended only for the benefit o f the not-for-profit public sector 
facilities (WHO, 2003c). Countries requiring ART-LUM send their orders to WHO which 
procures on their behalf from Novartis. Some stakeholders in Kenya have queried the 
legality of this pooled procurement system since government tenders are usually awarded 
on a competitive basis and therefore term this arrangement ‘anticompetitive’. Such critics 
argue from the point of view that there are other artemisinin-based combination therapies 
(ACTs) on the market and that the government need not restrict itself to Coartem® (PSK, 
2004) Whereas such accusations are largely without scientific merit (because the other 
available ACTs are unsuitable for Kenya (AS-MEF) or are contrary to WHO policy (AQ- 
AS, AQ-SP), leaving only ART-LUM), they have nonetheless resulted in a hostile 
environment for Coartem® and a delay in its roll-out (Chapter 2).
The debate on Coartem® has also brought to the fore the inconsistency of certain elements 
within the KNDP. Walley and colleagues (2000) argue that for a National Drug or 
Pharmaceutical Policy to work successfully, ‘each element should be complementary to all 
other elements, or at least neutral’. The National Malaria Control Programme (NMCP) 
advocates the use of ACTs (specifically Coartem®) and discourages the use of artemisinin
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monotherapies because of the risk of selecting resistant parasites. Therefore, the presence 
of these products in the market is seen as a threat to the national antimalarial drug policy 
(MoH, 2004b). The paradox is that by law, an arm of the KNDP-drug registration-is only 
allowed to look at the safety, quality, and efficacy of drugs seeking market approval (GoK, 
1989). The PPB contends that artemisinin monotherapies in the market have proved their 
safety, quality and efficacy and there is therefore no legal basis on which not to register 
them or to deregister existing ones if  need be (Interview with KENREG1, 05/07/04). 
Adding to this conundrum is the inclusion of artemisinin monotherapies like 
dihydroartemisinin in the KEDL, on which public sector drug procurement is largely based 
(MoH, 2003). Further, Coartem® is not included in the KEDL (MoH, 2004b). There is 
clearly a need to coordinate elements of the KNDP to ensure a coherent and mutually 
supportive policy framework for Coartem® in Kenya.
Coartem® was initially registered in Kenya as a four-dose regimen for the private sector 
and could only be obtained from pharmacies (Pharmacy Only medicine). Subsequent 
studies showed that a six-dose regimen was more efficacious and this is what has been 
registered for provision through the public sector through the WHO-Novartis agreement 
(Prof R Snow, personal communication). Two issues need to be addressed in this public- 
private dichotomy. First is how the four-dose regimen already in circulation in the private 
sector and that of failed drugs such as SP will be mopped up in an environment where 
there is no effective recall mechanism for drugs. Second, the exclusion of the private-for- 
profit sector in the WHO-Novartis agreement also means that there is an incentive for 
leakage of the product from the private sector to the public sector where it will fetch higher 
profits than the commercially available one. Although ‘public Coartem®’ and ‘private 
Coartem®’ have different packaging (see Figures 3.4 and 3.5), this has not stopped 
products marked GoK from being sold in the private sector in the past. One of the
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proposed strategies to minimise this is the introduction o f price controls in the private 
sector to a maximum of USD 2.40 per adult dose and USD 0.90 per child dose i.e. similar 
to what it would cost the government. The legality of such a measure in an environment of 
economic liberalisation remains to be seen and there are no obvious precedents for this.
Figure 3.4: Public sector Coartem®
Figure 3.5: Private sector Coartem*
Coartem® 20/120 d> N O V A R T I S
artemether.
lumafantrin.
Antipaludico
Antipaludtque
16 compr. 20/120 mg
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3.5 Summary
Drugs in Kenya are regulated by the PPB. The PPB licenses drug outlets, manufacturers, 
and distributors (channels); registers pharmacists and pharmaceutical technologists 
(personnel); and registers new products for the market. The PPB is also mandated to ensure 
drugs are safe, efficacious and of high standard of quality post-registration by way of post­
market surveillance (enforcement).
Interviews and documentary evidence revealed a number of shortcomings of the present 
framework. A substantial number of antimalarial drugs in Kenya do not pass through the 
registration pipeline (Chapter 5). Such drugs can only be detected through a functional 
post-marketing surveillance system. There is no functional post-marketing surveillance 
system in Kenya and this poses a logistical challenge to moping up failing antimalarial 
drugs like SP and generally unregistered and unsafe drugs in the market. For a national 
drug or pharmaceutical policy to work, each element should be complementary to all the 
other elements or at least neutral. There is a clear disconnect between some elements of the 
KNDIP such as drug registration and the objectives of some vertical programmes such as 
the National Malaria Control Programme’s antimalarial drug policy. There is need to 
harmonise elements of the KNDIP to make sure that none of the components undermines 
malaria control in Kenya.
Drug regulation in developing countries like Kenya is a challenging task and more needs to 
be invested to ensure the safety, quality and efficacy of drugs not only at the time of 
registration, but post-registration. The introduction of new single-source ACTs for malaria 
case-management present particular and new challenges to already fragile systems.
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CHAPTER 4:
Fever management practices and drug use 
among households in sentinel districts
118
4.1 Introduction
The basic premise that appropriate case-management will result in demonstrable gains in 
child survival depends critically upon whether the right drug (safe, efficacious and of 
acceptable quality) is administered at the correct dose as early as possible in the disease 
event and that treatment courses are completed (Goodman et al., 2001). African heads of 
State met in Abuja in April 2000 and agreed, as part of the Roll Back Malaria (RBM) 
initiative, to ensure that at least 60% of all fevers would be managed in this way by the 
year 2010 (WHO, 2000c). This objective is in line with the Kenya National Malaria 
Strategy (KNMS) described previously in Section 2.4.2. Chapter 2 provided the context of 
drug use and its role within the KNMS and the broader health sector, whilst Chapter 3 
described the structure and weaknesses of the legislative and regulatory framework for 
drugs in the formal health sector and the private sector. This chapter focuses on the 
sources, costs, timing, and types of treatment for fevers among children under five years of 
age in the four study districts. In addition, the extent to which current paediatric fever 
management falls short of anticipated targets set by the Kenyan government will be 
examined.
4.2 Materials and methods
4.2.1 Study sites
Snow et al. (1998) divided Kenya into areas of low, moderate, high, and unstable malaria 
endemicity (Section 2.3). The model has been simplified by the National Malaria Control 
Programme for planning and management of disease control with the country being 
divided into the following four areas (http://www.kmis.org. accessed 30/07/04):
1. Endemic areas: transmission common every year, immunity acquired by the 
community before adulthood and risks of disease and death from malaria are 
concentrated amongst children below five years and pregnant women.
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2. Highland, epidemic-prone areas: on an average year there is potential for limited 
transmission and therefore low risk of malaria, but variations in rainfall and 
ambient temperatures between years can lead to epidemics which may occur every 
three to five years.
3. Arid, epidemic prone-areas: unable to support the breeding o f malaria vectors 
except around either man-made water bodies or perennial rivers. Consequently, 
malaria infection risks are extremely low, locally acquired clinical disease is rare 
and the population do not develop immunity. However, unusual rainfall and 
flooding can lead to severe epidemic crisis conditions which although rare can lead 
to devastating levels o f disease and death among the entire population.
4. Low risk areas: these represent areas with exceptionally low risk of acquiring 
malaria infection.
Figure 4.1: Map of Kenya showing the study districts
Four districts were purposively sampled for 
this thesis in collaboration with the DOMC 
so that they may coincidentally form part of 
a baseline for monitoring progress towards 
targets set in the KNMS. The four districts 
were sampled to represent the various P. 
falciparum  ecological settings in Kenya and 
reflect the diverse population and climatic 
conditions across the country and 
coincident with DOMC districts used to 
monitor antimalarial drug sensitivity (Figure 4.1). Greater Kisii district was selected to 
represent an area of “highland” transmission; Kwale: seasonal, intense transmission; 
Bondo: perennial, intense transmission and Makueni; semi-arid, acute seasonal
transmission. A detailed description of each of the districts and their basic demographic,
health, literacy, and malariometric indicators follows.
In iuR  Ocean
Study Districts
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4.2.1.1 Greater Kisii
Greater Kisii, which covers a land area of 1,310 km2, comprises Kisii Central and Gucha 
districts and is one of the twelve districts that make up Nyanza province of Kenya. The 
district is in the western highlands at an altitude between 1400 to 2200 metres above sea 
level. The district lies between latitude 0.500° and 0.967°S and longitude 34.700° and 
35.083°E. The Abagusii, who are the main ethnic group in the district, are an agricultural 
community and grow both cash crops like tea, coffee and pyrethrum and subsistence crops 
like maize, beans, finger millet, potatoes, bananas and groundnuts for home consumption. 
The total population of the district during the 1999 national census was 952,725 people 
with a population density of 706 persons per square kilometre and children under five 
comprising 15.6% of the population (CBS, 2001a). The climate is highland equatorial and 
average annual rainfall is well above 1500 mm per annum. There are two main rainy 
seasons; the long rains, which occur from March to June, and the short rains from 
September to November. The 1999 national census revealed that 31.4% of Abagusii males 
(15 to 54 years of age) and 25.9% of Abagusii females remained economically inactive. 
The typical Abagusii house is made of mud and has an iron roof (CBS, 2001c). A 1994 
Central Bureau of Statistics (CBS) survey among 261 Abagusii children aged 6 to 60 
months showed that 40.6% of the children were stunted, 23.4% undernourished and 6.2% 
wasted (CBS, 1994).
4.2.1.2 Kwale
Kwale district covers a land area of 8,335 km2. The district is in Coast province of Kenya, 
near the border with Tanzania. Kwale is adjacent to the Indian Ocean on the southeast of 
the country and lies at an altitude range of 0 to 650 metres above sea level. The district lies 
between latitude 3.550° and 4.667°S and longitude 38.450° and 39.667°E (CBS, 2001a). 
The Mijikenda, who are the main ethnic group in the district, comprise nine sub-groups,
121
two (Wadigo and Waduruma) of which form the main inhabitants of Kwale with the other 
groups settling in other adjacent districts of Coast province (Mwangudzu, 1983). The main 
economic activity of the Mijikenda is agriculture with crop income accounting for almost a 
third of monthly household income in Kwale. The most commonly cultivated crops are 
maize, coconut, and cashew nuts. Tourism is also a major economic activity, the main 
attractions being wildlife, historical sites, and other coastal features. During the 1999 
national population census, the total population of Kwale district was 952,725 with a 
population density of only 60 persons per square kilometre, a tenth that of Greater Kisii 
district. Children under five comprised 17.3% of the population of Kwale (CBS, 2001a). 
The climate is described as monsoon, hot and dry from January to April while June to 
August is the coolest period of the year. The annual average rainfall varies from 900 to 
1500 mm per annum along the coastal strip and 500 to 600 mm further inland. There are 
two rainy seasons; the long rains, which occur from March to July, and the short rains from 
November to December. The 1999 national census revealed that 17.7% of the male 
residents of Kwale (15 to 54 years of age) and 29.9% of females remained economically 
inactive (CBS, 2001c). A 1994 CBS survey showed the prevalence of stunting, under­
nutrition and wasting among children in Kwale aged 6 to 60 months to be 53%, 29.1% and 
5.2% , respectively (CBS, 1994).
4.2.1.3 Bondo
Like Greater Kisii, Bondo district is in Nyanza province of Kenya. The district lies 
between latitudes 0.400°S and 0.050°N and longitude 33.967° to 34.433°E and covers a 
land area of just 987 km2. The district is adjacent to Lake Victoria, a large fresh water lake 
in western Kenya shared between Kenya, Uganda and Tanzania (CBS, 2001a). The Luo 
are the main ethnic group in the district accounting for 95% of the population. Polygamy is 
common among the Luo with different wives living with their children in different houses
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within a single-family compound (Cohen & Odhiambo, 1989). The Luo are mainly 
subsistence farmers and grow maize, sorghum, beans, cassava, finger millet, and sweet 
potatoes. Cash crops include cotton and sugar cane. In 1999, the district had a population 
of 238,780 people with a population density of 240 persons per square kilometre and 
children under five comprising 16.9% of the population (CBS, 2001a). There are two rainy 
seasons in Bondo: the long rains which occur between March to June and the short rains 
between August and November. The district is drier to the south along the shores of Lake 
Victoria, but wet towards the hinterland with increasing altitude. In 1999, 26.9% of males 
aged 15 to 54 in Bondo were economically inactive. Likewise 30.9% of their female 
counterparts were economically inactive (CBS, 2001c). In a 1994 CBS survey among 138 
children aged 6 to 60 months, the prevalence of stunting, under-nutrition and wasting was 
33.8%, 15.8% and 3.8% , respectively (CBS, 1994).
4.2.1.4Makueni
Makueni district is situated in Eastern province of Kenya. The district lies between 
latitudes 1.523° and 2.987°S and longitudes 37.144° and 38.517°E and covers a land area of 
8,226 km2. In 1999, the district’s population stood at 771,545 persons and there were 93.8 
persons per square kilometre, although this varied with the northern wetter areas being 
more densely populated than the southern dry areas. Children under five years of age 
accounted for approximately 14% of the total population (CBS, 2001a). Rainfall is limited 
and seasonal averaging 800 mm to 1200 mm per year in the cool and wet hilly areas to the 
north and central parts of the district, and 200 mm to 900 mm in the hot and dry low-lying 
areas. The district is mainly inhabited by the WaKamba (97% of the population) who live 
in compounds consisting of 2 to 4 huts and a food store. The WaKamba grow maize, 
beans, pigeon peas, and cowpeas for subsistence and coffee and cotton for cash. In the 
1999 census, 27.3% of males aged 15 to 54 years in Makueni were economically inactive.
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Likewise 39.5% of their female counterparts were economically inactive (CBS, 2001a). 
The prevalence o f stunting, wasting, and under-nutrition among 148 children aged 6-60 
months was undertaken by the CBS in Makueni district in 1994: 50% of children were 
stunted, 22.3% under-nourished and 2.7% wasted (CBS, 1994).
4.2.2 Basic district level indicators
Table 4.1 shows some important demographic, poverty, literacy and health service 
indicators for the four study districts. Greater Kisii was the most densely populated of the 
four districts, followed by Bondo, Makueni, and Kwale, respectively. The populations in 
the districts essentially live in rural areas with over 80% of households in all districts found 
in rural enumeration areas (EAs). In Kwale, an EA had, on average, 604 people, in Greater 
Kisii 482, in Makueni 437 and Bondo 355 people in 1999. Greater Kisii had the largest 
number of households with 190,091 followed by Makueni 144,320, Kwale 92,594, and 
Bondo 56,607.
The 1999 population figures were projected to 2002 so that population data used in the 
analysis was that of the year when most of the surveys presented in later chapters were 
conducted. The projected population for 2002 for Bondo was 242,098, Greater Kisii 
965,963, Kwale 505,447 and Makueni 781,327. The ratio of health facilities, personnel, 
beds, and retail outlets were computed using the 2002 projected population (Table 4.1). 
The number of people per health facility using the 2002 population showed that overall; 
there were fewer people per health facility in Makueni (1:3,887) followed, in order of 
decreasing coverage, by Bondo (1:4,567), Kwale (1:5,157) and Greater Kisii (1:5,221). 
The ratios of clinical health workers to population showed that in Greater Kisii, there was 1 
health worker for every 1,177 people, followed in order of decreasing coverage by Kwale 
1:1,300, Makueni 1:1,760 and Bondo 1:2,070. The coverage of inpatient beds was the
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highest in Greater Kisii with 1 hospital or health centre bed for every 480 people. This was 
followed by Bondo with 1:760, Kwale 1: 1,000 and Makueni 1:1,100. The ratio of retail 
outlets to population was 1:482 in Greater Kisii, 1:598 in Bondo, 1:756 in Makueni and 
1:888 in Kwale.
The most recent poverty report derived from a household survey conducted in 1997 by the 
CBS showed that 57% of people in Greater Kisii lived below the poverty line (living on 
less than ICES 1,239 per adult per month in 1997 or 19.6 USD). The district was ranked the 
17th poorest district in Kenya. In Kwale, 61% of people lived below the poverty line in 
1997. The district was ranked the 14th poorest in Kenya. Bondo was ranked 15th poorest 
district in Kenya and 58% of people in Siaya district, of which Bondo was part during the 
survey, lived below the poverty line. With 74% households classified as living below the 
poverty line, Makueni ranked second poorest in the country after Homa Bay district in 
Nyanza Province (CBS, 2000a). This finding has been backed up by a more recent survey 
which found that about 70% of households in Makueni were living in poverty (Nantulya et 
al., 2001).
Among poor adults aged 15 years and above, the lowest literacy rates in the four districts 
were recorded in Kwale with only 46% of poor people able to read or write a short, simple 
sentence. Literacy rates among the poor in the other districts were 78%, 63% and 75%, for 
Greater Kisii, Bondo, and Makueni, respectively. Among the non-poor, the lowest literacy 
rates were recorded in Bondo with 62% of those surveyed able to read and write. Literacy 
rates among the non-poor in the other districts were 84% for Greater Kisii, 65% for Kwale 
and 79% for Makueni (CBS, 2000b).
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Table 4.1: Demographic, poverty, literacy, and health service indicators for the four study 
districts.
Indicator Greater Kisii Kwale Bondo Makueni
Demographic
Area (km2) 1,310 8,295 960 8,266
Total population for 1999 (% rural) 952,725 (94) 496,133 (89) 238,780 (92) 771,545 (97)
Annual population growth rate (%) 0.0046 0.0062 0.0046 0.0042
Projected* population for 2002 965,963 505,447 242,098 781,327
Population density for 2002 (people per km2) 737 61 252 95
Number o f EAs 1999 (% rural) 1,975 (94) 822 (80) 673 (95) 1,766 (95)
Number o f households 1999 (% rural) 190,091 (86) 92,594 (84) 56,607 (93) 144,320 (94)
Average number o f  people per EA (1999) 482 604 355 437
Poverty and Literacy indices
Percent living below poverty line* (district poverty 
ranking) 57% (17) 61% (14) 58% (15) 74% (2)
Literacy rates* among poor adults >= 15 years 78% 46% 63% 75%
Literacy rates among non-poor adults >=15 years 84% 65% 62% 79%
Health facilities and personnel
MoH 44 50 21 59
Mission/NGO 23 10 10 29
Private 118 38 22 113
Total number o f  facilities 185 98 53 201
Retail outlets 2,002 569 405 1,034
Doctors 61 14 8 25
Clinical Officers 84 50 19 53
Laboratory technologists/technicians 123 56 24 41
Nurses 553 269 66 325
Total health personnel 821 389 117 444
Health service indices
Health facility: population 1: 5,221 1: 5,157 1:4,567 1:3,887
Retail outlets: population 1:482 1: 888 1: 598 1:756
Doctors: population 1: 15,835 1; 36,103 1:30,262 1:31,253
Clinical Officers: population 1: 11,500 1: 10,110 1: 12,742 1: 14,742
Laboratory technologists/technicians: population 1:7,853 1: 9,025 1: 10,087 1: 19,057
Nurses: population 1: 1,747 1: 1,880 1:3,668 1:2,404
Total health personnel: population 1: 1,177 1; 1,300 1:2,070 1: 1,760
Beds: population 1:480 1: 1,000 1: 761 1: 1,100
*  t  ,The equation ~PI999 =1 * 2002 e was used in the projection o f  population, where P J999 was the 1999 population census and 
P 2 0 0 2  was the required 2002 population, t  was the number o f  years between 1999 and 2002 and r  was the average annual 
growth rate (Deichmann, 1996).
* Overall poverty line-urban and rural households living on less than KES 1,239 per adult per month in 1997 (CBS, 
2000a).
* Literacy defined as ability to read and write a short, simple statement (CBS, 2000b).
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Table 4.2 shows selected malariometric data for the four districts based on data abstracted 
from the MARA/ARMA collaborative programme, involving a comprehensive review of 
all published and unpublished data on prevalence of malaria infection in childhood and 
malaria vectors in the sub-region (Omumbo & Snow, 2004). Data showed that Plasmodium 
falciparum  prevalence rates among children aged 0 to 10 years varied between the districts 
with Greater Kisii (low transmission) and Makueni (semi-arid, acute seasonal 
transmission) having the lowest prevalence (17 and 16%, respectively). Bondo with 
intense, perennial transmission and Kwale with seasonal intense transmission had similar 
P. falciparum  prevalence rates in this age group. Among school-going children, the trend 
in P. falciparum  prevalence was similar, although Kwale showed a similar prevalence to 
Greater Kisii (32% and 31% , respectively). Anopheles gambiae and An. funestus were the 
principal vectors in Greater Kisii, Kwale, and Bondo; information on the types of vectors 
was not available for Makueni. These community-based parasitological surveys suggest 
that Greater Kisii and Makueni are best described as hypo-mesoendemic, Kwale as hyper­
endemic and Bondo as hyper-holoendemic15.
15 Hypoendemicity-parasite rates not exceeding 10% in children aged 2-9 years, but may be higher for part of 
the year. Mesoendemicity-parasite rates between 11-50% in the same age group. Hyperendemicity-parasite 
rates constantly over 50% in the same age group. Holoendemicity-parasite rates constantly over 75% among 
infants aged 0-11 months (Metselaar & Van Theil, 1959).
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In 2001, the DOMC reviewed outpatient and in-patient health facility records of 
government facilities (GoK) in the districts in collaboration with the DHMTs (DOMC, 
2001b; 2001c; 200Id; 200le). From these surveys, it can be deduced that malaria is a 
common occurrence in the districts accounting for between 42 and 50% of outpatients 
among adults and between 50 and 58% among children less than 15 years (Table 4.2). 
Among children less than 15 years, malaria also accounted for 34 to 55% of all inpatient 
admissions and between 23 and 36% of all-cause mortality in hospital. Likewise, for 
adults, the disease accounted for 19 to 46% of all hospital admissions and 15 to 26% of all­
cause mortality in hospital. Overall, case-fatality rates for hospitalised malaria patients 
ranged from 4.2 to 12.3% in the districts.
Figures 4.2 to 4.5 show paediatric (<15 years) malaria admissions in the district hospitals 
of the four districts plotted against monthly rainfall from 1998 to 2000. The acute seasonal 
nature of clinical malaria in Greater Kisii is evident from Figure 4.2 with the peaks in 
paediatric malaria admission coinciding with the long rains and demonstrating marked 
between-year variation; so is the seasonal nature of clinical malaria in Kwale with the 
peaks in paediatric malaria admission coinciding with the long and short rains (Figure 4.3). 
There is lack of any marked seasonal pattern of clinical malaria in Bondo despite small 
peaks in paediatric malaria admission coinciding with the long and short rains (Figure 4.4). 
The acute seasonal nature of clinical malaria in Makueni is evident from Figure 4.5 with 
the peaks in paediatric malaria admission coinciding with the long rains (DOMC, 2001b; 
2001c; 200Id; 200le).
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Figure 4.2: Monthly malaria paediatric admissions among children < 1 5  years to Kisii
District General Hospital (red) between 1998 and 2000 against rainfall in mm (blue).
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Figure 4.3: Monthly malaria paediatric admissions among children < 15 years to 
Msambweni District General Hospital, Kwale (red) between 1998 and 2000 against rainfall 
in mm (blue).
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Figure 4.4: Monthly malaria paediatric admissions among children < 1 5  years to Bondo
District General Hospital (red) between 1998 and 2000 against rainfall in mm (blue).
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Figure 4.5: Monthly malaria paediatric admissions among children < 1 5  years to Makueni 
District General Hospital (red) between 1998 and 2000 against rainfall in mm (blue).
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From the EANMAT database, the latest drug sensitivity studies (2003 for the other 
districts, and 2001 for Kwale) suggest that adequate clinical and parasitological response 
(ACPR) on Day 14 for SP was below 75% (change phase, see Chapter 1) for Greater Kisii 
and Bondo and above 75% for Kwale and Makueni (Table 4.2). However, ACPR on Day 
28 was less than 50% in the study districts where follow up was done for 28 days. For AQ, 
ACPR on Day 14 was above 75% for all study districts. However, ACPR on Day 28 was 
below 75% for Makueni and marginally above 75% (77%) for Greater Kisii. Data were not 
available for Kwale district (Table 4.2. See Chapter 2 for more details on clinical efficacy 
of SP and AQ in Kenya).
4.2.3 The community survey: sampling approaches and study design 
Maps of EAs, created by the CBS during the 1999 national census and representing 
approximately 1,000 people or 100 homesteads, were digitised and displayed within a 
Geographic Information System (GIS) platform (MAPINFO, Version 6.0, 1985-2000, New 
York, USA). Details of the development of the district-level GIS maps are presented 
elsewhere (Noor et al., 2003). The GIS platform was used to construct a sampling frame of 
EAs to serve as the primary sampling units in each district. In the last national census 
(1999), an EA was defined by the CBS as an area representing between 500 and 1000 
people or 100 homesteads and which can be covered by a single enumerator or census 
officer during the census night. EAs were classified as urban or rural based on a mixture of 
population size, infrastructure and expert judgment (CBS, 2001a; Noor et al., 2003).
In each district, a population of 25,000 people was targeted for the community survey 
representing approximately 2,500 homesteads. This sample was selected to provide 
adequate power to define under-five mortality from retrospective reports of mortality 
events in each homestead during the preceding 12 months. Further, sampling of EAs was 
done to represent each district’s settlement pattern with urban and rural EAs being sampled
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until the target population in each strata was attained for each district. Table 4.3 shows the 
numbers of urban and rural EAs in the initial sampling frame for the four study districts, 
their respective population counts and the eventual numbers of EAs sampled for the 
community survey. Figure 4.6 shows the spatial distribution of sampled EAs in each of the 
districts. High-resolution road, topographical and landmark maps were generated for each 
sampled EA to assist in fieldwork.
Table 4.3: Sampling frame for the 2001 community survey in four districts of Kenya. 
Figures in parentheses represent the equivalent 1999 population.
Greater Kisii Kwale Bondo Makueni
Number o f  EAs 673 1,975 822 1,766
(952,725) (496,133) (238,780) (771,545)
Number o f  urban EAs 36 118 164 95
(57,164) (54,575) (19,102) (23,146)
Number o f  sampled EAs 66 54 48 62
(25,244) (25,040) (25,463) (25,928)
Number o f urban EAs sampled 3 6 12 5
(1,591) (1,982) (2,770) (904)
4.2.4 Survey procedures
In each district, a local survey team of about 45 people with at least 12 years basic 
education was recruited. Staff were fluent in English, Kiswahili (the national language) and 
the local vernacular of each district and were trained over three days in the survey 
instruments, how to approach households and check data in the field and how to obtain 
informed consent for interviews. Field supervisors were recruited to oversee each district’s 
survey work. Team leaders checked all data, completeness of homestead coverage, and 
technical details on a daily basis. Further on-going checks were performed at district and 
central levels to allow rapid clarification of issues arising.
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Questionnaires (Appendix II) were translated into the local languages: KiKisii (Greater 
Kisii), KiKamba (Makueni), KiLuo (Bondo) and Kiswahili (Kwale) and piloted in each 
district to identify ambiguities in translation and inconsistencies in question interpretation 
according to local vernacular. Once in the districts, interviews were conducted within all 
homesteads of each sampled EA using the standard questionnaire. Interviews were 
conducted in Greater Kisii from December 2nd to 21st 2001, in Kwale from November 30th 
2001 to January 26th 2002, in Bondo from December 5th 2001 to January 26th 2002 and in 
Makueni from November 30th 2001 to January 31st 2002.
)
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Verbal consent was obtained from the head of the homestead for the interview to proceed.
 ^ Homesteads were given unique codes and data collected included basic demographic data;
information on exposure to indoor residual house-spraying and public awareness 
campaigns on malaria control; use of insecticide-treated nets, use of malaria curative and 
preventative strategies amongst pregnant women, the homestead’s longitude and latitude 
using hand-held global positioning units; and treatment seeking behaviour for recent fevers 
in children under five years of age.
Reported fever was used as an entry point as this forms the prompt for malaria case- 
management guidelines by formal health service providers across Africa especially through 
the proposed Integrated Management of Childhood Illness (IMCI) (Gove, 1997). 
Furthermore, many communities in Kenya are unable to distinguish malaria-specific 
paroxysms from generalised fever and it is the latter that serve as the treatment action 
prompts (Section 2.5). More precise biological definitions of clinical malaria, involving 
elevated body temperatures and parasitology, are unable to establish treatment practices 
among morbid events that have resolved and for which “normal practice” can be defined.
At the homestead level, one child was selected randomly from the resident under five-year 
age group. This was done by putting the names of all children under five on pieces of 
paper, putting these in a hat or bag and asking the homestead head to select one child for 
interview. If the selected child was absent from the household then one further selection 
was made. Mothers or caretakers o f the child were asked whether s/he had had a fever
)
during the preceding 14 days and whether the child had a fever since the morning of the 
interview. Further enquiries were made to establish the duration o f illness and the actions 
taken in response to illness recognition over the preceding 14 days. This approach to 
defining fever period prevalence and “appropriate” actions currently forms the basis of the 
RBM monitoring and evaluation tools within national demographic and health surveys run
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by the MEASURE programme; (WHO & UNICEF, 2003). A two-week recall period is 
generally deemed optimum for morbidity surveys (Kroeger, 1985). In a study in an urban 
area of neighbouring Ethiopia comparing daily morbidity interviews with fortnightly 
interviews, Freij and Wall found that recent illness was overestimated and earlier events more 
easily forgotten, so that in a two-week recall period over- and under-reporting largely 
cancelled each other out (op cit Kroeger, 1983).
All actions involving the use of westem-style medicines were investigated further using 
photo-illustrated drug charts of common proprietary antimalarial (AM) and antipyretic 
(AP) drugs available in the retail sector (Figure 4.7 for example). In addition, any health 
cards or medical notes were examined to record the drugs prescribed. The name of the 
providers and the time and costs of each action were also recorded.
Figure 4.7: An example of a product contained in the photo-illustrated visual aid used in 
the community survey.
Antimalarial
Tablets.
ifadoxine and Pyrimethamine Tablets 
USP 500 : 25mg
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4.2.5 Data quality assurance, analysis, and statistical approaches
Apart from range and consistency checks in the field in each district by project supervisors, 
at least 10% of interviews in each district were redone by supervisors to ensure 
reproducibility of responses. Complete re-interviews are generally not feasible nor 
recommended since motivating respondents to give second interviews is both difficult and 
maybe counterproductive in the long run (Kroeger, 1985). In all cases, there was 
concordance between first and second interviews, which supported the accuracy of 
reporting, and thus the reliability of survey data. In addition, in 10% of interviews, field 
teams were accompanied by supervisors to gauge their skill and performance; no issues 
were identified among any of the survey teams in the study districts.
All data were entered twice using MS-Access 2000 developed data-entry screens. The data 
entered by two independent clerks were verified for errors and corrected from the original 
proformas. Data were then subjected to a series of range and consistency checks to identify 
unlikely, outlying responses. These were re-checked with proformas, field supervisors, and 
a decision made on whether transcription errors had been made at the point of interview or 
whether the entries were to be deleted.
Analysis of frequencies was undertaken using combinations of Epi-Info Version 6.04d 
(Centers for Disease Control, USA), MS-Excel 2000, MS-Access 2000 (Microsoft Corp., 
Redmond, USA), and SPSS version 9.0 for Windows (SPSS Inc., Chicago, USA). Non- 
parametric Kruskal Wallis test was used to compare medians and chi-square tests 
(Pearson’s X2) used to compare proportions. When comparing many groups, such tests only 
point out that at least one group is different from at least one other, thus necessitating post- 
hoc multiple comparisons (like the Bonferroni correction after one-way ANOVA) to 
pinpoint exactly which group is different (Bland & Altman, 1995).
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For post-hoc multiple comparisons after a chi-squared test, the Marascuilo procedure was 
used. The procedure involves three steps. Assuming sample sizes of ni (z-1, 2, ..., k) from
k  populations, the first step is to compute the differences ( p t -  p j ) (where i is not equal to
test statistics. The second step is to pick a significance level (95% or O'of 5%) and compute 
the corresponding critical values for the Marascuilo procedure from the equation:
critical ry value. Those pairs that have a test statistic that exceeds the critical value are 
significant at the a  level (Marascuilo, 1966).
Because most of the continuous variables in the data collected were not normally 
distributed even after a range of possible transformations, medians (and interquartile
differences. StatsDirect, Version 2.3.8, (StatsDirect, Cheshire, UK) was used to compute 
post-hoc multiple comparisons for Kruskal-Wallis and the Dwass-Steel-Crichlow-Fligner 
method, which is used in most situations, is reported here. In subsequent chapters, this 
same analytical approach is used.
4.3 Results
4.3.1 Description o f  population covered
Coverage of the community survey was high with more than 97% of all homesteads 
agreeing to be enumerated in all districts. In all districts save Makueni, the target
k(k  — 1)j)  among all —------- pairs of proportions. The absolute values of these differences are the
k ( k - 1)The third step is to compare each o f the   test statistics against its corresponding
ranges) were used to describe them and hence the Kruskal-Wallis test was used to examine
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population of 25,000 people was attained. Overall, the survey covered about 103,270 
persons in the four districts and the first round of survey work was completed in the field 
within six weeks. There were between two to three households per homestead. The average 
homestead had approximately six sleeping rooms and an equivalent number of beds or 
sleeping mats. 9,272 homesteads with 18,983 resident children under five years of age 
were visited. Forty-six children were erroneously recruited for the childhood fever module 
as their dates of birth indicated they were older than five years; these were excluded from 
subsequent analysis (Table 4.4).
Table 4.4: Basic characteristics of the study populations in four districts of Kenya.
Greater
Kisii
Kwale Bondo Makueni Total
Number o f homesteads that
Refused 2 8 3 .12 25
Absent/deserted 1 38 32 50 121
Data missing 0 9 6 3 18
Total number o f homesteads sampled (coverage) 1,840
(99.8%)
2,262
(97.6%)
2,753
(98.5%)
2,417
(97.4%)
9,272
(98.3%)
Total population sampled 25,242 27,446 27,272 23,310 103,270
Total number o f  resident children aged < 5 years 4,949 5,412 4,756 3,866 18,983
Average number o f homes per homestead 3.0 2.4 2.6 1.7 2.4
Average number o f  sleeping rooms per homestead 8.2 5.2 5.3 4.6 5.7
Average number o f  beds/sleeping mats per homestead 7.8 6.1 6.0 5.3 6.2
Number o f children aged < 5 years sampled for detailed 
fever survey
1,425 1,627 1,644 1,591 6,287
Number o f  children erroneously recruited and 
subsequently found to be >= 5 years
5 16 16 9 46
( 4.3.2 Children with fever
6,287 mothers or guardians were interviewed about fever among their children in the 
preceding 14 days. Mothers or guardians reported a recent fever among 2,655 children 
(42.4%). The male-to-female ratio of children with reported fevers was 1.12:1. Overall, the 
median age of febrile patients was 26 months (Inter quartile range (IQR): 16, 40). Of the
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children who had reported a fever in the 14-day recall period, 1,090 (17.3%) still had a 
fever on the day of the interview. The median duration of resolved fevers in last two weeks 
was four days (IQR: 3, 7). There were significant differences between districts both in 
fever prevalence in the recall period (^=513.6, df=3, p<0.001, no two districts were alike 
using the Marascuilo procedure at p=0.05) and reported fevers on the day of interview 
(**=241.4, df=3, pO.OOl, no two districts were alike using the Marascuilo procedure at 
p=0.05). These differences seemed to mirror the district malaria ecologies with Makueni, 
an area of semi-arid, acute seasonal malaria reporting the lowest period prevalence of 
fevers (20.8%); Bondo, an area of intense perennial transmission reporting the highest 
(59.3%) and the other districts in-between (Table 4.5).
Table 4.5: Basic indicators describing 6,287 children under five years of age interviewed 
about fever in the previous 14 days in four districts of Kenya.
Greater Kisii Kwale Bondo Makueni Total
Number interviewed about fever 1,425 1,627 1,644 1,591 6,287
Number with fever over last 14 days (%) 581
(40.8%)
768
(47.2%)
975
(59.3%)
331
(20.8%)
2,655
(42.2%)
Number with fever on day o f  survey (%) 291
(20.4%)
252
(15.5%)
441
(26.8%)
106
(6.7%)
1,090
(17.3%)
Urban interviews 99 304 103 86 592
Rural interviews 1,326 1,323 1,541 1,505 5,695
Fever prevalence among urban children (%) 36
(36.4%)
134
(44.1%)
58
(56.3%)
36
(41.9%)
264
(44.6%)
Fever prevalence among rural children (%) 545
(41.1%)
634
(47.9%)
917
(59.5%)
295
(19.6%)
2,391
(42.0%)
Male: Female ratio o f  fevers 1.25:1 1.21:1 0.98:1 1.14:1 1.12:1
Median age o f children with fever [IQR: 25%, 75%] 27
[16,40]
24
[16,37]
27 
[17, 42]
27
[15,40]
26 
[16, 40]
Median duration o f resolved fevers in days [IQR: 5 4 4 3 4
25%, 75%] [3 ,7] [3 ,7 ] [3, 7] [2, 7] [3 ,7 ]
Percent o f  all febrile children who accessed any 448 529 682 249 1,908
source o f intervention (77.1%) (68.9%) (69.9%) (75.2%) (71.9%)
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4.3.3 Treatment actions
 ^ In this and subsequent sections, the term public formal sector implies GoK health facilities,
Mission and NGO facilities and Community Health Workers (CHWs) which are 
essentially not-for-profit. Mission and NGO facilities have been classified as “public” 
formal providers because in Kenya these are largely run as not-for-profit facilities and 
indeed health personnel (with formal training) in this sector are either seconded from the 
Ministry of Health or directly employed by Missions and NGOs using funds provided by 
bilateral and multilateral donors or charities (Koinange, 1996). Private formal sector 
implies for-profit private clinics and hospitals. Retail sector implies general retailers, 
pharmacies, and itinerant vendors. “Other” actions are those involving homemade 
remedies, self-medication with western drugs within the home and use of traditional 
healers. Table 4.6 shows a summary of the first actions taken for the 2,655 reported fevers 
in the four districts. Overall, 28.1% of fevers were reportedly untreated. A test of 
proportions showed that there was a significant difference between fever treatment rates in 
the districts (^=14.9, df=3, p=0.002, Marascuilo procedure reveals Greater Kisii different 
from Kwale and from Bondo at p=0.05) and between rural and urban populations (^=5.5, 
df=l, p=0.019). For fevers where an action was reportedly taken, the commonest actions 
were treatment at public formal facilities (29.9% of fevers) or treatment using the retail 
sector (26.0%).
The use of the retail sector was significantly higher in Makueni than in all other districts 
(^=21.6, df=3, p<0.001, Marascuilo procedure reveals Makueni different from all other
\
districts at p=0.05). Further, Makueni had a higher proportion of fevers treated at private 
formal facilities than all the other districts (^=20.7, df=3, p<0.001, Marascuilo procedure 
reveals Makueni different from all other districts). Treatment through prayers, homemade 
remedies, traditional healers, or self-medication with western drugs available in the home 
was 7.0 %. There were no significant differences in the use o f public formal facilities
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between rural and urban populations (30.1 versus 26.5%, X2=1.5, df=l, p=0.225) or in the 
use of the retail sector between rural and urban communities (25.8 versus 27.7%, X^O.4,
)
df=l, p=0.516). However, urban populations were more likely to use private formal 
facilities than were rural populations (X2=44.1, df=l, p<0.001) and rural populations more 
likely to resort to actions within the home than were urban populations (x2=5.8, df=l,
p=0.016).
Table 4.6: First action taken for 2,655 fevers reported over the last 14 days in children less 
than 5 years of age in four districts in Kenya.
Action
taken
Greater 
Kisii 
Number of 
fevers (% )
Kwale 
Number of 
fevers (%)
Bondo 
Number of 
fevers (%)
Makueni 
Number of 
fevers (%)
Rural 
Number 
of fevers 
(% )
Urban 
Number 
of fevers 
(%)
Total 
Number of 
fevers (%)
No action 133 239 293 82 689 58 747
reported (22.9%) (31.1%) (30.1%) (24.8%) (28.8%) (22.0%) (28.1%)
Public 218 219 286 66 719 70 789
formal* (37.5%) (28.5%) (29.3%) (19.9%) (30.1%) (26.5%) (29.9%)
Retail 142 206 224 118 617 73 690
sector* (24.4%) (26.8%) (23.0%) (35.7%) (25.8%) (27.7%) (26.0%)
Private 42 62 88 52 190 54 244
formal* (7.2%) (8.1%) (9.0%) (15.7%) (8.0%) (20.5%) (9.2%)
Other 46 42 84 13 176 9 185
actions5 (7.9%) (5.5%) (8.6%) (3.9%) (7.4%) (3.4%) (7.0%)
Total 581 768 975 331 2391 264 2,655
* GoK clinics and hospitals, not-for-profit clinics and hospitals, and Community Health Workers (CHW)
* General retail shops, drug vendors and pharmacies
* Private for-profit clinics and hospitals
® Homemade remedies, prayers, self-medication with western pharmaceuticals in the home, and traditional healers
4.3.4 Treatment costs
1,712 fevers were analysed for drug and transport costs of first actions. Over 85% of 
children paid for drugs in all facility types and among urban and rural populations. 
Approximately 20% of those who used GoK clinics paid for transport to these facilities and 
twice as many paid for transport to GoK hospitals, consistent with the fact that the latter 
are more distant from most households. Urban populations were twice as likely to pay for 
transport to GoK clinics than were rural populations 13.6, df=l, p<0.001), but less
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likely to pay for transport to GoK hospitals than were rural populations (x^=3.9, df=l, 
p=0.048), consistent with the fact that GoK clinics are mostly located in rural areas and 
GoK hospitals in urban areas. The same pattern was evident for Mission and NGO 
facilities and private facilities as well: Mission and NGO clinics were more accessible than 
Mission and NGO hospitals (17 versus 30%) and private clinics more accessible than 
private hospitals (16% versus 75%). The retail sector, Bamako Initiatives (BI) and 
Community Health Workers (CHWs) remained the most accessible in terms of distance; 
less than 10% of those who used these facilities paid for transport (Table 4.7).
Table 4.8 shows the median costs associated with drugs and transport for fevers where a 
cost was incurred. Overall, the pattern in costs of drugs was that private clinics charged the 
highest amount (median KES 150, inter-quartile range (IQR) 50, 250), whereas cost of 
drugs at retail outlets was the lowest (median KES 17, IQR 7, 50). GoK hospitals, Mission 
and NGO clinics, and hospitals charged 100 KES for drugs. In contrast, GoK clinics 
charged almost half what the GoK hospitals charged (60 versus 100 KES).
There were significant differences in costs of drugs between the districts. Private hospitals 
were reportedly used in only one district, Kwale, while Mission and NGO hospitals were 
used in Greater Kisii and Bondo only. For the remaining facility types where it was 
possible to make a head-to-head comparison across the districts, costs of drugs were 
significantly higher in GoK clinics in Greater Kisii and Kwale than in Bondo (Kruskal 
Wallis=12.7, df=3, p=0.005). There were no significant differences between the costs of 
drugs obtained from Mission and NGO clinics in the districts (Kruskal Wallis=4.8, df=3, 
p=0.188). BI sites and CHWs in Kwale and Bondo charged the least for drugs (12 and 40 
KES, respectively), compared to Greater Kisii and Makueni (110 and 120 KES, 
respectively, Kruskal Wallis=15.3, df=3, p=0.016). Drugs obtained from GoK hospitals in 
Greater Kisii were significantly costlier than those obtained from the same facilities in
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Kwale or Bondo (Kruskal Wallis=9.9, df=3, p=0.019). Drugs obtained from retailers in 
Greater Kisii were almost twice the price of those obtained from Kwale and Makueni (25 
KES versus 14 and 11, respectively) and those from Kwale almost half of Bondo (Kruskal 
Wallis=16.3, df=3, p=0.001). Private sector clinics in Bondo charged the lowest for drugs 
(80 KES) while other districts charged at least twice as much from these providers 
(Kruskal Wallis=22.2, df=3, p<0.001).
Rural populations paid significantly less for drugs obtained from GoK clinics and private 
clinics than did their urban counterparts (Kruskal Wallis=5.2, df==l, p=0.023 and Kruskal 
Wallis=13.6, df=l, p<0.001, respectively). There were no differences in cost of drugs 
between rural and urban populations in Mission and NGO clinics ((Kruskal Wallis=T.9, 
df=l, p=0.163), GoK hospitals (Kruskal Wallis=0.2, df=l, p=0.657), in the retail sector 
(Kruskal Wallis=2.0, df=l, p=0.153), and in private hospitals (Kruskal Wallis <0.1, df=l, 
p>0.999) (Table 4.8).
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4.3.5 Drugs used to manage fever and their sources
Of the 1,908 fevers where any intervention was sought, 1,805 (94.6%) involved the use of 
westem-style medications. 2,888 westem-style medications were dispensed or 
administered for reported first actions (Table 4.9). The most widely dispensed classes of 
medications were the AP (52.1%) and the AM drugs (30.5%). Across all types of treatment 
facilities, the most widely accessed AM drugs were SP combinations (37.7% of AM drugs) 
and amodiaquine (AQ, 31.3%). Two hundred and forty (8.3%) medications could not be 
identified from drug charts or recalled by the respondents and at least 60% of these were 
obtained from the GoK facilities. There were no significant differences between rural and 
urban populations in encounters with AP (^=0.6, df=l, p=0.438), AQ (x?=0.1, df=l, 
p=0.750), CQ (^<0.1, df=l, p=0.906), QN (^=2.0, df=l, p=0.154), SP (^=0.9, df=l, 
0.337), or with unknown drugs (^=2.7, df=l, p=0.103). However, urban populations were 
more likely to encounter a non-AM or AP drug than were their rural counterparts (x?=12.3, 
df=l, p<0.001).
Table 4.10 shows drug use from an illness perspective (as opposed to product perspective 
in 4.9). Again, there were no significant differences in the patterns of drug use between 
rural and urban populations except in the use of non-AM or AP drugs as in Table 4.9 
(^=10.7, df=l, p=0.001). With regard to use of AM drugs, overall, 804 fevers (30.3%) 
were treated with at least one AM drug, and 72 fevers (2.7%) were treated with more than 
one AM. The most commonly used AM drug classes were from the SP group (12.1% of 
fevers) and AQ (9.7% of fevers). Most of the AM treated fevers occurred in the GoK 
facilities (46.9% of AM treated fevers). The highest AM treatment rates were found among 
fevers treated through the GoK facilities and Mission and NGO facilities (56.3% and 
51.8% , respectively). Of fevers treated through private clinics, retail outlets or with home 
remedies, 49.2%, 32.9%, and 33.7% , respectively received an AM drug. Use of SP drugs 
rather than other AM drugs was also more common in the GoK and Mission sectors. Of
148
i
377 fevers given an AM drug in the GoK sector, 45.6% received an SP drug; 41.4% of AM 
treated fevers in the Mission and NGO sector received SP in contrast to 40.0%, 30.8%, and 
13.8%, respectively, for those treated first through private clinics, retail outlets, or with 
home-based treatments. The commonest AM drug class used in the retail sector was AQ 
(40.5% of AM treated fevers in the retail sector).
Tables 4.11 and 4.12 show the types of AM and AP drugs used at home or purchased from 
the retail sector to manage fever. These were considered because drugs accessed from 
other sectors (e.g. the public formal sector) remain largely unknown to patients, but those 
purchased by patients are more likely to be identified by them. Overall, 12 brands of SP, 8 
of AQ and 6 of CQ, were reportedly used within the home or purchased from the retail 
sector. Although there were many brands reportedly used, in most cases some brands 
seemed to predominate: over 60% of encounters with SP were with Fansidar® (Hoffmann 
La Roche. Switzerland) and Falcidin® (Cosmos Limited, Kenya); over 60% of encounters 
with AQ were with Malaratab® (Cosmos Limited, Kenya) and Amobin® (Regal 
Pharmaceuticals, Kenya), and over 80% of encounters with CQ were with unbranded CQ 
and with Malaraquin® (GlaxoSmithKline, UK). All encounters with QN were with 
unbranded generic QN (Table 4.11). The data on AM brand used are used more elaborately 
in Section 7.3 to see how differential brand use, combined with drug quality, and 
adherence to dosage regimen affect effectiveness. For AP drugs, overall, over 60% of 
encounters were with paracetamol: Panadol ya Watoto® (GlaxoSmithKline, UK), Panadol 
Extra® (GlaxoSmithKline, UK) and generic unbranded paracetamol. Of particular concern 
is the fact that aspirin and other nonsteroidal anti-inflammatory drugs (ibuprofen) were 
reportedly used in approximately 25% of the fevers treated at home or through shop- 
bought drugs, although these are contra-indicated in children below 12 years of age.
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Table 4.11: Brands of 271 antimalarial drugs used at home or purchased from the retail 
sector by 256 febrile children under five in four districts in Kenya expressed as the percent 
) encounter with a brand as a function of the total in each AM class. T implies tablets and S,
suspensions. Asterix on T or S indicates products not registered with the PPB up to and 
including May 31st 2002.
Products Greater Kisii Kwale Bondo Makueni Total Number of
fevers
SP
Amalar® (T) 0 0 2 0 2 2
(8.7%) (2.6%) (2.7%)
Falcidin® (T&S) 2 2 1 2 7 7
(8.0%) (13.3%) (4.3%) (15.4%) (9.2%) (9.5%)
Falcigo® (S’) 0 0 0 2 2 2
(15.4%) (2.6%) (2.7%)
Falcistat® (T) 0 0 0 1 1 1
(7.7%) (1.3%) (1.4%)
Fansidar® (T) 17 7 14 5 43 43
(68.0%) (46.7%) (60.9%) (38.5%) (56.6%) (58.1%)
Kelfalin® (S) 1 0 0 0 1 1
(4.0%) (1.3%) (1.4%)
Medifan® (S ) 3 1 1 0 5 5
(12.0%) (6.7%) (4.3%) (6.6%) (6.8%)
Metakelfin® (T) 2 2 1 0 5 5
(8.0%) (13.3%) (4.3%) (6.6%) (6.8%)
Nopyrin® (S*) 0 1 0 0 1 1
(6.7%) (1.3%) (1.4%)
Orodar® (T) 0 0 0 2 2 2
(15.4%) (2.6%) (2.7%)
Pyralfin* (S’) 0 0 0 1 1 1
(7.7%) (1.3%) (1.4%)
SP unspecified (T) 0 1 3 1 5 5
(6.7%) (13.0%) (7.7%) (6.6%) (6.8%)
Unidar® (T ) 0 1 0 0 1 1
(6.7%) (1.3%) (1.4%)
AQ
Amobin® (T&S) 12 1 4 0 17 16
(32.4%) (4.3%) (10.8%) (15.5%) (15.0%)
AQ unspecified (T) 1 1 6 2 10 10
(2.7%) (4.3%) (16.2%) (15.4%) (9.1%) (9.3%)
Betaquine® (T ) 0 1 2 2 5 5
(4.3%) (5.4%) (15.4%) (4.5%) (4.7%)
Camoquin® (T&S') 2 2 1 2 7 7
(5.4%) (8.7%) (2.7%) (15.4%) (6.4%) (6.5%)
Emoquin® (S) 1 1 2 0 4 4
(2.7%) (4.3%) (5.4%) (3.6%) (3.7%)
Falciquin® (S ) 1 2 2 0 5 5
(2.7%) (8.7%) (5.4%) (4.5%) (4.7%)
Malaramed® (S ) 1 0 0 0 1 1
(2.7%) (0.9%) (0.9%)
Malaratab® (T&S) 18 15 19 7 59 58
(48.6%) (65.2%) (51.4%) (53.8%) (53.6%) (54.2%)
Uniquin® (T&S) 1 0 1 0 2 2
(2.7%) (2.7%) (1.8%) (1.9%)
CQ
CQ unspecified (T) 1 10 19 4 34 34
(25.0%) (31.3%) (73.1%) (40.0%) (47.2%) (50.0%)
Dawaquin® (T) 0 3 0 6 9 9
(9.4%) (60.0%) (12.5%) (13.2%)
Dawaquin junior® (S’) 0 1 0 0 1 1
(3.1%) (1.4%) (1.5%)
Homaquin® (T) 0 4 1 0 5 5
(12.5%) (3.8%) (6.9%) (7.4%)
Malaraquin® (T ) 2 14 5 0 21 21
(50.0%) (43.8%) (19.2%) (29.2%) (30.9%)
Oroquin® (T) 1 0 0 0 1 1
(25.0%) (1.4%) (1.5%)
Phinaquine® (S) 0 0 1 0 1 1
(3.8%) (1.4%) (1.5%)
QN
QN unspecified (T) 0 3 10 0 13 13
(100.0%) (100.0%) (100.0%) (100.0%)
152
)Table 4.12: Brands of 699 antipyretic drugs used at home or purchased from the retail sector by 597 febrile 
children under five in four districts in Kenya expressed as the percent encounter with a brand as a function of 
the total AP in district and overall. T implies tablets and S, suspensions.
Products Greater Kisii Kwale Bondo Makueni Total Number of fevers
Aspirin
Aspirin unspecified (T) 10 46 3 10 69 69
(7.7%) (19.8%) (1.3%) (8.8%) (9.9%) (11.6%)
Dispirin® (T) 0 1 0 0 1 1
(0.4%) (0.1%) (0.2%)
Junior Aspirin® (T) 0 2 0 2 4 4
(0.9%) (1.8%) (0.6%) (0.7%)
Totoprin® (T) 0 0 0 2 2 2
(1.8%) (0.3%) (0.3%)
Aspirin, Paracetamol & Caffeine
Action® (T) 2 17 1 3 23 23
(1.5%) (7.3%) (0.4%) (2.6%) (3.3%) (3.9%)
APC® (T) 0 1 0 0 1 1
(0.4%) (0.1%) (0.2%)
Hedapan® (T) 0 0 0 1 1 1
(0.9%) (0.1%) (0.2%)
Hedex® (T) 0 4 3 1 8 8
(1.7%) (1.3%) (0.9%) (1.1%) (1.3%)
Mara Moja® (T) 1 14 2 0 17 17
(0.8%) (6.0%) (0.9%) (2.4%) (2.8%)
Nopen® (T) 0 3 0 0 3 3
(1.3%) (0.4%) (0.5%)
Ibuprofen
Brufen® (T) 3 2 5 1 11 11
(2.3%) (0.9%) (2.2%) (0.9%) (1.6%) (1.8%)
Ibufen® (S) 0 0 1 0 1 1
(0.4%) (0.1%) (0.2%)
Ibumex® (S) 3 2 0 0 5 5
(2.3%) (0.9%) (0.7%) (0.8%)
Mediprofen® (S) 0 1 0 0 1 1
(0.4%) (0.1%) (0.2%)
Ponafen® (S) 1 0 3 0 4 4
(0.8%) (1.3%) (0.6%) (0.7%)
Paracetamol
Acemol® (T) 0 1 0 0 1 1
(0.4%) (0.1%) (0.2%)
Cafenol® (T) 0 1 1 0 7 7
(0.4%) (0.4%) (0.3%) (0.3%)
Calpol® (S) 3 24 9 3 39 39
(2.3%) (10.3%) (4.0%) (2.6%) (5.6%) (6.5%)
Dawanol® (T) 4 1 2 2 1
(3.1%) (0.4%) (0.9%) (1.8%) (0.1%) (0.2%)
Panadol® (T&S) 26 4 23 1 54 53
(20.0%) (1.7%) (10.3%) (0.9%) (7.7%) (8.9%)
Panadol ya Watoto® (T) 63 56 95 21 235 235
(48.5%) (24.1%) (42.6%) (18.4%) (33.6%) (39.4%)
Paracetamol unspecified (T) 5 17 16 60 98 98
(3.8%) (7.3%) (7.2%) (52.6%) (14.0%) (16.4%)
Paracetmol & Caffeine
Cold Cap® (T) 2 3 2 1 8 8
(1.5%) (1.3%) (0.9%) (0.9%) (1.1%) (1.3%)
Panadol Extra® (T) 6 32 57 6 101 101
(4.6%) (13.8%) (25.6%) (5.3%) (14.4%) (16.9%)
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4.3.6 Timing o f treatment
Table 4.13, Figure 4.8, and Figure 4.9 show the cumulative proportions of fevers treated as 
a function o f time across the study districts. Overall, 13.6% of fevers were treated within 
24 hours. Further, 5.3% of fevers were treated with an AM within 24 hours and 14.7% 
within 48 hours. However, very few fevers were treated with SP, the first-line drug at the 
time of the survey, within 24 and 48 hours (2.3 and 6.7%, respectively). There were 
differences between the districts in the fever treatment rates; significantly more fevers were 
treated in Greater Kisii (19.6%) than in Bondo or Kwale districts within 24 hours (x2=29.6, 
df=3, p<0.001, Marascuilo procedure Greater Kisii different from Bondo and Kwale at 
p=0.05). In addition, more fevers in Greater Kisii were treated with an AM drug (9.6%) 
and with SP (5.0%), within 24 hours than in Kwale and in Bondo (^=30.8, df=3, p<0.001 
and 28.4, df=3, p<0.001, respectively. Marascuilo procedure Kwale and Bondo different 
from Greater Kisii at p=0.05).
At 48 hours, Greater Kisii had the highest treatment rate compared to the other districts 
(X2=57.8, df=3, p<0.001, Greater Kisii different from all districts using Marascuilo 
Procedure at p=0.05 and Kwale different from Bondo) and, the highest rates of treatment 
with AM at 48 hours (^=52.0, df=3, p<0.001, Greater Kisii different from all districts 
using Marascuilo Procedure at p=0.05) and the highest rates of treatment with SP at 48 
hours 0^=53.4, df-3, p<0.001, Greater Kisii different from all districts using Marascuilo 
Procedure at p=0.05). Over 48 hours, significantly more fevers in Greater Kisii were 
treated than in Kwale or Bondo (^=14.9, df=3, p=0.002) with the district being different 
from Kwale and Bondo using the Marascuilo Procedure at p=0.05. The same pattern was 
evident for treatment with an AM over 48 hours (^=21.6, df=3, p<0.001) and with SP over 
48 hours (^=39.7, df=3, p<0.001). There were no differences between rural and urban 
populations in treatment rates within 24 hours (^=1.3, df=l, p=0.256), but urban
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populations had higher treatment rates at 48 hours (^=5.9, df=l, p=0.015) and over 48 
) hours (^=5.5, df=l, p=0.019). However, and significantly, there were no differences
between rural and urban populations in access to AM drugs within 24 (^=0.3, df=l, 
p=0.559), 48 (x2=l -7, df=l, p=0.198) and over 48 hours (^=0.8, df=l, p=0.385) and to SP 
within 24 (^=0.8, df=l, p=0.371), 48 (rf=0.2, df=l, p=0.642) and over 48 hours (^=0.1, 
df=l, p=0.732). The overall delay in seeking any treatment was two days for Greater Kisii 
(IQR: 1, 3) and Kwale (IQR: 2, 4) and three days for Bondo (IQR: 2, 5) and Makueni 
(IQR: 2, 4).
155
)Table 4.13: Cumulative proportion of fevers treated with an antimalarial (AM) and with 
sulfur-pyrimethamine (SP) in four districts of Kenya as a function o f time.
Place Treatm ent Tim e
24 hours 48 hours Over 48 hours
Greater Kisii Any treatment 114 287 448
(19.6%) (49.4%) (77.1%)
AM 56 147 220
(9.6%) (25.3%) (37.9%)
SP 29 76 107
(5.0%) (13.1%) (18.4%)
Kwale Any treatment 91 292 529
(11.8%) (38.0%) (68.9%)
AM 27 111 208
(3.5%) (14.5%) (27.1%)
SP 12 48 89
(1.6%) (6.3%) (11.6%)
Bondo Any treatment 103 294 682
(10.6%) (30.2%) (69.9%)
AM 38 118 275
(3.9%) (12.1%) (28.2%)
SP 10 34 77
(1.0%) (3.5%) (7.9%)
Makueni Any Rx 54 121 249
(16.3%) (36.6%) (75.2%)
AM 20 44 101
(6.0%) (13.3%) (30.5%)
SP 10 21 47
(3.0%) (6.3%) (14.2%)
Rural Any treatment 320 877 1702
(13.4%) (36.7%) (71.2%)
AM 129 371 718
(5.4%) (15.5%) (30.0%)
SP 57 163 290
(2.4%) (6.8%) (12.1%)
Urban Any treatment 42 117 206
(15.9%) (44.3%) (78.0%)
AM 12 49 86
(4.5%) (18.5%) (32.6%)
SP 4 16 30
(1.5%) (6.1%) (11.4%)
Total Any treatment 362 994 1,908
(13.6%) (37.4%) (71.9%)
AM 141 390 804
(5.3%) (14.7%) (30.3%)
SP 61 179 320
(2.3%) (6.7%) (12.1%)
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Figure 4.8: Cumulative proportion of access to different first treatment sources among 
2,655 febrile children in four districts in Kenya as a function of time. Treatment sources 
defined as private formal (private for profit clinics and hospitals); public formal 
(government, mission and NGO not-for-profit dispensaries, health centres and hospitals, 
community health workers); retail sector (general retail shops and pharmacies); other 
(western pharmaceuticals administered at home, home remedies, prayers and traditional 
healers), (a) Greater Kisii (green, n=581 fevers), (b) Kwale (blue, n=768 fevers), (c) Bondo 
(yellow, 0=975 fevers) and (d) Makueni (red, n=331 fevers).
40.0 i
35.0
30.0
« 25.0
= 20.0  a
V-o
S  15.0
10.0  
5.0 -I
Private form al
24 48 O ver 48
lim e  since onset of fever (hours)
£  15.0
Time since onset of fever
Retail sector
*  25.0
s  20.0
£  15.0
24 48 O ver 48
Time since onset of Fever (hours)
» 25.0
I
=  20.0  «
e
*  15.0 
10.0 
5.0 
0.0
24 48 O ver 48
lim e  since o nset o f fever (hours)
)
157
Figure 4.9: Cumulative proportion of 2,655 febrile children in four districts in Kenya who 
accessed at least one antimalarial drug from different sources as a function of time. 
Treatment sources defined as private formal (private for profit clinics and hospitals); public 
formal (government, mission and NGO not-for-profit dispensaries, health centres and 
hospitals, community health workers); retail sector (general retail shops and pharmacies); 
other (western pharmaceuticals administered at home, home remedies, prayers and 
traditional healers), (a) Greater Kisii (green, n=581 fevers), (b) Kwale (blue, n=768 
fevers), (c) Bondo (yellow, n=975 fevers) and (d) Makueni (red, n=331 fevers).
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4.4 Discussion
4.4.1 General observations
A number of broad observations can be made from the community survey of 6,287 
children whose caretakers were interviewed about fevers in the last 14 days in the four 
study districts. First, reported fever was a common event among children under five. The 
overall period prevalence of fever among this age group was 42.2 %, which is consistent 
with what has been previously reported for children under five in Kenya (NCPD, 1989; 
1994; 1999). Second, there were significant differences in period prevalence of fever 
between the four districts that seemed to mirror their distinct malaria ecologies. Third, a 
substantial number o f fevers (42%) were treated outside the public formal sector using 
mostly western pharmaceuticals. Fourth, less than 3% of fevers were treated within 24 
hours with the nationally recommended first-line AM drug, SP, and obtained largely from 
the formal public sector. Finally, access and use of AM drugs between different service 
providers varied between the districts sampled. These observations and their policy 
implications will be discussed in the following sub-sections, but first the limitations of the 
study are discussed.
4.4.2 Study limitations
In most studies, treatment seeking for fevers is described as a hierarchical process where 
caretakers or patients first seek cheaper alternatives before progressing to the formal sector 
in the course of the illness. Studies undertaken at formal public facilities have shown that a 
high proportion of fevers are first treated at home with shop-bought AM and AP drugs 
before presenting to the health facility (Snow et al., 1992; Marsh et al., 1999). It is also 
acknowledged that caretakers’ responses to questions on health seeking are not always 
accurate. In a study in Malawi, Nwanyanwu et a l (1996) found discordance between 
mothers’ history of use of AM drugs among their children and the results of subsequent
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urine tests. A number o f reasons have been postulated to try to explain these discrepancies. 
In some cases, the illness episode is too minor and self-limiting for the mother to recall 
whether or not it was treated, and when treated with what drugs (McCombie, 2002). At 
times, the caretakers’ perception of the aims and objectives of the interview lead them to 
give responses that they think the interviewees want to hear (Deming et al., 1989; Slutsker 
et al., 1994; Nwanyanwu et al., 1996). In this chapter, emphasis has been placed on the 
first actions for treatment seeking obtained through community-wide rapid household 
surveys, much like the demographic and health surveys. Under reporting of treatment 
actions might have occurred especially among the “no action” group and among fevers 
reportedly treated first at formal public and private facilities.
In addition, no reliable information could be obtained from the community survey on 
adherence to dosage regimen. This is because data collected were inadequate in the sense 
that only the brands used and the total amounts consumed were collected without any 
indication as to the period over which (and how) the products were consumed. There is 
therefore need for more carefully-conducted research on adherence to AM dosage regime, 
much like the data used for the effectiveness model in Chapter 7.
4.4.3 Sources and types o f  treatment
Among the study populations, only 39.1% of fevers were reported to have been treated at a 
formal public or private clinical facility as a first action. This suggests that most people 
seek treatment outside the formal health sector, which is consistent with the findings of 
other workers in Kenya (Section 2.5) and across Africa (Section 1.8). Although a majority 
of fevers were treated outside the formal public sector, the proportion treated in this way 
receiving any AM drug (56 versus 37%), as well as receiving the first line recommended 
AM drug (25 versus 13%) was higher than for those seeking treatment from any other
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source. This points to the need for measures to improve prescribing practices in private 
sector clinics and fever management practices at home (Abuya, 2001). Further, the use of 
western pharmaceuticals was very high with about 95% of treated fevers being exposed to 
western pharmaceuticals. The most commonly used drugs were the AP and the AM drugs, 
an observation that has been made before in Kenya and elsewhere in Africa (Sections 2.5 
and 1.8). Among the AP and AM drugs used at home or obtained from the retail sector, the 
most widely accessed classes were paracetamol containing products for AP, and SP and 
AQ products for AM. Further, among these classes, a handful of brands were mostly used. 
The public health implications of this finding are discussed in relation to drug quality and 
effectiveness in Chapter 7.
4.4.4 Timing o f  treatment
Results indicate that there was a median waiting period of two days (IQR: 2, 4) across the 
four districts to any form of treatment for children less than five years of age. Among 
children presenting to a health facility in The Gambia with malaria, Greenwood et al. 
(1987) found that the mean duration between the onset of symptoms and development of 
severe complications was 1.8 days, and mean duration between onset of symptoms and 
death was 2.8 days. Considering that roughly 40% of the paediatric fevers reported are 
probably malaria (Greenwood et al., 1987; Brinkmann & Brinkmann, 1991), this delay in 
treatment seeking is of great concern. There is therefore need to encourage prompt 
treatment of fevers with appropriate first-line AM drugs as close to home as possible to 
reduce the risk of severe complications in this age group. Furthermore, more formative 
research is needed to understand why people delay seeking treatment to better target 
information, education and communication (IEC).
161
4.4.5 Use o f antimalarial drugs and the role o f the retail sector
The findings also showed that by the time of interview, only 30.8 % of reported fevers had 
been treated with AM drugs, 5.3% within 24 hours, and 14.7% within 48 hours. Across the 
districts, the public formal sector was found to be the most common source of early AM 
treatment with Greater Kisii having the best access to AM drugs and to SP. Better access to 
AM and to SP in Greater Kisii can be explained by proximity to public sector health 
facilities (which are best at availing these drugs, Table 4.10). Although the other districts 
have a more favourable health facility to population ratio (Table 4.1), over 99% of the 
population of Greater Kisii live within 5 km of a health facility. In contrast, 80% of the 
population in Bondo and only 65% of the population of Kwale and Makueni live within 5 
km of a health facility (Noor et al., 2003). Distance is therefore an important factor in 
accessing prompt, effective treatment for fever and malaria.
Outside the formal sector, the retail sector seems to have the greatest potential in 
improving access to AM drugs. This is because this sector is generally more accessible 
geographically, there are more outlets per head than the formal sector (10 retail outlets for 
every health facility, Table 4.1), and .treatment from this source involves less time and 
money. However, being a requisition-based supply system rather than the government run 
allocation system that is amenable to restricted supply in AM drugs in line with policy 
(Section 3.3.1), there is a predisposition towards demand-driven choice of drugs. AQ, a 
second line drug is freely available and sold in shops and pharmacies in Kenya (Siringi, 
2001) and the study districts are no exception (Section 5.3.4). This paradox creates a 
dilemma for the policy-practice interface and a better engagement of the retailers is 
required to restrict access to second-line treatment policy-recommended drugs (Section 
5.4.1).
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Approximately 33% of fevers treated at home or through the retail sector received an AM 
drug. This figure is comparable to a median of 38% (interquartile range (IQR) 28 to 53%) 
across eight districts in Kenya derived previously from a variety of studies (Section 2.5.1). 
Conversely, 53% of fevers treated through a formal clinic received an AM drug. This is 
much lower than a median of 91% (IQR 89 to 94%) previously derived for fevers treated 
through the formal sector in Kenya (Section 2.5.1). As explained in the study limitations, 
underreporting of treatment actions is not uncommon in surveys of this type and mothers 
are known to give incorrect answers to questions depending on the perceived purpose of 
the survey (Section 4.4.2).
4.4.6 Costs o f  drugs at government facilities
From the early independence days, through to the introduction of user charges in GoK 
facilities, children under five had been exempted from charges at health facilities. The fact 
that the majority of children under five in the community survey reportedly paid for drugs 
could have two, mutually reinforcing explanations. During the introduction o f user charges 
in the 1980s and 1990s, there was a concomitant drive towards decentralisation of health 
services to the district level to improve efficiency and accountability at the grassroots 
(Owino & Munga, 1997). This policy however was marred by implementation problems 
(Owino, 1997; Owino & Munga, 1997; Wang'ombe, 1997) leading to confusion in the 
health sector as to what constitutes “official” policy and what is not. In a number of press 
reports, the MoH has reiterated its policy of free health-care for under fives or for specific 
diseases like malaria flittp://www.nationmedia.com. accessed 07/12/04), but because 
decentralisation has entrusted the day-to-day running of facilities to DHMTs who have 
discretionary powers, it is possible that overlapping lines of authority sometimes result in 
conflicting messages, leaving each facility or district to interpret “policy” differently 
resulting in different waiver and exemption schemes. Another possibility is that
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prescriptions made at GoK facilities are filled from the retail sector since stock-outs of 
essential drugs are a common occurrence in GoK facilities; therefore, guardians report 
having paid for drugs even when they bought them from the private sector.
4.4.7 Gap between the Abuja Target and current practice
In terms o f promptness and appropriateness of AM therapy, results indicate that only 2.3% 
of fevers in the four communities were managed in the first 24 hours using SP, the 
recommended first-line therapy for uncomplicated malaria in Kenya in 2001. It is known 
that most treatments are incorrect or sub-optimal among populations across the continent 
(Section 1.8). Further, effective treatment is likely to be much lower than those who were 
simply treated with the correct drug (Krause & Sauerbom, 2000). In the Abuja declaration, 
African Heads o f States committed themselves and their countries to ensuring that 60% of 
fevers in the continent are treated promptly within the first 24 hours with safe, effective, 
quality AM drugs (WHO, 2000c). If all drugs were effective for the 5.3% fevers where 
AM drugs were accessed in the four districts within 24 hours, there still remains a huge 
gap between policy and practice. To bridge this gap a major investment in improving 
prompt access to AM drugs through improved behaviour change initiatives and improved 
physical access is required if  morbidity and mortality due to malaria is to be halved by the 
year 2010. And this is true of formal health sector as well as the retail sector.
4.4.8 Implications for ART-LUM, the new first-line policy
Although most fevers are treated outside the formal public sector, fevers treated within the 
public sector are more likely to receive the first-line AM drug than those treated outside 
this sector. The findings show that 25.7% of fevers treated through the GoK facilities and 
21.4% of those treated through the Mission and NGO sectors received SP, the first-line 
drug in 2001. Although this figure is low compared to previous studies in Kenya (Section
2.5), the finding nonetheless has a potential for exploitation. It is proposed that the new 
AM policy (ART-LUM) will be introduced in a staggered manner and will be distributed 
within the GoK and Mission and NGO sectors within the first two years of implementation 
(Section 2.5.2). Barring stock-outs in these two sectors, it means that more fevers 
presenting to public sector facilities will have better access to ART-LUM than fevers 
presenting to the private-for-profit sector and the retail sector since drug use in the formal 
sector is driven by prescription practices and that in the retail sector by patient choice. 
There is therefore need to encourage guardians of children below five to seek treatment for 
fevers and malaria in public sector health facilities. If current treatment seeking behaviour 
for fevers continues, almost 90% of children treated at home or through the retail sector 
will not have access to ART-LUM (about 10% receive first-line AM). This figure will 
most likely be much higher since ART-LUM is several times the cost of SP (Section
5.3.5). There is therefore a need to 1) encourage use of first-line AM drugs in the retail 
sector through targeted IEC materials and more specifically to 2) explore mechanisms to 
reduce prices of ART-LUM in the retail sector to guarantee better access to ART-LUM in 
this sector. The latter has been raised in a number o f meetings by the DMS (Section 
2.7.3.2)
Overall 8.3% of western pharmaceuticals dispensed were unknown by the respondents, 
almost all of these were provided by GoK facilities. This finding is hardly surprising given 
that caretakers at GoK facilities are rarely told what their children are suffering from nor is 
enough time spent in explaining medications prescribed or dispensed to them (Zurovac et 
al., 2005). There is need to improve patient prescribing and dispensing practices in public 
sector health facilities to improve patient adherence to ART-LUM. This is important 
because ART-LUM is taken over three days and has a complex dosing interval. In
165
addition, ART-LUM requires fatty meals for adequate absorption to take place. Poor 
adherence to ART-LUM will therefore result in lower drug effectiveness (see Chapter 7).
4.5 Summary
In this chapter, data were presented on the four study districts, the characteristics of the 
study populations, fever management practices, and drug use patterns. The districts were 
found to be diverse in their literacy, poverty, and malariometric indices and in their fever 
management and drug use patterns. Fever was found to be a common occurrence among 
children under five in Kenya with significant differences between the study districts, 
reflecting their respective malaria transmission characteristics. There were also differences 
between the districts in treatment rates, access to AM drugs and to SP, the first-line drug in 
2001 .
Although most fevers either remained untreated or were treated outside the formal public 
sector, fevers treated through this sector had the highest chance of receiving an AM drug or 
SP. There is therefore a need to improve access to formal sector providers during the early 
phases of implementation of the new AM policy, ART-LUM. The retail sector was also 
found to be an important source of treatment for fevers close to home and efforts must be 
made to improve drug supply, costs and delivery in this sector so that a more uniform and 
equitable access to AM drugs is maintained.
Finally, a policy-practice gap was found to exist between the Abuja target and current 
fever management practices. This gap needs to be bridged if  mortality and morbidity due 
to malaria is to be halved by 2010. A substantial investment in behaviour change initiatives 
in both the public and private sector is required. In the next chapter, the role of the retail
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sector in AM service delivery and its potential for rolling back malaria will be explored in 
further detail.
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ICHAPTER 5:
Availability, range, and costs of anti-malarial 
drugs and other commodities in the Kenyan 
retail sector
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5.1 Introduction
During the 2001 community survey, it was clear that the use of antimalarial (AM) and 
antipyretic (AP) drugs from the retail sector was common across all four study districts 
(Section 4.3.5) and that these findings were consistent with other studies in Kenya 
(Sections 2.5). Furthermore, the Division of Malaria Control (DOMC) has acknowledged 
that the retail sector is an important service provider for the home management of fevers 
(including malaria), as articulated in the Kenya National Malaria Strategy (KNMS), and is 
working in collaboration with partners in the health sector to explore ways to encourage 
appropriate drug use and provide relevant information for fever management through this 
sector (DOMC, 200If). This is in line with a WHO effort to improve access to AM drugs 
at household levels (WHO, 2003b). Such approaches to strengthen the retail sector require 
careful definition of the problems of AM service delivery by this sector. This chapter 
describes some of the features of the retail sector in the four sentinel districts. Data are 
presented on: the range and prices of AM drugs in the retail sector; knowledge of retailers 
regarding the use of AM drugs; and availability of non-drug commodities used in the fight 
against malaria. The variation in accessibility to a range o f AM products, prices and 
retailer knowledge is used to describe the potential weaknesses of this sector for fever 
management and ways in which these might be redressed.
5.2 Study location, design, and methods
The studies were conducted in the four districts described in Section 4.2.1.
I
5.2.1 Developing a national A M  database
A national list of all AM drugs in the Kenyan market was developed starting August 2001 
from three principal sources: two commercially available drug and medical devices price
)
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lists (SMS, 2001; Kimotho et al., 2002) and lists of registered AM drugs available at the 
Pharmacy and Poisons Board (PPB) of the Ministry of Health (PPB, 1996; 2001). The 
derived list included details of products such as brand names, dosage forms, strengths, 
manufacturers, trade packs, trade prices, and registration status.
For sulfur-pyrimethamine (SP) and amodiaquine (AQ) products, an attempt was made to 
triangulate the details of each product in the list with the manufacturers or dealers by 
regular correspondence via telephone, e-mail or fax. A further attempt was made to obtain 
samples of such products (by direct purchase) since official lists would not contain drugs 
that were considered to be in the country illegally. Digital photographs of oral preparations 
of AQ and SP were taken using a Nikon Coolpix 990 and photographs stored as JPEG files 
and exported into Word for Windows. This additional database was used as a visual aid for 
the community survey discussed earlier in Section 4.2.4.
Regular updates of AM drug ranges and prices were obtained from the two product lists 
and registration updates from the PPB list via regular visits to the PPB or via Kenya 
Gazette notices obtained from the Government Printers. This national AM database was 
used as a comparator for the range and prices of over-the-counter (OTC) AM products in 
the periphery (districts). Injections and suppositories, which would not ordinarily be 
available OTC, were excluded from analysis. To make the AM database temporally 
comparable to subsequent surveys in the districts, a period up to and including May 31 
2002 was selected as the cut-off point.
5.2.2 Retail audit sample
A retail audit was carried out between May and June 2002 where the unit of study was the 
retail outlet. Outlets were first identified from a commercial database subsequently visited
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to verify if  a) they still existed; b) they still sold AM drugs or not; and c) to secure consent 
for a more detailed study at a later date. This exercise was followed by a more in-depth 
audit using a structured questionnaire (see Appendix III). Detailed steps of how the audit 
was carried out are given in the following sub-sections.
5.2.2.1 Retail outlet census
5.2.2.1.1 The primary database
Data on retail outlets was purchased from Research International East Africa Limited, a 
commercial market research organisation that carried out a retail outlet census in Kenya 
between 1999-2000. In this survey, outlets were positioned using hand-held Global 
Positioning Systems (GPS). Information was collected on a number of parameters 
summarised broadly thus:
Outlet Location: Location was defined in terms of administrative boundaries, 
longitude/latitude, and street address (where relevant). Under the first, outlets were mapped 
to the sub-location level. The longitude, latitude and physical or street addresses of the 
outlets were also recorded. A final category was that of the site profile; whether or not the 
outlet was in a city centre, town centre, shopping centre, next to infrastructure like main 
roads, railways, airports and so on.
Type o f  outlets: Outlets were divided into 44 types. Examples were wholesale, wholesale 
and retail, hypermarket, mega market, food kiosk, wines and spirits shops, open market 
stalls, duty free shop, chain store, self-service store, and other.
Stock details: Under this, stock type was divided into 22 categories ranging from non­
alcoholic beverages (sodas, coffee, etc) to miscellaneous items like batteries and shoe 
polish. Each category was subdivided and coded. For instance, antimalarial drugs (stock 
type M) were sub-divided into tablets (1), syrups (2), and “other” (3). Stock sources were 
categorised into manufacturer, distributor, wholesaler, salesmen, retailers, imports, other, 
and each given a code.
Personnel: Details of the respondent were taken down; so were the number of employees 
(both full-time and part-time) and their weekly working hours.
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5.2.2.1.2 Data management fo r  sampling
Descriptive data on each outlet were used to identify outlets that stocked and sold AM or 
AP products at the time o f the retail census (1999-2000). Data were then displayed in 
Maplnfo (Version 6.0, 1985-2000) and physical addresses compared against correct 
coordinates of market centres obtained from topographic maps and GPS data from various 
sources (CBS, 2001a; Noor et al., 2003). Any errors in positioning in 1999-2000 data were 
then corrected and positions of outlets redefined to the market centre. Except for 
pharmacies, (Category 1 outlets), all other outlets reported to be selling over-the-counter 
(OTC) AM and AP drugs during the census, were grouped into two categories defined by 
the number of fulltime sellers. A Large duka/shop (Category 2) was defined as a store that 
sold its products over the counter with more than one person serving customers during 
normal working hours, while a Small dukalshop (Category 3) was defined as any outlet 
having only one person serving customers during normal working hours. This 
categorisation was based on the fact that the busier the shop (which is an indicator of stock 
and its turnover) the more staff are required to serve customers. Where there was an 
obvious discrepancy between this criteria and the situation on the ground, a combination of 
this and the stock was used to reclassify category 2 and 3 outlets.
The CBS classification of urban and rural areas was used to define “urban” or “rural” 
outlets (Section 4.2.3). In subsequent sections therefore, the terms “rural” or “urban” 
outlets imply outlets found in enumeration areas (EA) considered rural or urban according 
to the CBS definition. Shops were assigned to their relevant EAs after the retail audit.
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5.2.2.13 Sampling
Outlets thus identified and defined were sampled based upon the estimates of the numbers 
of retail outlets in each district and the expected prevalence o f key parameters of interest. 
Calculations were done using Epi-Info, version 6.04d (Centers for Disease Control, USA). 
Table 5.1 shows a sample district (Greater Kisii) and estimated prevalence of key 
parameters derived from studies conducted in Kilifi district (Dr V Marsh, personal 
communication). Sample sizes were derived to achieve between 5-10% precision and 95% 
confidence in the parameters of interest. It was estimated that the ratio of pharmacies to 
large shops to small shops would be 1:2:8. A minimum of 20 pharmacies in each district 
were targeted (all were included if less than 20). Large dukas were randomly sampled to 
achieve a minimum of 40 outlets per district, randomisation taking care of the rural/urban 
divide. Where Large Dukas were less than 40, all were included. For smaller outlets, a 
random sample of 160 per district was selected, randomisation also taking care of the 
rural/urban divide. Overall, about two hundred and twenty (220) outlets were assessed in 
each district. Samples were randomly selected using a simple raffle where strips of papers 
with the codes of the outlets were written, folded, shuffled, and picked until the required 
number of outlets in each category was achieved.
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Table 5.1: Sampling approaches for the Retail Audit Survey carried out in four districts of 
Kenya in 2002.
Parameter Estimated
prevalence
(Kilifi)
e.g. Greater Kisii 
(Number of 
outlets=2002)
Total
Types o f  OTC drugs sold in private retail outlets (brand names 
and pharmacological groups)
50% sell AM 92-322 340-1028
Presence in shop o f  effective first line AM drugs:
Within date
Adequate quality
Recommended type
Adequately stored
75%
75%
10%
60%
70-252
70-252
34-129
88-311
262-836
262-836
132-465
327-1000
Presence in shop o f  DOMC guidelines on use o f  OTC AM and 
AP drags (leaflet, poster, other)
0%
Seller knows DOMC recommendations for AP use with AM 
drags (e.g. SP plus paracetamol)
5% 70 265
Seller can use reference materials for dose and regime for AM 
and AP drags according to age o f  user (drag charts on packages 
or other according with DOMC recommendations):
For single dose AM regimes 
For multi-dose AM regimes
50%
20%
91-322
60-219
340-1028
226-743
Seller is willing to provide information on use o f OTC drags to 
customers
50% 92-322 340-1028
*
Figures in colum ns (x-y) represent required sample size for 5%-10% precision and 95% Cl.
5.2.2.2 Locating outlets
Each district was visited between February 18th and May 30th 2002 to sensitise the local 
administration and the Ministry of Health (MoH) personnel to the aims and objectives of 
the study. Bondo district was visited between February 18th and March 2nd; Greater Kisii 
between March 3rd and 23rd; Makueni between April 23rd and May 7th; and Kwale between 
May 13th and 30th. In addition, each selected shop was visited to establish its precise 
geographical position using a hand-held GPS unit (Magellan GPS 315 or Garmin etrex) 
and confirm that the outlet was still retailing AM drugs. Shopkeepers were informed of the 
purposes of the study and asked for permission to be interviewed later. Replacements were 
made both at this stage and later for shops and pharmacies that had closed (n=99); were not 
identifiable at the district level owing to incorrect or insufficient details on the original
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1999-2000 database (n=201); had no AM during recruitment (n=60); had no AM during 
the main survey (n=38) or where the shopkeepers refused to participate (n=5).
5.2.3 Retail audit fieldwork
A Retail Audit proforma (Appendix III) was designed and used to capture basic 
information on a number of parameters of interest. These were outlet’s position, 
advertising for AM, AP and other malaria resource materials, characteristics of retailers 
and the outlets, brands of AM and AP drugs, pharmacological groups, wholesale source, 
retail prices and basic storage conditions. Information was also sought on the presence in 
the outlets of insecticide treated bed nets (ITN), insecticides for treating nets, insecticides 
for indoor residual house spraying, mosquito coils, aerosols, and repellents. In addition, 
information was collected on official information, education, and communication (IEC) 
materials from the DOMC (posters and leaflets), branded advertisements, and shopkeeper 
knowledge of AM doses for adult and paediatric clients (two-year olds). Questionnaires 
were piloted in Mtondia, Kilifi district between January 10th and 20th 2002 and revised 
according to problems identified by field staff and selected shopkeepers.
Twenty field workers (FWs) were recruited and trained in survey methodology using 
standard training manuals. All but two of the FWs had at least a first degree, mostly in the 
social sciences and their research experience ranged from six months to five years. FWs 
were trained in Nairobi for three days. Briefing notes on each data collection form were 
prepared before the audit and used to brief the interviewers on how to handle each 
question. Training included role-play and mock interviews to ensure standardised 
approaches.
FWs were provided with the randomly selected outlet list and asked to interview the usual
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retailers and not those who occasionally stood in for them. Where there was more than one 
seller in the outlet, the longest serving seller was selected and interviewed. One of the FWs 
was selected as a team leader to co-ordinate fieldwork in each district. The team leader 
handled complaints, took corrective action, and evaluated interviewer performance and 
output.
Two techniques were used to ensure the quality of the data in the field: accompaniment, 
where FWs were accompanied by the supervisor in 10% of all interviews to gauge 
interviewer performance; back-checking where the team leader randomly sampled 10% of 
all shops and redid the interviews to ensure reproducibility of responses. In addition, all 
questionnaires were reviewed at the end of each day to ensure all questions had been 
answered and coded correctly. All completed questionnaires were re-reviewed within three 
days of receipt in Nairobi and any further queries returned to the districts for resolution. 
All data were entered twice using MS-Access 2000 developed data-entry screens, verified 
and cleaned as discussed previously in Section 4.2.5.
5.2.4 Statistical approaches
This has been covered in depth in Section 4.2.5. In addition, univariate and multivariate 
analysis was undertaken for questions on doses of AM drugs (Section 5.3.8).
5.3 Results
5.3.1 Characteristics o f retail drug outlets and retailers
Figure 5.1 shows the geographic coverage of the 880 outlets audited in 2002, while the key 
characteristics of the audited retailers are shown in Table 5.2. There was a good geographic 
spread of the outlets, representative of all four districts. Four small shops (all in Bondo 
district) were excluded from subsequent analyses since they remained closed even after
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three consecutive visits. The proportion of main sellers who were male ranged from 35.0% 
in Bondo to 70.0% in Kwale with significant differences between the districts (x2=59.4, 
df=3, p<0.001). Further multiple comparisons using the Marascuilo Procedure shows that 
Kwale district was different from all other district in this regard and Greater Kisii from 
Bondo (p=0.05).
Overall, a typical main seller was a 30 year-old male or female with 10 years of schooling, 
selling drugs at a 4.3 year-old outlet for a median 3.0 years. There were significant 
differences between the districts in the age of main seller (Kruskal-Wallis=43.7, df=3, 
p<0.001), years of schooling (Kruskal-Wallis=17.4, df=3, p=0.001), age o f outlet (Kruskal- 
Wallis=17.4, df=3, p=0.001) and length of period the main seller worked in the outlet 
(Kruskal-Wallis=47.8 df=3, p<0.001). Further multiple comparisons after Kruskal-Wallis 
test show that Greater Kisii district differed from Kwale, Bondo, and Makueni in age of 
main seller, years of schooling and years of service in the outlet. For the length of time the 
outlet had been open, Greater Kisii differed only from Kwale and from Bondo. In terms of 
years of service at the retail outlet, main sellers tended to have worked longer at their 
outlets in Greater Kisii than Kwale or Bondo, and longer in Kwale than in Makueni (Table 
5.2).
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5.3.2 Preventative antimalarial measures
Table 5.3 shows the relative availability of malaria preventative measures in the districts. 
The most widely available measures were mosquito coils (sold in 67.9% of outlets) and 
aerosols (30.5% of outlets). Fifty (5.7%) outlets were found to be retailing branded 
mosquito nets, with significant differences between the districts (11.0% for Kwale versus 
<6% in the other districts, ^=14.5, df=3, p=0.002). Forty-three (86%) o f these outlets were 
selling Supanet® which is marketed by Population Services International (PSI) under a 
social marketing programme. Supanet® was available in all the districts at a price range of 
200-400 KES. Eight other brands of treated nets were identified: Aggrevo® was available 
in one outlet in Greater Kisii at a price of 350 KES. Magic marble®, Nettee®, Didisnet® 
and Dawanet® were sold in Kwale (price range 450 to 550 KES) while Western Kenya 
net® and Mmbunet® were exclusively found in Bondo (price o f 400 KES). Unbranded nets 
were also sold in outlets in Bondo at a price range of 300 to 600 KES. Apart from 
Supanet®, the additional brand Globe® was also sold in Makueni.
Forty-eight outlets (5.5%) were retailing insecticides for treating mosquito nets, with price 
ranging from 30 and 100 KES per net treatment. The majority of the 48 outlets (90%) were 
retailing PSI’s Powertab®. Outlets in Kwale district were almost twice as likely to sell 
insecticides for treating nets than were outlets in the other districts (11.0% versus <6% in 
Greater Kisii, Bondo and Makueni, ^=16.2, df=3, p=0.001). Three brands o f insecticides 
for treating nets were identified. Powertab® was found in all districts (at 30 to 95 KES), 
KO Tab® in Kisii, Kwale and Bondo (at 30-86 KES) and Fendona® in Kwale only (at 100 
KES). Two outlets (a pharmacy in Bondo and one in Greater Kisii) sold insecticides for 
indoor residual house spraying and two brands, Flower® and Icon 10WP®, were identified, 
retailing at KES 204 and 650, respectively.
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From an outlet type perspective, a greater proportion of large shops (11.8%, price range 
200 to 600 KES) sold treated nets than did pharmacies (5.7%, price range 350 to 550 KES) 
and small shops (4.2%, price range 200 to 450 KES). Conversely, a greater proportion of 
pharmacies sold insecticides for treating nets than large or small shops (22.9%, 8.1% and 
2.9%, respectively). The price ranges of insecticides for treating nets were 50 to 300 KES 
in pharmacies, 35 to 86 KES in large shops, and 30 to 90 KES in small shops. Only 18.6% 
of pharmacies sold mosquito coils compared to 82.0% of large shops and 69.8% of small 
shops. Aerosols were sold in 34.3% of pharmacies, 58.4%, and 23.1% of large and small 
shops, respectively. Repellents were sold in 7.1% of pharmacies, 6.2% of large shops, and 
2.0% of small shops. Prices and brands of mosquito coils, aerosols, and repellents were not 
investigated.
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Table 5.3: Availability of preventative antimalarial measures in 876* retail outlets audited 
in 2002 in four districts of Kenya (Greater Kisii n=228, Kwale n=210, Bondo n=217, 
Makueni n=221). Figures in bracket show proportion of outlets selling a given item. 
Figures next to individual brands are price or price ranges in KES.
Outlets Greater
Kisii
Kwale Bondo Makueni Total P values^
Selling Bed nets: 11 (4.8%) 23 (11.0%) 8 (3.7%) 8 (3.6%) 50 (5.7%) 0.002
Supanet® 280-400 200-400 200-400 350 200-400
Aggrevo® 350 na na na 350
Magic Marble® na 500 na na 500
Nettee® na 450 na na 450
Didisnet® na 500 na na 500
Western Kenya Net® na na 400 na 400
Mmbunet® na na 400 na 400
Globe® na na na 400 . 400
Dawanet® na 550 na na 550
Unbranded net na na 300-600 na 300-600
Selling Insecticides for bed 
nets:
9 (3.9%) 23(11.0% ) 7 (3.2%) 9(4.1% ) 48 (5.5%) 0.001
Powertab® 50-95 30-95 50-86 50-90 30-95
KOtab® 50 30-50 50-86 na 30-86
Fendona® na 100 na na 100
Selling Insecticides for 
indoor residual spraying:
1 0 1 (0.5%) 0 1 (0.1%) 0.385
Icon 10WP® 650 na na na 650
Flower® na na 204 na 204 .
Selling Mosquito coils 125 (54.8%) 174 (82.9%) 140 (64.5%) 156 (70.6%) 595 (67.9%) <0.001
Selling Aerosols 70 (30.7%) 90 (42.9%) 48 (22.1%) 59 (26.7%) 267 (30.5%) <0.001
Selling mosquito repellents 8 (3.5%) 6 (2.9%) 4(1.8% ) 10 (4.5%) 28 (3.2%) 0.441
Four shops in Bondo were excluded from analysis. They remained closed even after three repeated visits.
 ^ Proportions compared using Pearson’s Chi-Square.
5.3.3 General drug stocks
Retailers were asked a series of close-ended questions on common drugs in stock, i.e. if  
they stocked AP, anti-diarrhoeal (AD), anticough (AC) and antihelminthic (AH) drugs. 
Table 5.4 shows the results to these questions. There were differences in the proportion of 
outlets selling the various drug classes between the districts, except in the case of AP drugs 
(y2=3.96, df=3, p=0.266). Nearly all outlets (>97% of outlets) sold AP drugs in all districts.
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Table 5.4: Stocks of common drugs available in 876* retail outlets in four districts in 
Kenya in 2002 (AP=Antipyretic, AD=Antidiarrhoeial, AC=Anticough, 
AH=Antihelminthic)
Outlets selling Greater Kisii Kwale Bondo Makueni Total
AP drugs 225 209 211 218 863
(98.7) (99.5) (97.2) (98.6) (98.5)
AD drugs 113 166 114 152 545
(49.6) (79.0) (52.5) (68.8) (62.2)
AC drugs 151 196 168 168 683
(66.2) (93.3) (77.4) (76.0) (78.0)
AH drugs 85 124 62 85 356
(37.3) (59.0) (28.6) (38.5) (40.6)
Four shops in Bondo were excluded from analysis. They remained closed even after three repeated visits.
5.3.4 Range o f AM  drugs at national and district levels
Table 5.5 shows the results of the national audit of AM drugs in circulation, their 
registration status with the PPB, whether locally manufactured or imported and their 
associated prices. From the national audit, 218 AM products (oral) were identified, 135 
(61.9%) of which were registered with the PPB. All artemisinin (ART) and mefloquine 
(MEF) tablets were registered while none of the ART suspensions or halofantrine (HAL) 
products were registered. Almost half of first and second-line AM drugs remained 
unregistered; of 65 SP products identified 34 (52.3%) were registered with the PPB whilst 
for AQ, 51.5% of products were registered with the PPB.
Overestimation of products at the national level could have occurred because only first 
time product registration was considered. This means that products which were registered 
but never marketed for commercial reasons or those which were initially marketed but later 
withdrawn by the PPB (for regulatory reasons) or the manufacturer or dealer (for 
commercial reasons) could potentially have been included in the list. Data needed to clear 
such doubts were unavailable from the PPB.
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Table 5.5: National audit o f oral anti-malarial drugs available on the Kenyan market in 
2002
Generic Name # Brands 
identified  
(registered)*
# Brands 
manufactured in 
Kenya (registered)
#  Brands 
im ported into 
Kenya  
(registered)
M edian (IQR) price 
(KES) o f Rx course1
Median (IQR) price 
(USD) o f Rx course1
SP tablets 49 (29) 11(7) 38 (22) 15.0 
[9.9, 25.5]
0.19 
[0.13, 0.32]
SP suspensions 
and drops1
16(5) 11(3) 5 (2 ) 30.6
[22 .3 ,41 .6]
0.39 
[0.28, 0.53]
AQ tablets 22 (12) 12(7) 10(5) 13.5
[10 .8 ,43 .2]
0.17 
[0.14, 0.55]
AQ suspensions 11(5) 9 (5 ) 2 (2 ) 21.7
[12 .0 ,38 .3]
0.28 
[0.15, 0.49]
CQ tablets 43 (33) 17(10) 26 (23) 7.4 
[6.0, 15.3]
0.09 
■ [0.08,0.19]
CQ syrups 2 2 (1 0 ) 17(6) 5 (4 ) 3.7 
[2.5, 23.7]
0.05 
[0.03, 0.30]
QN tablets 25 (19) 9 (7 ) 16(12) 215.5  
[189.0, 248.9]
2.73
[2.40,3.16]
QN drops and 
mixtures
3 (1 ) 3 (1 ) 0 176.4 
[147.0, 236.3]
2.24
[1.87,3.00]
ART tabs 11(11) 1(1) 10(10) 420.0  
[327.9, 438.1]
5.34
[4.16,5.56]
ART suspensions 1 (0) 0 1 (0 ) 304.5 
[304.5, 304.5]
3.86 
[3.86, 3.86]
MEF tablets 4 (4 ) 0 4 (4 ) 397.5 
[301.5, 751.1]
5.04 
[3.83, 9.53]
HAL tablets 1 (0) 0 1 (0 ) 627.0 
[627.0, 627.0]
7.96  
[7.96, 7.96]
HAL
suspensions
1(0 ) 0 1 (0 ) 222.9  
[222.9, 222.9]
2.83 
[2.83, 2.83]
* Registration: only first time registration was considered; withdrawals, re-registration after expiry o f the mandatory 5- 
year period or lack thereof was not considered. Registration period covers up to and including May 31 2002.
1 For packaged commodities, the calculations were derived per tablet and per recommended dose for adults. Where 
possible, large, bulk packaging was selected for individual suppliers to provide the cheapest values.
* Liquid dosage forms (suspensions, syrups, mixtures and paediatric drops) were all priced per dosage per child aged 1-5 
years -  not adult treatment courses. The mean dose per product was calculated as the mid-point between the DOMC 
recommended dose for a 1 year old (lower limit o f 10kg) and a 5 year old (upper limit o f 18kg)
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Figure 5.2 shows the stocking frequencies of the various AM drug classes encountered in 
the districts. AQ (the second-line drug at the time) was stocked by over 95% of retail 
outlets, followed by SP (the first-line drug), which was stocked by only 29% of retail 
outlets. CQ, which had been replaced by SP in 1998 as first-line drug was still available in 
retail outlets (17%). Other AM drugs were available in less than 10% of retail outlets.
Tables 5.6 to 5.10 present further details of the district level data in terms of the specific 
products encountered, their registration status and their relative stocking frequencies per 
retail category. Overall, AQ, SP, and CQ tablets were available in all retail categories in all 
the districts. AQ, SP and CQ syrups were available in all pharmacies and some general 
retail shops, but artemisinin (ART) products, halofantrine (HAL) and mefloquine (MEF) 
were exclusively sold in pharmacies.
Figure 5.2: Stocking frequencies of AM drugs in retail outlets audited in 2002
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For AQ tablets, 13 brands were identified of which six (46.2%) were registered with the 
PPB. Three brands (which were not registered) were only encountered in the districts and 
were not recorded during the national audit. These were Amowin® in Greater Kisii and 
Vanida® and Maratab® in Makueni. Malaratab® was the most widely stocked AQ tablet, 
found in 87.9% of outlets. Twelve brands of AQ syrup were encountered, 5 (41.7%) 
registered with the PPB; the most widely stocked being Amobin®, found in 4.3% of retail 
outlets.
Thirty brands of SP tablets were encountered in the districts, the two most widely stocked 
being Falcidin® (stocked by 19.9% of outlets) and Fansidar® (8.8%). Sixteen brands 
(53.3%) were registered with the PPB. Zentakelfin®, Sudorin® and Lansidar® (all 
unregistered) were available in some district level pharmacies and not recorded during the 
national audit. Fifteen brands of SP suspensions were also encountered. Of these, only 
Falcidin® and Kelfalin® were registered with the PPB. Pyralfin® syrup was the most widely 
stocked (found in 2.5% of outlets) followed by Falcidin® syrup (2.1%). The number of 
brands and registration status of the other AM classes were as follows: CQ tablets (12, 
41.7% registered), CQ syrups (9, 44.4% registered), QN tablets (3, 66.7% registered), QN 
syrups (4, 25% registered), MEF tablets (4, all registered), HAL tablets (1, not registered), 
HAL syrup (1, not registered), ART tablets and combinations (7, all registered), ART 
syrups (2, none registered), others (2, all registered). Products identified in the districts, but 
not recorded during the national audit were: C-quin® and SK-quine® tablets (CQ), Flaci- 
quin® tablets, Quinaquin® and Quinamor® syrups (QN), and Artesiane® syrup (ART). All of 
these remained unregistered with the PPB.
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Table 5.6: Range of AQ products available in 876* retail outlets in four districts in Kenya
in 2002 expressed as percent outlet type selling given product. Asterix indicates products
not registered with PPB up to May 31, 2002.
Pharmacies Large shops Small shops Total
AQ tablets
Malaratab® . 71.4% 89.4% 89.3% 87.9%
Betaquine®* 21.4% 16.1% 15.2% 15.9%
Emoquin®* 11.4% 3.7% 3.4% 4.1%
Alphaquine®* 1.4% 5.6% 3.6% 3.8%
Laeoquin® 2.9% 1.9% 2.6% 2.5%
Camoquin® 22.9% - - 1.8%
AQ unspecified 8.6% - - 0.7%
Kamoc®* 8.6% - - 0.7%
Uniquin® 7.1% - 0.2% 0.7%
Amobin® 5.7% - - 0.5%
Amowin®* 4.3% - - 0.3%
Diaquin^ 1.4% 0.6% 0.2% 0.3%
Vanida®* - - 0.3% 0.2%
Maratab®* 1.4% - - 0.1%
AQ suspensions
Amobin®* 51.4% 0.6% 0.2% 4.3%
Malaramed®* 35.7% 0.6% - 3.0%
Malaratab® 34.3% - 0.2% 2.9%
Falciquin®’ 22.9% - 0.2% 1.9%
Kamoc®* 22.9% - 0.2% 1.9%
Malarabit®* 17.1% - - 1.4%
Emoquin® 12.9% - - 1.0%
Camoquin®* 11.4% - - 0.9%
Uniquin® 11.4% - - 0.9%
Amoquin®’ 4.3% - 0.2% 0.5%
Laeoquin® 5.7% - - 0.5%
Diaquin® 1.4% - - 0.1%
*
Four shops in Bondo were excluded from analysis. They remained closed even after three repeated visits.
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Table 5.7: Range of SP tablet products available in 876* retail outlets in four districts in
Kenya in 2002 expressed as percent outlet type selling given product. Asterix indicates
products not registered with PPB up to May 31, 2002.
Pharmacies Large shops Small shops Total
Falcidin® 42.9% 27.3% 15.5% 19.9%
Fansidar® 81.4% 5.0% 1.9% 8.8%
Orodar® 42.9% 6.2% 3.4% 7.1%
Metakelfm® 74.3% 1.2% 0.8% 6.7%
Pyralfm®* 25.7% - - 2.1%
Malodar® 12.9% 1.2% 0.9% 1.9%
Laefin®* 17.1% - 0.2% 1.5%
Malareich® 11.4% - 0.8% 1.5%
Amalar® 14.3% - 0.3% 1.4%
Malidar®* 12.9% - - 1.0%
Metfin®’ 11.4% - - 0.9%
Nopyrin®' 8.6% 0.6% 0.2% 0.9%
Malostat® 10.0% - - 0.8%
Zentakelfin®* 8.6% - 0.2% 0.8%
Fanlar® 2.9% - 0.5% 0.6%
Intadoxin® 5.7% 0.6% - 0.6%
UB-Gomal® 5.7% - 0.2% 0.6%
Malastin® 5.7% - - 0.5%
Rimodar** 5.7% - - 0.5%
Lansidar®* 4.3% - - 0.3%
Methomine® 2.9% - 0.2% 0.3%
SP unspecified 4.3% - - 0.3%
Unidar®* 4.3% - - 0.3%
Viparum® 2.9% - 0.2% 0.3%
Falcigo®' 2.9% - - 0.2%
Fansmax® 2.9% - - 0.2%
Maladar® - 0.6% 0.2% 0.2%
Metakin®* 2.9% - - 0.2%
Methomine-S®' 2.9% - - 0.2%
Laridox®* 1.4% - - 0.1%
Sudorin®' 1.4% - - 0.1%
*
Four shops in Bondo were excluded from analysis. They remained closed even after three repeated visits.
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Table 5.8: Range of SP suspension products available in 876* retail outlets in four districts
in Kenya in 2002 expressed as percent outlet type selling given product. Asterix indicates
products not registered with PPB up to May 31, 2002.
Pharmacies Large shops Small shops Total
Pyralfin®* 31.4% - - 2.5%
Falcidin® 24.3% - 0.2% 2.1%
Intadoxin®* 20.0% - 0.2% 1.7%
Falcigo®* 18.6% - - 1.5%
Medifan®* 14.3% - 0.2% 1.3%
Orodar®* 11.4% - - 0.9%
Falcimax®* 10.0% - - 0.8%
Kelfalin® 8.6% - - 0.7%
Lansidar®’ 8.6% - - 0.7%
Malidar®’ 8.6% - - 0.7%
Nopyrin®* 5.7% - - 0.5%
Laefin®’ 4.3% - - 0.3%
Unidar®* 4.3% - - 0.3%
Fansmax®* 1.4% - - 0.1%
Viparum®’ 1.4% - - 0.1%
Four shops in Bondo were excluded from analysis. They remained closed even after three repeated visits.
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Table 5.9: Range of CQ products available in 876* retail outlets in four districts in Kenya
in 2002 expressed as percent outlet type selling given product. Asterix indicates products
not registered with PPB up to May 31, 2002.
Pharmacies Large shops Small shops Total
CQ tablets
Dawaquin® 4.3% 5.6% 4.2% 4.5%
CQ unspecified 25.7% 1.2% 1.9% 3.7%
Malaraquin®* - 3.1% 2.9% 2.7%
Homaquin® 2.9% 1.2% 1.9% 1.8%
Oroquin® 5.7% 0.6% 0.9% 1.3%
Intaclor®* 1.4% - 0.3% 0.3%
Cosmoquin® - 0.6% - 0.1%
C-Quin®* 1.4% - - 0.1%
Maxaquin®* 1.4% - - 0.1%
Nivaquine® - - 0.2% 0.1%
Novaclor®* 1.4% - - 0.1%
Oraclor®* 1.4% - - 0.1%
Rohoquin^’ 1.4% - - 0.1%
CQ suspensions
Mediquine® 17.1% - - 1.4%
Phinaquine® 15.7% - - 1.3%
Oroquin®* 12.9% - - 1.0%
Novaclor®* 8.6% - - 0.7%
Bioquin®* 2.9% - - 0.2%
Gestaquin® 1.4% - - 0.1%
Intaclor® 1.4% - - 0.1%
Rohoquin-P®’ 1.4% - - 0.1%
SK-Quine®* 1.4% - - 0.1%
Four shops in Bondo were excluded from analysis. They remained closed even after three repeated visits.
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Table 5.10: Range o f  quinine (Q N), halofantrine (HAL), m efloquine (M EF), artemisinin (ART) and 
proguanil (PRO) products available in 876 retail outlets in four districts in Kenya in 2002  expressed as 
percent outlet type selling given product. Asterix indicates products not registered with PPB up to M ay 31, 
2002 .
Pharmacies Large shops Small shops Total
QN tablets
QN unspecified 38.6 - - 3.1
Quinitab® 12.9 - - 1.0
Flaci-Quin®' 1.4 - - 0.1
Kwinil® 1.4 - - 0.1
QN suspensions
QN unspecified 48.6 0.6 0.2 4.1
Quinaquin®' 14.3 0.6 - 1.3
Quinamor®' 12.9 - - 1.0
Quinitab® 8.6 - - 0.7
Quinidril®’ 7.1 - 0.6
HAL tablets
Halfan* 31.4 - - 2.5
HAL suspensions
Halfan® 25.7 - - 2.1
MEF tablets
Mephaquin® 20.0 - - 1.6
Lariam® 2.9 - - 0.2
Mefliam® 1.4 - - 0.1
Meflotas® 1.4 - - 0.1
ART tablets
Artenam® 22.9 - - 1.8
Cotecxin® 21.4 - - 1.7
Arsumax® 20.0 - - 1.6
Annate® 14.3 - - 1.1
Coartem® 11.4 - - 0.9
Larither® 7.1 - - 0.6
Alaxin® 1.4 - - 0.1
ART suspensions
Cotecxin®’ 27.1 - - 2.2
Artesiane®' 7.1 - - 0.6
PRO tablets
Paludrine® 25.7 - - 2.1
PRO unspecified 17.1 - - 1.4
*
Four shops in Bondo were excluded from analysis. They remained closed even after three repeated visits.
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5.5.5 Prices o f products at national and district levels
The registration status of the products encountered during the national audit has been 
discussed in Section 5.3.4. For product prices, standardised dose regimens were used to 
enable comparisons between the AM classes. AQ, CQ, SP and QN doses were based on the 
malaria standard treatment guidelines of the DOMC of the MoH (DOMC, 1998). For all 
other AM drugs (which are not the subject of DOMC guidelines), The East African 
Pharmaceutical Loci, a regional formulary for healthcare professionals, was used (Kimotho 
et al., 2002). Where possible, large bulk packaging was selected per supplier to provide the 
cheapest national or source values to enable a description o f price differentials between 
national and district levels to be established (albeit with limited success).
Overall, at the national level, CQ syrup (for children less than five years) was the cheapest 
form of therapy for uncomplicated malaria at a median price of 3.7 KES (IQR 2.5, 23.7) 
while HAL tablets were the most expensive at 627.0 KES (IQR 627.0, 627.0). An adult 
dose of SP was priced at 15.0 KES (IQR 9.9, 25.5) while a standard dose for a paediatric 
patient on SP suspensions was priced nearly twice as much. AQ tablet and suspension 
prices were comparable to SP (13.5 KES for an adult dose and 21.7 KES for a paediatric 
dose, respectively). The price range for QN, MEF, and ART products was 176.4 to 420 
KES, at least 10 times that of SP tablets (Table 5.5).
Price data for the districts were treated in a similar manner and are summarised in Table 
5.11. Further, Figures 5.3 and 5.4 show prices of adult and paediatric doses of SP and AQ 
(first- and second-line, respectively at the time of the surveys), CQ (first-line AM till 1998, 
but still in circulation) and the ART derivatives. Taken together, a number of observations 
emerge. First, in both pharmacies and shops, CQ remained the cheapest therapy among 
adults (price range 8.3 to 37.5 KES) and children (13.8 to 20.6 KES) for treatment of
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uncomplicated falciparum malaria, followed by SP and AQ. The price of SP tablets ranged 
from 20 to 40 KES in the districts for an adult treatment course, representing between a 
33% and 167% mark-up when compared to the cheapest prices obtained from 
manufacturers at factory gates. A similar adult course of AQ tablets was 60 KES compared 
to the cheapest prices at factory gates of 14 KES. The price ranges for SP and AQ 
suspensions were 26.3 to 39.4 KES and 32.2 to 43.8 KES, respectively. In contrast, QN, 
HAL, MEF, and ART remained relatively expensive. In this latter group, QN syrup was 
the least expensive, ranging from 210 to 315 KES per paediatric treatment course. ART 
tablets and combinations were priced at 560 to 583.3 while their suspensions (for 
paediatric treatment courses) ranged from 367.5 to 411.3 KES equivalent to about 5 US 
dollars at the exchange rate of the survey period (Central Bank o f Kenya (CBK) exchange 
rate for last working day of June 2002 was 78.8 KES to the USD).
Table 5.15 shows that there were significant differences in the price of an adult dose of AQ 
between the districts (Kruskal-Wallis=l 1.6, df=3, p=0.009) with Bondo being significantly 
different from both Kwale and Makueni. There were also significant differences in the 
prices of CQ (Kruskal-Wallis=26.4, df=3, p<0.001) and QN (Kruskal-Wallis=9.8, df=3, 
p=0.021) between the districts. For CQ, Greater Kisii was found to be significantly 
different from Kwale and Bondo, and Kwale different from Bondo, and Bondo from 
Makueni. For QN, the only difference was between Greater Kisii and Kwale. For the 
paediatric formulations, there were significant differences in the price of AQ between the 
districts (Kruskal-Wallis=18.6, df=3, pO.OOl) and also in the prices of QN (Kruskal- 
Wallis=8.2, df=3, p=0.042). For AQ, the differences were between Makueni and Kwale, 
and Makueni and Bondo. For QN, only Greater Kisii was significantly different from 
Bondo.
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A comparison of the prices of adult doses of AQ, SP and CQ between pharmacies, large 
shops and small shops reveals that there were differences in the prices of AQ between 
large and small shops (Kraskal-Wallis=18.3, df=2, pO.OOl). For SP and CQ, there were 
differences between pharmacies and large shops and between pharmacies and small shops 
(Kruskal-Wallis=38.1, df=2, pO.OOl and Kruskal-Wallis=53.8, df=2, pO.OOl for SP and 
CQ, respectively). There were no large shops stocking SP suspensions. A comparison of 
SP suspensions between pharmacies and small shops reveals no significant difference 
(Kruskal-Wallis=0.9, df=l, p=0.347). There were no large or small shops with CQ syrups. 
All retail outlet categories stocked AQ syrups and the difference in paediatric prices 
between the retail outlet types was not significant (Kruskal-Wallis=2.0, df=2, p=0.373).
There were no significant differences in the adult prices of AQ between rural and urban 
outlets (Kruskal-Wallis=2.8, df=l, p=0.093). Likewise, there were no significant 
differences in the adult prices of SP (Kruskal-Wallis=0.02, df=l, p=0.879), CQ (Kruskal- 
Wallis=1.2, df=l, p=0.282) QN (Kruskal-Wallis=0.9, df=l, p=0.348), HAL (Kruskal- 
Wallis=1.8, df=l, p=0.178), MEF (Kruskal-Wallis<0.001, df=l, p>0.999), and ART 
(Kruskal-Wallis=0.3, df=l, p=591) between rural and urban settings. For paediatric 
formulations, HAL was only found in urban settings; therefore, there was no rural 
comparator. There were no significant differences between paediatric doses of AQ in rural 
and urban settings (Kruskal-Wallis=0.9, df=l, p=0.353) or that o f other AM drugs in these 
settings: SP (Kruskal-Wallis=0.9, df=l, p=0.339); CQ (Kruskal-Wallis=0.1, df=l, 
p=0.707); QN (Kruskal-Wallis=0.7, df=l, p=0.412), and ART (Kruskal-Wallis=T.5, df=l, 
p=0.214).
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Table 5.11: Median prices in KES [interquartile ranges (IQR)] of treatment courses of AM 
drug classes available at district level outlets in 2002 by district and rural/urban outlets
Greater Kisii Kwale Bondo Makueni Rural Urban Total
SP Tablets 30.0 
[20.0, 60.0]
30.0 
[20.0, 40.0]
30.0 
[20.0, 60.0]
25.0 
[20.0,53.3]
30.0 
[20.0, 45.0]
30.0 
[20.0, 60.0]
30.0
[20.0,51.3]
SP Syrups 35.0
[32.8,41.6]
39.4 
[29.2, 43.8]
39.4 
[32.8, 43.8]
39.4 
[35.0,43.8]
39.4 
[35.0, 43.8]
35.0 
[31.7, 43.8]
35.0 
[35.0, 43.8]
AQ Tablets 60.0 
[60.0, 60.0]
60.0 
[45.0, 60.0]
60.0 
[60.0, 75.0]
60.0 
[60.0, 60.0]
60.0 
[60.0, 60.0]
60.0 
[60.0, 60.0]
60.0 
[60.0, 60.0]
AQ Syrups 43.8
[32.8,43.8]
43.8 
[36.5, 58.3]
43.8
[32.8,51.0]
36.5
[25.5,43.8]
43.8 
[35.4, 47.4]
36.5 
[29.2, 49.2]
40.1 
[31.0, 47.4]
CQ Tablets 35.0 
[20.0, 35.0]
35.0 
[30.0, 40.0]
10.0 
[8.3, 35.0]
35.0
[15.6,35.0]
35.0 
[23.8, 35.0]
35.0
[10.0,35.0]
35.0 
[20.0, 35.0]
CQ Syrups 20.6 
[20.6, 30.9]
25.2 
[22.9, 27.5]
13.8
[4.1,20.6]
20.6
[10.2,25.8]
17.2 
[5.0, 24.1]
20.6
[4.1,24.8]
20.6 
[4.5, 24.1]
QN Tablets 252.0 
[189.0,267.8]
378.0 
[315.0, 409.5]
315.0
[252.0,315.0]
252.0
[189.0,252.0]
283.5 
[252.0,362.3]
252.0
[189.0,315.0]
252.0
[189.0,315.0]
QN Syrups 262.5
[237.7,315.0]
315.0 
[252.0, 378.0]
315.0 
[295.3,367.5]
315.0
[238.0,315.0]
315.0 
[262.5, 367.5]
315.0
[252.0,315.0]
315.0
[257.3,315.0]
ART tablets 500.0 
[450.0, 583.3]
560.0 
[495.0, 623.0]
595.0 
[490.0, 700.0]
583.3 
[520.8, 595.8]
525.0 
[490.0, 560.0]
560.0 
[484.2, 630.0]
560.0 
[484.2, 627.1]
ART
suspensions
367.5 
[302.7,393.8]
411.3
[324.6,428.8]
389.4
[287.8,393.8]
371.9 
[350.0, 393.8]
415.6
[415.6,415.6]
393.8
[350.0,402.5]
393.8
[350.0,404.5]
MEF tablets 580.0 
[476.5, 750.0]
600.0 
[600.0, 895.0]
590.0 
[535.0, 607.5]
600.0 
[600.0, 600.0]
600.0 
[575.0, 630.0]
600.0 
[577.5, 620.0]
HAL tablets 750.0 
[610.0, 788.0]
833.0 
[762.5, 847.5]
780.0 
[747.5, 781.0]
675.0 
[650.0, 700.0]
840.0 
[840.0, 840.0]
780.0 
[720.0, 800.0]
780.0 
[730.0, 807.5]
HAL suspension 280.0
[243.6,281.1]
294.0 
[270.2, 327.6]
274.4 
[264.3,288.4]
238.0 
[224.0, 252.0]
280.0 
[252.0, 292.6]
280.0 
[252.0, 292.6]
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Figure 5.3: Prices of adult doses of AQ, SP, CQ and ART in Kenya Shillings (KES) in four 
districts of Kenya. Greater Kisii (red), Kwale (green), Bondo (blue) and Makueni (purple). Central 
Bank of Kenya mean exchange rate to the US dollar in June was 78.8 KES (last working day of the 
month selected, http://www.centralbank. go.ke. accessed 07/12/04).
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Figure 5.4: Prices of paediatric doses of AQ, SP, CQ and ART in Kenya Shillings (KES) in four 
districts of Kenya. Greater Kisii (red), Kwale (green), Bondo (blue), and Makueni (purple). Central 
Bank of Kenya mean exchange rate to the US dollar in June was 78.8 KES (last working day of the 
month selected, http://www.centralbank.go.ke. accessed 07/12/04).
O0W
2
a
o
’- a
0
1T3
CD
CCS
PU
600
500-
400-
300-
200 -
100 -
0
N = 73 20 53 35
AQ SP CQ ART
196
Figure 5.5 shows median prices in KES of AQ, SP, CQ and ART tablets and suspensions 
against their cheapest national prices to demonstrate mark-ups. Because large shops and 
small shops did not stock all these products and their tablet and suspensions as well, they 
were excluded from this part of the analysis. There was no consistency in the mark-ups. 
The smallest mark-up was on SP suspensions at 14% and the highest on CQ suspensions at 
four and half times the price of the cheapest national source. Mark-ups on CQ tablets, ART 
tablets and ART suspensions were 35, 33, and 29%, respectively. AQ tablets in retail 
pharmacies were priced almost three times the cheapest national price (344%), while SP 
tablets and AQ suspensions were priced twice the national price (100 and 101%, 
respectively), suggesting a very high variability in regulations for different products in the 
retail pharmacy sector.
Figure 5.5: Median prices (KES) of AQ, SP, CQ and ART drugs in 70 retail pharmacies in 
Kenya (pink) against the cheapest national prices (blue) for the same category. The gap 
between the two lines represents the mark-up from factory gates.
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5.3.6 Sources o f wholesale AM drugs to retailers
For pharmacies, because of the wide range of products, it was not possible to ask the 
wholesale source of individual products. Therefore, respondents were asked the primary 
wholesale source of AM drugs in stock at the time. For large and small dukas, the source 
of each product audited was inquired. For the analysis in this section, the wholesale source 
of most products in stock was adopted as the primary source of AM drugs for each outlet. 
Drug sources thus defined were classified into eight classes as shown in Table 5.12. 
Results demonstrate that overall pharmacies obtained their AM drugs mostly from 
pharmaceutical wholesalers outside the districts (67.1%). Large shops obtained their drugs 
from general wholesalers outside the districts (39.8%) or inside the district 34.8%. Most 
small shops (45.3%) obtained AM drugs from general wholesalers within the districts. A 
substantial proportion of small shops (23.3%) also obtained their AM drugs from general 
wholesalers outside the districts. Mobile or itinerant vendors supplied a good number of 
small shops (14.0%) and large shops (7.5%), but not pharmacies.
Differences were observed in terms of drug supply between districts. The majority of 
pharmacies (75.0%), large shops (70.8%), and small shops (69.4%) in Greater Kisii 
sourced AM drugs from within the district. In contrast, all pharmacies in Kwale sourced 
AM drugs from outside the district (mostly Mombasa), as did most large shops (75.0%) 
and a good proportion of small shops (42.5%). Also most pharmacies in Bondo and 
Makueni (90.0% and 80.0%, respectively) sourced AM drugs from neighbouring districts 
(Kisumu for Bondo and Machakos and Nairobi for Makueni). Most small shops in 
Makueni (52.8%) obtained AM drugs from within the district while half o f the large shops 
did so from neighbouring districts. Company drug representatives and direct purchases 
from pharmaceutical companies did not represent main sources of AM drugs for any of the 
districts.
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5.3.7 Advertising and Information, Education and Communication (IEC)
Official MoH IEC materials were observed in the outlets together with branded advertising 
for malaria drugs, AP drugs, and malaria preventative measures (Table 5.13). Adverts were 
classified into two types: wall paintings (for example Figure 5.6) which covered the fa9ade 
or all of the building in which the outlet was housed and other adverts such as branded 
light boxes or promotional posters (for example Figure 5.7). Results demonstrated that wall 
adverts were very rare; less than 1% of all outlets had them with no significant differences 
between the districts 0^=3.82, df=3, p=0.281). In contrast, almost a third of all outlets 
(34.9%) had other promotional materials for malaria within the retail outlets, with no 
significant differences between the districts (x2=4.86, df=3, p=0.182). There were 
significant differences between the districts in the presence of DOMC posters (^=8.76, 
df=3, p=0.033) and leaflets (^=12.9, df=3, p=0.005), although these were very rarely 
available (<3% of outlets).
Retailers were also asked if their outlet had been visited in the preceding 12 months by 
MoH personnel for the purposes of inspection. Overall, 41.6% of outlets had been 
inspected, with differences between the districts ((x2=78.8, df=3, p<0.001). Makueni and 
Bondo districts had higher inspection rates (46.6 and 63.6%, respectively) while less than 
30% of outlets in Kwale and Greater Kisii had been inspected.
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Table 5.13: Presence of advertising and IEC materials for malaria in 876 retail outlets in 
the four study districts in 2002.
Greater Kisii Kwale Bondo Makueni Total P values
Wall adverts* 4
(1.8%)
2
(1.0%)
2
(0.9%)
0 8
(0.9%)
0.281
Other adverts* 72
(31.6%)
73
(34.8%)
71
(32.7%)
90
(40.7%)
306
(34.9%)
0.182
With DOM C  
leaflets
7
(3.1%)
0 1
(0.5%)
1
(0.5%)
9
(1.0%)
0.005
With DOM C  
posters
10
(4.4%)
1
(0.5%)
3
(1.4%)
5
(2.3%)
19
(2.2%)
0.033
Outlet inspected 
last 12 months*
67
(29.4%)
56
(26.7%)
138
(63.6%)
103
(46.6%)
364
(41.6%)
<0.001
Does the outlet have branded wall painting advertisement for malaria products? If yes, indicate branded product(s)
* Does the outlet have branded advertising materials on display that are not wall paintings for malaria products (AM & AP 
brands, nets, insecticides, etc)? If yes, indicate all branded products advertised.
* Has the shop/pharmacy being visited in the last 12 months by MoH inspectors?
Figure 5.6: Wall advert for Malaraquin®, a brand of CQ, among other drugs.
£  BBSs* iPanadol
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Figure 5.7: Promotional poster for Falcidin®, (a brand of SP) and Malaratab® (an AQ 
brand).
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5.3.8 Retailer A M  dosing knowledge
Retailers were asked whether or not they would give advice on the use of drugs purchased 
from them. In all, 721 retailers (82.3%) said they would. These retailers were further asked 
to state an adult and paediatric dose for a specified product. Some shops were excluded 
from analysis because of non-specific responses to the questions asked; for instance “... I 
would give a full dose (sic) . . .” without stating what the full dose was or “...swallow 
tablets (sic) at one go ...” without stating the number of tablets, to be taken (Table 5.14). 
Because fieldworkers were given the discretion to choose which product to base the 
questions on in this section and because of differences in availability of the various AM 
classes (most general retailers had AQ only), equal numbers were not achieved. As such, 
545 retailers were questioned on AQ, 29 retailers were queried about CQ and 147 about 
SP.
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Retailers were more likely to refer children to health workers (50.1%) than adults (0.1%) 
and more likely to dose an adult correctly than a two-year old child (x2=463.9, df=l, 
p<0.001 and df=l, p<0.001, respectively). More retailers were able to state the
correct adult dose of SP (53.5%) than for AQ (32.0%) or CQ (17.9%) with significant 
differences between these rates 0^=26.8, df=2, p<0.001). This pattern was also evident for 
paediatric doses; more retailers could state the correct paediatric dose for SP (43.0%) than 
AQ (2.0%) (x2=86.1, df=l, p<0.001). None of the retailers could state the correct CQ dose 
for a two-year old child.
Table 5.14: Retailer knowledge about AM drug dosages among 721 retailers in 2002
Correct dose Incorrect dose Referrals Excluded* Total
Adult*
AQ 173
(32.0%)
368 1 3 545
CQ 5
(17.9%)
23 0 1 29
SP 76
(53.5%)
66 0 5 147
Total 254
(35.7% )
457 1
(0.1%)
9 721
Paediatric*
AQ 4
(2.0%)
194 278
(58.4%)
69 545
CQ 0 8 16
(66.7%)
5 29
SP 49
(43.0%)
65 27
(19.1%)
6 147
Total 53
(16.6% )
267 321
(50.1% )
80 721
★
Do you ever give advice on how drugs in your shop should be used? If yes, what advice would you give about tab/susp
(one o f  the AM  brands stocked) for an adult?
* For this same brand, i f  a mother asked you how much she should give to her child o f  2 years, how would you advice 
her?
* Outlets were excluded for giving non-specific responses
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For each category (adult and paediatric), data were abstracted and a univariate and 
multivariate analysis was undertaken to see if correct dose was independently associated 
with a number of parameters for which data were available from the retail audit (these are 
shown in Tables 5.15 to 5.17) and which could potentially influence dosing knowledge. 
For an adult dose, the univariate analysis revealed that retailers were almost three times as 
likely to give a correct response on dose for a single dose regimen like SP than they were 
for multiple dose regimen like AQ and CQ (unadjusted odds ratio 2.5, p<0.001). All 
variables with p <0.25 in univariate analysis were further fitted into a logistic regression 
model (adjusted odds ratios and p values are shown in Table 5.15). Results indicate that 
only the type of drug (single-dose versus multiple) was significantly associated with 
correct dosing knowledge (adjusted odds ratio 2.38, p<0.001). Data for dosing for a two- 
year old child were treated in a similar way (Table 5.16). Although the univariate analysis 
showed that pharmacies (unadjusted odds ratio 3.33, p<0.001), presence in the outlet of 
DOMC posters (unadjusted odds ratio 7.18, pO .O ll), SP (unadjusted odds ratio 38.07, 
p<0.001) and use of a reference material for dose were positively correlated with correct 
dose, this association was retained only for the type of drug in multivariate analysis 
(adjusted odds ratio 45.6, p<0.001). Likewise, a logistic regression analysis was carried out 
for the determinants of referral of children to health workers (Table 5.17). General retail 
outlets were 20 times more likely to refer to a health worker than were pharmacies 
(adjusted odds ratio 0.05, p<0.001) and questions on AQ and CQ were three times more 
likely to be referred by retailers to health workers than were those on SP (adjusted odds 
ratio 0.30, p<0.001).
204
Table 5.15: Univariate and multivariate analysis of various predictors of correct retailer
dosing of adults.
Parameter Univariate analysis 
(Unadjusted odds ratios, p 
values)
Multivariate analysis 
(Adjusted odds ratios, p 
values)
District 0.93, p=0.379 na*
Outlet location (urban/rural) 0.85, p=0.322 na
Type o f  outlet (pharmacy/general retail) 0.98, p=0.952 na
Presence in shop o f  wall adverts for malaria and malaria- 
related products
0.30, p=0.262 na
Presence in shop o f  other adverts for malaria and malaria- 
related products
1.06, p=0.731 na
Outlet age (in years) 0.99, p=0.324 na
Age o f main seller 0.99, p=0.142’' 0.99, p=0.527
Sex o f main seller 1.22, p=0.208’ 1.26, p=0.163
Level o f  education o f  main seller (in years) 1.05, p=0.069’ 1.02, p=0.582
Employment duration o f  main seller (in years) 0.97, p=0.068* 0.98, p=0.340
Presence in shop o f  DOMC leaflets 0.51, p=0.404 na
Presence in shop o f  DOMC posters 0.59, p=0.370 na
Drug regimen asked about (single dose [SP] or multiple [AQ 
or CQ])
2.53, p< 0 .00 l’ 2.38, p<0.01
*
Included in a logistic regression model using Stata, Version 8.2 (Stata Corp., College Station, USA) 
^na-not applicable
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Table 5.16: Univariate and multivariate analysis of various predictors of correct retailer
dosing of a two-year old child.
Parameter Univariate analysis 
(Unadjusted odds ratios, p 
values)
Multivariate analysis 
(Adjusted odds ratios, p 
values)
District 0.93, p=0.640 na
Outlet location (urban/rural) 0.98, p=0.942 na
Type o f  outlet (pharmacy/general retail) 3.33, p<0.001* 0.79, p=0.585
Presence in shop o f  wall adverts for malaria and malaria- 
related products
na na
Presence in shop o f  other adverts for malaria and malaria- 
related products
1.56, p=0.143* 0.67, p=0.308
Outlet age (in years) 1.00, p=0.894 na
Age o f main seller 1.01, p=0.453 na
Sex o f main seller 1.30, p=0.392 na
Level o f  education o f main seller (in years) 1.06, p=0.262 na
Employment duration o f  main seller (in years) 1.02, p=0.576 na
Presence in shop o f  DOMC leaflets 1.69, p=0.651 na
Presence in shop o f  DOMC posters 7.18, p=0.011* 1.66, p=0.528
Drug regimen asked about (single dose [SP] or multiple 
[AQ or CQ])
38.07, p<0.001* 45.6, p<0.001
If reference material (drugs packaging, etc) was used 
before stating dose
2.44, p=0.003* 1.82, p=0.138
*
Included in a logistic regression model using Stata, Version 8.2 (Stata Corp., College Station, USA) 
^na-not applicable
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Table 5.17: Univariate and multivariate analysis of various predictors of referral of a two- 
year old child by retailers to health workers.
Parameter Univariate analysis 
(Unadjusted odds ratios, p 
values)
M ultivariate analysis 
(Adjusted odds ratios, p 
values)
District 0.92, p=0.245* 0.96, p=0.597
Outlet location (urban/rural) 1.02, p=0.888 na
Type o f outlet (pharmacy/general retail) 0.02, pO.OOl* 0.05, p<0.001
Presence in shop o f  wall adverts for malaria and malaria- 
related products
1.33, p=0.708 na
Presence in shop o f  other adverts for malaria and malaria- 
related products
0.729, p=0.055* 1.13, p=0.528
Outlet age (in years) 1.02, p=0.113* 0.98, p=0.344
Age o f main seller 1.02, p=0.002* 1.02, p=0.074
Sex o f main seller 1.02, p=0.908 na
Level o f  education o f main seller (in years) 1.00, p=0.990 na
Employment duration o f main seller (in years) 1.04, p=0.006* 1.03, p=0.302
Presence in shop o f  DOMC leaflets 1.00, p=0.996 na
Presence in shop o f  DOMC posters 1.14, p=0.799 na
Drug regimen asked about (single dose [SP] or multiple 
[AQ or CQ])
0.17, pO.OOl* 0.30, pO.OOl
If reference material (drugs packaging, etc) was used 
before stating dose
1.08, p=0.642 na
*
Included in a logistic regression model using Stata, Version 8.2 (Stata Corp., College Station, USA) 
^na-not applicable
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5.4 Discussion
In this chapter, a number of potential strengths and weaknesses in the retail sector delivery 
of AM services have been identified, which are presented and discussed below; with 
special emphasis on the implications for the new first-line AM drug, ART-LUM 
(Coartem®). An important caveat to the interpretation of the results in this chapter is the 
study limitations. About 300 outlets in the original RI database had to be replaced because 
they had closed (99) or they could not be traced owing to insufficient details in the 
database (201). This is a likely source of bias in the study. A second likely source of bias in 
using the RI database is the fact that new outlets established since the census would have 
been left out of the sampling frame for the retail audit, i.e. there is a bias against new 
outlets being included in the sampling frame. Indeed, Conteh & Hanson (2003) posit that 
such lists are notoriously unreliable in developing countries and the best way of 
constructing a sampling frame for studying private providers of public health products 
(PHPs) is a full census of all outlets in a locality backed up by regular updates to account 
for “new” outlets. Such an approach has for instance been used by Goodman and 
colleagues in Tanzania to study the retail market for antimalarial drugs (Goodman et al., 
2004).
Another likely source of bias, especially with regard to the stocking of drugs and their 
prices, is the timing of the retail audit. The study was conducted in June 2002 which is the 
peak malaria season in most of the study districts and when most retailers are likely to 
stock antimalarial drugs. The drug prices are also likely to be high in this season when 
there is a higher demand for antimalarial drugs than the rest of the year. Establishing 
seasonal variations in provision of PHPs in the retail sector calls for a longitudinal study 
design (Conteh & Hanson, 2003) and not the cross-sectional design used in the current 
study.
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5.4.1 A vailability o f wide range o f AM drugs
There was a wide range of AM oral products available nationally and in the four study 
districts. Over 49 brands of SP tablets were identified nationally, 30 (61%) of which were 
available at the district level retail outlets sampled in the four districts. Likewise, 22 brands 
of AQ tablets were identified during the national audit, about 13 (59%) of which were in 
retail circulation in the study districts. Conversely, there were brands which were in retail 
circulation at the district level, but which had not been identified during the central audit 
and which were unregistered by the PPB.
One serious consequence of a wide range of products available to largely biomedically ill- 
informed, rural populations is brand confusion, which may lead to unintentional repeated 
doses of the same drug class and consequently, dose-dependent adverse effects (Osei & 
Beecham, 1990). Brand confusion also leads to a delay in seeking treatment during self- 
medication (Mwenesi, 1993). Another inevitable consequence of multiple brands is 
“generic substitution”. Whereas generic substitution (replacing expensive brand names for 
cheaper, non-branded or branded alternatives) has been fervently argued to cut prices, in a 
situation where the patient is uninformed, unscrupulous service providers could potentially 
give generic products in place of the “original” and still charge for the prices of the latter. 
Anecdotal evidence suggests that this indeed happens in Kenya; especially in pharmacies 
where staff are invariably more knowledgeable than the majority of clients they serve. For 
instance, while sampling drug products for a WHO sponsored multi-country study of 
which Kenya was part (see Chapter 6 for results of this study), investigators from the 
National Quality Control Laboratory were surprised that “generic” products they sampled, 
especially from Coast province, were priced as much as the originator brands (Dr E Ogaja, 
personal communication).
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The most widely available AM in the retail sector was AQ sold in over 95% of outlets 
surveyed. AQ is a prescription-only-medication (POM) and was second-line treatment at 
the time of the survey. In contrast, SP, the first-line drug in 2002 was available in only 
29% of outlets surveyed. The situation was found to be different in neighbouring Tanzania. 
A similar study carried out between May and August of 2000 when CQ was still the first- 
line drug for uncomplicated malaria in Tanzania, found that 33% of general retail shops 
and 98% of pharmacies stocked CQ, while SP, the second-line treatment, was sold in <1% 
of general retail shops and in 37% of pharmacies (Goodman et al., 2004). This points to 
the fact that there is a policy-practice disconnect in Kenya in drug scheduling and in the 
national malaria policy. Aggressive promotion of first-line AM drugs over and above all 
others and restriction of access to second-line drugs may be needed to redress this 
situation. This was attempted by the DOMC in 2000 during the transition from CQ to SP 
when they actually provided named SP brands in information posters to community (see 
Figure 5.8 for example). There was a realisation even then that not all SP products in the 
market would be of good quality, therefore only those brands whose quality had been 
assured by NQCL were put on DOMC IEC materials. But clearly, the stocking of drugs by 
retailers is still driven by market forces and not by government policy decisions and 
preferences. Closer cooperation and consultation with local pharmaceutical manufacturers 
and importers of AM drugs during policy changes is required but difficult to manage 
because the dynamics of drug policy changes put government and industry at different 
ends of an ‘interest spectrum’; government’s interest lies in the well-being of its citizens; 
the pharma industry interests are in profit margins. Whereas governments change policy in 
a slow, ponderous and usually unpredictable way (Chapter 2), industry quite like having 
guarantees and predictability (which the government invariably can not give) and so have a 
vested interest in maintaining the status quo since they have drugs already in the market 
and need to recoup their investments, whether such drugs are failing or not. There is
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therefore a need for innovative strategies to engage industry early on in the policy change 
process without compromising public health.
Figure 5.8: DOMC poster with NQCL quality-assured brands of SP
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5.4.2 Prices o f  A M  drugs
The results indicate that the cheapest therapy using ART derivatives were priced at about 
five US dollars (368 KES) for a child o f one to five years, and seven US dollars (560 KES) 
for an adult in the study districts. The results are consistent with a contemporaneous WHO 
study in Kenya for 2002 that aimed to pilot tools developed for a drug pricing 
methodology developed by Health Action International in collaboration with WHO. 
Results in Figure 5.9 indicate that the price ranges o f adult patient packs o f ART products 
were approximately five to seven US dollars, comparable to those in the present study.
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Figure 5.9: Price (USD) o f artemisinin antimalarial products in the private sector in Kenya 
(WHO, 2002)
10.CO T
B.CO - -
I'e.cc--
4.C0 - -
2.00
DHA/B'S AS/l2rS
DHA/8's Dfiyftaartemisinin table's (pack of 8) 
AS/!2's Ar!esunaie &Nets (pack oH2)
AM/14fs A M /Syrup
AiY/M's Artejnether iabfefs (pack o f }2)
A ilffiyrup Artemelter Syrpp (120 mfy
In a study conducted in May 2000, Myhr (2000) surveyed the prices o f 15 essential drugs 
in private pharmacies, private-for-profit hospitals, and public sector hospitals in five 
countries: Kenya, Uganda, Tanzania, Ethiopia, and Norway. Data from this survey on 
prices o f AM drugs (artemether and mefloquine) in private pharmacies in Kenya were 
abstracted by way o f comparison with the present study, i.e. the retail audit. In Myhr’s 
study, the unit price range (one tablet) for artemether 50mg in Kenya was estimated to be 
between 0.62 to 0.68 US dollars which is slightly higher than in the present study (0.45- 
0.73), but comparable to that in neighbouring Uganda (0.47-0.72). However, the prices of 
originator mefloquine (Hoffmann La Roche) and generic mefloquine in Myhr’s study were 
comparable to that obtained in the retail audit (Table 5.18). The prices from the Myhr 
study, however, would be higher than those in the present study if  inflation over the period 
2000-2002 were taken into consideration (7%, 3.3%, 1.9% in 2000, 2001 and 2002 
respectively http://www.indexmundi. com/g/g. asnx?c=ke&v=71. accessed 21/06/05), 
suggesting that drug prices have been on the decline in real terms over this period. Generic 
drugs were found to be cheaper than originator products (Myhr, 2000). Figure 5.10 shows 
data abstracted from the retail audit for SP and AQ which reinforces the fact that generic
AM drugs are cheaper than originator AM drugs. Further, even among generics, branded 
generics are more expensive than those marketed under the international non-proprietary 
name (INN), for instance “sulfadoxine pyrimethamine tablets” or “amodiaquine tablets”.
The present study showed that there were significant differences in the prices of some AM 
drugs at the district levels. Myhr (2000) found that the same was true at country levels and 
concludes that these variations were explained by the dictum “.. .pharmaceutical pricing is 
about the law o f the jungle where might is right and drugs are very far from being equity 
priced” (Myhr, 2000). Drug prices are therefore set according to what the market can bear, 
whether that market is a resource-poor country’s like Kenya or a wealthy nation’s like 
Norway.
Table 5.18: Variations in unit prices (in US dollars)* and availability of tracer AM drug 
products in private pharmacies in five countries in 2000 compared with the Retail Audit, 
2002 .
Present chapter M yhr 2000
Retail audit 2002 
(n=70)
Kenya
(n=17)
Uganda
(n=8)
Tanzania
(n=10)
Ethiopia
(n=10)
Norway51
Artemether 50mg 
tablets USD (min, max)
0.62
(0.45-0.73)
0.64
(0.62-0.68)
0.58
(0.47-0.72)
0.88
(0.63-1.1)
naT na
Mefloquine 250mg 
tablets- Roche USD  
(min, max)
3.7 
(3.6-3.7)
3.7 
(3.6-3.7)
na 5.5 
(2.8-8.1)
na 3.1
Mefloquine 250mg 
tablets- generic USD  
(min, max)
1.9 
(1.2-2.9)
2.0 1.8 
(1.2-2.5)
3.1 
(1.9-5.0)
na na
*The Central Bank o f  Kenya mean exchange rate o f  the KES to USD was 78.8 at the time o f  survey.
* na-not available
* Norwegian retail prices were abstracted from the official price list
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Figure 5.10: Differences in the 2002 unit prices (in KES) o f generic and originator 
products for SP (500/25mg tablets, green) and AQ (200mg tablets, red) in Kenya. CBK 
mean exchange rate to the US dollar was 78.8 KES on June 28,2002.
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In contrast to the price o f ARTs, the first-line therapy o f SP in June 2002 was less than one 
US dollar per adult treatment course (20 to 40 KES). This has created expectations that 
therapies for malaria must be considerably less than a dollar. This o f course raises issues in 
terms o f affordability to the public o f new ART combinations all o f which are in excess of 
one USD per adult treatment course. The retail sector is an important source o f  treatment 
and it seems unlikely that poor households would be able to afford the new therapy over 
the counter. Even in the government sector, this has policy implications and financial 
sustainability has resulted in a delay in policy implementation o f the new ART-LUM 
policy in Kenya (Section 2.7.3.2). Greater access to these products by way o f bulk 
purchase through the government sector (as is currently the arrangement with WHO and
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Novartis) or regulatory measures that down-regulate ART products to OTC status (as is 
planned after studying the safety of ART-LUM under operational use in Kenya) might 
benefit from economics of scale thus bringing the prices down.
Four-dose ART-LUM (see private sector Coartem®, Figure 3.5) was found in eight district 
level pharmacies (i.e. 11% of pharmacies) in Greater Kisii, Bondo and Kwale (but not in 
Makueni) at a median price of 600 KES (7.6 USD, interquartile range 492 KES (6.2 USD), 
794 KES (10.1 USD). Overall, there were no variations in the prices of ART derivatives 
and combinations like ART-LUM between the districts. This is probably because ARTs 
were available only in pharmacies where retail mark-ups are more uniform than in general 
retail shops. The Pharmaceutical Society of Kenya (PSK) recommends that retailers put a 
33% mark-up on the trade price of medicines and an additional dispensing fee of KES 20 
per prescription for POM drugs (Kimotho et al., 2002), although Myhr reports mark-ups of 
15% among wholesalers in Kenya and 20% among retailers (Myhr, 2000). The profit 
margin of ARTs on the cheapest national prices was 29% in this study, comparable to the 
PSK recommended mark-up. Down regulation of Coartem® from POM to OTC to increase 
access in general retail shops is likely to result in wide variations in prices since 
“pharmaceutical pricing is about the law of the jungle” (Myhr, 2000). The results also 
demonstrate that drug scheduling in Kenya is largely ineffective. AQ a POM drug and 
second-line at the time of the study was available in over 95% of shops, yet SP, the first- 
line drug, which was OTC, was relatively unavailable. This lack of adherence to drug 
schedules will further encourage leakage of public sector Coartem® into the private sector 
where there will be a ready market and where the application of rules is lax.
A surprise finding that opens opportunities for increased regulation o f the retail sector to 
detect ‘leakage’ was the fact that a high proportion of retailers across all the districts
215
reported that they were visited by MoH personnel in the preceding 12 months (30 to 64%). 
Although the precise nature of these visits is still unclear, anecdotal evidence from the 
retailers suggests that inspectors usually instruct retailers to remove expired drugs or failed 
drugs like CQ from the shelves. Good inspection rates can be used to reinforce key drug 
policy messages to ensure a better chance of programmatic success.
Differences were noted between pharmacies and general retail shops in terms of drug 
sources and drug ranges, with pharmacies getting their drug supplies from wholesale 
pharmacies and general retail shops obtaining theirs from general wholesalers. This has 
also been noted in neighbouring Tanzania (Goodman et al., 2004). Pharmacies also had a 
wider range of antimalarial products. However, there were no discemable differences 
between pharmacies and general retail shops in terms of product prices and retailer 
knowledge of antimalarial drugs. Given the de jure  licensing and inspection requirements 
for pharmacies in Kenya, one would expect that they be manned by well qualified staff 
with better knowledge of antimalarial drugs than is the case for general retailers. It seems 
from the results however that such regulations are only “on paper” and not properly 
enforced, an observation made in Chapter 3 with regard to drug registration and post­
marketing surveillance and in this Chapter with regard to enforcement of prescription-only 
status of AQ. There is need to engage the Pharmacy and Poisons Board and other 
regulatory bodies to ensure the success of the national antimalarial drug policy.
5.4.3 Retailer knowledge of AM dosage
Of concern for OTC drugs generally is the poor knowledge of AM drug use by 
shopkeepers especially with regard to paediatric use (Marsh et al., 1999). Whereas 
approximately a third of the general retailers interviewed in the present study could state 
the correct AQ dose for adults, less than 2% could state the correct dose for a two-year old
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child. The logistic regression models also revealed that the type o f drug (single dose versus 
multiple doses) was the biggest predictor of correct dosing and of referral to health 
workers; they were more likely to get SP dose correct than the multiple dose regimen. One 
limitation of the present study, however, was that direct questioning about normal practice 
was used rather than simulated client surveys, which would probably have been a better 
method of investigating retailer behaviour. It has been observed that asking service 
providers hypothetical questions has an element of bias since respondents tend to give 
“socially desirable” responses, i.e. they overestimate what they think is expected of them 
and underestimate what they think they ought not to do or say, as such the rates given here 
are probably overestimates. Such response bias is minimised in simulated client surveys 
where real-life scenarios are presented to service providers by way, for example of a ‘sick’ 
adult (decoy), and drugs being actually purchased or dispensed. In such surveys, actual 
practice is therefore captured (Madden et a l,  1997).
There are only a few studies on retailer knowledge o f AM drugs in Kenya and the few that 
have been done are not exactly comparable. Marsh et al. (1999) for instance used the 
proportion of retail clients who purchased an adequate dose of AM in Kilifi (as opposed to 
a hypothetical patient in the retail audit) or proportion of clients who reportedly adhered to 
retail-bought AM drugs from community-wide cross-sectional surveys (Section 2.5.2). 
Nonetheless some broad similarities and differences can be drawn. The present retail audit 
in four study districts was comparable to the pre-training period of the Kilifi study in Table 
5.19, which shows that although retailer knowledge o f AM is concordant with those who 
purchased correct dose in Marsh’s study (29.8% versus 31.8%), the proportion of retailers 
who gave advice were different between the present retail audit and the Kilifi study. 
However, the sample size for advice on AM was very small in the Kilifi study compared to 
the retail audit. Included in Table 5.19 are the results of retailer knowledge after a
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programme of retailer training on dosing knowledge and general advice. Post-training 
follow-up in Kilifi revealed that these gains were maintained over time with 86 to 99% of 
trained retailers giving correct dose of AM drugs (Marsh et al., 2004). Similar studies in 
Bungoma have shown that although retailer knowledge of AM dosing is poor, this can be 
improved with minimal training and resource input (Tavrow et al., 2003).
Marsh’s study in Kilifi is part of a wider KEMRI/Wellcome Trust and DOMC 
collaboration that aims to improve antimalarial service delivery in the retail sector. The 
initial pilot studies in Kilifi were funded by the DflD. In July 2004, this study was scaled- 
up to five other districts: Kwale, Busia, Makueni, Gucha and Nandi North, using funds 
availed through the Round II application to the Global Fund for AIDS, TB and Malaria 
(GFATM). Further, between July and November 2004, the DOMC conducted a training of 
trainers (TOT) workshop for district public health officers and district health education 
officers from Nyanza, Western and Rift Valley provinces and it is hoped that the 
programme will be scaled-up to the national level using this strategy (Mr B Adika, 
personal communication).
Table 5.19: Retailer knowledge about AM drug use in Kilifi and in the Retail audit study 
districts.
Marsh et al (1999) 
Kilifi
Retail Audit 2002 
Greater Kisii, 
Kwale, Bondo, 
Makueni
Before Training 
Dec/Jan 95/96
After training 
June/July 1999
After training 
Dec/Jan 96/97
No training1
Give advice on use of AM drug 2.0% (0.4-3.6)t 93.5% (88.8-96.3) 97.5 (92.3-99.3) 82.3% (79.6-84.7)
Purchase adequate dose* of AM (all 
AM sales)
31.8% (26.6-37.6) 82.7% (76.3-87.3) 89.9% (82.7-94.4) 29.8% (27.0-32.7)
’Adequate dose according to national standard treatment guidelines
* Fleiss-Quadratic 95% confidence intervals
* Retailers in the audit were assumed not to have been trained for lack of information
)
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ART-LUM, the new first-line AM policy, is a multiple dose regimen and retailers are 
therefore likely to give poor advice to retail clients on its use, based on the results of this 
chapter. If ART-LUM is deregulated and made available as an OTC drug (Section 3.4.4), 
then clear, unambiguous training materials and retailer training programmes would be 
required to make retail outlets function as appropriate outlets for ACTs. The univariate 
analysis did show that the presence in the retail outlet of DOMC posters was associated 
with correct dosing for a two-year old child. Although less than 5% of outlets had these 
posters, this positive correlation points to the fact that well-designed IEC materials do 
make a difference in malaria control.
5.5 Summary
Although an important source of treatment for fevers and malaria, the Kenyan retail sector 
is fraught with a number of weaknesses that are likely to mitigate against appropriate case- 
management of malaria in the home. Drugs availed through the retail sector follow client 
demand, which is not always in line with policy. It is evident that AQ was in higher 
demand in the retail sector than SP, the first-line dug at the time. This coupled with poor 
retailer dosing knowledge of multiple dose regimens is likely to impact negatively on the 
implementation of the newly launched policy involving a 6-dose drug regimen. The fact 
that drug schedules are not adequately enforced (since POM drugs are available OTC) also 
means that public sector ART-LUM might leak into the private retail sector where drugs 
are not equitably priced, but where pricing follows the laws o f the jungle and where “might 
is right”. A similar situation prevails for ITN. The KEMRI/Wellcome Group in 
collaboration with other stakeholders and with the DOMC has pioneered a shop-keeper 
retailer programme in Kilifi to try and redress some of these deficiencies. This has being 
scaled-up to five other districts and it is envisaged to cover the rest of the country in the 
near future, but clearly, training alone is not enough. Strategies are needed to better engage
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the local pharmaceutical manufacturers and drug importers in drug policy changes, 
although this, as discussed earlier, is fraught with its own challenges. There is a need for 
more equitable pricing of drugs and non-drug commodities and the role of price controls in 
redressing this needs to be investigated further. In addition, there is a need for stricter and 
wider inspections of drug distribution channels to reign-in the unscrupulous trade in errant 
drugs, to stop leakage of public sector drugs into the private sector, and to ensure drugs are 
stocked according to national policy. All these strategies need to involve the community by 
way of clear and unambiguous IEC materials from the DOMC.
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CHAPTER 6:
Quality of antimalarial drugs in the Kenyan 
retail sector
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6.1 Introduction
The quality of essential drugs available over-the-counter to populations at risk is receiving 
a renewed international interest (WHO, 1999b; 1999c) and is the cause of major political 
and public health concern in several countries including Kenya 
(http://www.nationmedia.com, accessed 19/11/04; http://www.allafrica.com, accessed 
19/11/04). Several reports have cast doubt on the quality of drugs in the Kenyan market in 
general (Kibwage et al., 1988; 1991; 1998) and that of antimalarial (AM) drugs in 
particular (Kibwage & Ngugi, 2000).
The debate on the quality of essential drugs especially intensified in June 2001, just before 
and following the passing of the Kenya Industrial Properties Bill 2001, which sought to 
improve access to these products (and especially generic antiretroviral drugs, ARVs) 
through parallel importation by, and compulsory licensing of local pharmaceutical firms. 
Since a significant fraction of the generic drugs sold in Kenya are imported from other 
developing countries, concerns had been raised on the quality o f such generic drugs, which 
include ARVs. This concern has been compounded by the limited capacity of the existing 
government departments to ensure that only drugs of proven quality are available to the 
public through a strict registration process, as indicated by the presence in the market of 
unregistered products (Chapter 5). The quality of AM drugs in Kenya is therefore part of a 
wider drug quality and regulation problem (Chapter 3).
The Ministry of Health (MoH) has highlighted in the Kenya National Malaria Strategy 
(KNMS) that it will be committed to guaranteeing access to quality controlled AM 
products through a joint effort by the DOMC, the Pharmacy & Poisons Board (PPB), and 
the National Quality Control Laboratory (NQCL) (Section 2.4.3). To-date, the few studies 
that have been done on the quality of AM drugs in Kenya, and in the sub-region, have been
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ad hoc, focused on products found in major urban centres or those submitted to the PPB 
for purposes of registration (reviewed in Section 1.9). There has been a dearth of 
independent studies on the quality of OTC AM drugs available at the peripheral (district) 
retail level where malaria therapies are routinely sought. This chapter describes the quality 
of AM products containing sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) 
available in the retail sector. SP and AQ were the first and second-line treatment for 
uncomplicated malaria in July 2002 when the study was conducted.
6.2 Materials and methods
The sampling of products was done between February and May 2002 coincidental with the 
first round of the retail audit survey (Chapter 5); the four study districts are described in 
detail in Chapter 4.
6.2.1 Sampling drug products
Products containing SP and AQ were purchased from wholesale outlets identified during 
the pre-sensitisation rounds of the retail audit (Section 5.2.2.2). Data obtained from this 
first round were assessed in terms of a frequency distribution of common products and 
major wholesale suppliers for AQ and SP products separately for each district. The top 10 
wholesalers for AM products in each district were visited to purchase AQ and SP branded 
products and a simple proforma completed on details pertaining to the wholesale supplier 
(Appendix IV). To cover as many products as possible, if  a given product had been 
purchased from the preceding district or wholesaler, preference was given to the one, 
which had not been hitherto sampled. Between 60-100 tablets, or 7-10 bottles of 
suspensions/syrups/drops, of each product of interest were purchased. The price of the 
product (s), the date of purchase, quantity, and storage conditions were recorded on the 
proforma. The samples were each provided with a unique identifier
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(district+wholesaler+product) and details of packaging, manufacturer, manufacture date, 
expiry date, whether they contained dosing schedules and so on, were entered into a 
database (Microsoft-Excel 2000, Microsoft Corp., Redmond, USA). Drug samples were 
first subjected to visual inspection to assess factors predictive of poor quality drugs and 
then evaluated by standard United States Pharmacopoeial tests (USP, 2000) described 
below.
6.2.2 Visual inspection
This entailed taking details of packaging, quality of labelling and pharmaceutical elegance 
of the samples (broken tablets, discolouration, mottling, sedimentation, etc). These were 
entered into a standard database and compared with the outcome of the standard 
pharmacopoeial tests described below.
6.2.3 Laboratory methods
6.2.3.1 Reagents
Reference standards of sulfadoxine (Lots F-l and F-2), pyrimethamine (Lots G and H) and 
AQ hydrochloride (Lot G-l) were purchased from the United States Pharmacopoeial 
Commission, Rockville, MD, USA. Phenacetin (Lot 13615-018) was purchased from the 
Sigma-Aldrich Chemicals Co. Dorset, United Kingdom. All other reagents and solvents 
were either of analytical or high-pressure liquid chromatographic (HPLC) grades and were 
purchased from BDH Chemicals Limited, Poole, UK.
6.2.3.2 Analytical methods 
USP test for content
Content tests essentially determine the amount of active ingredient in a product, which is 
expressed as a percentage of the label claim. Sample preparation and assay for SP and AQ
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were performed according to USP specifications (USP, 2000). SP was assayed by HPLC 
while AQ was assayed spectrophotometrically (UV/VIS PU8725 Philips scientific, 
Cambridge, UK). The HPLC system consisted of a HP 1050 Pump (Hewlett Packard 
GmbH, Waldbronn, Germany) equipped with a Rheodyne injector (model 7125) with a 20 
pL loop (Rheodyne), HP 1050 variable wavelength UV/VIS detector set at 254nm 
(Hewlett Packard GmbH, Waldbronn, Germany). A Hypersil BDS RPig 5 pm (250 x 4.6 
mm ID) (Thermo Hypersil -Keystone, UK) column attached to a Lichrosopher 100 RPis 5 
pm guard column (Merck, Germany) immersed in a water-bath or enclosed in a column 
heater at 40 °C was used as a stationary phase. The mobile phase consisted of a mixture of 
acetonitrile and 5% glacial acetic acid (25:75v/v) delivered at a flow rate of 2.0 ml/min. 
The mobile phase was degassed by ultra-sonication before use. A computer equipped with 
HP Chemstation program for LC systems was used to process and store data on the 
generated chromatograms.
USP Dissolution test
Dissolution tests are done to determine the amount of active ingredient that is available for 
absorption and are used as surrogate markers of in vivo bioavailability. Tests were done for 
tablet formulations only. A six-station Erweka DT 600 dissolution apparatus (Erweka 
Gmbh, Frankfurt, Germany) was used. For SP, the dissolution medium was 1000ml 
phosphate buffer, pH 6.8 (USP, 2000) maintained at 37 ± 0.5 °C, while for AQ 900ml of 
distilled water maintained at 37 ± 0.5 °C was used as the dissolution medium. Paddle speed 
was set at 75 revolutions per minute (rpm) for SP and 50 rpm for AQ and amount of active 
ingredient in solution determined after 30 minutes.
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6.3 Data analysis
Drug product content (% label claim) and tablet dissolution rates were estimated as 
described in the USP (USP, 2000). USP specifications give dichotomous outcomes: either 
a product has passed or failed the requisite tests. Further analysis was performed to 
investigate whether there was any association between several product aesthetic factors 
(like packaging) and the outcome of the USP tests (passing/failing according to USP 
specifications). The analysis also included comparisons, based on the above specifications, 
between locally manufactured products and those imported into the country using simple 
chi-squared tests and logistic regressions. Stocking frequencies for AM products (used in 
sampling products) were expressed in terms of the number of outlets selling a particular 
product at the time of the retail audit survey (2002).
6.4 Results
6.4.1. Sampling products fo r  chemical analysis
Table 6.1 shows the most common (top five) AQ and SP products encountered in the retail 
sector during the first round of the survey on which sampling drug products for QC was 
based. Results demonstrate that 1) the generic product Malaratab® was the most frequently 
encountered AQ product while Falcidin® was the most frequent SP product and that 2) 
tablet formulations predominated compared to the suspensions. Both Malaratab® and 
Falcidin® are manufactured locally by Cosmos Pharmaceuticals Limited.
For SP tablets, 23 brands were encountered of which 19 (82.6%) were sampled for 
analysis. For AQ tablets, 13 brands were encountered of which 11 (84.6%) were sampled 
for analysis. Likewise, for the liquid formulations, 13 SP suspensions/paediatric drops 
were encountered of which 12 (92.3%) were sampled; 12 AQ suspensions were 
encountered of which 11 (91.7%) were sampled for analysis. The sampling method used
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therefore yielded good brand or product coverage. Unbranded generic products (those 
using the International Non-proprietary Name, INN) were not sampled for analysis.
Table 6.1: Stocking frequencies of top five common SP and AQ branded products across 
856 retail outlets visited during the initial round of the retail audit survey in 2002. Data 
presented as proportion of audited retail outlets stocking a given product.
SP AQ
Brand Stocking frequency* Brand Stocking frequency’
Tablets Tablets
Falcidin® 159(18.6% ) Malaratab® 735 (85.9%)
Fansidar® 81 (9.5%) Betaquine® 115(13.4%)
Metakelfin® 54(6.3% ) Alphaquine® 37 (4.3%)
Orodar® 49 (5.7%) Emoquin® 23 (2.7%)
Malodar® 16(1.9%) Camoquin® 17(2.0%)
Others 115(13.4% ) Others 42 (4.9%)
Suspensions Suspensions
Pyralfin® 20 (2.3%) Amobin® 30 (3.5%)
Falcigo® 14(1.6%) Malaramed® 24 (2.8%)
Falcidin® 13 (1.5%) Malaratab® 17(2.0%)
Intadoxin® 12(1.4%) Falciquin® 16(1.9%)
Medifan® 11 (1.3%) Kamoc® 13(1.5%)
Others 41 (4.8%) Others 34 (4.0%)
*
Proportion o f audited outlets stocking a given product
Tables 6.2 and 6.3 give further details of the samples collected, their manufacturers, 
countries of origin, formulations, and number of batches sampled. About half the SP 
brands (48%) were imported from the Indian sub-continent, with most of the remaining 
being manufactured in Kenya (48%) and one brand (Fansidar®) was imported from 
Switzerland (Table 6.2). In contrast, 80% of AQ brands sampled were locally 
manufactured (Table 6.3).
)
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Table 6.2: Manufacturers, countries of origin, formulations, strengths and batches of 64 SP
samples analysed following the retail audit in 2002.
Brand (M anufacturer, Country of Origin) Formulation Strength Number of unique 
batches tested
0$Amalar (Brown & Burke, India) Tablets 500mg/25mg 2
0£)Falcidin (Cosmos, Kenya) Tablets
Suspensions
500mg/25mg 
250mg/12.5mg per 5ml
4
4
Falcigo (Biodeal, Kenya) Tablets
Suspensions
500mg/25mg 
250mg/12.5mg per 5ml
1
3
Fanlar (Dawa, Kenya) Tablets 500mg/25mg 2
Fansidar (Roche, Switzerland) Tablets 500mg/25mg 4
Falcimax (Sphinx, Kenya) Suspensions 250mg/12.5mg per 5ml 3
Fansimax® (Maxs, Kenya) Tablets
Suspensions
500mg/25mg 
250mg/12.5mg per 5ml
1
1
Intadoxin (Regal, Kenya) Tablets
Suspensions
500mg/25mg 
250mg/12.5mg per 5ml
1
3
09Lansidar (Ekta Exports, India) Suspensions 250mg/12.5mg per 5ml 1
Lansidar® (Unibios, India) Suspensions 250mg/12.5mg per 5ml 1
Laridox® (Ipca, India) Tablets 500mg/25mg 1
Malareich (Smithkline Beecham, India) Tablets 500mg/25mg 3
09Malastin (Emil, India) Tablets 500mg/25mg 1
09Malidar (Umedica, India) Tablets 500mg/25mg 2
09Malidar (Gracure, India) Suspensions 250mg/12.5mg per 5ml 2
Malodar® (Lab & Allied, Kenya) Tablets 500mg/25mg 3
09Malostat (Intas, India) Tablets 500mg/25mg 1
09Medifan (Medivet, Kenya) Suspensions 250mg/12.5mg per 5ml 2
09Methomine-S (Universal Pharmacy, Kenya) Tablets 500mg/25mg 1
Nopyrin® (Flamingo, India) Tablets
Suspensions
500mg/25mg 
250mg/12.5mg per 5ml
1
1
09Orodar (Elys, Kenya) Tablets
Suspensions
500mg/25mg 
250mg/12.5mg per 5ml
2
2
09Pyralfin (Lupin, India) Tablets
Suspensions
500mg/25mg 
250mg/12.5mg per 5ml
1
2
Unidar® (PMC, Kenya) Tablets
Suspensions
500mg/25mg 
250mg/12.5mg per 5ml
3
2
Viparum® (Universal Pharmacy, Kenya) Tablets 500mg/25mg 2
09Viparum (Unknown*, India) Tablets 500mg/25mg 1
*
Only local agent identified by name (Bulk Medicals, Kenya), not manufacturer.
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Table 6.3: Manufacturers, countries of origin, formulations, strengths and batches of 52
AQ samples analysed following the retail audit in 2002.
Brand (Manufacturer, Country o f Origin) Formulation Strength Number of unique 
batches tested
OPAlphaquine (Dawa, Kenya) Tablets 200mg 1
OPAmobin (Regal, Kenya) Tablets
Suspensions
200mg 
50mgper 5ml
3
4
OPAmoquin (Novelty, Kenya) Suspensions 50mg per 5 ml 1
OPAmowin (Caplin Point, India) Tablets 200mg 1
Betaquine® (Beta Healthcare, Kenya) Tablets 200mg 4
OPCamoquin (Parke-Davis, Senegal) Tablets
Suspensions
200mg 
50mg per 5 ml
4
3
Diaquin (Maxs, Kenya) Tablets 200mg 1
OPEmoquin (Elys, Kenya) Tablets
Suspensions
200mg 
50mg per 5ml
3
2
OPFalciquin (Sphinx, Kenya) Suspensions 50mg per 5 ml 3
Kamoc® (Gracure, India) Tablets
Suspensions
200mg 
50mg per 5 ml
2
1
Laeoquin (Lab & Allied, Kenya) Tablets
Suspensions
200mg 
50mg per 5ml
2
1
Malarabit® (Biodeal, Kenya) Suspensions 50mg per 5 ml 1
Malaramed® (Medivet, Kenya) Suspensions 50mg per 5 ml 4
Malaratab (Cosmos, Kenya) Tablets
Suspensions
200mg 
50mg per 5 ml
6
2
Uniquin® (PMC, Kenya) Tablets
Suspensions
200mg 
50mg per 5 ml
2
1
6.4.2. General quality o f AM  products: shelf life and storage conditions 
In the main retail audit survey (Section 5.2.3), information was collected on product 
storage conditions and shelf life. Of 2,401 audited oral AM products, 234 (9.7%) had 
expired by the time o f the survey (June 2002). Figure 6.1 shows median remaining shelf- 
life (in months) of the remaining 2,167 AM products by chemical group. Overall, AQ 
products had the longest remaining shelf life (46 months, interquartile range [IQR] 30, 48), 
followed by SP (median 30 months, IQR 23, 35). Chloroquine (CQ), quinine (QN), and
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“other” products (OTH in the figure refers to mefloquine, halofantrine, proguanil and 
mepacrine) had remaining shelf lives of 22 (IQR 15, 28), 17 (IQR 10, 25) and 19 (IQR 18, 
27) months, respectively. Products containing artemisinin (ART) had remaining median 
shelf life of 12 months (IQR 9, 23). The majority of products (97.2%) were found to satisfy 
the basic storage conditions set out in the study (namely stored off the floor, out of direct 
sunlight, in a dry area and away from food stuffs).
Figure 6.1: Shelf life of 2,167 audited, un-expired oral AM products in 876 retail outlets in 
four districts of Kenya by chemical group.
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6.4.3 Chemical analyses
The results for the analysis of SP and AQ for active ingredient content and tablet 
dissolution rates are summarised in Tables 6.4 and 6.5, respectively. Overall, 116 samples 
of SP and AQ were analysed in 2002 for content and dissolution of which 47 (40.5%) did
)
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not meet the USP specifications for content and/or dissolution. Details are given in the 
following sections for each drug class separately.
6.4.3.1 SP samples
Sixty-four SP samples were analysed by HPLC (37 tablet batches and 27 suspensions). 
For dissolution, six different solutions were each analysed once and for the content 
determination, two different solutions were each analysed three times. The amount of 
active ingredient released in 30 min was calculated by comparison with the USP chemical 
reference substance with an assigned purity of 100%. The USP monograph acceptance 
criteria (6 tablets) for SP require that the amount released in 30 minutes for sulfadoxine 
(SDX) or pyrimethamine (PMT) should be at least 60 % of label claim and that the content 
of SDX or PMT in any sample should be 90 -  110 % of label claim. Overall, 45.3% of SP 
samples failed to meet these criteria. For the tablet forms 13 (35.1%) samples failed to 
meet the official requirements: 10 samples (76.9% of failures) failed dissolution alone, 2 
(15.4%) samples failed content alone, and 1 (7.7%) failed both tests. A disproportionate 
percentage of SP products failing dissolution and content tests (90% and 100%, 
respectively) had problems with the PMT component. Further, the only sample, which 
failed both dissolution and content, did so with respect to PMT alone.
Twenty-seven (27) SP suspensions were analysed for content (limits 90-110% of L.C). 
Results in Table 6.5 show that sixteen samples (59.3%) failed to meet official 
requirements: 0 (0% of failures) with respect to the SDX component only, 13 (81.3%) with 
respect to PMT only and 3 (18.7%) with respect to both active ingredients. One sample had 
no detectable PMT and can only be said to be substandard (not counterfeit) according to 
the WHO, which defines fake or counterfeit drugs as those "...deliberately and fraudulently
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mislabelled with respect to identity and/or source..." (WHO, 1999c). The bulk of SP 
failures can again be attributed to PMT (Table 6.4).
Table 6.4: Results of 37 SP tablets and 27 SP suspensions analysed in 2002. Amount 
sulfadoxine (SDX) and pyrimethamine (PMT) is expressed as percent label claim. USP 
limits for content of SDX and PMT range from 90-110% and amount SDX/PMT released 
into dissolution medium within 30 min should be >= 60%. Pass means within limit, and 
low and high fail means lower or higher than lim it, respectively. na=not applicable.
Content Dissolution
Low fail Pass High fail Low fail Pass
SDX PMT SDX PMT SDX PMT SDX PMT SDX PMT
SP tablets 0 3
(8.1%)
37
(100.0%)
34
(91.9%)
0 0 1
(2.7%)
11
(29.7%)
36
(97.3%)
26
(70.3%)
SP
suspensions
2
(7.4%)
12
(44.4%)
21
(77.8%)
12
(44.4%)
4
(14.8%)
3
(11.1%)
na na na na
6.43.2 AQ samples
Fifty-two (52) AQ samples (29 tablet forms and 23 suspensions) were analysed 
spectrophotometrically. The results obtained for the samples are presented in Table 6.5. 
For dissolution, six different solutions were each analysed once and for the content 
determination, two different solutions were each analysed three times. The amount (% 
L.C.) released in 30 minutes and content (% L.C.) of AQ were calculated by comparison 
with the USP chemical reference substance with an assigned purity of 100%. The USP 
monograph acceptance criteria (6 tablets) for AQ require that the amount released in 30 
min for AQ should be more than 75% of the LC and the content of AQ in all samples 
should be 93-107% of LC. Results show that 11 (37.9%) tablet samples failed the requisite 
tests: 1 (9.1% of AQ tablet failures) for dissolution alone, 7 (63.6%) for AQ content alone 
and 3 (27.3%) failed both tests. Results indicate that 7 (30.4%) suspensions failed the 
content test with 6 (85.7% of failures) being below the lower limit and one sample above 
the higher limit (Table 6.5).
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Table 6.5: Results of 29 AQ tablets and 23 AQ suspensions analysed in 2002. Amount AQ 
is expressed as percent label claim. USP limits for content of AQ range from 93-107% and 
amount AQ released into dissolution medium within 30 min should be >= 75%. Pass 
means within limit, and low and high fail means lower or higher than lim it, respectively. 
na=not applicable.
Content Dissolution
Low fail Pass High fail Low fail Pass
10 19 0 4 25
AQ tablets (34.5%) (65.5%) (13.8%) (86.2%)
6 16 1 na na
AQ suspensions (26.1%) (69.6%) (4.3%)
6.4.4 Visual inspection: factors associated with poor quality drugs 
Due to the limited number of samples and the attendant limited Events Per Variable (EPV), 
only 4 factors were included in a logistic regression model with the outcome variable being 
whether a sample passed or failed the USP requirements. As a rule of thumb, at least 10 
EPVs are required for good model prediction (Peduzzi et al., 1996). The results were 
inconclusive; none of the explanatory variables (retail prices, import status of the product, 
signs of physical instability, presence of expiry dates on package) were statistically 
associated with a poor outcome (Table 6.6).
Table 6.6: Characteristics of samples passing or failing the USP specifications for 
dissolution and/or content.
Variable Number of observations Failure rate P value 
(univariate)*
P value 
(multivariate)
Mean retail price per unit* Passed-69
Failed-47
12.5 (7.5)
12.5 (9.2)
0.789 0.916
Local vs. Imported products Local-80
Imported-36
Local-42.5% 
Imported-36.1%
0.197 0.477
Expiry indicated No expiry on pack-8 
Expiry on pack-108
No expiry on pack-25.0% 
Expiry on pack-41.7%
0.580 0.493
Physical instability1' Absent-83
Present-33
Absent-37.3% 
Present-48.5%
0.372 0.389
’Pearson’s Chi-square for proportions and one-way ANOVA for mean.
*Unit consisted o f  a tablet or 5ml o f suspension.
*For tablets signs o f  physical instability included swelling, fusion, mottling, etc. For suspensions, lack o f  uniformity o f  
colour, sedimentation, etc.
233
6.5 Discussion
Drugs are an essential health commodity and the vagaries in their performance attract a lot 
of public attention. Figure 6.2 shows examples of newspaper headlines that appeared in 
December 2001 in the Kenyan press about drugs expiring in the Kenya Medical Supplies 
Agency’s central warehouses in Nairobi. Such headlines are not restricted to Kenya alone. 
The same concerns about quality of drugs was raised in the USA in 2003 following 
imports of fake drugs by health management organisations from outside the USA (mostly 
Mexico.) (http://www.bbc.co.uk, accessed 07/12/04)
Figure 6.2: Public concern about drug quality, an example o f newspaper headlines in 
Kenya
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6.5.1 General quality and shelf life
The results suggest that product expiration is a problem in the retail sector; about 10% of 
products audited in the main retail survey were past their expiry dates. However, the 
majority of products stocked (97%) were found to satisfy the basic storage conditions set 
out in the study (namely stored off the floor, out of direct sunlight, in a dry area and away 
from food stuffs).
It is important to note that the manufacturer’s “shelf life” applies only to products whose 
integrity has not been breached, i.e. products should be in their original containers (e.g. 
blister pack). Once this integrity is breached, shelf life no longer applies. This is especially 
important for the artemisinin derivatives, which take up, and react with water thus making 
them less effective. It is even more important for AQ, which on reaction with water forms 
a toxic quinone imine metabolite implicated in adverse reactions to AQ (Maggs et al., 
1987; Christie et al., 1989; Winstanley et al., 1990).
6.5.2 Chemical analyses
One main limitation of the chemical analyses is the fact that a test for impurities was not 
done. Impurities can arise as by-products of the manufacturing process or may be because 
of a chemical reaction (with light, air, water) whilst the product is in storage. A key 
impurity in Aspirin (acetyl salicylic acid) for instance, and whose content has to be limited 
in the final product is salicylic acid, a potentially toxic compound. Whilst in storage, 
aspirin can also be hydrolysed by moisture to form this parent compound; adrenalin 
undergoes auto-oxidation if exposed to light, thus its storage in amber-coloured bottles; a 
cyanide salt is used as a raw material in the manufacture of chlorproguanil. Limiting 
impurities therefore is an important aspect of quality assurance.
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The above limitation notwithstanding, the content and dissolution tests reveal a large 
number of substandard AQ and SP products in the market (40.5%) which is consistent with 
reports of substandard essential drugs across the developing world (Taylor et al., 2001). 
These results also suggest that for SP products, pyrimethamine accounts for a 
disproportionate number of dissolution and content failures. A similar problem has also 
been noted by other workers, and it has been suggested that this is due to the poor 
solubility of pyrimethamine (Kibwage & Ngugi, 2000; WHO, 2003d).
Of particular concern is the poor quality of SP suspensions in the market; 59.3% failed to 
meet the official requirements, especially with regard to the pyrimethamine component. 
This is despite the fact that during analysis, an ideal situation is simulated. The suspensions 
are first ultra-sonicated to evenly disperse the active ingredient and then the content of 
active ingredient in a given volume of suspension (equivalent to a given weight of active 
ingredient) is determined. In practice, mothers will not be able to replicate such ideal 
conditions. Moreover, there were sedimentation problems with most suspensions sampled 
in the survey. In addition, it is known that there is great variability in the ‘tea spoons’ that 
mothers use to measure suspensions for their children (Kabati et al., 1998). There is 
therefore need for greater controls on the quality of AM suspensions in the market since 
the burden of malaria is greatest in children under five who are expected to use these 
preparations.
Also in line with previous reports is the finding that no differences existed between the 
quality of local and imported products (WHO, 2003d), suggesting that the phenomenon of 
poor quality drugs is one that is common to many countries or that products intended for 
export to developing countries are not manufactured to the same standards as those 
consumed in the exporting countries (WHO, 1995). Although a substantial proportion of
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samples did not comply with the USP specifications, most products, which failed, did so 
marginally. In general, more products failed by being below the required specifications 
compared to those, which failed by being above the required specifications. These failures 
can be attributed to poor quality control during manufacture (Kibwage & Ngugi, 2000; 
Taylor et al., 2001), and reflects the fact that most developing countries including Kenya 
have limited regulatory mechanisms for enforcing Good Manufacturing Practices (GMP).
In Kenya, there are about 40 pharmaceutical manufacturing plants. The pharmaceutical 
Inspectorate department of the Pharmacy and Poisons Board is still in its infancy and even 
a dedicated team can inspect a given plant at most once a year. The presence in the market 
of poor quality drugs also gives credence to an oft-repeated comment in Kenya that 
manufacturers and suppliers tend to put forward very good samples at registration, and 
then do not adhere to GMP once the drug is registered. There is a need for local industries 
to invest in GMP requirements and subsequently encourage them to adhere to GMP 
standards, and for the MoH to support its drug regulatory arm by providing additional 
financial and human resources to not only enforce GMP, but to carry out stringent checks 
on products in circulation. Since most drugs are imported from abroad, there is need to 
tighten controls at ports of entry. One possible and cheap way of detecting poor quality 
drugs at ports of entry is through the use of semi-quantitative tests such as the Mini-Lab™ 
which relies on simple colour reactions to quickly identify substandard products (Jahnke & 
Kusters, 2001). However, as has been stated earlier, such tests will not be able to 
distinguish counterfeit from substandard products since according to the WHO definition, 
an element of intention to defraud must be ascribed to the former and this requires 
investigations into the sources of the suspected counterfeit products. Further, counterfeit 
products can have the right ingredients at the right amounts (i.e. they can pass all the
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requisite tests) and will not necessarily be sub-standard, making their detection ever harder 
using even full laboratory investigations (WHO, 1999c).
Only SP and AQ were considered in this study because these were the first and second-line 
treatment for uncomplicated falciparum malaria in 2002. Although the products analysed 
were sampled from the private retail sector, a recent WHO multi-country study found that 
there were no differences in the quality of AM drugs sourced from the various public and 
private sector distribution chains. Public sector outlets were just as likely to have poor 
quality antimalarial drugs as their private sector counterparts. Table 6.7 shows Kenya 
specific data abstracted from this study and demonstrates that poor quality AM drugs is a 
general problem across all the sectors, and that for SP products, dissolution is almost 
always the problem, as has been shown earlier. Poor quality drugs in the government and 
the private sector in Kenya could be explained by the fact that the government procures 
drugs from the same manufacturers and importers that distribute drugs to the private sector.
Table 6.7: Percentage antimalarial products sampled from various collection points in 
Kenya within specifications (WHO, 2003 d).
Level o f collection Chloroquine syrup Chloroquine tablets SP tablets
Content Content Dissolution Content Dissolution
Teaching hospital 1/1 0/1 1/1 2/2 1/2
(100.0%) (100.0%) (100.0%) (50.0%)
District hospital 0/1 0/1 1/1 2/2 1/2
(100.0%) (100.0%) (50.0%)
District medical stores 2/2 1/2 1/2 4/4 0/4
(100.0%) (50.0%) (50.0%) (100.0%)
Health centre 1/1 1/1 1/1 2/2 1/2
(100.0%) (100.0%) (100.0%) (100.0%) (50.0%)
Pharmacy 2/3 2/3 3/3 6/6 3/6
(66.7%) (66.7%) (100.0%) (100.0%) (50.0%)
Vendor/shop 1/1 2/3 2/3 8/8 5/8
(100.0%) (66.7%) (66.7%) (100.0%) (62.5%)
Total 7/9 6/11 9/11 24/24 11/24
(77.8%) (54.5%) (81.8%) (100.0%) (45.8%)
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Reasons for poor quality of drugs are varied and include widespread counterfeiting 
(Newton et al., 2001; Rozendaal, 2001), excessive decomposition of active ingredient due 
to high temperature and humidity (Hogerzeil et al., 1991; 1992), poor storage conditions 
(Kibwage & Ondari, 1988; Kibwage et al., 1991; 1992) and poor quality assurance during 
manufacture (Kibwage et al., 1991; 1992; Aluoch-Orwa et al., 1995; Shakoor et al., 1997; 
Kibwage, 1998; Kibwage & Ngugi, 2000; Kinyawa et a l, 2000). Weak legislation and 
regulatory mechanisms also contribute to poor quality of drugs (Roy, 1994; Siringi, 2001).
In the case of malaria, a poor quality drug increases the risks of therapeutic failure even 
when the parasites are fully sensitive to the ingested compounds. This is because most drug 
failures are due to lower contents or dissolution scores, which is comparable to taking low 
doses of the drug. Sub-therapeutic drug levels could in turn lead to selection of drug 
resistant strains of Plasmodium falciparum with resistance soon spreading to the rest of the 
parasite population (Taylor et al., 1995). The widespread resistance to pyrimethamine, and 
the fact that most SP samples which fail, do so with respect to the pyrimethamine 
component, is probably not a coincidence. The problem of poor quality drugs is 
compounded by the fact that most people self-treat minor ailments using drugs obtained 
from the retail sector (Sections 1.8 and 2.5.1), such drugs are used inappropriately 
(Deming et al., 1989; Massele et al., 1993; Slutsker et al., 1994; Marsh et al., 1999) and 
mechanisms to regulate drug use are weak or non-existent (WHO, 1999a). Given the fact 
that the range of affordable AM drugs is limited, the impact of poor quality on the “Useful 
Therapeutic Life” (UTL) of AM drugs needs urgent attention.
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6.5.3 Visual inspection
Although the results of the visual inspection were inconclusive, this method has proved to 
be very useful in identifying fake and substandard AM products in Southeast Asia. Newton 
et a l (2001) compared the results o f a simple dye test with those obtained through visual 
inspection o f artesunate samples by an independent evaluator blinded to the results of the 
chemical tests. The authors found that price, quality of printing, and that of the holograms 
reliably predicted fake artesunate. Figure 6.3 shows genuine Guilin Pharma (China) 
artesunate beside first, second and third generation fake artesunate in circulation in 
Southeast Asia. First generation fake artesunate found in Lao and Cambodia in 1998 were 
poorly designed. They had a dull (as opposed to refractile) hologram and did not have the 
genuine ‘Guilin Pharma’ legend. Subsequent attempts at counterfeiting have been more 
sophisticated; second generation holograms were well crafted, they however had a 
different expiry, manufacture dates, and still did not have the ‘Guilin Pharma’ legend; third 
generation holograms were very identical to the genuine one, they had better printing, but 
still did not have the ‘Guilin Pharma’ legend (Figure 6.3). The use of cheap, visual 
inspection techniques to evaluate drug quality have therefore been very useful in Southeast 
Asia and need to be evaluated better in resource-constrained settings like Kenya.
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Figure 6.3: Genuine Guilin Pharma artesunate against three generations o f fake artesunate 
in Southeast Asia (Dr P Newton, personal communication).
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6.5.4 Implications for ART-LUM
ART-LUM, the new first-line AM policy since April 2004 in Kenya, is a single-source, 
high value product, manufactured by a reputable international company (Novartis Pharma 
AG) to GMP. Therefore, sub-standard ART-LUM is unlikely to be a problem in the 
market. However, as is common with such high-value products, unscrupulous businessmen 
eager for quick profits are likely to counterfeit it. There is need to strengthen post­
marketing surveillance of products in the market to identify sub-standard and counterfeit 
AM drugs in the market and to deal appropriately with such practices. The observation that 
the median remaining shelf life of artemisinin products in the private sector (12 months) 
was lower than for other drugs means that drug distribution mechanisms in the Kenyan 
public sector (historically less efficient than the private sector) need to be strengthened to 
avoid expiry and drug wastages (ART-LUM has short shelf life of 24 months and because 
of the hydrophilic nature of artemisinins, this applies to all ACTs (Dr W Muiruri, personal 
communication). In addition, those in the private sector need to be inspected regularly and 
informed clearly about shelve lives of AM drugs and be encouraged to remove expired 
products from their shelves.
6.6 Summary
This chapter sought to answer two questions in the light of reports of poor quality drugs in 
Kenya. Is there a problem with the quality of AM drugs in Kenya? and if so what is the 
extent of the problem? Most SP and AQ products sampled could not be said to be 
counterfeit according to the WHO definition, but there have been reports of counterfeit 
artesunate in Southeast Asia (Newton et al., 2001) and of other drugs elsewhere in Africa 
(Section 1.9). It is possible that counterfeiting for SP and AQ was not much of a problem 
in Kenya because these are low value products. However, this could change with the new 
first-line policy, ART-LUM, which costs at least 10 times that of SP and has been adopted
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by tens of governments in Africa as first-line AM drug for uncomplicated malaria (Section 
1.7.4). Results also show that there is a problem with the quality of first and second line 
AM drugs in the market and that a third to a half of the products in circulation are 
substandard. A substantial proportion of these products marginally failed (mainly by being 
below) the pharmacopoeial specifications, probably because of poor quality control during 
manufacture. This reflects the fact that most developing countries including Kenya have 
limited regulatory mechanisms for enforcing Good Manufacturing Practices (GMP) and 
generally have poor or non-functional post-marketing surveillance systems. Since most 
drugs are imported from abroad, there is a need to improve controls at ports of entry using 
cheap, semi-quantitative techniques like the Mini-Lab™. However, reports of poor quality 
drugs need to be tempered with common sense. Communities in Kenya differ in their drug 
use patterns (Section 4.4.5); therefore, different poor quality drugs will have different 
impacts on public health. A poor quality drug whose use is minimal will not have the same 
public health impact as one whose use is widespread. The relationship between drug 
quality, adherence to dosage regimen, clinical efficacy, and drug effectiveness will be 
explored in more detail in the next chapter.
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CHAPTER 7:
The difference between effectiveness and 
efficacy of anti-malarial drugs in Kenya
7.1 Introduction
Efficacy refers to how an intervention works under optimum conditions whereas 
effectiveness refers to how an intervention works under real-world conditions. In an 
efficacy trial, the intervention is delivered in a uniform manner to a specific, narrowly 
defined target population so that any positive or negative results can be directly attributed 
to the intervention. On the other hand, the goal of effectiveness trials is to investigate how 
interventions work under routine operational conditions among a broadly defined target 
population. Poor effectiveness results might therefore be attributed to lack of proper 
implementation or weak acceptance or adherence by participants rather than any reduced 
efficacy (Glasgow et al., 2003).
A number of studies have tried to make a clear distinction between efficacy and 
community effectiveness (Tanner et al., 1993; Lengeler & Snow, 1996; Krause & 
Sauerbom, 2000) and generally follow the principals of community effectiveness defined 
by Tugwell et al. (1985). In their seminal article, Tugwell et al. (1985) showed how a 
simple multiplicative model could be used to evaluate community effectiveness of drugs 
used in the management of hypertension or hip replacement in osteoarthritis. In both cases, 
community effectiveness was much lower than predicted from carefully controlled efficacy 
trials (Table 7.1). This same concept has been replicated by other workers in the evaluation 
of the effectiveness of insecticide treated bed nets (Lengeler & Snow, 1996), malaria 
treatment practices (Krause & Sauerbom, 2000) and overall effectiveness of disease 
control tools (Tanner et al., 1993).
245
Table 7.1: Sample calculations for community effectiveness (Tugwell et al., 1985)
Example Efficacy Diagnostic
accuracy
Provider
compliance
Patient
compliance
Coverage Community
effectiveness
Hypertension
a) Under current conditions 76% 95% 66% 65% 90% 28%
b) Under improved patient 
and provider compliance
76% 95% 90% 90% 90% 53%
Osteoarthritis
a) Under current conditions 60% 75% 98% 87% 70% 27%
b) Under conditions o f  
improved diagnostic 
accuracy and coverage
60% 90% 98% 87% 90% 41%
In much of sub-Saharan Africa, changes in antimalarial (AM) drug policy are largely 
driven by evidence from comparative clinical efficacy studies (in which treatment is 
directly observed). This is certainly true for the East African countries of Kenya, Uganda, 
Tanzania, Burundi and Rwanda under the auspices of EANMAT (Section 2.6.1). Clinical 
efficacy studies are performed under controlled environments with quality-assured 
antimalarial (AM) drugs and supervised dosing. In sharp contrast, the treatment of 
childhood fevers in Kenya is often undertaken at home (without professional supervision) 
using combinations of antipyretic (AP) and AM drugs (mostly obtained from the retail 
sector) (Section 1.8): 49% and 30% of fevers among children under five in the study 
districts were first treated with AP and AM drugs , respectively (Section 4.3.5). Such drugs 
can be of poor quality (41% of SP and AQ brands, Section 6.4.3) and used inappropriately 
(Marsh et a l,  1999; Okonkwo et al., 2001; Yeboah-Antwi et al., 2001; Nshakira et al., 
2002). In this chapter, a number of critical factors that are likely to influence clinical 
efficacy under operational conditions are explored. In addition, a quantifiable model of 
drug effectiveness is proposed, based on the nationally recommended first and second line 
drugs in Kenya at the time of the surveys (2001 to 2003). The implications for the new 
first-line AM drug, ART-LUM are also discussed.
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7.2 Materials and methods
7.2.1 Study sites
This chapter uses combinations of drug efficacy data (Section 2.6.2), drug access/use 
(Section 4.3.5), drug quality (Section 6.4.3), and adherence from the four surveyed districts 
described in detail in Section 4.2.1.
7.2.2 Estimation o f effectiveness
The effectiveness of SP and AQ was estimated from three variables: adherence to 
recommended dose regimen, drug quality, and clinical efficacy. The present thesis did not 
attempt to define adherence, as these methods were too complex for the rapid community 
survey. Rather, estimates of adherence to SP and AQ dose regimens in Kenya were 
obtained through detailed household surveys of treatment seeking behaviour for recent 
fevers among children under 5 years in two districts during 2003 (Makueni and Kwale), 
undertaken by Dr. V. Marsh and colleagues (unpublished data). Detailed information was 
collected on the management of recent fevers from a two stage, randomised cluster sample 
of 4000 households from four suitable rural divisions in each district. Approximately 20 
randomly selected clusters of households, where each cluster contained an average of 100 
households, were used.
Reported over-the-counter (OTC) drug use information was collected in local languages 
using a structured questionnaire and samples of tablets and packaging of locally available 
brands to support drug identification. Where available, remaining tablets, syrup bottles or 
packaging were inspected. A supervisor repeated ten per cent of all antimalarial drug use 
interviews. Concordance between first and second interviews supported the accuracy of 
reporting by eliminating recording errors and minimising recall bias. Information was 
collected on the total amount of a specified antimalarial drug given, the number of days of
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administration and the age of the child. Treatments were coded as ‘adequate’, ‘high dose’ 
or Tow dose’ by comparison with national standard treatment guidelines (DOMC, 1998). 
For the present analysis, patients who took a higher dose than recommended and those who 
took an adequate dose were combined into a single group labelled ‘adequate adherence’. 
Whereas a high dose would conceivably lead to higher incidence of side effects or toxicity, 
it would still give maximum clinical efficacy; in this regard therefore, this group is no 
different from the adequate dose group.
Data on the quality of SP and AQ products are described in detail in Chapter 6. These data 
were refined for the present analysis such that in addition to classifying products as having 
passed or failed the pharmacopoeial tests, a quality index (ranging from 0 to 1) was derived 
by multiplying results of content and dissolution tests performed on test batches. Products 
with content or dissolution greater than 1 (those with content and/or dissolution more than 
label claim) were given the highest possible score of 1. Suspensions were given an ideal 
dissolution score of 1. For each of the drug classes SP, AQ, and each product i the quality 
index Q was expressed as:
Qi = DiCi , where D  and C are the dissolution and content scores, respectively.
Where more than one batch of a product was tested, mean proportionate content was 
multiplied by mean proportionate dissolution. Where no quality tests were conducted for a 
given product, averaging other products for which results were available derived an 
approximate quality index. In earlier published work (Amin et al., 2004), a quality index of 
1 was assumed for products obtained from the formal sector. In Kenya, drug supply to 
government health facilities is predominantly through an essential drugs kit system. Supply 
usually follows award of a tender handled through an independent procurement agency.
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Tenders are usually awarded based on, among other things, good quality as judged on 
submitted samples, thus a quality index of 1 for such products seemed plausible. The 
Mission and NGO facilities also use a similar centralized drug procurement system and 
might differ only as far as disbursement to the facilities is concerned (Section 3.3.1). As 
has been shown in Section 6.5.1, however, there is no difference in the quality of drugs 
accessed from the private retail sector or the government sector in Kenya. As such, quality 
indices for SP and AQ reportedly obtained from the public sector (marked “formal” in the 
tables) have been revised to those of the most likely supplier to this sector, i.e. Cosmos 
Limited, Kenya (Crown Agents, personal communication). For SP “formal’, a quality 
index equivalent to that of Falcidin® (0.854) has been assumed and for AQ “formal”, a 
quality index equivalent to Malaratab® (0.751) has been assumed.
Thirdly, the proportionate use of SP and AQ was determined by a community survey of 
childhood fever treatment practices conducted in the same districts in 2001 and described 
previously (Section 4.2.3). Finally, estimates of clinical efficacy were derived from 
national surveillance data of SP and AQ monotherapy undertaken within the four sentinel 
districts fhttp.7/www.eanmat.org. accessed 28/08/04) from January 2000 to February 2003. 
There have been changes in the definitions of efficacy of AM drugs overtime, as such the 
effectiveness of SP and AQ are presented bearing in mind these definitions (Section 1.7.3).
The predicted effectiveness of SP and AQ was estimated from (a) adherence to dose 
regimen, (b) quality of products used (weighted for proportionate use in the community 
and considering sectoral variation in quality) and (c) clinical efficacy, using the equation:
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Where: E=Effectiveness, e=efficacy, A=Adherence, n=number of products, i=given
i - n
product i, Q=quality index, and U=proportionate product use. The term ^  QjUi defines the
/ • = i
use-weighted quality index.
7.2.3 Parameter uncertainty
To explore the impact of parameter uncertainty on the effectiveness estimates, a best- and 
worst-case scenario analysis was conducted. Estimates for e, A, Q and U in the equation 
were substituted by values representing a plausible range for the point estimates 
(Drummond et al., 1997). Plausible ranges for e were determined by considering the 
maximum and minimum value for clinical efficacy from the various studies in the study 
districts. In some cases, these ranges painted a rather rosy picture of clinical efficacy in the 
sentinel districts and were contradicted by data from non-EANMAT sources (Section 
2.6.2). For instance, the worst Day 14 ACPR for AQ was reported by AMREF as 61.3% in 
Mwea (Table 2.5), yet the EANMAT minimum value was 84% (Table 7.1). In such cases, 
non-EANMAT min-max ranges were used in the sensitivity analysis.
Plausible ranges for adherence to AQ were not available from the literature, thus those for
chloroquine (CQ), a close congener, were used. The worst reported adherence to a three-
day regimen for CQ (2.8%) was in Kilifi, Kenya (Marsh et al., 1999). This was rounded
off to the nearest probability of 10%. The best was reported by Yeboah-Antwi et al. (2001)
in Ghana at 49.8% (rounded off to approximate probability of 50%). Adherence to SP was
varied from 50 to 80%. Estimates for Q and U are derived from the survey data since there
were no comparators in the literature, use-adjusted quality index (QU) was varied from 70
to 90% for both SP and AQ since their derived QU indices were similar. Efficacy estimates
for the non-adherent group (and plausible ranges) were intuitively derived on the
assumption that they would be lower than the lower value of the plausible range for the
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adherent group. In the sensitivity analysis, these figures were altered to the same 
magnitude as the adequate adherence group.
7.3 Results
Table 7.2 shows the clinical efficacy (e) of SP and AQ derived from national surveillance 
data between January 2000 and February 2003. For AQ, Day 14 ACR was estimated to be 
95.8% (84.0 to 100.0%) across nine studies in the four districts and for SP it was estimated 
to be 80.1% (48.4 to 100.0%) from a similar number of studies in the four districts. Day 14 
ACPR for AQ was 95.2% (84.0 to 100.0) and that for SP was 74.1% (45.2 to 96.8). Day 28 
ACR for AQ and SP was 95.1% (91.6 to 99.1) and 80.2% (70.4 to 91.6), respectively. 
Using the new WHO definition, Day 28 ACPR of AQ was estimated at 77.7% (69.0 to 
87.0) and that of SP at 72.0% (62.5 to 83.1). As has been explained in Section 7.2.3, the 
lower ranges of Day 14 AQ clinical efficacy were revised (to 80.7 to 100.0% ACR and
61.3 to 100.0% ACPR, respectively) to take into account non-EANMAT data that showed 
worse clinical efficacy of AQ; the EANMAT SP ranges shown included worst and best- 
case clinical efficacy reported by non-EANMAT sources and so there was no need to 
adjust these.
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Table 7.2: Summary of EANMAT drug efficacy studies (9 SP and 9 AQ) in four sentinel 
sites in Kenya between January 2000 and February 2003 (http://www.eanmat.org, accessed 
28/08/04)
Patients completing 
follow-up
ACR* (old definition) ACPRf (new definition)
AQ day 14 outcomes 593 95.8% (80.7MOO.O) 95.2% (61.3M00)
AQ day 28 outcomes 340 95.1% (91.6-99.1) 77.7% (69.0-87.0)
SP day 14 outcomes 528 80.1% (48.4-100) 74.1% (45.2-96.8)
SP day 28 outcomes 291 80.2% (70.4-91.6) 72.0% (62.5-83.1)
ACR (Adequate clinical response)- achieved if there is no parasitaemia or no fever on Day 14 without previously 
meeting the criteria for ETF or LTF (WHO, 1996)
^ACPR (Adequate Clinical and Parasitological Response)-absence of parasitaemia on Day 14 (or Day 28), irrespective of 
axillary temperature, without previously meeting any of the criteria for ETF, LTF or LPF (WHO, 2003a)
* Lower range from AMREF data (Table 2.5)
Table 7.3 shows the quality assurance and frequency of use data for SP products. Table 7.4 
presents the same frequencies for AQ. Use-weighted quality indices were computed for SP 
and AQ from results in these tables as described in the methods section. These were 
estimated to be 83.1% and 83.8% for SP and AQ, respectively.
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Table 7.3: Results of SP products analysed in 2002 and their respective proportionate use
in four communities in Kenya.
Product (i)
Number (of total) batches passing 
content and/or dissolution
Quality index 
(Q)
Product proportionate use in the 
community (U)
SP tablets
Amalar® 2/2 0.912 0.007
Falcidin® 4/4 0.854 0.033
Falcigo® 0/1 0.642 0.000
Falcistat® nt 0.750* 0.003
Fanlar® 2/2 0.868 0.000
Fansidar® 4/4 0.809 0.664
Fansimax® 0/1 0.672 0.000
Intadoxin® 0/1 0.484 0.010
Laridox® 1/1 0.933 0.000
Malareich® 3/3 0.899 0.000
Malastin® 0/1 0.682 0.000
Malidar® 0/2 0.588 0.000
Malodar® 3/3 0.785 0.000
Malostat® 0/1 0.763 0.000
Methomine-S® 0/1 0.517 0.000
Nopyrin® 1/1 0.678 0.016
Orodar® 2/2 0.864 0.026
Pyralfm® 1/1 0.994 0.003
Unidar® 1/3 0.548 0.007
Viparum® 0/3 0.566 0.000
SP unspecified formal* nt 0.854 0.046
SP unspecified retail* nt 0.750* 0.030
Sub-Total 1 24/37 0.845
SP suspensions
Falcidin® 3/4 0.988 0.053
Falcigo® 0/3 0.918 0.016
Falcimax® 0/3 0.905 0.000
Fansimax® 1/1 1.000 0.000
Intadoxin® 1/3 0.957 0.003
Lansidar® 1/2 0.931 0.000
Malidar® 0/2 0.841 0.000
Medifan® 2/2 0.977 0.036
Nopyrin® 0/1 0.919 0.010
Orodar® 1/2 0.909 0.000
Pyralfm® 1/2 0.962 0.030
Unidar® 1/2 0.995 0.000
Viparum® nt 0.950* 0.007
Sub-Total 2 11/27 0.155
SP Total 33/64 1.000
SP-sulfadoxine-pyrimethamine. nt-not tested. Product (i)-tablet or paediatric suspension. Batch-unique identifier given to 
a product by manufacturer. Quality index (Q)-product of content and dissolution tests. For suspensions, only content test 
done ’Quality index estimated from the average quality index of the other products in the category. Community use index 
(U)-number of encounters with product as proportion of total in the class. *Formal-drug obtained from government, 
Mission, or NGO sector and given quality index of Falcidin®. *Retail-drug obtained from outside formal sector.
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Table 7.4: Results of AQ products analysed in 2002 and their respective proportionate use
in four communities in Kenya.
Product (i)
Number (of total) 
batches passing 
content and/or 
dissolution Quality index (Q)
Product proportionate use in the 
community (U)
AQ tablets
Alphaquine® 1/1 0.766 0.000
Amobin® 3/3 0.897 0.087
Amoquin® nt 0.800* 0.091
Amowin® 1/1 0.850 0.000
Betaquine® 2/4 0.432 0.033
Camoquin® 3/4 0.845 0.043
Diaquin® 1/1 0.898 0.000
Emoquin® 2/3 0.763 0.000
Kamoc® 2/2 0.914 0.000
Laeoquin® 1/2 0.691 0.000
Malaratab® 2/6 0.751 0.243
Uniquin® 2/2 0.879 0.004
AQ unspecified formal* nt 0.751 0.018
AQ unspecified retail* nt 0.800* 0.014
Sub-Total 1 20/29 0.533
AQ suspensions
Amobin® 1/4 0.845 0.214
Amoquin® 1/1 0.947 0.000
Camoquin® 3/3 1.000 0.058
Emoquin® 1/2 0.933 0.033
Falciquin® 3/3 0.966 0.040
Kamoc® 0/1 0.827 0.000
Laeoquin® 0/1 0.618 0.000
Malarabit® 1/1 0.956 0.000
Malaramed® 3/4 0.960 0.004
Malaratab® 2/2 0.960 0.105
Uniquin® 1/1 0.998 0.014
Sub-Total 2 16/23 0.467
AQ Total 36/52 1.000
AQ-amodiaquine. nt-not tested. Product (i)-tablet or paediatric suspension. Batch-unique identifier given to a product by 
manufacturer. Quality index (Q)-product of content and dissolution tests. For suspensions, only content test done.*Quality 
index estimated from the average quality index of the other products in the category. Community use index (U)-number 
of encounters with product as proportion of total in the class. *Formal-drug obtained from government, Mission, or NGO 
sector and given quality index of Malaratab®. *Retail-drug obtained from outside formal sector.
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Table 7.5 shows adherence (A) to SP and AQ in Kwale and Makueni. 66.7% of patients on 
SP and 13.8% of those on AQ were considered as having “adequately adhered” (correct 
dose for correct duration). Table 7.6 summarises the results o f Tables 7.2 to 7.5 to derive 
overall effectiveness estimates for SP and AQ according to the various definitions. Using 
the latest WHO definition of clinical efficacy (Day 28 ACPR), a point estimate for 
effectiveness of 51% was obtained for SP, with worst/best case estimates of 28 to 70% 
thus:
Point estimate:
[0.667*0.720*0.831] + [0.333*0.4*0.831] = 0.510 or 51%
Worst estimate:
[0.5*0.6*0.7] + [0.5*0.2*0.7] = 0.28 or 28%
Best estimate:
[0.8*0.8*0.9] + [0.2*0.7*0.9] = 0.702 or 70%.
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Likewise, overall effectiveness of AQ was estimated to be 45% (29 to 68%). The observed 
differences between adherence to one-day versus three-day regimen (66.7% versus 13.8%) 
would probably account for most of the differences between the estimated effectiveness of 
AQ and SP in Kenya.
Table 7.5: Adherence (A) to recommended dose regimen for children under 5 years using 
OTC SP and AQ drugs for a recent fever in Kwale and Makueni districts (2002-3)
SP AQ
Adequate* or High dose Low dose Adequate* or High dose Low dose
Kwale 29/46 17/46 10/60 50/60
(63.0%)f (37.0%) (16.7%) (83.3%)
Makueni 23/32 9/32 3/34 31/34
(71.9%) (28.1%) (8.8%) (91.2%)
Total 52/78 26/78 13/94 81/94
(66.7%) (33.3%) (13.8%) (86.2%)
* Adequate dose for age, based on national standard treatment guidelines. High dose/Low dose implies higher or lower 
than those on guidelines.
* Values in parentheses represent proportions in each category
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Table 7.6: Effectiveness versus efficacy of SP and AQ in Kenya.
Adequate
adherence
group*
Inadequate
adherence
group*
SP Estimated efficacy day 14 ACR (A) 0.801 (0.5-1.0)* 0.4 (0.2-0.7)1
Estimated efficacy day 28 ACR (B) 0.802 (0.7-0.9)* 0.4 (0.2-0.7) 1
Estimated efficacy day 14 ACPR (C) 0.741 (0.5-1.0) * 0.4 (0.2-0.7)1
Estimated efficacy day 28 ACPR (D) 0.720 (0.6-0.8)* 0.4 (0.2-0.7)1
Use-weighted quality 0.831 (0.7-0.9)* 0.831 (0.7-0.9)1
Proportion of patients 0.667 (0.5-0.8)* 0.333 (0.5-0.2)*
Overall SP effectiveness (A) 0.55 (0.25-0.85)§
Overall SP effectiveness (B) 0.56 (0.32-0.77)5
Overall SP effectiveness (C) 0.52 (0.25-0.85)5
Overall SP effectiveness (D) 0.51 (0.28-0.70)§
AQ Estimated efficacy day 14 ACR (A) 0.958 (0.8-1.0)1 0.5 (0.4-0.6)*
Estimated efficacy day 28 ACR (B) 0.951 (0.9-1.0)* 0.5 (0.4-0.6)*
Estimated efficacy day 14 ACPR (C) 0.952 (0.6-1.0)1 0.5 (0.4-0.6)*
Estimated efficacy day 28 ACPR (D) 0.777 (0.6-0.9)1 0.5 (0.4-0.6) 1
Use-weighted quality 0.838 (0.7-0.9)1 0.838 (0.7-0.9)1
Proportion of patients 0.138 (0.1-0.5)* 0.862 (0.9-0.5)*
Overall AQ effectiveness (A) 0. 47 (0.32-0.72) *
Overall AQ effectiveness (B) 0.47 (0.32-0.72)§
Overall AQ effectiveness (C) 0.47 (0.29-0.72) *
Overall AQ effectiveness (D) 0.45 (0.29-0.68)5
*Took adequate dose or higher than adequate according to the standard treatment guidelines (STGs)
* Took lower dose than recommended by STGs
* Estimated plausible ranges for parameters
5 Point/base estimate; in brackets wors^est estimate
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7.4 Discussion
In this chapter, combinations of clinical efficacy, quality and adherence to first and second 
line AM drugs available in Kenya have been examined using empirical observations from 
four districts. Analysis of these composite data suggest that despite a clinical efficacy of 
over 72% for SP (ACPR on Day 28) in government clinics during the period of 
observation, SP effectiveness may be as low as 51% under common usage patterns. 
Likewise, the effectiveness of AQ might be as low as 45% compared to a clinical efficacy 
of 78%.
7.4.1 Need to weight quality by use
Quality assurance of AM drugs in developing countries is usually sporadic. Products in 
circulation are rarely sampled for quality checks because of institutional or financial 
constraints (Chapter 3). Therefore, linking use and distribution to quality assurance would 
be a practicable way to focus on the small number of AM drugs that are critical to the 
community at any one time. In the parsimonious model suggested in this chapter, drug 
quality was adjusted by community use to arrive at a use-weighted quality index. This 
takes into consideration the relative importance of the various products, i.e. how often they 
are used. For example, although the quality indices for most SP suspensions were well over 
90%, SP suspensions were reportedly used in only 16% of cases where SP was the drug of 
choice. Conversely (and intuitively), a sub-standard but widely used product is of greater 
public health concern.
7.4.2 Study limitations
This simple model has a number of limitations. First, it was assumed that there is a linear 
relationship between and within the various parameters. In reality, this might not always be 
true as the dose(adherence)-response relationships are typically sigmoidal. Secondly, data
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on adherence were limited to only two of the study sites. However, observations are 
consistent with the very few other carefully conducted studies of adherence (Marsh et al., 
1999; Okonkwo et al., 2001; Yeboah-Antwi et a l, 2001; Nshakira et al., 2002) which 
suggest that three day regimens are poorly adhered to under routine conditions with 2.8% 
(Marsh et al., 1999) to 49.8% (Yeboah-Antwi et al., 2001) of patients taking the correct 
dose for the appropriate duration. Given a high quality, highly efficacious drug, adherence 
would probably be the single biggest impediment to drug effectiveness and may reduce 
efficacy to true effectiveness by as much as 40%. However, there is a need to model 
pharmacodynamics of drugs against their adherence since some drugs are know to be 
“forgiving”, i.e. they give a favourable response even among the poorly adhering 
(Urquhart, 1998; Hughes & Walley, 2003). Adherence to dosage regimen is especially 
important in the light of artemisinin-based combination therapies like ART-LUM, which 
have a complex dosing regimen and whose effectiveness could potentially be compromised 
by poor adherence.
A third limitation of this model is its scope. A more elaborate model has been used by 
Krause and Sauerbom (2000) in Burkina Faso in calculating community effectiveness of 
malaria treatment. In this model, seven steps were considered to be essential in malaria 
treatment: a) utilisation of health services; b) completeness of history taking; c) 
completeness of clinical examination; d) prescription of correct dosage of antimalarial 
drugs; e) buying correct amount of drug by patients; f) compliance in drug taking; and g) 
clinical efficacy of the antimalarial drugs. From these parameters, the authors concluded 
that the effectiveness of malaria treatment using CQ in Burkina Faso was approximately 
3% in 2000 (Figure 7.1). Although the broad principles of Krause and Sauerbom’s model 
were used for the present study, the proposed model was pared down to a few, salient 
parameters. This was because a) drug effectiveness was considered to be a function of
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adherence, quality and clinical efficacy for patients who had reported access to a given 
drug; and b) elements of quality of care of different providers was not possible to estimate 
accurately and for all sectors from which drugs were accessed in Kenya. Further, a 
consideration of these two factors would require expansion of the present work to that of 
performance of the Kenyan health sector in delivering antimalarial services to patients and 
would therefore be outside the scope of the present study.
Figure 7.1: Proportion of effective procedures (in % columns) and estimated effectiveness 
(in % lines) of seven steps in the process of treating malaria (Krause & Sauerbom, 2000).
100%  -
utilization of history-taking clinical drug d o s a g e  drug buying drug taking drug efficacy*
serv ices  exam ination
7.4.3 Plausible ranges
Plausible ranges were assigned to account for uncertainty. In some models, the 95% 
confidence interval around the point estimate is used as the plausible range. This was not 
possible for all of the parameters of the model in this chapter since some parameters were 
derived and did not exist in literature (e.g. the quality and use-weighted quality indices). 
Moreover, as the uncertainty around the estimate of effectiveness is the product of each
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individual uncertainty estimate, focusing on details with some parameters, when no data 
existed for the remainder seemed counterproductive.
7.4.4 Projected effectiveness ofART-LUM, the new first-line policy 
An attempt was made to estimate the effectiveness of ART-LUM, the new first-line policy 
in the Government o f Kenya (GoK) sector in a method similar to the one described in this 
chapter. Since ART-LUM will be sourced from a single company (Novartis Pharma AG) 
and will presumably be manufactured to GMP, a quality index o f 1 is plausible. Day 28 
ACPR for ART-LUM in Kilifi, Kenya was estimated at 92.4% in a recent study among 92 
children under five who completed follow-up (Dr M Makanga, personal communication). 
In the absence of other studies on ART-LUM in Kenya (to provide the minimum and 
maximum reported clinical efficacy as in SP and AQ), the Fleiss quadratic 95% confidence 
interval was used as the range for the sensitivity analysis (90.1 to 99.2%, calculated using 
EPI-Info version 6.0d4, Centers for Disease Control, USA). On a scale of 0 to 1, these 
represent approximate probabilities of 0.9 to 1.0 (or 90% to 100%).
Very few studies have been done on adherence to ACTs in Africa. In two recent studies in 
Zambia and in the Sudan, Deporteere et al. (2004a; 2004b) estimated the adherence to SP- 
artesunate and ART-LUM. In the Zambian study, guardians o f 162 children aged five 
years or below with confirmed malaria in the Maheba Refugee Camp treated with SP- 
artesunate (SP-AS) were interviewed about use of the drug on the day following the last 
administered dose. Compliance was determined using the pill count method to see how 
many tablets or sachets were used over the treatment period and what drug remained on the 
day o f the interview. Children were put in three categories: those who had one or more 
doses of the drug left (certainly non-compliant); those with no drug left and who had 
reported drug use according to exact instructions of the health worker (probably compliant)
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and those with no drug left, but who had not used the drugs according to health worker 
instructions (probably non-compliant). From this study, those who were probably 
complaint were estimated to be 39.4% (Depoortere et al., 2004a). In another study in the 
Sudan in 2004, using a similar methodology, the authors estimated adherence to ART- 
LUM as 59.1% among 93 children aged five or below (Depoortere et a l,  2004b).
In a study in Mbarara, Uganda, Fogg et al. (2004) estimated adherence to six-dose ART- 
LUM. Patients (all age groups) with uncomplicated malaria were given the first dose of 
ART-LUM then instructed on how to take the remaining five doses. A combination of pill 
counts and questionnaires were then used to measure adherence after doses were estimated 
to have been completed (day 3). Adherence was defined as in the Depoortere studies 
above. Among 210 patients for whom data were complete, 10% were probably or 
definitely non-adherent and 90% probably adherent.
In yet another study in Rufiji, Tanzania, 253 out-patients (>=2 months of age) presenting 
to the Ikwiriri health centre with uncomplicated malaria and who had been given SP-AS 
were recruited for a study on adherence. Adherence was measured at 24 and 48 hours 
based on self-reports and pill counts, and defined as correct dose for the day of follow up 
and by number of tablets completed using pill count. A composite measure for adherence 
was derived from these two methods; complete adherence to SP-AS was estimated to be 
75% (Kachur et al., 2004).
Using the average of these four estimates (65.9%) as the point estimate, and their extremes 
(39.1 to 90.0%) as worst- and best-case scenarios, modelled effectiveness for ART-LUM 
was estimated to be 85% (72 to 99%), far superior to either SP (51%, 28 to 70%) or AQ 
(45%, 29 to 68%). Although the estimated adherence to ART-LUM seems high for a three-
262
day regimen and therefore counterintuitive, there is evidence to suggest that patients are 
more likely to adhere to more effective drugs like ART-LUM (even three-day regimen) 
better than failing drugs like CQ and AQ of a similar dosage regimen (Yeung & White, 
2005).
7.5 Summary
The chapter highlights the important differences between efficacy and effectiveness of 
widely used first and second line anti-malarial drugs under routine formal and retail sector 
use in Kenya. It shows that a drug’s effectiveness cannot be measured reliably through in 
vivo clinical efficacy tests and factors related to brand use, brand quality and adherence 
should all be considered when defining replacement drugs for failing nationally 
recommended therapeutics. It also demonstrates that with the limited available data, the 
new first-line treatment, ART-LUM may prove to be more effective under operational 
conditions than either SP or AQ.
The data needed to populate this parsimonious model of effectiveness can be collected in 
the sentinel districts as part of monitoring and evaluation of the RBM investments in 
Kenya. Surveys are already planned to evaluate mid-point targets for 2005/2006 on fever 
management practices and coverage of ITNs among other process and outcome indicators 
(Prof RW Snow, personal communication). Existing tools on fever management practices 
in the districts can be improved to collect better data on adherence to the antimalarial 
drugs. In addition, quick preliminary analyses would give a sense of brand preference by 
communities and thus guide sample collection for quality control. Such data can 
subsequently be used to model effectiveness and might have an increased programmatic 
utility over routine efficacy testing of the antimalarial drugs.
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CHAPTER 8:
Conclusions
8.1 Introduction
A renewed interest in the control and management of malaria has followed the launch of 
the Roll Back Malaria (RBM) initiative in 1998. RBM seeks to reduce malaria morbidity 
and mortality by 50% by 2010. In Africa, where access to clinical and laboratory facilities 
are limited, the main strategy for achieving this goal is prompt, presumptive treatment of 
fever. The retail sector in Africa plays a very important role in fever management, with 
fevers often first being treated with antimalarial or antipyretic drugs obtained from the 
retail sector (Section 1.8.1.2 and 4.4.3). Rather than alienate this sector, the Kenyan 
Government has embarked on targeted training programmes to enhance service delivery 
(Section 5.4.3). Training programmes, however, will achieve little public health value if  
drugs in the retail sector are sub-standard or counterfeit (Section 6.4.3), and if relevant 
regulatory mechanisms and legislation are wanting (Section 3.4.3). Sub-standard and 
counterfeit drugs are a hindrance to the effectiveness of strategies promoting home-based 
care.
8.2 Summary of key findings
The thesis addressed three broad themes: measuring the extent of prompt access to 
antimalarial drugs; modelling drug effectiveness under operational conditions allowing for 
sub-standard products and adherence; and lastly the policy environment under which drugs 
are regulated. These were put in the context of antimalarial drug policy changes in Kenya. 
The key findings were:
8.2.1 Access to services and to treatment
• About 39% of fevers among children under five years of age in Kenya are treated 
through the formal sector and 29% through the retail sector. A substantial 
proportion of fevers (28%) remain untreated.
• Most fevers are treated with antipyretic (49%) or antimalarial drugs (30%), a 
finding that is consistent with what has previously been reported by other workers 
in Kenya, and in Africa
• Fevers treated through the formal sector have a higher chance of receiving an
antimalarial drug than those treated through other sectors (56 versus 37%)
• A waiting period of between two and three days is common before treatment is 
sought
• Overall, less than 3% of paediatric fevers were treated within 24 hours with SP in 
2001, the first-line drug at the time of the study, against an international target of 
60% fevers to be treated presumptively as malaria by 2006.
8.2.2 Drug effectiveness
• 41% of first and second-line antimalarial drugs were found to be substandard
• When differential brand use and adherence to SP and AQ were combined with drug
quality, the modelled effectiveness of SP was estimated to be 51% and that of AQ 
to be 45%; compared with a clinical efficacy of 72% and 78% for SP and AQ, 
respectively
• The modelled effectiveness of ART-LUM, the proposed new first-line drug, was 
85%, far better than either SP or AQ
8.2.3 Drug regulation and antimalarial drug policy changes
• About half of first and second-line drugs in Kenya are unregistered and their safety, 
quality, and efficacy cannot be guaranteed.
• There is no functional post-marketing surveillance system to protect the market 
from the trade in sub-standard and counterfeit antimalarials or to mop up failing 
antimalarial drugs like SP
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• Antimalarial drug policy changes in Kenya are not linear, scientific processes, but 
cyclical, both scientific and political endeavours
8.3 Future extension and applications of effectiveness models
Chapter 7 brought together a number of parameters that are important for the effectiveness 
of the antimalarial drugs (quality, efficacy, adherence, and differential brand use). Here, an 
attempt is made to extend this to a far more important concept than drug effectiveness, that 
of antimalarial drug policies with the premise that effective drugs (riot efficacious) are of 
no use to communities if they remain inaccessible to the majority of those who need them. 
Although not exhaustive, the few parameters used in the proposed model serve as a 
conceptual framework for thinking about the effectiveness of drug policies, and requires 
further work.
Figure 8.1 and Table 8.1 show the conceptual framework of community drug policy 
effectiveness and the parameter estimates used to derive preliminary figures for SP and 
AQ. The entry point to the model is treatment seeking for fevers. From the findings in 
Chapter 4, about 39% of paediatric fevers will be treated through the formal sector, 29% 
through the retail sector, and about 28% remain untreated. Of those seeking treatment from 
the formal sector, 55% will receive the first-line drug (SP in 2001-2003) and 5% AQ 
(Zurovac et al., 2004). Conversely, for those seeking treatment through the retail sector, 
only 10% will receive SP and 14%, AQ (Section 4.4.3). Zurovac and colleagues’ data are 
quoted here because, as explained in Chapter 4, mothers do not accurately recall drugs 
obtained from the formal sector unlike the retail sector where they purchase drugs of their 
choice.
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The next step in the framework is the proportion of those who receive either drug and are 
given an adequate dose. For SP in the formal sector, about 34% will receive an adequate 
dose according to the national treatment guidelines, 45% higher than recommended and 
22% lower than recommended (Zurovac et al., 2005). For AQ, 10% will receive an 
adequate dose, 29% a higher than recommended and 62% lower than recommended 
(Zurovac et al., 2002). Similar to the earlier assumption in Chapter 7, those who are 
prescribed an adequate or high dose will presumably derive the same benefit in terms of 
efficacy (hence the terms “adequate prescription”, and “full efficacy”). Conversely, those 
who receive a lower dose will derive some benefit from the drug, thus “inadequate 
prescription” and “partial efficacy” in Table 8.1.
In the retail sector, the “prescription step” is missing from the conceptual framework 
because clients’ have a choice on what to buy or not to buy depending on their ability and 
willingness to pay. It therefore means that adherence patterns for drugs obtained from the 
retail sector are actually composite figures of a) what is bought (adequate, over- or under­
dose), and b) how what is bought is used, thus obviating the prescription step in the formal 
sector. Likewise, for the adherence parameter (again in the manner of Chapter 7), about 
67% of those who obtain SP from the retail sector “adequately adhere” and 14% of those 
who purchase AQ adequately adhere. These two groups have been assumed to derive “full 
efficacy” from the drugs, while those who inadequately adhere, have been assumed to 
derive partial benefit, thus “partial efficacy” in Table 8.1, i.e. adherence is not an all or 
none scenario but a continuum (the same assumption was made for drug quality by way of 
the quality index in Chapter 7).
The third step is at the level of the drug. Different brands will be accessed from the 
different sectors and the preference for these brands will differ, thus the need to weight
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quality with use. The use-weighted quality indices for SP were similar in both sectors, i.e. 
both were 83%; that for AQ was marginally higher in the formal sector (85%) than in the 
retail sector (81%).
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Table 8.1: Parameters used to populate an example community effectiveness model for sulfadoxine- 
pyrimethamine (SP) and amodiaquine (AQ)
Parameter Point estimate (plausible 
range)*
Reference
No action Fevers where no action was taken naT na
Formal sector1 Fevers accessing the formal sector 39.1% (5 to 83%) Table 4.6 (Figure 2.5)
Retail sector8 Fevers accessing the retail sector 29.2% (11 to 77%) Table 4.6 (Figure 2.6)
SP Fevers treated with AQ in: 
Formal sector 
Retail sector
55.3% (52.3 to 58.3%) 
9.5% (7.6 to 11.9%)
Zurovac et al. (2004) (95% Cl)1 
Table 4.12 (95% Cl)
AQ Fevers treated with AQ in: 
Formal sector 
Retail sector
5.1% (3.8 to 6.6%) 
13.8% (11.5 to 16.5%)
Zurovac et al. (2004) (95% Cl) 
Table 4.12 (95% Cl)
E s p Full efficacy of SP 
Partial efficacy for SP
72.0% (60.0 to 80.0%) 
40.0% (20.0 to 70.0%)
Table 7.6
E a q Full efficacy o f AQ 
Partial efficacy o f AQ
77.7% (60.0 to 90.0 %) 
50.0% (40.0 to 60.0%)
Table 7.6
P sp “Adequate prescription1” of SP 
“Inadequate prescription” of SP
78.5% (75.7 to 81.4%) 
21.5% (18.6 to 24.3%)
Zurovac et al. (2005) (95% Cl)
P a q “Adequate prescription” of AQ 
“Inadequate prescription” o f AQ
38.4% (29.6 to 47.9%) 
61.6% (52.1 to 70.4%)
Zurovac et al. (2002) (95% Cl)
A s p “Adequate adherence"” to SP 
“Inadequate adherence” to SP
66.7 (50.0 to 80.0%) 
33.3% (20.0 to 50.0%)
Table 7.6
A a q “Adequate adherence” to AQ 
Inadequate adherence to AQ
13.8% (10.0 to 50.0%) 
86.2% (50.0 to 90%)
Table 7.6
Qu Quality-weighted for brand use: SP 
Formal sector 
Retail sector
83.1% (70.0 to 90.0%) 
83.4% (70.0 to 90.0%)
Further analysis of Table 7.6
Qu Quality-weighted for brand use: AQ 
Formal sector 
Retail sector
84.7% (70.0 to 90.0%) 
81.4% (70.0 to 90.0%)
Further analysis of Table 7.6
* Plausible range for sensitivity analysis (worst and best case scenario as in Chapter 7)
^na-not applicable
* Formal sector- GoK clinics and hospitals, not-for-profit clinics and hospitals, and Community Health Workers (CHW) 
5 Retail sector- General retail shops, drug vendors and pharmacies
 ^95% confidence interval
11 “Adequate prescription”-those prescribed an adequate dose or higher than recommended. Inadequate adherence- 
prescribed lower dose than recommended
** “Adequate adherence”-those who took an adequate dose or higher than recommended. “Inadequate adherence”-took 
lower dose than recommended.
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By multiplying the estimates from steps one to three, the overall community effectiveness 
of SP was estimated to be 12.4% (0.9 to 42.3%); 11% (0.7 to 35.9%) in the formal sector 
and 1.4% (0.2 to 6.4%) in the Retail sector. That for AQ was estimated to be 2.4% (0.3 to 
13.0%); 0.9% (<0.1 to 4.4%) in the formal sector and 1.5% (0.2 to 8.6%) in the retail 
sector (Figure 8.2).
Figure 8.2: An example of community effectiveness of first and second-line antimalarial 
drugs in Kenya
1 0 0  n  T t
80 - 
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60 - 
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0  Drug Efficacy □ Drug effectiveness □ Community effectiveness
If ART-LUM, the proposed first-line policy, is taken up to the same extent as SP in the 
formal sector (where it will be introduced first), and prescription behaviour does not 
change (and using the drug effectiveness estimates from Chapter 7), the combined 
community effectiveness for ART-LUM is projected to be 18.6% (1.8 to 50.6%). This is 
despite the fact that the drug has been assumed to be available through the formal sector 
only; if it availed in the retail sector at cost, the community effectiveness will increase.
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There are two main, implicit assumptions made in this final chapter: 1) that patients who 
adhere to medications adequately will benefit more from them than those who do not; 2) 
that there is a linear relationship between the parameters used in Figure 8.1. The limitations 
of the later assumption as far as drug effectiveness is concerned have been discussed in 
Chapter 7 and a recent review by Yeung & White (2005) suggests indeed that for the 
artemisinins, even a less than perfect adherence affords better outcome than intuition 
would have suggested for drugs with a complex dosage regimen. This is certainly welcome 
news, but more data are needed to better model community effectiveness and more 
specifically, the contribution of adherence to drug effectiveness.
The second assumption of linearity between access and drug effectiveness (to afford a 
combined estimate) might not hold for all patients as well. In classical pharmacology, it is 
acknowledged that therapeutic outcome is not always dependent on drug factors alone, but 
that a dynamic interplay between host factors, parasite factors, and product factors results 
in a favourable or unfavourable outcome. Most patients with mild malaria recover without 
recourse to drugs owing to natural immunity, and of those who do not; very few will 
progress to severe malaria. In short, more data and a better understanding o f the interplay 
between the factors in community effectiveness are required to produce better models.
8.4 Conclusion
Providing effective drugs only is not the panacea to effective therapeutic drug policies, 
particularly if  they remain inaccessible to rural populations at risk in Kenya. The RBM 
targets on prompt, effective treatment of fevers are unlikely to be met without an increased 
investment in behaviour change initiatives and provision of effective and affordable 
therapeutics at all levels of the health service, including the retail sector. International
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funds are required to ensure the community effectiveness of ART-LUM since Kenya 
cannot afford it.
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Appendices
APPENDIX I
Abdinasir Amin, Kenya Medical Research Institute (KEMRI)AVellcome Trust Collaborative
Programme, Nairobi, Kenya.
PhD Research Questions. Views and experiences of Kenyan academia on drug regulation
I am trying to gather the views and experiences of academia, industry, and regulators on 
drug regulation in Kenya and the United Kingdom. I am specifically interested in the 
regulation o f antimalarial drugs and how 1) this compares with that of other drugs e.g. anti­
diabetics 2) how this differs between countries 3) and how the process has applied to newly 
registered antimalarial and anti-diabetic products. With your permission, I would like to 
tape-record our conversation, as this would enable me to concentrate on the conversation 
better and to also accurately analyse the data collected afterwards. The information you 
provide will be kept confidential and will be used only in this thesis.
Thanking you in advance.
Abdinasir Amin, PhD student. Supervised by Professors Robert Snow, Tom Walley, 
Gilbert Kokwaro, and Peter Winstanley.
Questions
1. Could you briefly tell me about your academic interests?
2. Could you describe for me the history of drug regulation in Kenya?
3. How about that of the pharmaceutical industry in Kenya?
4. How are drugs supplied: in the public sector? In the private sector?
5. How are drugs regulated in this country?
6. What is the role of drug regulation Kenya?
7. How is a balance maintained between the need to promote local industries on 
one hand (economic need) and the need to regulate industry (public health need)
8. What criteria are used to register new drugs?
9. In your experience/opinion, do the criteria differ for different drugs?
10. What happens after the drug is in the market?
11. Do you have any views on drug regulation in the developed countries e.g. UK?
12. Does the process differ from the developing world Kenya? In what ways?
13. Is there anything you would like to add on?
14. Do you have any questions for me?
Thanks once again.
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APPENDIX II
Serial No [ ] ] [__]__1__]
COMMUNITY SURVEY: PROJECT 1586 
(Form DOMC/HH1)
District-Enumeration-Homestead number -[ ]-I__|__|__]-[__|__|__]
Section 2: Childhood fevers 
Identify all resident children below 5 years of age and put their names in a hat or bag to randomly
select one child. If there is no child aged less than 5 years go to section 3.
No. of substitutions made...........................................  [ ] No. of these which were refusals...................................................  [__]
QUESTIONS & INSTRUCTIONS RESPONSES GOTO
32. Child’s name/ Jina la mtoto. r 1
33. Mother’s name/ Jina la m am a m toto r ]
34. Father’s name / /  Jina la  baba m toto r i
35. Child’s sex (M/F)/ /  m toto wa kike au kium e r i
36. Child’s date o f  birth (dd-mm-yy)/ Tarehe ya  kuzaliwa  
(siku / mweziV m waka r i l-r i l-r i i
37. Does the child sleep with the mother (Y/N) /  Na  
huyu m toto hulala pam oja na m am a r l
38. Does the child sleep on 1. A bed with a mattress; 2. A  
bed A bed without a mattress; 3. On a mattress or mat 
on the floorU e huyu hulalia 1. K itanda kilicho
na godoro 2. K itanda kisicho na godoro
3.kwa godoro au m keka chin i?
[ _ ]
39. Does the child usually sleeD under a bed net (Y/N) /  Je  
huyu m toto hulala kwenye/ndani y a  neti kwa  
kawaida.
L J
IF NO GO 
TO 48
41. If .yes, did the child sleep under a bed net last
night (Y/N/D)/ K am a ndio, huyu m toto alilala  
kw enye/ndani y a  neti usiku uliyopita (N /  L) L I
42. From whom was the bed net purchased/obtained 
N eti hiyo ilinunuliwa au kupatikana  
Kutoka kwa nani.
r ir i
43. How much did the net cost -  i f  free indicate 0000 
(KES) /  Hiyo neti iligharimu pesa  ngapi L L L U
44. Has the net ever been treated with dawa
(Y/N/D)? /  H ii neti im eshaw ahi kutiwa dawa r ]
IFN /D  
GO TO 48
45. If yes, was the net treated in the last 6 months (Y/N/D)/ 
K am a ndio, je  ilitiwa dawa katika m iezi sita  iliyopita r ]
IFN /D  
GO TO 48
46. If yes, where and who treated the net/ Kama ndiyo, 
ilitiliw a dawa m ahali gan i na ni nani alit\yeitia dawa
r ir i i
47. How much was paid for the net treatment
-  if  free indicate 000 (KES)/ N i pesa n sap i zilitum ika  
kutia neti h ii dawa
r i i i
48. Does the child sleep in a room where the 
walls have been sprayed with a long lasting 
insecticide within the last 12 months (Y/N)/ 
Je  m toto hulala kw a chum ba ambacho  
kutaZake zim enyunyiziwa dawa y a  mbu  
inayodum u m uda m refu katika m iezi 
kum i na m iw ili Iliyopita?
[ _ ] IF NO GO 
TO SECT. 
3
49. Has the child had a fever or hot body 
in the last 14 days (Y/N)/
N a m toto am ew ahi kuw a nahom a au 
m w ili wenye jo to  sana katika siku kum i
i _ J
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na nne zilizopita
50. For how many days was/has the child 
been unwell/
N i kw a siku ngapi huyu m toto  
am ekuwa hajisikii vizurL
r i i
5 1. Is the child suffering from a fever or hot body TODAY (Y/N) 
/H uyu m toto ana hom a au jo to  J ingi m w ilini leo
[ _ ]
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APPENDIX III
Division of Malaria Control, Ministry of Health 
Retail outlet audit 
(Form DOMC/RS1)
Enumerator’s Name & Code................... [____________________________________ ][__|__|__]
1. Outlet nam e........................................................... [____________________________________ ]
2. Outlet I D .............................................................................................................. 1 1-f I 1 I 1
3. Today’s date...............................................................................................[__I ] - [ I I -1 I ]
4. Position:
District...................................................[____________________________________ ][__]
Location............................... .... [ if 1 1
Sub-location........................ ...r ir 1 1
Enumeration Area name.... ...r if 1 1
Longitude............................ ............... [_]-[ i_j -[ _ l _ _I_J
Latitude............................... ................ [_ ] - [  1 1 H 1 1 1
5. Type:
Category A: 1. Rural or 2. Urban {see notes) ................................................................................ [_]
Category B: 1. Private pharmacy; 2. Large Duka {see notes)',
3: Small Duka/Kiosk {see notes).............................................................................[_]
6. Advertising
a. Does the outlet have branded wall painting advertisement for malaria
products (Y /N )............................................................................................................................[_]
-If yes, indicate branded product (s)
Brand 1............................. [ _____________________________________]-[__|__ |_]
Brand 2 ____________________[_____________________________________ ]-[__|__ |_]
Brand 3 ____________________[_____________________________________ ]-[__|__ |_]
Brand 4 ____________________[_____________________________________ ]-[__|__ |_]
Brand 5 ____________________[_____________________________________ ]-[__|__ |_]
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Outlet ID L_M_|_U_J
b. Does the outlet have branded advertising materials on display that are not wall
paintings for malaria products (AM & AP brands, nets, insecticides, etc) (Y /N ).............[ ]
-If yes, indicate all branded products advertised:
AM brands
Brand 1........................................ [_____________________________________]-[__|_|__ ]
Brand 2 ........................................ [____________________________________ H I M
Brand 3 ........................................ [_____________________________________]-[__j_|__ ]
Brand 4 ........................................ [_____________________________________]-[__|_|__ ]
Brand 5 ........................................ [_____________________________________]-[__|_j__ ]
Brand 6 ........................................ [ H  I l_ ]
Brand 7 ........................................ [_____________________________________]-[__|_|__ ]
AP brands
Brand 1 f  ]-[___|_I__]
Brand 2______________[_________________________ H_J_J_J
Brand 3 ............................ [_________________________ H I_I_]
Brand 4 ............................ [_________________________ H I_I_]
Brand 5 ......................................... [____________________________________ ]-[__|_|_]
Brand 6 ......................................... [____________________________________
Brand 7 ......................................... [____________________________________ ]-[__I_I_]
Brand 8 ......................................... [_____________________________________]-[__|_|_]
Brand 9 ......................................... [____________________________________
Brand 10....................................... [_____________________________________]-[__|_|_]
Comment Box on advertising
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Interview person found in shop
Outlet ID [_J-U _U _]
7. Date business was established (mm/yy).............................................................. [__|__]-[__|__]
8. Name of main seller..............................................[____________________________________ J
9. Details of main seller:
Age (years) ______________________________________________________ [__|_ ]
Sex (M/F)............................................................................................................................ [ _ ]
Level of education attained {specify).......[_____________________________________ J
How long has main seller worked in outlet (years).................................................. [_|__]
10. Details of other respondent if not main seller
Name..................................................................... [________________________________ J
Age (years)...................................................................................................................... [_I__]
Sex (M/F).............................................................................................................................[ _ ]
Level of education attained {specify)....... [_____________________________________ ]
How long has respondent worked in outlet (years)________________________ [__|__]
Comment Box on respondents)
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outlet id  r i-r i i i i
11. Types of drugs available for sale today: (AM = anti-malarials; AP = Anti-pyretics)
Mark (Y/N)
Antimalarial (AM )______________________________________________________ [_]
Anti-Pyretic (AP)_______________________________________________________ [_]
Anti-Diarrhoeal....................................................................................................................[_]
Cough/Cold medication__________________________________________________ [_]
Worm medication................................................................................................................ [_]
Other {specify only fo r  shops; not pharmacies)..............................................................[_]
Specify other 1 ............................................. [____________________________________ ]
Specify other 2 .......................................................... [____________________________________ ]
Specify other 3 _____________________________[____________________________________ ]
Specify other 4 .......................................................... [___________________________________ J
Specify other 5 .......................................................... [__________________________________  1
Comment Box type of drugs available today
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Outlet ID [ ]-[ | |_ |  ]
13. Other shop resources: Indicate if the following are present today:
a. Division of malaria control leaflets (see notes) (Y /N )_____________________________ [__]
b. Division of malaria control posters (see notes) (Y /N)_____________________________ [__]
c. Bed nets (Y/N)______________________________________________________________ [__]
-If yes, brand names, retail prices and quantity currently in stock
{If not branded, indicate source)
Brand 1/Source 1[ H i l l  H  I I ]
Brand 2/Source 2[_______________________________]-[__ | | |__]-[__|__ |_]-[ |__ ]
Brand 3/Source 3[ H I M  H  1 1 H__l_ .]
d. Insecticides for treating bed nets (Y/N)....................................................................................[__]
-If yes, brand names and retail prices {if not branded, indicate source)
Brand 1/Source 1...............[________________________________]-[__ |__|__|_]-[__ 1__]
Brand 2/Source 2 ...............[________________________________]-[__ |__|__|_]-[__1__]
Brand 3/Source 3 ...............[________________________________]-[__ |__|__|_]-[__ |__]
e. Insecticides for indoor residual house-spraying (Y /N )_____________________________ [__]
-If yes, brand names and retail prices {if not branded, indicate source)
Brand 1/Source 1...............[________________________________]-[__ |__|__|_]-[__ |__]
Brand 2/Source 2 ...............[________________________________]-[__ |__|__|_]-[__ |__]
f. Mosquito coils (Y/N)................................................................................................................... [__]
g. Aerosol insecticides (Y/N)......................................................................................................... [__]
h. Mosquito repellent body gels/creams (Y/N)............................................................................ [__]
Comment Box on malaria resource materials
311
Outlet ID L _ J - [ _ I _ U _ ]
14. Now ask respondent the following questions', (if not main seller, respondent needs at least 
3 months in shop or pharmacy fo r  data to be valid)
a) Do you ever give advice on how drugs in your shop should be used? (Y/N).................[__]
b) If yes, what advice would you give about______________ tab/susp (one o f the AM  brands
stocked) for an adult? Record response verbatim below. Probe fo r  every advice given
c) For this same brand, if a mother asked you how much she should give to her child of 2 
years, how would you advice her? Record response verbatim below. Probe again fo r  every 
advice given
d) Did the shopkeeper consult a drug reference material in c) above? (Y/N).................... [__]
-If yes, describe the reference [_______________________________________________ ]
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15. As per retailer’s experience, which are the most popular AM brands
(in order o f  preference)
Brand I... 
Brand II . 
Brand III 
Brand IV 
Brand V .
i i
. u  
_ u
i i
16. Why does retailer think his/her customers prefer them to other similar products? Probe 
fo r  all possible reasons
17. Ask the retailer to quantify the retail turnover of these brands I to V in terms of number 
of tablets or bottles of syrups/suspensions sold per week:
Brand I. [_ 
Brand II [_ 
Brand III[_ 
Brand IV[ 
Brand V [_
J-LIJ-L
J-LIJ-L
J-LIJ-L
J-LU-L
J-LU-L
18. Has the shop/pharmacy being visited in the last 12 months by MoH inspectors? 
(Y /N)...............................................................................................................................
i i 
i i 
i i i 
L I J  
I 1
■LJ
Comment Box on 015-019
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Outlet ID [_J-U _U _]
General Comments on this Retail Outlet:
1.
2.
3.
4.
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APPENDIX IV 
Division o f Malaria Control, Ministry o f Health
Anti-malarial Drug Wholesalers Survey 
(Form DOMC/RS4)
Enumerator’s Name & Code.... ..........r it i l1 1
1. Wholesaler’s ID ................. ........[ M i l l l _]
2. Wholesaler’s name............. . .......r 1
3. Owner’s name..................... .......r 1
4. Location
District [_ J L J
Location................................... r ][ 1 1 1
Sub-location.................. ......... r .][ 1 1 1
Enumeration Area name [____________________________________ ] [_|__|__]
Longitude I__1 - [__I__1 - [__I__1__J__1__1
Latitude..................................................... ........[ ]-[ i I ]-[ I I I I l
Physical address...................................... .... r l
Telephone number.................................. .... r i
5. Today’s date................................................................................................[__|__]-[__|__]-[__|__]
6. Following explanation of the purpose of the survey did the wholesaler agree
to participate in the survey (Y /N )..........................................................................................[__]
If yes, continue
Brand Sampled Chemical
Code
(AQ/SP)
Brand
Code
Number of
tablets/etc
purchased
Cost
per
unit
Storage conditions 
(see notes)
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